DrugDDI.d505
DrugDDI.d505.s0
No formal drug /drug interaction studies with Plenaxis@ were performed.

No/DT formal/JJ drug/NN /drug/NN interaction/NN studies/NNS with/IN Plenaxis/NN @/NN were/VBD performed/VBN ./.


DrugDDI.d505
DrugDDI.d505.s1
Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis@.

Cytochrome/NN P-450/NN is/VBZ not/RB known/VBN to/TO be/VB involved/VBN in/IN the/DT metabolism/NN of/IN Plenaxis/NN @./NNS


DrugDDI.d505
DrugDDI.d505.s2
Plenaxis@ is highly bound to plasma proteins (96 to 99%).

Plenaxis/NN @/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN proteins/NNS (/-LRB- 96/CD to/TO 99/CD %)./NN


DrugDDI.d505
DrugDDI.d505.s3
Laboratory Tests Response to Plenaxis@ should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.

Laboratory/NN Tests/NNS Response/NN to/TO Plenaxis/NN @/NN should/MD be/VB monitored/VBN by/IN measuring/VBG serum/NN total/JJ testosterone/NN concentrations/NNS just/RB prior/RB to/TO administration/NN on/IN Day/NN 29/CD and/CC every/DT 8/CD weeks/NNS thereafter/RB ./.


DrugDDI.d505
DrugDDI.d505.s4
Serum transaminase levels should be obtained before starting treatment with Plenaxis@ and periodically during treatment.

Serum/NN transaminase/NN levels/NNS should/MD be/VB obtained/VBN before/IN starting/VBG treatment/NN with/IN Plenaxis/NN @/NN and/CC periodically/RB during/IN treatment/NN ./.


DrugDDI.d103
DrugDDI.d103.s0
Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control.

Certain/JJ drugs/NNS tend/VBP to/TO produce/VB hyperglycemia/NN and/CC may/MD lead/VB to/TO loss/NN of/IN blood/NN glucose/NN control/NN ./.


DrugDDI.d103
DrugDDI.d103.s1
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel-blocking drugs , and isoniazid .

These/DT drugs/NNS include/VBP the/DT thiazides/NNS and/CC other/JJ diuretics/NNS ,/, corticosteroids/NNS ,/, phenothiazines/NNS ,/, thyroid/NN products/NNS ,/, estrogens/NNS ,/, oral/JJ contraceptives/NNS ,/, phenytoin/NN ,/, nicotinic/JJ acid/NN ,/, sympathomimetics/NNS ,/, calcium/NN channel-blocking/JJ drugs/NNS ,/, and/CC isoniazid/NN ./.


DrugDDI.d103
DrugDDI.d103.s2
When such drugs are administered to a patient receiving Acarbose , the patient should be closely observed for loss of blood glucose control.

When/WRB such/JJ drugs/NNS are/VBP administered/VBN to/TO a/DT patient/NN receiving/VBG Acarbose/NN ,/, the/DT patient/NN should/MD be/VB closely/RB observed/VBN for/IN loss/NN of/IN blood/NN glucose/NN control/NN ./.


DrugDDI.d103
DrugDDI.d103.s3
When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin , patients should be observed closely for any evidence of hypoglycemia.

When/WRB such/JJ drugs/NNS are/VBP withdrawn/VBN from/IN patients/NNS receiving/VBG Acarbose/NN in/IN combination/NN with/IN sulfonylureas/NN or/CC insulin/NN ,/, patients/NNS should/MD be/VB observed/VBN closely/RB for/IN any/DT evidence/NN of/IN hypoglycemia/NN ./.


DrugDDI.d103
DrugDDI.d103.s4
Intestinal adsorbents (e. g., charcoal ) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly.

Intestinal/JJ adsorbents/NNS (/-LRB- e./FW g./FW ,/, charcoal/NN )/-RRB- and/CC digestive/JJ enzyme/NN preparations/NNS containing/VBG carbohydrate-splitting/JJ enzymes/NNS (/-LRB- e./FW g./FW ,/, amylase/NN ,/, pancreatin/NN )/-RRB- may/MD reduce/VB the/DT effect/NN of/IN Acarbose/NN and/CC should/MD not/RB be/VB taken/VBN concomitantly/RB ./.


DrugDDI.d103
DrugDDI.d103.s5
Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.

Acarbose/NN has/VBZ been/VBN shown/VBN to/TO change/VB the/DT bioavailabillty/NN digoxin/NN when/WRB they/PRP are/VBP co-administered/VBN ,/, which/WDT may/MD require/VB digoxin/NN dose/NN adjustment/NN ./.


DrugDDI.d103
DrugDDI.d103.s6
Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , propranolol , or ranitidine .

Studies/NNS in/IN healthy/JJ volunteers/NNS have/VBP shown/VBN that/IN Acarbose/NN has/VBZ no/DT effect/NN on/IN either/CC the/DT pharmacokinetics/NNS or/CC pharmacodynamics/NNS of/IN digoxin/NN ,/, nifedipine/NN ,/, propranolol/NN ,/, or/CC ranitidine/NN ./.


DrugDDI.d103
DrugDDI.d103.s7
Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.

Acarbose/NN did/VBD not/RB interfere/VB with/IN the/DT absorption/NN or/CC disposition/NN of/IN the/DT sulfonylurea/NN glyburide/NN in/IN diabetic/JJ patients/NNS ./.


DrugDDI.d103
DrugDDI.d103.s8
Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).

Acarbose/NN may/MD affect/VB digoxin/NN bioavailabillty/NN and/CC may/MD require/VB dose/NN adjustment/NN of/IN digoxin/NN by/IN 16/CD %/NN (/-LRB- 90/CD %/NN confidence/NN interval/NN :/: 8-23/CD %/NN )/-RRB- ,/, decrease/VB mean/NN C/NN max/NN digoxin/NN by/IN 26/CD %/NN (/-LRB- 90/CD %/NN confidence/NN interval/NN :/: 16-34/CD %/NN )/-RRB- and/CC decrease/VB mean/JJ trough/NN concentrations/NNS of/IN digoxin/NN by/IN 9/CD %/NN (/-LRB- 90/CD %/NN confidence/NN limit/NN :/: 19/CD %/NN decrease/NN to/TO 2/CD %/NN increase/NN )./NN


DrugDDI.d103
DrugDDI.d103.s9
The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.

The/DT amount/NN of/IN metformin/NN absorbed/VBD while/IN taking/VBG Acarbose/NN was/VBD bioequivalent/JJ to/TO the/DT amount/NN absorbed/VBN when/WRB taking/VBG placebo/NN ,/, as/IN indicated/VBN by/IN the/DT plasma/NN AUC/NN values/NNS ./.


DrugDDI.d103
DrugDDI.d103.s10
However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin .

However/RB ,/, the/DT peak/JJ plasma/NN level/NN of/IN metformin/NN was/VBD reduced/VBN by/IN approximately/RB 20/CD %/NN when/WRB taking/VBG Acarbose/NN due/IN to/TO a/DT slight/JJ delay/NN in/IN the/DT absorption/NN of/IN metformin/NN ./.


DrugDDI.d103
DrugDDI.d103.s11
There is little if any clinically significant interaction between Acarbose and metformin .

There/EX is/VBZ little/JJ if/IN any/DT clinically/RB significant/JJ interaction/NN between/IN Acarbose/NN and/CC metformin/NN ./.


DrugDDI.d518
DrugDDI.d518.s0
Catecholamine-depleting drugs , such as reserpine , may have an additive effect when given with beta-blocking agent s.

Catecholamine-depleting/JJ drugs/NNS ,/, such/JJ as/IN reserpine/NN ,/, may/MD have/VB an/DT additive/JJ effect/NN when/WRB given/VBN with/IN beta-blocking/JJ agent/NN s/NNS ./.


DrugDDI.d518
DrugDDI.d518.s1
Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.

Patients/NNS treated/VBN with/IN acebutolol/NN plus/CC catecholamine/NN depletors/NNS should/MD ,/, therefore/RB ,/, be/VB observed/VBN closely/RB for/IN evidence/NN of/IN marked/JJ bradycardia/NN or/CC hypotension/NN which/WDT may/MD present/VBP as/IN vertigo/NN ,/, syncope/presyncope/NN ,/, or/CC orthostatic/JJ changes/NNS in/IN blood/NN pressure/NN without/IN compensatory/JJ tachycardia/NN ./.


DrugDDI.d518
DrugDDI.d518.s2
Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonist s and alpha-adrenergic stimulants , including those contained in proprietary cold remedies and vasoconstrictive nasal drops.

Exaggerated/JJ hypertensive/JJ responses/NNS have/VBP been/VBN reported/VBN from/IN the/DT combined/JJ use/NN of/IN beta-adrenergic/JJ antagonist/NN s/NN and/CC alpha-adrenergic/JJ stimulants/NNS ,/, including/VBG those/DT contained/VBN in/IN proprietary/JJ cold/JJ remedies/NNS and/CC vasoconstrictive/JJ nasal/JJ drops/NN ./.


DrugDDI.d518
DrugDDI.d518.s3
Patients receiving beta-blockers should be warned of this potential hazard.

Patients/NNS receiving/VBG beta-blockers/NN should/MD be/VB warned/VBN of/IN this/DT potential/JJ hazard/NN ./.


DrugDDI.d518
DrugDDI.d518.s4
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agent s by nonsteroidal anti-inflammatory drugs has been reported.

Blunting/NN of/IN the/DT antihypertensive/JJ effect/NN of/IN beta-adrenoceptor/NN blocking/NN agent/NN s/NNS by/IN nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS has/VBZ been/VBN reported/VBN ./.


DrugDDI.d518
DrugDDI.d518.s5
No significant interactions with digoxin , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral contraceptives , tolbutamide , or warfarin have been observed.

No/DT significant/JJ interactions/NNS with/IN digoxin/NN ,/, hydrochlorothiazide/NN ,/, hydralazine/NN ,/, sulfinpyrazone/NN ,/, oral/JJ contraceptives/NNS ,/, tolbutamide/NN ,/, or/CC warfarin/NN have/VBP been/VBN observed/VBN ./.


DrugDDI.d452
DrugDDI.d452.s0
DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin .

DIAMOX/NN modifies/VBZ phenytoin/NN metabolism/NN with/IN increased/VBN serum/NN levels/NNS of/IN phenytoin/NN ./.


DrugDDI.d452
DrugDDI.d452.s1
This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy.

This/DT may/MD increase/VB or/CC enhance/VB the/DT occurrence/NN of/IN osteomalacia/NN in/IN some/DT patients/NNS receiving/VBG chronic/JJ phenytoin/NN therapy/NN ./.


DrugDDI.d452
DrugDDI.d452.s3
By decreasing the gastrointestinal absorption of primidone , DIAMOX may decrease serum concentrations of primidone and its metabolites , with a consequent possible decrease in anticonvulsant effect.

By/IN decreasing/VBG the/DT gastrointestinal/JJ absorption/NN of/IN primidone/NN ,/, DIAMOX/NN may/MD decrease/VB serum/NN concentrations/NNS of/IN primidone/NN and/CC its/PRP$ metabolites/NNS ,/, with/IN a/DT consequent/JJ possible/JJ decrease/NN in/IN anticonvulsant/JJ effect/NN ./.


DrugDDI.d452
DrugDDI.d452.s4
Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone .

Caution/NN is/VBZ advised/JJ when/WRB beginning/VBG ,/, discontinuing/VBG ,/, or/CC changing/VBG the/DT dose/NN of/IN DIAMOX/NN in/IN patients/NNS receiving/VBG primidone/NN ./.


DrugDDI.d452
DrugDDI.d452.s5
Because of possible additive effects with other carbonic anhydrase inhibitors , concomitant use is not advisable.

Because/IN of/IN possible/JJ additive/JJ effects/NNS with/IN other/JJ carbonic/JJ anhydrase/NN inhibitors/NNS ,/, concomitant/JJ use/NN is/VBZ not/RB advisable/JJ ./.


DrugDDI.d452
DrugDDI.d452.s6
Acetazolamide may increase the effects of other folic acid antagonists .

Acetazolamide/NN may/MD increase/VB the/DT effects/NNS of/IN other/JJ folic/JJ acid/NN antagonists/NNS ./.


DrugDDI.d452
DrugDDI.d452.s7
Acetazolamide may increase or decrease blood glucose levels.

Acetazolamide/NN may/MD increase/VB or/CC decrease/VB blood/NN glucose/NN levels/NNS ./.


DrugDDI.d452
DrugDDI.d452.s8
Consideration should be taken in patients being treated with antidiabetic agents .

Consideration/NN should/MD be/VB taken/VBN in/IN patients/NNS being/VBG treated/VBN with/IN antidiabetic/JJ agents/NNS ./.


DrugDDI.d452
DrugDDI.d452.s9
Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.

Acetazolamide/NN decreases/VBZ urinary/JJ excretion/NN of/IN amphetamine/NN and/CC may/MD enhance/VB the/DT magnitude/NN and/CC duration/NN of/IN their/PRP$ effect/NN ./.


DrugDDI.d452
DrugDDI.d452.s10
Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.

Acetazolamide/NN reduces/VBZ urinary/JJ excretion/NN of/IN quinidine/NN and/CC may/MD enhance/VB its/PRP$ effect/NN ./.


DrugDDI.d452
DrugDDI.d452.s11
Acetazolamide may prevent the urinary antiseptic effect of methenamine .

Acetazolamide/NN may/MD prevent/VB the/DT urinary/JJ antiseptic/JJ effect/NN of/IN methenamine/NN ./.


DrugDDI.d452
DrugDDI.d452.s12
Acetazolamide increases lithium excretion and the lithium may be decreased.

Acetazolamide/NN increases/VBZ lithium/NN excretion/NN and/CC the/DT lithium/NN may/MD be/VB decreased/VBN ./.


DrugDDI.d452
DrugDDI.d452.s13
Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.

Acetazolamide/NN and/CC sodium/NN bicarbonate/NN used/VBN concurrently/RB increases/VBZ the/DT risk/NN of/IN renal/JJ calculus/NNS formation/NN ./.


DrugDDI.d452
DrugDDI.d452.s14
Acetazolamide may elevate cyclosporine levels.

Acetazolamide/NN may/MD elevate/VBP cyclosporine/NN levels/NNS ./.


DrugDDI.d60
DrugDDI.d60.s0
As DIFFERIN Gel has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol , astringents , spices or lime ) should be approached with caution.

As/IN DIFFERIN/NN Gel/NN has/VBZ the/DT potential/NN to/TO produce/VB local/JJ irritation/NN in/IN some/DT patients/NNS ,/, concomitant/JJ use/NN of/IN other/JJ potentially/RB irritating/JJ topical/JJ products/NNS (/-LRB- medicated/JJ or/CC abrasive/JJ soaps/NNS and/CC cleansers/NNS ,/, soaps/NNS and/CC cosmetics/NNS that/WDT have/VBP a/DT strong/JJ drying/NN effect/NN ,/, and/CC products/NNS with/IN high/JJ concentrations/NNS of/IN alcohol/NN ,/, astringents/NNS ,/, spices/NNS or/CC lime/NN )/-RRB- should/MD be/VB approached/VBN with/IN caution/NN ./.


DrugDDI.d60
DrugDDI.d60.s1
Particular caution should be exercised in using preparations containing sulfur , resorcinol , or salicylic acid in combination with DIFFERIN Gel.

Particular/JJ caution/NN should/MD be/VB exercised/VBN in/IN using/VBG preparations/NNS containing/VBG sulfur/NN ,/, resorcinol/JJ ,/, or/CC salicylic/JJ acid/NN in/IN combination/NN with/IN DIFFERIN/NN Gel/NN ./.


DrugDDI.d60
DrugDDI.d60.s2
If these preparations have been used it is advisable not to start therapy with DIFFERIN Gel until the effects of such preparations in the skin have subsided.

If/IN these/DT preparations/NNS have/VBP been/VBN used/VBN it/PRP is/VBZ advisable/JJ not/RB to/TO start/NN therapy/NN with/IN DIFFERIN/NN Gel/NN until/IN the/DT effects/NNS of/IN such/JJ preparations/NNS in/IN the/DT skin/NN have/VBP subsided/VBN ./.


DrugDDI.d409
DrugDDI.d409.s0
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin , amikacin ), amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs (e.g., ibuprofen ), tacrolimus , vancomycin .

Before/IN using/VBG this/DT medication/NN ,/, tell/NN your/NN doctor/NN or/CC pharmacist/NN of/IN all/DT prescription/NN and/CC nonprescription/NN products/NNS you/VBZ may/MD use/VB ,/, especially/RB of/IN :/: aminoglycosides/NN (/-LRB- e.g./FW ,/, gentamicin/NN ,/, amikacin/NN )/-RRB- ,/, amphotericin/NN B/NN ,/, cyclosporine/NN ,/, non-steroidal/JJ anti-inflammatory/JJ drugs/NNS (/-LRB- e.g./FW ,/, ibuprofen/NN )/-RRB- ,/, tacrolimus/NN ,/, vancomycin/NN ./.


DrugDDI.d409
DrugDDI.d409.s1
Do not start or stop any medicine without doctor or pharmacist approval.

Do/VBP not/RB start/VBP or/CC stop/NN any/DT medicine/NN without/IN doctor/NN or/CC pharmacist/NN approval/NN ./.


DrugDDI.d167
DrugDDI.d167.s0
Drug /Laboratory Interactions : No formal drug interaction studies have been performed with Campath .

Drug/NN /Laboratory/NN Interactions/NNS :/: No/DT formal/JJ drug/NN interaction/NN studies/NNS have/VBP been/VBN performed/VBN with/IN Campath/NN ./.


DrugDDI.d167
DrugDDI.d167.s1
An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies .

An/DT immune/JJ response/NN to/TO Campath/NN may/MD interfere/VB with/IN subsequent/JJ diagnostic/JJ serum/NN tests/NNS that/WDT utilize/VBP antibodies/NNS ./.


DrugDDI.d450
DrugDDI.d450.s0
Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron .

Because/IN alosetron/NN is/VBZ metabolized/VBN by/IN a/DT variety/NN of/IN hepatic/JJ CYP/JJ drug-metabolizing/JJ enzymes/NNS ,/, inducers/NNS or/CC inhibitors/NNS of/IN these/DT enzymes/NNS may/MD change/VB the/DT clearance/NN of/IN alosetron/NN ./.


DrugDDI.d450
DrugDDI.d450.s1
Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4 , CYP2C9 , and CYP2C19 .

Fluvoxamine/NN is/VBZ a/DT known/JJ strong/JJ inhibitor/NN of/IN CYP1A2/NN and/CC also/RB inhibits/VBZ CYP3A4/NN ,/, CYP2C9/NN ,/, and/CC CYP2C19/NN ./.


DrugDDI.d450
DrugDDI.d450.s2
In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.

In/IN a/DT pharmacokinetic/JJ study/NN ,/, 40/CD healthy/JJ female/NN subjects/NNS received/VBD fluvoxamine/NN in/IN escalating/JJ doses/NNS from/IN 50/CD to/TO 200/CD mg/NN per/IN day/NN for/IN 16/CD days/NNS ,/, with/IN coadministration/NN of/IN alosetron/NN 1/CD mg/NN on/IN the/DT last/JJ day/NN ./.


DrugDDI.d450
DrugDDI.d450.s3
Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.

Fluvoxamine/NN increased/VBD mean/JJ alosetron/NN plasma/NN concentrations/NNS (/-LRB- AUC/NN )/-RRB- approximately/RB 6-fold/RB and/CC prolonged/VBD the/DT half-life/NN by/IN approximately/RB 3-fold/RB ./.


DrugDDI.d450
DrugDDI.d450.s4
Concomitant administration of alosetron and fluvoxamine is contraindicated.

Concomitant/JJ administration/NN of/IN alosetron/NN and/CC fluvoxamine/NN is/VBZ contraindicated/VBN ./.


DrugDDI.d450
DrugDDI.d450.s5
Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotic s and cimetidine , has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.

Concomitant/JJ administration/NN of/IN alosetron/NN and/CC moderate/JJ CYP1A2/NN inhibitors/NNS ,/, including/VBG quinolone/NN antibiotic/JJ s/NN and/CC cimetidine/NN ,/, has/VBZ not/RB been/VBN evaluated/VBN ,/, but/CC should/MD be/VB avoided/VBN unless/IN clinically/RB necessary/JJ because/IN of/IN similar/JJ potential/JJ drug/NN interactions/NNS ./.


DrugDDI.d450
DrugDDI.d450.s6
Ketoconazole is a known strong inhibitor of CYP3A4 .

Ketoconazole/NN is/VBZ a/DT known/JJ strong/JJ inhibitor/NN of/IN CYP3A4/NN ./.


DrugDDI.d450
DrugDDI.d450.s7
In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.

In/IN a/DT pharmacokinetic/JJ study/NN ,/, 38/CD healthy/JJ female/JJ subjects/NNS received/VBD ketoconazole/NN 200/CD mg/NN twice/RB daily/JJ for/IN 7/CD days/NNS ,/, with/IN coadministration/NN of/IN alosetron/NN 1/CD mg/NN on/IN the/DT last/JJ day/NN ./.


DrugDDI.d450
DrugDDI.d450.s8
Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.

Ketoconazole/NN increased/VBD mean/JJ alosetron/NN plasma/NN concentrations/NNS (/-LRB- AUC/NN )/-RRB- by/IN 29/CD %./NN


DrugDDI.d450
DrugDDI.d450.s9
Caution should be used when alosetron and ketoconazole are administered concomitantly.

Caution/NN should/MD be/VB used/VBN when/WRB alosetron/NN and/CC ketoconazole/NN are/VBP administered/VBN concomitantly/RB ./.


DrugDDI.d450
DrugDDI.d450.s10
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin , telithromycin , protease inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.

Coadministration/NN of/IN alosetron/JJ and/CC strong/JJ CYP3A4/JJ inhibitors/NNS ,/, such/JJ as/IN clarithromycin/NN ,/, telithromycin/NN ,/, protease/NN inhibitors/NNS ,/, voriconazole/NN ,/, and/CC itraconazole/NN has/VBZ not/RB been/VBN evaluated/VBN but/CC should/MD be/VB undertaken/VBN with/IN caution/NN because/IN of/IN similar/JJ potential/JJ drug/NN interactions/NNS ./.


DrugDDI.d450
DrugDDI.d450.s11
The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.

The/DT effect/NN of/IN induction/NN or/CC inhibition/NN of/IN other/JJ pathways/NNS on/IN exposure/NN to/TO alosetron/NN and/CC its/PRP$ metabolites/NNS is/VBZ not/RB known/VBN ./.


DrugDDI.d450
DrugDDI.d450.s12
In vitro human liver microsome studies and an in vivo metabolic probe study demonstrated that alosetron did not inhibit CYP enzyme s 2D6, 3A4, 2C9, or 2C19.

In/FW vitro/FW human/JJ liver/NN microsome/NN studies/NNS and/CC an/DT in/FW vivo/FW metabolic/JJ probe/NN study/NN demonstrated/VBD that/IN alosetron/NN did/VBD not/RB inhibit/VB CYP/NN enzyme/NN s/NN 2D6/NN ,/, 3A4/NN ,/, 2C9/NN ,/, or/CC 2C19/NN ./.


DrugDDI.d450
DrugDDI.d450.s13
In vitro, at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1-mg dosage, alosetron inhibited CYP enzyme s 1A2 (60%) and 2E1 (50%).

In/FW vitro/FW ,/, at/IN total/JJ drug/NN concentrations/NNS 27-fold/RB higher/JJR than/IN peak/NN plasma/NN concentrations/NNS observed/VBN with/IN the/DT 1-mg/JJ dosage/NN ,/, alosetron/NN inhibited/VBD CYP/NN enzyme/NN s/NN 1A2/NN (/-LRB- 60/CD %/NN )/-RRB- and/CC 2E1/NN (/-LRB- 50%)./NN


DrugDDI.d450
DrugDDI.d450.s14
In an in vivo metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase .

In/IN an/DT in/FW vivo/FW metabolic/JJ probe/NN study/NN ,/, alosetron/NN did/VBD not/RB inhibit/VB CYP2E1/NN but/CC did/VBD produce/VB 30/CD %/NN inhibition/NN of/IN both/CC CYP1A2/NN and/CC N-acetyltransferase/NN ./.


DrugDDI.d450
DrugDDI.d450.s15
Although not studied with alosetron , inhibition of N- acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , procainamide , and hydralazine .

Although/IN not/RB studied/VBN with/IN alosetron/NN ,/, inhibition/NN of/IN N-/NN acetyltransferase/NN may/MD have/VB clinically/RB relevant/JJ consequences/NNS for/IN drugs/NNS such/JJ as/IN isoniazid/NN ,/, procainamide/NN ,/, and/CC hydralazine/NN ./.


DrugDDI.d450
DrugDDI.d450.s16
The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed.

The/DT effect/NN on/IN CYP1A2/NN was/VBD explored/VBN further/RB in/IN a/DT clinical/JJ interaction/NN study/NN with/IN theophylline/NN and/CC no/DT effect/NN on/IN metabolism/NN was/VBD observed/VBN ./.


DrugDDI.d450
DrugDDI.d450.s17
Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agent s ethinyl estradiol and levonorgestrel ( CYP3A4 substrates).

Another/DT study/NN showed/VBD that/IN alosetron/NN had/VBD no/DT clinically/RB significant/JJ effect/NN on/IN plasma/NN concentrations/NNS of/IN the/DT oral/JJ contraceptive/JJ agent/NN s/NN ethinyl/NN estradiol/NN and/CC levonorgestrel/NN (/-LRB- CYP3A4/NN substrates/NNS )./CD


DrugDDI.d450
DrugDDI.d450.s18
A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride .

A/DT clinical/JJ interaction/NN study/NN was/VBD also/RB conducted/VBN with/IN alosetron/NN and/CC the/DT CYP3A4/NN substrate/NN cisapride/NN ./.


DrugDDI.d450
DrugDDI.d450.s19
No significant effects on cisapride metabolism or QT interval were noted.

No/DT significant/JJ effects/NNS on/IN cisapride/NN metabolism/NN or/CC QT/NN interval/NN were/VBD noted/VBN ./.


DrugDDI.d450
DrugDDI.d450.s20
The effect of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined.

The/DT effect/NN of/IN alosetron/NN on/IN monoamine/NN oxidases/NNS and/CC on/IN intestinal/JJ first/JJ pass/NN secondary/JJ to/TO high/JJ intraluminal/JJ concentrations/NNS have/VBP not/RB been/VBN examined/VBN ./.


DrugDDI.d450
DrugDDI.d450.s21
Based on the above data from in vitro and in vivo studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the major CYP enzyme 3A4, as well as the CYP enzyme s 2D6, 2C9, 2C19, 2E1, or 1A2.

Based/VBN on/IN the/DT above/JJ data/NNS from/IN in/FW vitro/FW and/CC in/FW vivo/FW studies/NNS ,/, it/PRP is/VBZ unlikely/JJ that/IN alosetron/NN will/MD inhibit/VB the/DT hepatic/JJ metabolic/JJ clearance/NN of/IN drugs/NNS metabolized/VBN by/IN the/DT major/JJ CYP/NN enzyme/NN 3A4/NN ,/, as/RB well/RB as/IN the/DT CYP/NN enzyme/NN s/NN 2D6/NN ,/, 2C9/NN ,/, 2C19/NN ,/, 2E1/NN ,/, or/CC 1A2/NN ./.


DrugDDI.d450
DrugDDI.d450.s22
Alosetron does not appear to induce the major cytochrome P450 ( CYP ) drug metabolizing enzyme 3A.

Alosetron/NN does/VBZ not/RB appear/VB to/TO induce/VB the/DT major/JJ cytochrome/NN P450/NN (/-LRB- CYP/NN )/-RRB- drug/NN metabolizing/NN enzyme/NN 3A/NN ./.


DrugDDI.d450
DrugDDI.d450.s23
Alosetron also does not appear to induce CYP enzyme s 2E1 or 2C19.

Alosetron/NN also/RB does/VBZ not/RB appear/VB to/TO induce/VB CYP/NN enzyme/NN s/NNS 2E1/NN or/CC 2C19/NN ./.


DrugDDI.d450
DrugDDI.d450.s24
It is not known whether alosetron might induce other enzymes.

It/PRP is/VBZ not/RB known/VBN whether/IN alosetron/NN might/MD induce/VBP other/JJ enzymes/NNS ./.


DrugDDI.d503
DrugDDI.d503.s0
The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.

The/DT interaction/NN of/IN Activase/NN with/IN other/JJ cardioactive/JJ or/CC cerebroactive/JJ drugs/NNS has/VBZ not/RB been/VBN studied/VBN ./.


DrugDDI.d503
DrugDDI.d503.s1
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.

In/IN addition/NN to/TO bleeding/JJ associated/VBN with/IN heparin/NN and/CC vitamin/NN K/NN antagonists/NNS ,/, drugs/NNS that/WDT alter/VBP platelet/NN function/NN (/-LRB- such/JJ as/IN acetylsalicylic/JJ acid/NN ,/, dipyridamole/NN and/CC Abciximab/NN )/-RRB- may/MD increase/VB the/DT risk/NN of/IN bleeding/JJ if/IN administered/VBN prior/RB to/TO ,/, during/IN ,/, or/CC after/IN Activase/NN therapy/NN ./.


DrugDDI.d503
DrugDDI.d503.s2
Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.

Use/NN of/IN Antithrombotics/NN Aspirin/NN and/CC heparin/NN have/VBP been/VBN administered/VBN concomitantly/RB with/IN and/CC following/VBG infusions/NNS of/IN Activase/NN in/IN the/DT management/NN of/IN acute/JJ myocardial/JJ infarction/NN or/CC pulmonary/JJ embolism/NN ./.


DrugDDI.d503
DrugDDI.d503.s3
Because heparin , aspirin , or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.

Because/IN heparin/NN ,/, aspirin/NN ,/, or/CC Activase/NN may/MD cause/VB bleeding/JJ complications/NNS ,/, careful/JJ monitoring/NN for/IN bleeding/JJ is/VBZ advised/JJ ,/, especially/RB at/IN arterial/JJ puncture/NN sites/NNS ./.


DrugDDI.d503
DrugDDI.d503.s4
The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibit ed in The NINDS t-PA Stroke Trial.

The/DT concomitant/JJ use/NN of/IN heparin/NN or/CC aspirin/NN during/IN the/DT first/JJ 24/CD hours/NNS following/VBG symptom/NN onset/NN were/VBD prohibit/VB ed/NN in/IN The/DT NINDS/NN t-PA/NN Stroke/JJ Trial/NN ./.


DrugDDI.d503
DrugDDI.d503.s5
The safety of such concomitant use with Activase for the management of acute ischemic stroke is unknown.

The/DT safety/NN of/IN such/JJ concomitant/JJ use/NN with/IN Activase/NN for/IN the/DT management/NN of/IN acute/JJ ischemic/JJ stroke/NN is/VBZ unknown/JJ ./.


DrugDDI.d0
DrugDDI.d0.s0
Special consideration should be given to the administration of ETHYOL@ in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.

Special/JJ consideration/NN should/MD be/VB given/VBN to/TO the/DT administration/NN of/IN ETHYOL/NN @/NN in/IN patients/NNS receiving/VBG antihypertensive/JJ medications/NNS or/CC other/JJ drugs/NNS that/WDT could/MD cause/VB or/CC potentiate/VB hypotension/NN ./.


DrugDDI.d153
DrugDDI.d153.s0
Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides , procaine , or thiazolesulfone.

Renal/JJ clearance/NN measurements/NNS of/IN PAH/NN cannot/MD be/VB made/VBN with/IN any/DT significant/JJ accuracy/NN in/IN patients/NNS receiving/VBG sulfonamides/NNS ,/, procaine/NN ,/, or/CC thiazolesulfone/NN ./.


DrugDDI.d153
DrugDDI.d153.s2
Probenecid depresses tubular secretion of certain weak acids such as PAH.

Probenecid/NN depresses/VBZ tubular/JJ secretion/NN of/IN certain/JJ weak/JJ acids/NNS such/JJ as/IN PAH/NN ./.


DrugDDI.d153
DrugDDI.d153.s3
Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.

Therefore/RB ,/, patients/NNS receiving/VBG probenecid/NN will/MD have/VB erroneously/RB low/JJ ERPF/NN and/CC Tm/NN PAH/NN values/NNS ./.


DrugDDI.d342
DrugDDI.d342.s0
Aminosalicylic acid may decrease the amount of digoxin ( Lanoxin , Lanoxicaps ) that gets absorbed into your body.

Aminosalicylic/JJ acid/NN may/MD decrease/VB the/DT amount/NN of/IN digoxin/NN (/-LRB- Lanoxin/NNP ,/, Lanoxicaps/NNP )/-RRB- that/WDT gets/VBZ absorbed/VBN into/IN your/JJ body/NN ./.


DrugDDI.d342
DrugDDI.d342.s1
In the case that you are taking digoxin while taking aminosalicylic acid , higher doses of digoxin may be needed.

In/IN the/DT case/NN that/WDT you/RB are/VBP taking/VBG digoxin/NN while/IN taking/VBG aminosalicylic/JJ acid/NN ,/, higher/JJR doses/NNS of/IN digoxin/NN may/MD be/VB needed/VBN ./.


DrugDDI.d342
DrugDDI.d342.s2
Aminosalicylic acid may also decrease the absorption of vitamin B12 , which can lead to a deficiency.

Aminosalicylic/JJ acid/NN may/MD also/RB decrease/VB the/DT absorption/NN of/IN vitamin/NN B12/NN ,/, which/WDT can/MD lead/VB to/TO a/NN deficiency/NN ./.


DrugDDI.d342
DrugDDI.d342.s3
Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid .

Therefore/RB you/NN may/MD need/VBP to/TO take/VB a/DT vitamin/NN B12/NN supplement/NN while/IN taking/VBG aminosalicylic/JJ acid/NN ./.


DrugDDI.d63
DrugDDI.d63.s0
Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 ( CYP3A4 ) and CYP2C8 .

Amiodarone/NN is/VBZ metabolized/VBN to/TO desethylamiodarone/NN by/IN the/DT cytochrome/NN P450/NN (/-LRB- CYP450/NN )/-RRB- enzyme/NN group/NN ,/, specifically/RB cytochromes/NN P450/NN 3A4/NN (/-LRB- CYP3A4/NN )/-RRB- and/CC CYP2C8/NN ./.


DrugDDI.d63
DrugDDI.d63.s1
The CYP3A4 isoenzyme is present in both the liver and intestines.

The/DT CYP3A4/NN isoenzyme/NN is/VBZ present/JJ in/IN both/CC the/DT liver/NN and/CC intestines/NNS ./.


DrugDDI.d63
DrugDDI.d63.s2
Amiodarone is also known to be an inhibitor of CYP3A4 .

Amiodarone/NN is/VBZ also/RB known/VBN to/TO be/VB an/DT inhibitor/NN of/IN CYP3A4/NN ./.


DrugDDI.d63
DrugDDI.d63.s3
Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4 .

Therefore/RB ,/, amiodarone/NN has/VBZ the/DT potential/NN for/IN interactions/NNS with/IN drugs/NNS or/CC substances/NNS that/WDT may/MD be/VB substrates/NNS ,/, inhibitors/NNS or/CC inducers/NNS of/IN CYP3A4/NN ./.


DrugDDI.d63
DrugDDI.d63.s4
While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, chiefly with the oral formulation, the potential for other interactions should be anticipated.

While/IN only/RB a/DT limited/JJ number/NN of/IN in/FW vivo/FW drug-drug/JJ interactions/NNS with/IN amiodarone/NN have/VBP been/VBN reported/VBN ,/, chiefly/RB with/IN the/DT oral/JJ formulation/NN ,/, the/DT potential/NN for/IN other/JJ interactions/NNS should/MD be/VB anticipated/VBN ./.


DrugDDI.d63
DrugDDI.d63.s5
This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics .

This/DT is/VBZ especially/RB important/JJ for/IN drugs/NNS associated/VBN with/IN serious/JJ toxicity/NN ,/, such/JJ as/IN other/JJ antiarrhythmics/NNS ./.


DrugDDI.d63
DrugDDI.d63.s6
If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured.

If/IN such/JJ drugs/NNS are/VBP needed/VBN ,/, their/PRP$ dose/NN should/MD be/VB reassessed/VBN and/CC ,/, where/WRB appropriate/JJ ,/, plasma/NN concentration/NN measured/VBN ./.


DrugDDI.d63
DrugDDI.d63.s7
In view of the long and variable half-life of amiodarone , potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone .

In/IN view/NN of/IN the/DT long/JJ and/CC variable/JJ half-life/NN of/IN amiodarone/NN ,/, potential/NN for/IN drug/NN interactions/NNS exists/VBZ not/RB only/RB with/IN concomitant/JJ medication/NN but/CC also/RB with/IN drugs/NNS administered/VBN after/IN discontinuation/NN of/IN amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s8
Since amiodarone is a substrate for CYP3A4 and CYP2C8 , drugs /substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone .

Since/IN amiodarone/NN is/VBZ a/DT substrate/NN for/IN CYP3A4/NN and/CC CYP2C8/NN ,/, drugs/NNS /substances/NNS that/WDT inhibit/VBP these/DT isoenzymes/NNS may/MD decrease/VB the/DT metabolism/NN and/CC increase/VB serum/NN concentration/NN of/IN amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s9
Reported examples include the following: Protease Inhibitors : Protease inhibitors are known to inhibit CYP3A4 to varying degrees.

Reported/VBN examples/NNS include/VBP the/DT following/NN :/: Protease/NN Inhibitors/NNS :/: Protease/NN inhibitors/NNS are/VBP known/VBN to/TO inhibit/VB CYP3A4/NN to/TO varying/VBG degrees/NNS ./.


DrugDDI.d63
DrugDDI.d63.s10
A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.

A/DT case/NN report/NN of/IN one/CD patient/NN taking/VBG amiodarone/NN 200/CD mg/NN and/CC indinavir/NN 800/CD mg/NN three/CD times/NNS a/DT day/NN resulted/VBD in/IN increases/NNS in/IN amiodarone/NN concentrations/NNS from/IN 0.9/CD mg/L/NN to/TO 1.3/CD mg/L/NN ./.


DrugDDI.d63
DrugDDI.d63.s13
Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.

Monitoring/NN for/IN amiodarone/NN toxicity/NN and/CC serial/JJ measurement/NN of/IN amiodarone/NN serum/NN concentration/NN during/IN concomitant/JJ protease/NN inhibitor/NN therapy/NN should/MD be/VB considered/VBN ./.


DrugDDI.d63
DrugDDI.d63.s14
Histamine H2 antagonists : Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.

Histamine/NN H2/NN antagonists/NNS :/: Cimetidine/NN inhibits/VBZ CYP3A4/NN and/CC can/MD increase/VB serum/NN amiodarone/NN levels/NNS ./.


DrugDDI.d63
DrugDDI.d63.s15
Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone .

Other/JJ substances/NNS :/: Grapefruit/NN juice/NN given/VBN to/TO healthy/JJ volunteers/NNS increased/VBD amiodarone/NN AUC/NN by/IN 50/CD %/NN and/CC Cmax/NN by/IN 84/CD %/NN ,/, resulting/VBG in/IN increased/VBN plasma/NN levels/NNS of/IN amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s16
Grapefruit juice should not be taken during treatment with oral amiodarone .

Grapefruit/NN juice/NN should/MD not/RB be/VB taken/VBN during/IN treatment/NN with/IN oral/JJ amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s17
This information should be considered when changing from intravenous amiodarone to oral amiodarone .

This/DT information/NN should/MD be/VB considered/VBN when/WRB changing/VBG from/IN intravenous/JJ amiodarone/NN to/TO oral/JJ amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s18
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2 , CYP2C9 , CYP2D6 , and CYP3A4 .

Amiodarone/NN may/MD suppress/VBP certain/JJ CYP450/NN enzymes/NNS ,/, including/VBG CYP1A2/NN ,/, CYP2C9/NN ,/, CYP2D6/NN ,/, and/CC CYP3A4/NN ./.


DrugDDI.d63
DrugDDI.d63.s19
This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes.

This/DT inhibition/NN can/MD result/VB in/IN unexpectedly/RB high/JJ plasma/NN levels/NNS of/IN other/JJ drugs/NNS which/WDT are/VBP metabolized/VBN by/IN those/DT CYP450/CD enzymes/NNS ./.


DrugDDI.d63
DrugDDI.d63.s20
Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine .

Reported/VBN examples/NNS of/IN this/DT interaction/NN include/VBP the/DT following/NN :/: Immunosuppressive/JJ s/NN :/: Cyclosporine/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- administered/VBN in/IN combination/NN with/IN oral/JJ amiodarone/NN has/VBZ been/VBN reported/VBN to/TO produce/VB persistently/RB elevated/JJ plasma/NN concentrations/NNS of/IN cyclosporine/NN resulting/VBG in/IN elevated/JJ creatinine/NN ,/, despite/IN reduction/NN in/IN dose/NN of/IN cyclosporine/NN ./.


DrugDDI.d63
DrugDDI.d63.s21
HMG-CoA Reductase Inhibitors : Simvastatin ( CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.

HMG-CoA/NN Reductase/NN Inhibitors/NNS :/: Simvastatin/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- in/IN combination/NN with/IN amiodarone/NN has/VBZ been/VBN associated/VBN with/IN reports/NNS of/IN myopathy/rhabdomyolysis/NN ./.


DrugDDI.d63
DrugDDI.d63.s22
Cardiovasculars: Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.

Cardiovasculars/NN :/: Cardiac/JJ glycosides/NNS :/: In/IN patients/NNS receiving/VBG digoxin/NN therapy/NN ,/, administration/NN of/IN oral/JJ amiodarone/NN regularly/RB results/VBZ in/IN an/DT increase/NN in/IN serum/NN digoxin/NN concentration/NN that/WDT may/MD reach/VB toxic/JJ levels/NNS with/IN resultant/JJ clinical/JJ toxicity/NN ./.


DrugDDI.d63
DrugDDI.d63.s23
Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.

Amiodarone/NN taken/VBN concomitantly/RB with/IN digoxin/NN increases/VBZ the/DT serum/NN digoxin/NN concentration/NN by/IN 70/CD %/NN after/IN one/CD day/NN ./.


DrugDDI.d63
DrugDDI.d63.s24
On administration of oral amiodarone , the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.

On/IN administration/NN of/IN oral/JJ amiodarone/NN ,/, the/DT need/NN for/IN digitalis/NN therapy/NN should/MD be/VB reviewed/VBN and/CC the/DT dose/NN reduced/VBD by/IN approximately/RB 50/CD %/NN or/CC discontinued/VBD ./.


DrugDDI.d63
DrugDDI.d63.s25
If digitalis treatment is continued, serum levels should be closely monitored and patients observed for clinical evidence of toxicity.

If/IN digitalis/NN treatment/NN is/VBZ continued/VBN ,/, serum/NN levels/NNS should/MD be/VB closely/RB monitored/VBN and/CC patients/NNS observed/VBN for/IN clinical/JJ evidence/NN of/IN toxicity/NN ./.


DrugDDI.d63
DrugDDI.d63.s26
These precautions probably should apply to digitoxin administration as well.

These/DT precautions/NNS probably/RB should/MD apply/VB to/TO digitoxin/NN administration/NN as/IN well/NN ./.


DrugDDI.d63
DrugDDI.d63.s27
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone .

Antiarrhythmics/NNS :/: Other/JJ antiarrhythmic/JJ drugs/NNS ,/, such/JJ as/IN quinidine/NN ,/, procainamide/NN ,/, disopyramide/NN ,/, and/CC phenytoin/NN ,/, have/VBP been/VBN used/VBN concurrently/RB with/IN amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s28
There have been case reports of increased steady-state levels of quinidine , procainamide , and phenytoin during concomitant therapy with amiodarone .

There/EX have/VBP been/VBN case/NN reports/NNS of/IN increased/VBN steady-state/JJ levels/NNS of/IN quinidine/NN ,/, procainamide/NN ,/, and/CC phenytoin/NN during/IN concomitant/JJ therapy/NN with/IN amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s29
Phenytoin decreases serum amiodarone levels.

Phenytoin/NN decreases/VBZ serum/NN amiodarone/NN levels/NNS ./.


DrugDDI.d63
DrugDDI.d63.s30
Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.

Amiodarone/NN taken/VBN concomitantly/RB with/IN quinidine/NN increases/VBZ quinidine/NN serum/NN concentration/NN by/IN 33/CD %/NN after/IN two/CD days/NNS ./.


DrugDDI.d63
DrugDDI.d63.s31
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.

Amiodarone/NN taken/VBN concomitantly/RB with/IN procainamide/NN for/IN less/JJR than/IN seven/CD days/NNS increases/VBZ plasma/NN concentrations/NNS of/IN procainamide/NN and/CC n-acetyl/JJ procainamide/NN by/IN 55/CD %/NN and/CC 33/CD %/NN ,/, respectively/RB ./.


DrugDDI.d63
DrugDDI.d63.s32
Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone .

Quinidine/NN and/CC procainamide/NN doses/NNS should/MD be/VB reduced/VBN by/IN one-third/CD when/WRB either/DT is/VBZ administered/VBN with/IN amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s33
Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone ; .

Plasma/NN levels/NNS of/IN flecainide/NN have/VBP been/VBN reported/VBN to/TO increase/VB in/IN the/DT presence/NN of/IN oral/JJ amiodarone/NN ;/: ./.


DrugDDI.d63
DrugDDI.d63.s34
because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.

because/IN of/IN this/DT ,/, the/DT dosage/NN of/IN flecainide/NN should/MD be/VB adjusted/VBN when/WRB these/DT drugs/NNS are/VBP administered/VBN concomitantly/RB ./.


DrugDDI.d63
DrugDDI.d63.s35
In general, any added antiarrhythmic drug should be initiated at a lower than usual dose with careful monitoring.

In/IN general/JJ ,/, any/DT added/VBN antiarrhythmic/JJ drug/NN should/MD be/VB initiated/VBN at/IN a/DT lower/JJR than/IN usual/JJ dose/NN with/IN careful/JJ monitoring/NN ./.


DrugDDI.d63
DrugDDI.d63.s36
Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone .

Combination/NN of/IN amiodarone/NN with/IN other/JJ antiarrhythmic/JJ therapy/NN should/MD be/VB reserved/VBN for/IN patients/NNS with/IN life-threatening/JJ ventricular/JJ arrhythmias/NNS who/WP are/VBP incompletely/RB responsive/JJ to/TO a/DT single/JJ agent/NN or/CC incompletely/RB responsive/JJ to/TO amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s37
During transfer to oral amiodarone , the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone .

During/IN transfer/NN to/TO oral/JJ amiodarone/NN ,/, the/DT dose/NN levels/NNS of/IN previously/RB administered/VBN agents/NNS should/MD be/VB reduced/VBN by/IN 30/CD to/TO 50/CD %/NN several/JJ days/NNS after/IN the/DT addition/NN of/IN oral/JJ amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s38
The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.

The/DT continued/JJ need/NN for/IN the/DT other/JJ antiarrhythmic/JJ agent/NN should/MD be/VB reviewed/VBN after/IN the/DT effects/NNS of/IN amiodarone/NN have/VBP been/VBN established/VBN ,/, and/CC discontinuation/NN ordinarily/RB should/MD be/VB attempted/VBN ./.


DrugDDI.d63
DrugDDI.d63.s39
If the treatment is continued, these patients should be particularly carefully monitored for adverse effects, especially conduction disturbances and exacerbation of tachyarrhythmias, as amiodarone is continued.

If/IN the/DT treatment/NN is/VBZ continued/VBN ,/, these/DT patients/NNS should/MD be/VB particularly/RB carefully/RB monitored/VBN for/IN adverse/JJ effects/NNS ,/, especially/RB conduction/NN disturbances/NNS and/CC exacerbation/NN of/IN tachyarrhythmias/NN ,/, as/IN amiodarone/NN is/VBZ continued/VBN ./.


DrugDDI.d63
DrugDDI.d63.s40
In amiodarone -treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.

In/IN amiodarone/NN -treated/JJ patients/NNS who/WP require/VBP additional/JJ antiarrhythmic/NN therapy/NN ,/, the/DT initial/JJ dose/NN of/IN such/JJ agents/NNS should/MD be/VB approximately/RB half/NN of/IN the/DT usual/JJ recommended/VBN dose/NN ./.


DrugDDI.d63
DrugDDI.d63.s41
Antihypertensives : Amiodarone should be used with caution in patients receiving @- receptor blocking agents (e.g., propranolol , a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block; .

Antihypertensives/NNS :/: Amiodarone/NN should/MD be/VB used/VBN with/IN caution/NN in/IN patients/NNS receiving/VBG @/NN -/CC receptor/NN blocking/NN agents/NNS (/-LRB- e.g./FW ,/, propranolol/NN ,/, a/DT CYP3A4/NN inhibitor/NN )/-RRB- or/CC calcium/NN channel/NN antagonists/NNS (/-LRB- e.g./FW ,/, verapamil/NN ,/, a/DT CYP3A4/NN substrate/NN ,/, and/CC diltiazem/NN ,/, a/DT CYP3A4/NN inhibitor/NN )/-RRB- because/IN of/IN the/DT possible/JJ potentiation/NN of/IN bradycardia/NN ,/, sinus/NN arrest/NN ,/, and/CC AV/NN block/NN ;/: ./.


DrugDDI.d63
DrugDDI.d63.s42
if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.

if/IN necessary/JJ ,/, amiodarone/NN can/MD continue/VBP to/TO be/VB used/VBN after/IN insertion/NN of/IN a/DT pacemaker/NN in/IN patients/NNS with/IN severe/JJ bradycardia/NN or/CC sinus/NN arrest/NN ./.


DrugDDI.d63
DrugDDI.d63.s43
Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.

Anticoagulants/NNS :/: Potentiation/NN of/IN warfarin/NN -type/JJ (/-LRB- CYP2C9/NN and/CC CYP3A4/NN substrate/NN )/-RRB- anticoagulant/NN response/NN is/VBZ almost/RB always/RB seen/VBN in/IN patients/NNS receiving/VBG amiodarone/NN and/CC can/MD result/VB in/IN serious/JJ or/CC fatal/JJ bleeding/JJ ./.


DrugDDI.d63
DrugDDI.d63.s44
Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.

Since/IN the/DT concomitant/JJ administration/NN of/IN warfarin/NN with/IN amiodarone/NN increases/VBZ the/DT prothrombin/NN time/NN by/IN 100/CD %/NN after/IN 3/CD to/TO 4/CD days/NNS ,/, the/DT dose/NN of/IN the/DT anticoagulant/NN should/MD be/VB reduced/VBN by/IN one-third/CD to/TO one-half/NN ,/, and/CC prothrombin/NN times/NNS should/MD be/VB monitored/VBN closely/RB ./.


DrugDDI.d63
DrugDDI.d63.s45
Some drugs /substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).

Some/DT drugs/NNS /substances/RB are/VBP known/VBN to/TO accelerate/VB the/DT metabolism/NN of/IN amiodarone/NN by/IN stimulating/VBG the/DT synthesis/NN of/IN CYP3A4/NN (/-LRB- enzyme/NN induction/NN )./NN


DrugDDI.d63
DrugDDI.d63.s46
This may lead to low amiodarone serum levels and potential decrease in efficacy.

This/DT may/MD lead/VB to/TO low/JJ amiodarone/NN serum/NN levels/NNS and/CC potential/JJ decrease/NN in/IN efficacy/NN ./.


DrugDDI.d63
DrugDDI.d63.s47
Reported examples of this interaction include the following: Antibiotics : Rifampin is a potent inducer of CYP3A4 .

Reported/VBN examples/NNS of/IN this/DT interaction/NN include/VBP the/DT following/NN :/: Antibiotics/NNS :/: Rifampin/NN is/VBZ a/DT potent/JJ inducer/NN of/IN CYP3A4/NN ./.


DrugDDI.d63
DrugDDI.d63.s48
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone .

Administration/NN of/IN rifampin/NN concomitantly/RB with/IN oral/JJ amiodarone/NN has/VBZ been/VBN shown/VBN to/TO result/VB in/IN decreases/NNS in/IN serum/NN concentrations/NNS of/IN amiodarone/NN and/CC desethylamiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s49
Other substances, including herbal preparations : St. John@s Wort ( Hypericum perforatum ) induces CYP3A4 .

Other/JJ substances/NNS ,/, including/VBG herbal/NN preparations/NNS :/: St./NN John/NN @/NN s/NN Wort/NN (/-LRB- Hypericum/NN perforatum/NN )/-RRB- induces/VBZ CYP3A4/NN ./.


DrugDDI.d63
DrugDDI.d63.s50
Since amiodarone is a substrate for CYP3A4 , there is the potential that the use of St. John@s Wort in patients receiving amiodarone could result in reduced amiodarone levels.

Since/IN amiodarone/NN is/VBZ a/DT substrate/NN for/IN CYP3A4/NN ,/, there/EX is/VBZ the/DT potential/NN that/IN the/DT use/NN of/IN St./NN John/NN @/NN s/NN Wort/NN in/IN patients/NNS receiving/VBG amiodarone/NN could/MD result/VB in/IN reduced/VBN amiodarone/NN levels/NNS ./.


DrugDDI.d63
DrugDDI.d63.s51
Other reported interactions with amiodarone : Fentanyl ( CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.

Other/JJ reported/VBN interactions/NNS with/IN amiodarone/NN :/: Fentanyl/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- in/IN combination/NN with/IN amiodarone/NN may/MD cause/VB hypotension/NN ,/, bradycardia/NN ,/, and/CC decreased/VBN cardiac/JJ output/NN ./.


DrugDDI.d63
DrugDDI.d63.s52
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( CYP3A4 substrate) given for local anesthesia .

Sinus/NN bradycardia/NN has/VBZ been/VBN reported/VBN with/IN oral/JJ amiodarone/NN in/IN combination/NN with/IN lidocaine/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- given/VBN for/IN local/JJ anesthesia/NN ./.


DrugDDI.d63
DrugDDI.d63.s53
Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone .

Seizure/NN ,/, associated/VBN with/IN increased/VBN lidocaine/NN concentrations/NNS ,/, has/VBZ been/VBN reported/VBN with/IN concomitant/JJ administration/NN of/IN intravenous/JJ amiodarone/NN ./.


DrugDDI.d63
DrugDDI.d63.s54
Dextromethorphan is a substrate for both CYP2D6 and CYP3A4 .

Dextromethorphan/NN is/VBZ a/DT substrate/NN for/IN both/CC CYP2D6/NN and/CC CYP3A4/NN ./.


DrugDDI.d63
DrugDDI.d63.s55
Amiodarone inhibits CYP2D6 .

Amiodarone/NN inhibits/VBZ CYP2D6/NN ./.


DrugDDI.d63
DrugDDI.d63.s56
Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1 /2.

Cholestyramine/NN increases/VBZ enterohepatic/JJ elimination/NN of/IN amiodarone/NN and/CC may/MD reduce/VB its/PRP$ serum/NN levels/NNS and/CC t1/NN /2/CD ./.


DrugDDI.d63
DrugDDI.d63.s57
Disopyramide increases QT prolongation which could cause arrhythmia.

Disopyramide/NN increases/VBZ QT/NN prolongation/NN which/WDT could/MD cause/VB arrhythmia/NN ./.


DrugDDI.d63
DrugDDI.d63.s58
Fluoroquinolones , macrolide antibiotics , and azoles are known to cause QTc prolongation.

Fluoroquinolones/NNS ,/, macrolide/NN antibiotics/NNS ,/, and/CC azoles/NNS are/VBP known/VBN to/TO cause/VB QTc/NN prolongation/NN ./.


DrugDDI.d63
DrugDDI.d63.s59
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones , macrolide antibiotics , or azoles were administered concomitantly.

There/EX have/VBP been/VBN reports/NNS of/IN QTc/NN prolongation/NN ,/, with/IN or/CC without/IN TdP/NN ,/, in/IN patients/NNS taking/VBG amiodarone/NN when/WRB fluoroquinolones/NNS ,/, macrolide/NN antibiotics/NNS ,/, or/CC azoles/NNS were/VBD administered/VBN concomitantly/RB ./.


DrugDDI.d63
DrugDDI.d63.s60
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol , diltiazem , and verapamil .

Hemodynamic/JJ and/CC electrophysiologic/JJ interactions/NNS have/VBP also/RB been/VBN observed/VBN after/IN concomitant/JJ administration/NN with/IN propranolol/NN ,/, diltiazem/NN ,/, and/CC verapamil/NN ./.


DrugDDI.d63
DrugDDI.d63.s61
Volatile Anesthetic Agents :.

Volatile/JJ Anesthetic/JJ Agents/NNS :/: ./.


DrugDDI.d63
DrugDDI.d63.s62
In addition to the interactions noted above, chronic ( 2 weeks) oral Cordarone administration impairs metabolism of phenytoin , dextromethorphan , and methotrexate .

In/IN addition/NN to/TO the/DT interactions/NNS noted/VBN above/RB ,/, chronic/JJ (/-LRB- 2/CD weeks/NNS )/-RRB- oral/JJ Cordarone/NN administration/NN impairs/VBZ metabolism/NN of/IN phenytoin/NN ,/, dextromethorphan/NN ,/, and/CC methotrexate/NN ./.


DrugDDI.d63
DrugDDI.d63.s63
Electrolyte Disturbances Patients with hypokalemia or hypomagnesemia should have the condition corrected whenever possible before being treated with Cordarone I.V. , as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP.

Electrolyte/NN Disturbances/NNS Patients/NNS with/IN hypokalemia/NN or/CC hypomagnesemia/NN should/MD have/VB the/DT condition/NN corrected/VBN whenever/NN possible/JJ before/IN being/VBG treated/VBN with/IN Cordarone/NN I.V./NN ,/, as/IN these/DT disorders/NNS can/MD exaggerate/VB the/DT degree/NN of/IN QTc/NN prolongation/NN and/CC increase/VB the/DT potential/NN for/IN TdP/NN ./.


DrugDDI.d63
DrugDDI.d63.s64
Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics .

Special/JJ attention/NN should/MD be/VB given/VBN to/TO electrolyte/NN and/CC acid-base/NN balance/NN in/IN patients/NNS experiencing/VBG severe/JJ or/CC prolonged/JJ diarrhea/NN or/CC in/IN patients/NNS receiving/VBG concomitant/JJ diuretics/NNS ./.


DrugDDI.d539
DrugDDI.d539.s0
In vitro data indicate that NORVASC has no effect on the human plasma protein binding of digoxin , phenytoin , warfarin , and indomethacin .

In/FW vitro/FW data/NNS indicate/VBP that/IN NORVASC/NN has/VBZ no/DT effect/NN on/IN the/DT human/JJ plasma/NN protein/NN binding/NN of/IN digoxin/NN ,/, phenytoin/NN ,/, warfarin/NN ,/, and/CC indomethacin/NN ./.


DrugDDI.d539
DrugDDI.d539.s1
Effect of other agents on NORVASC .

Effect/NN of/IN other/JJ agents/NNS on/IN NORVASC/NN ./.


DrugDDI.d539
DrugDDI.d539.s2
CIMETIDINE : Co-administration of NORVASC with cimetidine did not alter the pharmacokinetics of NORVASC .

CIMETIDINE/NN :/: Co-administration/NN of/IN NORVASC/NN with/IN cimetidine/NN did/VBD not/RB alter/VB the/DT pharmacokinetics/NNS of/IN NORVASC/NN ./.


DrugDDI.d539
DrugDDI.d539.s3
GRAPEFRUIT JUICE: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine .

GRAPEFRUIT/NN JUICE/NN :/: Co-administration/NN of/IN 240/CD mL/NN of/IN grapefruit/NN juice/NN with/IN a/DT single/JJ oral/JJ dose/NN of/IN amlodipine/NN 10/CD mg/NN in/IN 20/CD healthy/JJ volunteers/NNS had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN amlodipine/NN ./.


DrugDDI.d539
DrugDDI.d539.s4
MAALOX ( antacid ): Co-administration of the antacid Maalox with a single dose of NORVASC had no significant effect on the pharmacokinetics of NORVASC .

MAALOX/NN (/-LRB- antacid/JJ )/-RRB- :/: Co-administration/NN of/IN the/DT antacid/JJ Maalox/NN with/IN a/DT single/JJ dose/NN of/IN NORVASC/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN NORVASC/NN ./.


DrugDDI.d539
DrugDDI.d539.s5
SILDENAFIL : A single 100 mg dose of sildenafil (Viagra@) in subjects with essential hypertension had no effect on the pharmacokinetic parameters of NORVASC .

SILDENAFIL/NN :/: A/DT single/JJ 100/CD mg/NN dose/NN of/IN sildenafil/NN (/-LRB- Viagra/NN @/NN )/-RRB- in/IN subjects/NNS with/IN essential/JJ hypertension/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetic/JJ parameters/NNS of/IN NORVASC/NN ./.


DrugDDI.d539
DrugDDI.d539.s6
When NORVASC and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.

When/WRB NORVASC/NN and/CC sildenafil/NN were/VBD used/VBN in/IN combination/NN ,/, each/DT agent/NN independently/RB exerted/VBD its/PRP$ own/JJ blood/NN pressure/NN lowering/JJ effect/NN ./.


DrugDDI.d539
DrugDDI.d539.s7
Effect of NORVASC on other agents.

Effect/NN of/IN NORVASC/NN on/IN other/JJ agents/NNS ./.


DrugDDI.d539
DrugDDI.d539.s8
ATORVASTATIN : Co-administration of multiple 10 mg doses of NORVASC with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin .

ATORVASTATIN/NN :/: Co-administration/NN of/IN multiple/JJ 10/CD mg/NN doses/NNS of/IN NORVASC/NN with/IN 80/CD mg/NN of/IN atorvastatin/NN resulted/VBD in/IN no/DT significant/JJ change/NN in/IN the/DT steady/JJ state/NN pharmacokinetic/JJ parameters/NNS of/IN atorvastatin/NN ./.


DrugDDI.d539
DrugDDI.d539.s9
DIGOXIN : Co-administration of NORVASC with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.

DIGOXIN/NN :/: Co-administration/NN of/IN NORVASC/NN with/IN digoxin/NN did/VBD not/RB change/VB serum/NN digoxin/NN levels/NNS or/CC digoxin/NN renal/JJ clearance/NN in/IN normal/JJ volunteers/NNS ./.


DrugDDI.d539
DrugDDI.d539.s10
ETHANOL ( alcohol ): Single and multiple 10 mg doses of NORVASC had no significant effect on the pharmacokinetics of ethanol .

ETHANOL/NN (/-LRB- alcohol/NN )/-RRB- :/: Single/JJ and/CC multiple/JJ 10/CD mg/NN doses/NNS of/IN NORVASC/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN ethanol/NN ./.


DrugDDI.d539
DrugDDI.d539.s11
WARFARIN : Co-administration of NORVASC with warfarin did not change the warfarin prothrombin response time.

WARFARIN/NN :/: Co-administration/NN of/IN NORVASC/NN with/IN warfarin/NN did/VBD not/RB change/VB the/DT warfarin/NN prothrombin/NN response/NN time/NN ./.


DrugDDI.d539
DrugDDI.d539.s12
In clinical trials, NORVASC has been safely administered with thiazide diuretics , beta-blockers , angiotensin-converting enzyme inhibitors , long-acting nitrates , sublingual nitroglycerin , digoxin , warfarin , non-steroidal anti-inflammatory drugs , antibiotics , and oral hypoglycemic drugs .

In/IN clinical/JJ trials/NNS ,/, NORVASC/NN has/VBZ been/VBN safely/RB administered/VBN with/IN thiazide/NN diuretics/NNS ,/, beta-blockers/NNS ,/, angiotensin-converting/JJ enzyme/NN inhibitors/NNS ,/, long-acting/JJ nitrates/NNS ,/, sublingual/JJ nitroglycerin/NN ,/, digoxin/NN ,/, warfarin/NN ,/, non-steroidal/JJ anti-inflammatory/JJ drugs/NNS ,/, antibiotics/NNS ,/, and/CC oral/JJ hypoglycemic/JJ drugs/NNS ./.


DrugDDI.d539
DrugDDI.d539.s13
Drug /Laboratory Test Interactions: None known.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: None/NN known/VBN ./.


DrugDDI.d117
DrugDDI.d117.s0
Probenecid decreases the renal tubular secretion of amoxicillin .

Probenecid/NN decreases/VBZ the/DT renal/JJ tubular/JJ secretion/NN of/IN amoxicillin/NN ./.


DrugDDI.d117
DrugDDI.d117.s1
Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin .

Concurrent/JJ use/NN of/IN amoxicillin/NN and/CC probenecid/NN may/MD result/VB in/IN increased/VBN and/CC prolonged/JJ blood/NN levels/NNS of/IN amoxicillin/NN ./.


DrugDDI.d117
DrugDDI.d117.s2
Chloramphenicol , macrolides , sulfonamides , and tetracy-clines may interfere with the bactericidal effects of penicillin .

Chloramphenicol/NN ,/, macrolides/NN ,/, sulfonamides/NNS ,/, and/CC tetracy-clines/NNS may/MD interfere/VB with/IN the/DT bactericidal/JJ effects/NNS of/IN penicillin/NN ./.


DrugDDI.d117
DrugDDI.d117.s5
Drug /Laboratory Test Interactions: High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST@, Benedict@s Solution, or Fehling@s Solution.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: High/JJ urine/NN concentrations/NNS of/IN ampicillin/NN may/MD result/VB in/IN false-positive/JJ reactions/NNS when/WRB testing/VBG for/IN the/DT presence/NN of/IN glucose/NN in/IN urine/NN using/VBG CLINITEST/NN @/NN ,/, Benedict/NN @/NN s/NN Solution/NN ,/, or/CC Fehling/NN @/NN s/NN Solution/NN ./.


DrugDDI.d117
DrugDDI.d117.s6
Since this effect may also occur with amoxicillin , it is recommended that glucose tests based on enzymatic glucose oxi-dase reactions (such as CLINISTIX@) be used.

Since/IN this/DT effect/NN may/MD also/RB occur/VB with/IN amoxicillin/NN ,/, it/PRP is/VBZ recommended/VBN that/IN glucose/NN tests/NNS based/VBN on/IN enzymatic/JJ glucose/NN oxi-dase/NN reactions/NNS (/-LRB- such/JJ as/IN CLINISTIX/NN @/NN )/-RRB- be/VB used/VBN ./.


DrugDDI.d117
DrugDDI.d117.s7
Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol , estriol-glucuronide, conjugated estrone , and estradiol has been noted.

Following/VBG administration/NN of/IN ampicillin/NN to/TO pregnant/JJ women/NNS ,/, a/DT transient/JJ decrease/NN in/IN plasma/NN concentration/NN of/IN total/JJ conjugated/VBN estriol/NN ,/, estriol-glucuronide/NN ,/, conjugated/VBN estrone/NN ,/, and/CC estradiol/NN has/VBZ been/VBN noted/VBN ./.


DrugDDI.d117
DrugDDI.d117.s8
This effect may also occur with amoxicillin .

This/DT effect/NN may/MD also/RB occur/VB with/IN amoxicillin/NN ./.


DrugDDI.d117
DrugDDI.d117.s10
Studies to detect mutagenic potential of amoxicillin alone have not been conducted; .

Studies/NNS to/TO detect/VB mutagenic/JJ potential/NN of/IN amoxicillin/NN alone/RB have/VBP not/RB been/VBN conducted/VBN ;/: ./.


DrugDDI.d117
DrugDDI.d117.s11
however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate ( AUGMENTIN ).

however/RB ,/, the/DT following/VBG information/NN is/VBZ available/JJ from/IN tests/NNS on/IN a/DT 4:1/JJ mixture/NN of/IN amoxicillin/NN and/CC potassium/NN clavulanate/NN (/-LRB- AUGMENTIN/NN )/-RRB- ./.


DrugDDI.d117
DrugDDI.d117.s12
AUGMENTIN was non-mutagenic in the Ame s bacterial mutation assay, and the yeast gene conversion assay.

AUGMENTIN/NN was/VBD non-mutagenic/JJ in/IN the/DT Ame/NN s/NN bacterial/JJ mutation/NN assay/NN ,/, and/CC the/DT yeast/NN gene/NN conversion/NN assay/NN ./.


DrugDDI.d117
DrugDDI.d117.s13
AUGMENTIN was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival.

AUGMENTIN/NN was/VBD weakly/RB positive/JJ in/IN the/DT mouse/NN lymphoma/NN assay/NN ,/, but/CC the/DT trend/NN toward/IN increased/VBN mutation/NN frequencies/NNS in/IN this/DT assay/NN occurred/VBD at/IN doses/NNS that/WDT were/VBD also/RB associated/VBN with/IN decreased/VBN cell/NN survival/NN ./.


DrugDDI.d117
DrugDDI.d117.s14
AUGMENTIN was negative in the mouse micronucleus test, and in the dominant lethal assay in mice.

AUGMENTIN/NN was/VBD negative/JJ in/IN the/DT mouse/NN micronucleus/NN test/NN ,/, and/CC in/IN the/DT dominant/JJ lethal/JJ assay/NN in/IN mice/NNS ./.


DrugDDI.d117
DrugDDI.d117.s15
Potassium clavulanate alone was tested in the Ame s bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays.

Potassium/NN clavulanate/NN alone/RB was/VBD tested/VBN in/IN the/DT Ame/NN s/NN bacterial/JJ mutation/NN assay/NN and/CC in/IN the/DT mouse/NN micronucleus/NN test/NN ,/, and/CC was/VBD negative/JJ in/IN each/DT of/IN these/DT assays/NNS ./.


DrugDDI.d117
DrugDDI.d117.s18
Reproduction studies have been performed in mice and rats at doses up to 10 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to amoxicillin .

Reproduction/NN studies/NNS have/VBP been/VBN performed/VBN in/IN mice/NNS and/CC rats/NNS at/IN doses/NNS up/RB to/TO 10/CD times/NNS the/DT human/JJ dose/NN and/CC have/VBP revealed/VBN no/DT evidence/NN of/IN impaired/JJ fertility/NN or/CC harm/NN to/TO the/DT fetus/NN due/JJ to/TO amoxicillin/NN ./.


DrugDDI.d117
DrugDDI.d117.s20
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Because/IN animal/NN reproduction/NN studies/NNS are/VBP not/RB always/RB predictive/JJ of/IN human/JJ response/NN ,/, this/DT drug/NN should/MD be/VB used/VBN during/IN pregnancy/NN only/RB if/IN clearly/RB needed/VBN ./.


DrugDDI.d117
DrugDDI.d117.s21
Labor and Delivery: Oral ampicillin -class antibiotics are poorly absorbed during labor.

Labor/NN and/CC Delivery/NN :/: Oral/JJ ampicillin/NN -class/NN antibiotics/NNS are/VBP poorly/RB absorbed/VBN during/IN labor/NN ./.


DrugDDI.d117
DrugDDI.d117.s22
Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions but moderately increased the height and duration of contractions.

Studies/NNS in/IN guinea/NN pigs/NNS showed/VBD that/IN intravenous/JJ administration/NN of/IN ampicillin/NN slightly/RB decreased/VBD the/DT uterine/NN tone/NN and/CC frequency/NN of/IN contractions/NNS but/CC moderately/RB increased/VBD the/DT height/NN and/CC duration/NN of/IN contractions/NNS ./.


DrugDDI.d117
DrugDDI.d117.s23
However, it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

However/RB ,/, it/PRP is/VBZ not/RB known/VBN whether/IN use/NN of/IN amoxicillin/NN in/IN humans/NNS during/IN labor/NN or/CC delivery/NN has/VBZ immediate/JJ or/CC delayed/VBN adverse/JJ effects/NNS on/IN the/DT fetus/NN ,/, prolongs/VBZ the/DT duration/NN of/IN labor/NN ,/, or/CC increases/VBZ the/DT likelihood/NN that/IN forceps/NN delivery/NN or/CC other/JJ obstetrical/JJ intervention/NN or/CC resuscitation/NN of/IN the/DT newborn/JJ will/MD be/VB necessary/JJ ./.


DrugDDI.d117
DrugDDI.d117.s24
Nursing Mothers: Penicillins have been shown to be excreted in human milk.

Nursing/VBG Mothers/NNS :/: Penicillins/NNS have/VBP been/VBN shown/VBN to/TO be/VB excreted/VBN in/IN human/JJ milk/NN ./.


DrugDDI.d117
DrugDDI.d117.s25
Amoxicillin use by nursing mothers may lead to sensitization of infants.

Amoxicillin/JJ use/NN by/IN nursing/JJ mothers/NNS may/MD lead/VB to/TO sensitization/NN of/IN infants/NNS ./.


DrugDDI.d117
DrugDDI.d117.s26
Caution should be exercised when amoxicillin is administered to a nursing woman.

Caution/NN should/MD be/VB exercised/VBN when/WRB amoxicillin/NN is/VBZ administered/VBN to/TO a/DT nursing/JJ woman/NN ./.


DrugDDI.d117
DrugDDI.d117.s27
Pediatric Use: Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed.

Pediatric/JJ Use/NN :/: Because/IN of/IN incompletely/RB developed/VBN renal/JJ function/NN in/IN neonates/NNS and/CC young/JJ infants/NNS ,/, the/DT elimination/NN of/IN amoxicillin/NN may/MD be/VB delayed/VBN ./.


DrugDDI.d117
DrugDDI.d117.s28
Dosing of AMOXIL should be modified in pediatric patients 12 weeks or younger (@3 months).

Dosing/NN of/IN AMOXIL/NN should/MD be/VB modified/VBN in/IN pediatric/JJ patients/NNS 12/CD weeks/NNS or/CC younger/JJR (/-LRB- @/NN 3/CD months/NNS )./NN


DrugDDI.d28
DrugDDI.d28.s1
Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret@ when the two agents were administered together.

Toxicologic/JJ and/CC toxicokinetic/JJ studies/NNS in/IN rats/NNS did/VBD not/RB demonstrate/VB any/DT alterations/NNS in/IN the/DT clearance/NN or/CC toxicologic/JJ profile/NN of/IN either/CC methotrexate/NN or/CC Kineret/NN @/NN when/WRB the/DT two/CD agents/NNS were/VBD administered/VBN together/RB ./.


DrugDDI.d28
DrugDDI.d28.s2
In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret@ and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).

In/IN a/DT study/NN in/IN which/WDT patients/NNS with/IN active/JJ RA/NN were/VBD treated/VBN for/IN up/RB to/TO 24/CD weeks/NNS with/IN concurrent/JJ Kineret/NN @/NN and/CC etanercept/NN therapy/NN ,/, a/DT 7/CD %/NN rate/NN of/IN serious/JJ infections/NNS was/VBD observed/VBN ,/, which/WDT was/VBD higher/JJR than/IN that/DT observed/VBN with/IN etanercept/NN alone/RB (/-LRB- 0%)./NN


DrugDDI.d28
DrugDDI.d28.s3
Two percent of patients treated concurrently with Kineret@ and etanercept developed neutropenia ( ANC 1 x 109/L ).

Two/CD percent/NN of/IN patients/NNS treated/VBN concurrently/RB with/IN Kineret/NN @/NN and/CC etanercept/NN developed/VBD neutropenia/NN (/-LRB- ANC/NN 1/CD x/NN 109/L/NN )/-RRB- ./.


DrugDDI.d552
DrugDDI.d552.s0
No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin .

No/DT clinically/RB relevant/JJ drug-drug/JJ interactions/NNS have/VBP been/VBN observed/VBN with/IN drugs/NNS likely/RB to/TO be/VB co-administered/VBN with/IN anidulafungin/NN ./.


DrugDDI.d290
DrugDDI.d290.s0
Caution should be observed when anileridine is coadministered with other opioids , sedatives , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression.

Caution/NN should/MD be/VB observed/VBN when/WRB anileridine/NN is/VBZ coadministered/VBN with/IN other/JJ opioids/NNS ,/, sedatives/NNS ,/, phenothiazines/NNS ,/, or/CC anesthetics/NNS ,/, as/IN these/DT agents/NNS may/MD increase/VB respiratory/JJ and/CC circulatory/JJ depression/NN ./.


DrugDDI.d224
DrugDDI.d224.s0
Ketoconazole / Itraconazole , Macrolides , Including Erythromycin .

Ketoconazole/NN //: Itraconazole/NN ,/, Macrolides/NN ,/, Including/VBG Erythromycin/NN ./.


DrugDDI.d582
DrugDDI.d582.s0
Atovaquone is highly bound to plasma protein (99.9%).

Atovaquone/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN protein/NN (/-LRB- 99.9%)./NN


DrugDDI.d582
DrugDDI.d582.s1
Therefore, caution should be used when administering MEPRON concurrently with other highly plasma protein- bound drugs with narrow therapeutic indices, as competition for binding sites may occur.

Therefore/RB ,/, caution/NN should/MD be/VB used/VBN when/WRB administering/VBG MEPRON/NN concurrently/RB with/IN other/JJ highly/RB plasma/NN protein-/NN bound/VBN drugs/NNS with/IN narrow/JJ therapeutic/JJ indices/NNS ,/, as/IN competition/NN for/IN binding/NN sites/NNS may/MD occur/VB ./.


DrugDDI.d582
DrugDDI.d582.s2
The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone .

The/DT extent/NN of/IN plasma/NN protein/NN binding/NN of/IN atovaquone/NN in/IN human/JJ plasma/NN is/VBZ not/RB affected/VBN by/IN the/DT presence/NN of/IN therapeutic/JJ concentrations/NNS of/IN phenytoin/NN (/-LRB- 15/CD mcg//NN mL/NN )/-RRB- ,/, nor/CC is/VBZ the/DT binding/NN of/IN phenytoin/NN affected/VBN by/IN the/DT presence/NN of/IN atovaquone/NN ./.


DrugDDI.d582
DrugDDI.d582.s3
Rifampin : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.

Rifampin/NN :/: Coadministration/NN of/IN rifampin/NN and/CC MEPRON/NN Suspension/NN results/VBZ in/IN a/DT significant/JJ decrease/NN in/IN average/JJ steady-/JJ state/NN plasma/NN atovaquone/NN concentrations/NNS ./.


DrugDDI.d582
DrugDDI.d582.s4
Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON .

Alternatives/NNS to/TO rifampin/NN should/MD be/VB considered/VBN during/IN the/DT course/NN of/IN PCP/NN treatment/NN with/IN MEPRON/NN ./.


DrugDDI.d582
DrugDDI.d582.s5
Rifabutin , another rifamycin , is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin .

Rifabutin/NN ,/, another/DT rifamycin/NN ,/, is/VBZ structurally/RB similar/JJ to/TO rifampin/NN and/CC may/MD possibly/RB have/VB some/DT of/IN the/DT same/JJ drug/NN interactions/NNS as/IN rifampin/NN ./.


DrugDDI.d582
DrugDDI.d582.s6
No interaction trials have been conducted with MEPRON and rifabutin .

No/NN interaction/NN trials/NNS have/VBP been/VBN conducted/VBN with/IN MEPRON/NN and/CC rifabutin/NN ./.


DrugDDI.d582
DrugDDI.d582.s7
Drug / Laboratory Test Interactions: It is not known if MEPRON interferes with clinical laboratory test or assay results.

Drug/NN //: Laboratory/NN Test/NN Interactions/NNS :/: It/PRP is/VBZ not/RB known/VBN if/IN MEPRON/NN interferes/VBZ with/IN clinical/JJ laboratory/JJ test/NN or/NN assay/NN results/NNS ./.


DrugDDI.d39
DrugDDI.d39.s0
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine .

When/WRB atropine/NN and/CC pralidoxime/NN are/VBP used/VBN together/RB ,/, the/DT signs/NNS of/IN atropinization/NN (/-LRB- flushing/NN ,/, mydriasis/NN ,/, tachycardia/NN ,/, dryness/NN of/IN the/DT mouth/NN and/CC nose/NN )/-RRB- may/MD occur/VB earlier/RBR than/IN might/MD be/VB expected/VBN than/IN when/WRB atropine/NN is/VBZ used/VBN alone/RB because/IN pralidoxime/NN may/MD potentiate/VB the/DT effect/NN of/IN atropine/NN ./.


DrugDDI.d39
DrugDDI.d39.s1
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime .

The/DT following/JJ precautions/NNS should/MD be/VB kept/VBN in/IN mind/NN in/IN the/DT treatment/NN of/IN anticholinesterase/NN poisoning/NN although/IN they/PRP do/VBP not/RB bear/VB directly/RB on/IN the/DT use/NN of/IN atropine/NN and/CC pralidoxime/NN ./.


DrugDDI.d39
DrugDDI.d39.s2
Since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions.

Since/IN barbiturates/NNS are/VBP potentiated/VBN by/IN the/DT anticholinesterases/NNS ,/, they/PRP should/MD be/VB used/VBN cautiously/RB in/IN the/DT treatment/NN of/IN convulsions/NNS ./.


DrugDDI.d554
DrugDDI.d554.s0
Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 span class= c94 @?

Co-administration/NN of/IN nelfinavir/NN at/IN steady-state/NN with/IN a/DT single/JJ dose/NN of/IN azithromycin/NN (/-LRB- 2/CD span/NN class=/NN c94/NN @/NN ?/.


DrugDDI.d554
DrugDDI.d554.s1
600 mg tablets) results in increased azithromycin serum concentrations.

600/CD mg/NN tablets/NNS )/-RRB- results/VBZ in/IN increased/VBN azithromycin/NN serum/NN concentrations/NNS ./.


DrugDDI.d554
DrugDDI.d554.s2
Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir , close monitoring for known side effects of azithromycin , such as liver enzyme abnormalities and hearing impairment, is warranted.

Although/IN a/DT dose/NN adjustment/NN of/IN azithromycin/NN is/VBZ not/RB recommended/VBN when/WRB administered/VBN in/IN combination/NN with/IN nelfinavir/NN ,/, close/JJ monitoring/NN for/IN known/JJ side/JJ effects/NNS of/IN azithromycin/NN ,/, such/JJ as/IN liver/NN enzyme/NN abnormalities/NNS and/CC hearing/NN impairment/NN ,/, is/VBZ warranted/VBN ./.


DrugDDI.d554
DrugDDI.d554.s3
Azithromycin did not affect the prothrombin time response to a single dose of warfarin .

Azithromycin/NN did/VBD not/RB affect/VB the/DT prothrombin/NN time/NN response/NN to/TO a/DT single/JJ dose/NN of/IN warfarin/NN ./.


DrugDDI.d554
DrugDDI.d554.s4
However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.

However/RB ,/, prudent/JJ medical/JJ practice/NN dictates/VBZ careful/JJ monitoring/NN of/IN prothrombin/NN time/NN in/IN all/DT patients/NNS treated/VBN with/IN azithromycin/NN and/CC warfarin/NN concomitantly/RB ./.


DrugDDI.d554
DrugDDI.d554.s5
Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.

Concurrent/JJ use/NN of/IN macrolides/NN and/CC warfarin/NN in/IN clinical/JJ practice/NN has/VBZ been/VBN associated/VBN with/IN increased/VBN anticoagulant/JJ effects/NNS ./.


DrugDDI.d554
DrugDDI.d554.s6
Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.

Drug/NN interaction/NN studies/NNS were/VBD performed/VBN with/IN azithromycin/NN and/CC other/JJ drugs/NNS likely/RB to/TO be/VB co-administered/VBN ./.


DrugDDI.d554
DrugDDI.d554.s7
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine .

When/WRB used/VBN in/IN therapeutic/JJ doses/NNS ,/, azithromycin/NN had/VBD a/DT modest/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN atorvastatin/NN ,/, carbamazepine/NN ,/, cetirizine/NN ,/, didanosine/NN ,/, efavirenz/NN ,/, fluconazole/NN ,/, indinavir/NN ,/, midazolam/NN ,/, rifabutin/NN ,/, sildenafil/NN ,/, theophylline/NN (/-LRB- intravenous/JJ and/CC oral/JJ )/-RRB- ,/, triazolam/NN ,/, trimethoprim/NN //: sulfamethoxazole/NN or/CC zidovudine/NN ./.


DrugDDI.d554
DrugDDI.d554.s8
Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin .

Co-administration/NN with/IN efavirenz/NN or/CC fluconazole/NN had/VBD a/DT modest/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN azithromycin/NN ./.


DrugDDI.d554
DrugDDI.d554.s9
No dosage adjustment of either drug is recommended when azithromycin is co administered with any of the above agents.

No/DT dosage/JJ adjustment/NN of/IN either/DT drug/NN is/VBZ recommended/VBN when/WRB azithromycin/NN is/VBZ co/RB administered/VBN with/IN any/DT of/IN the/DT above/JJ agents/NNS ./.


DrugDDI.d554
DrugDDI.d554.s10
Interactions with the drugs listed below have not been reported in clinical trials with azithromycin ; .

Interactions/NNS with/IN the/DT drugs/NNS listed/VBN below/IN have/VBP not/RB been/VBN reported/VBN in/IN clinical/JJ trials/NNS with/IN azithromycin/NN ;/: ./.


DrugDDI.d554
DrugDDI.d554.s12
Nonetheless, they have been observed with macrolide products.

Nonetheless/RB ,/, they/PRP have/VBP been/VBN observed/VBN with/IN macrolide/NN products/NNS ./.


DrugDDI.d554
DrugDDI.d554.s13
Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin @elevated digoxin concentrations.

Until/IN further/JJ data/NNS are/VBP developed/VBN regarding/VBG drug/NN interactions/NNS when/WRB azithromycin/NN and/CC these/DT drugs/NNS are/VBP used/VBN concomitantly/RB ,/, careful/JJ monitoring/NN of/IN patients/NNS is/VBZ advised/VBN :/: Digoxin/NN @/NN elevated/JJ digoxin/NN concentrations/NNS ./.


DrugDDI.d554
DrugDDI.d554.s14
Ergotamine or dihydro ergot amine@acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

Ergotamine/NN or/CC dihydro/NN ergot/NN amine/NN @/NN acute/JJ ergot/NN toxicity/NN characterized/VBN by/IN severe/JJ peripheral/JJ vasospasm/NN and/CC dysesthesia/NN ./.


DrugDDI.d554
DrugDDI.d554.s15
Cyclosporine , hexobarbital and phenytoin concentrations.

Cyclosporine/NN ,/, hexobarbital/NN and/CC phenytoin/NN concentrations/NNS ./.


DrugDDI.d554
DrugDDI.d554.s17
Repeat Treatment Studies evaluating the use of repeated courses of Zmax have not been conducted.

Repeat/NN Treatment/NN Studies/NNS evaluating/VBG the/DT use/NN of/IN repeated/JJ courses/NNS of/IN Zmax/NN have/VBP not/RB been/VBN conducted/VBN ./.


DrugDDI.d535
DrugDDI.d535.s0
Azlocillin should not be administered concomitantly with amikacin , ciprofloxacin , gentamicin , netilmicin , or tobramycin .

Azlocillin/NN should/MD not/RB be/VB administered/VBN concomitantly/RB with/IN amikacin/NN ,/, ciprofloxacin/NN ,/, gentamicin/NN ,/, netilmicin/NN ,/, or/CC tobramycin/NN ./.


DrugDDI.d517
DrugDDI.d517.s0
Injection : There is inadequate systematic experience with the use of baclofen injection in combination with other medications to predict specific drug-drug interactions.

Injection/NN :/: There/EX is/VBZ inadequate/JJ systematic/JJ experience/VBP with/IN the/DT use/NN of/IN baclofen/NN injection/NN in/IN combination/NN with/IN other/JJ medications/NNS to/TO predict/VB specific/JJ drug-drug/JJ interactions/NNS ./.


DrugDDI.d517
DrugDDI.d517.s1
Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.

Interactions/NNS attributed/VBN to/TO the/DT combined/JJ use/NN of/IN baclofen/JJ injection/NN and/CC epidural/JJ morphine/NN include/VBP hypotension/NN and/CC dyspnea/NN ./.


DrugDDI.d517
DrugDDI.d517.s2
SIDE EFFECTS (KEMSTRO) : The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).

SIDE/JJ EFFECTS/NNS (/-LRB- KEMSTRO/NN )/-RRB- :/: The/DT most/RBS common/JJ adverse/JJ reaction/NN during/IN treatment/NN with/IN baclofen/NN is/VBZ transient/JJ drowsiness/NN (/-LRB- 10-63%)./CD


DrugDDI.d517
DrugDDI.d517.s3
In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen tablets compared to 36% of those in the placebo group.

In/IN one/CD controlled/JJ study/NN of/IN 175/CD patients/NNS ,/, transient/JJ drowsiness/NN was/VBD observed/VBN in/IN 63/CD %/NN of/IN those/DT receiving/VBG baclofen/NN tablets/NNS compared/VBN to/TO 36/CD %/NN of/IN those/DT in/IN the/DT placebo/NN group/NN ./.


DrugDDI.d517
DrugDDI.d517.s15
The following laboratory tests have been found to be abnormal in a few patients receiving baclofen : increased SGOT, elevated alkaline phosphatase , and elevation of blood sugar.

The/DT following/JJ laboratory/NN tests/NNS have/VBP been/VBN found/VBN to/TO be/VB abnormal/JJ in/IN a/DT few/JJ patients/NNS receiving/VBG baclofen/NN :/: increased/VBN SGOT/NN ,/, elevated/JJ alkaline/NN phosphatase/NN ,/, and/CC elevation/NN of/IN blood/NN sugar/NN ./.


DrugDDI.d517
DrugDDI.d517.s16
The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets .

The/DT adverse/JJ experience/VBP profile/NN seen/VBN with/IN KEMSTROTM/NN was/VBD similar/JJ to/TO that/DT seen/VBN with/IN baclofen/JJ tablets/NNS ./.


DrugDDI.d500
DrugDDI.d500.s0
Bentiromide may interact with acetaminophen (e.g., Tylenol ), chloramphenicol (e.g., Chloromycetin ), local anesthetics (e.g., benzocaine and lidocaine ), para-aminobenzoic acid ( PABA )-containing preparations (e.g., sunscreens and some multivitamins ), procainamide (e.g., Pronestyl ), sulfonamides ( sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).

Bentiromide/NN may/MD interact/VB with/IN acetaminophen/NN (/-LRB- e.g./FW ,/, Tylenol/NN )/-RRB- ,/, chloramphenicol/NN (/-LRB- e.g./FW ,/, Chloromycetin/NN )/-RRB- ,/, local/JJ anesthetics/NNS (/-LRB- e.g./FW ,/, benzocaine/NN and/CC lidocaine/NN )/-RRB- ,/, para-aminobenzoic/JJ acid/NN (/-LRB- PABA/NN )/-RRB- -containing/JJ preparations/NNS (/-LRB- e.g./FW ,/, sunscreens/NNS and/CC some/DT multivitamins/NNS )/-RRB- ,/, procainamide/NN (/-LRB- e.g./FW ,/, Pronestyl/NN )/-RRB- ,/, sulfonamides/NNS (/-LRB- sulfa/NN medicines/NNS )/-RRB- ,/, thiazide/NN diuretics/NNS (/-LRB- use/NN of/IN these/DT medicines/NNS during/IN the/DT test/NN period/NN will/MD affect/VB the/DT test/NN results/NNS )/-RRB- ,/, and/CC pancreatic/JJ supplements/NNS (/-LRB- use/NN of/IN pancreatic/JJ supplements/NNS may/MD give/VB false/JJ test/NN results/NNS )./RB


DrugDDI.d194
DrugDDI.d194.s0
Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors .

Hypertensive/JJ crises/NNS have/VBP resulted/VBD when/WRB sympathomimetic/JJ amines/NNS have/VBP been/VBN used/VBN concomitantly/RB within14/CD days/NNS following/VBG use/NN of/IN monoamine/NN oxidase/NN inhibitors/NNS ./.


DrugDDI.d194
DrugDDI.d194.s1
DIDREX should not be used concomitantly with other CNS stimulants .

DIDREX/NN should/MD not/RB be/VB used/VBN concomitantly/RB with/IN other/JJ CNS/NN stimulants/NNS ./.


DrugDDI.d194
DrugDDI.d194.s2
Amphetamines may decrease the hypotensive effect of antihypertensives .

Amphetamines/NN may/MD decrease/VB the/DT hypotensive/JJ effect/NN of/IN antihypertensives/NNS ./.


DrugDDI.d194
DrugDDI.d194.s3
Amphetamines may enhance the effects of tricyclic antidepressants .

Amphetamines/NN may/MD enhance/VB the/DT effects/NNS of/IN tricyclic/JJ antidepressants/NNS ./.


DrugDDI.d194
DrugDDI.d194.s4
Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines .

Urinary/JJ alkalinizing/NN agents/NNS increase/VBP blood/NN levels/NNS and/CC decrease/VBP excretion/NN of/IN amphetamines/NN ./.


DrugDDI.d194
DrugDDI.d194.s5
Urinary acidifying agents decrease blood levels and increase excretion of amphetamines .

Urinary/JJ acidifying/JJ agents/NNS decrease/VB blood/NN levels/NNS and/CC increase/VB excretion/NN of/IN amphetamines/NN ./.


DrugDDI.d236
DrugDDI.d236.s0
Benzthiazide may interact with alcohol , blood thinner s, decongestant drugs (allergy, cold, and sinus medicines ), diabetic drugs , lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .

Benzthiazide/NN may/MD interact/VB with/IN alcohol/NN ,/, blood/NN thinner/NN s/NNS ,/, decongestant/JJ drugs/NNS (/-LRB- allergy/NN ,/, cold/NN ,/, and/CC sinus/NN medicines/NNS )/-RRB- ,/, diabetic/JJ drugs/NNS ,/, lithium/NN ,/, norepinephrine/NN ,/, NSAIDs/NNS like/IN Aleve/NN or/CC Ibuprofen/NN ,/, and/CC high/JJ blood/NN pressure/NN medications/NNS ./.


DrugDDI.d285
DrugDDI.d285.s0
No formal drug interaction studies with anti-neoplastic agents have been conducted.

No/DT formal/JJ drug/NN interaction/NN studies/NNS with/IN anti-neoplastic/JJ agents/NNS have/VBP been/VBN conducted/VBN ./.


DrugDDI.d285
DrugDDI.d285.s1
In Study 1, patients with colorectal cancer were given irinotecan /5-FU/leucovorin (bolus-IFL) with or without AVASTIN .

In/IN Study/NN 1/CD ,/, patients/NNS with/IN colorectal/JJ cancer/NN were/VBD given/VBN irinotecan/NN /5-FU/leucovorin/NN (/-LRB- bolus-IFL/NN )/-RRB- with/IN or/CC without/IN AVASTIN/NN ./.


DrugDDI.d285
DrugDDI.d285.s2
Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN .

Irinotecan/NN concentrations/NNS were/VBD similar/JJ in/IN patients/NNS receiving/VBG bolus-IFL/NN alone/RB and/CC in/IN combination/NN with/IN AVASTIN/NN ./.


DrugDDI.d285
DrugDDI.d285.s3
The concentrations of SN38, the active metabolite of irinotecan , were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.

The/DT concentrations/NNS of/IN SN38/NN ,/, the/DT active/JJ metabolite/NN of/IN irinotecan/NN ,/, were/VBD on/IN average/NN 33/CD %/NN higher/JJR in/IN patients/NNS receiving/VBG bolus-IFL/NN in/IN combination/NN with/IN AVASTIN/NN when/WRB compared/VBN with/IN bolus-IFL/NN alone/RB ./.


DrugDDI.d285
DrugDDI.d285.s4
In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia.

In/IN Study/NN 1/CD ,/, patients/NNS receiving/VBG bolus-IFL/NN plus/CC AVASTIN/NN had/VBD a/DT higher/JJR incidence/NN of/IN Grade/NN 3-4/JJ diarrhea/NN and/CC neutropenia/NN ./.


DrugDDI.d285
DrugDDI.d285.s5
Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.

Due/JJ to/TO high/JJ inter-patient/JJ variability/NN and/CC limited/JJ sampling/NN ,/, the/DT extent/NN of/IN the/DT increase/NN in/IN SN38/NN levels/NNS in/IN patients/NNS receiving/VBG concurrent/JJ irinotecan/NN and/CC AVASTIN/NN is/VBZ uncertain/JJ ./.


DrugDDI.d498
DrugDDI.d498.s0
In vitro studies have shown CASODEX can displace coumarin anticoagulant s, such as warfarin , from their protein -binding sites.

In/FW vitro/FW studies/NNS have/VBP shown/VBN CASODEX/NN can/MD displace/VB coumarin/NN anticoagulant/NN s/NNS ,/, such/JJ as/IN warfarin/NN ,/, from/IN their/PRP$ protein/NN -binding/JJ sites/NNS ./.


DrugDDI.d498
DrugDDI.d498.s1
It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulant s, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.

It/PRP is/VBZ recommended/VBN that/IN if/IN CASODEX/NN is/VBZ started/VBN in/IN patients/NNS already/RB receiving/VBG coumarin/NN anticoagulant/NN s/NNS ,/, prothrombin/NN times/NNS should/MD be/VB closely/RB monitored/VBN and/CC adjustment/NN of/IN the/DT anticoagulant/JJ dose/NN may/MD be/VB necessary/JJ ./.


DrugDDI.d222
DrugDDI.d222.s0
No formal drug interaction studies have been conducted with VELCADE .

No/DT formal/JJ drug/NN interaction/NN studies/NNS have/VBP been/VBN conducted/VBN with/IN VELCADE/NN ./.


DrugDDI.d222
DrugDDI.d222.s1
In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4 , 2C19, and 1A2.

In/FW vitro/FW studies/NNS with/IN human/JJ liver/NN microsomes/NNS indicate/VBP that/IN bortezomib/NN is/VBZ primarily/RB a/DT substrate/NN for/IN cytochrome/NN P450/NN 3A4/NN ,/, 2C19/NN ,/, and/CC 1A2/NN ./.


DrugDDI.d222
DrugDDI.d222.s2
Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy .

Patients/NNS who/WP are/VBP concomitantly/RB receiving/VBG VELCADE/NN and/CC drugs/NNS that/WDT are/VBP inhibitors/NNS or/CC inducers/NNS of/IN cytochrome/NN P450/NN 3A4/NN should/MD be/VB closely/RB monitored/VBN for/IN either/CC toxicities/NNS or/CC reduced/VBN efficacy/NN ./.


DrugDDI.d222
DrugDDI.d222.s3
During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics .

During/IN clinical/JJ trials/NNS ,/, hypoglycemia/NN and/CC hyperglycemia/NN were/VBD reported/VBN in/IN diabetic/JJ patients/NNS receiving/VBG oral/JJ hypoglycemics/NNS ./.


DrugDDI.d222
DrugDDI.d222.s4
Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.

Patients/NNS on/IN oral/JJ antidiabetic/JJ agents/NNS receiving/VBG VELCADE/NN treatment/NN may/MD require/VB close/JJ monitoring/NN of/IN their/PRP$ blood/NN glucose/NN levels/NNS and/CC adjustment/NN of/IN the/DT dose/NN of/IN their/PRP$ antidiabetic/JJ medication/NN ./.


DrugDDI.d134
DrugDDI.d134.s0
Co-administration of BOTOX@ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare -like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

Co-administration/NN of/IN BOTOX/NN @/NN and/CC aminoglycosides/NNS or/CC other/JJ agents/NNS interfering/VBG with/IN neuromuscular/JJ transmission/NN (/-LRB- e.g./FW ,/, curare/NN -like/JJ compounds/NNS )/-RRB- should/MD only/RB be/VB performed/VBN with/IN caution/NN as/IN the/DT effect/NN of/IN the/DT toxin/NN may/MD be/VB potentiated/VBN ./.


DrugDDI.d134
DrugDDI.d134.s1
The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown.

The/DT effect/NN of/IN administering/VBG different/JJ botulinum/NN neurotoxin/NN serotypes/NNS at/IN the/DT same/JJ time/NN or/CC within/IN several/JJ months/NNS of/IN each/DT other/JJ is/VBZ unknown/JJ ./.


DrugDDI.d134
DrugDDI.d134.s2
Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin .

Excessive/JJ neuromuscular/NN weakness/NN may/MD be/VB exacerbated/JJ by/IN administration/NN of/IN another/DT botulinum/NN toxin/NN prior/JJ to/TO the/DT resolution/NN of/IN the/DT effects/NNS of/IN a/DT previously/RB administered/VBN botulinum/NN toxin/NN ./.


DrugDDI.d398
DrugDDI.d398.s0
Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection .

Digitalis/NN toxicity/NN may/MD be/VB aggravated/VBN by/IN the/DT initial/JJ release/NN of/IN norepinephrine/NN caused/VBN by/IN Bretylium/NN Tosylate/NN Injection/NN ./.


DrugDDI.d398
DrugDDI.d398.s1
The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate .

The/DT pressor/NN effects/NNS of/IN catecholamines/NNS such/JJ as/IN dopamine/NN or/CC norepinephrine/NN are/VBP enhanced/VBN by/IN Bretylium/NN Tosylate/NN ./.


DrugDDI.d398
DrugDDI.d398.s3
Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate , these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.

Although/IN there/EX is/VBZ little/JJ published/VBN information/NN on/IN concomitant/JJ administration/NN of/IN lidocaine/NN and/CC Bretylium/NN Tosylate/NN ,/, these/DT drugs/NNS are/VBP often/RB administered/VBN concurrently/RB without/IN any/DT evidence/NN of/IN interactions/NNS resulting/VBG in/IN adverse/JJ effects/NNS or/CC diminished/VBN efficacy/NN ./.


DrugDDI.d316
DrugDDI.d316.s0
Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide .

Concomitant/JJ oral/JJ administration/NN of/IN ketoconazole/NN (/-LRB- a/DT known/JJ inhibitor/NN of/IN CYP3A4/NN activity/NN in/IN the/DT liver/NN and/CC in/IN the/DT intestinal/JJ mucosa/NN )/-RRB- caused/VBD an/DT eight-fold/JJ increase/NN of/IN the/DT systemic/JJ exposure/NN to/TO oral/JJ budesonide/NN ./.


DrugDDI.d316
DrugDDI.d316.s1
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole, ritonavir , indinavir , saquinavir , erythromycin , etc.) is indicated, reduction of the budesonide dose should be considered.

If/IN treatment/NN with/IN inhibitors/NNS of/IN CYP3A4/NN activity/NN (/-LRB- such/JJ as/IN ketoconazole/NN ,/, intraconazole/NN ,/, ritonavir/NN ,/, indinavir/NN ,/, saquinavir/NN ,/, erythromycin/NN ,/, etc./NN )/-RRB- is/VBZ indicated/VBN ,/, reduction/NN of/IN the/DT budesonide/NN dose/NN should/MD be/VB considered/VBN ./.


DrugDDI.d316
DrugDDI.d316.s2
After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times.

After/IN extensive/JJ intake/NN of/IN grapefruit/NN juice/NN (/-LRB- which/WDT inhibits/VBZ CYP3A4/NN activity/NN predominantly/RB in/IN the/DT intestinal/JJ mucosa/NN )/-RRB- ,/, the/DT systemic/JJ exposure/NN for/IN oral/JJ budesonide/NN increased/VBD about/RB two/CD times/NNS ./.


DrugDDI.d316
DrugDDI.d316.s3
As with other drugs primarily being metabolized through CYP3A4 , ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration.

As/IN with/IN other/JJ drugs/NNS primarily/RB being/VBG metabolized/VBN through/IN CYP3A4/NN ,/, ingestion/NN of/IN grapefruit/NN or/CC grapefruit/NN juice/NN should/MD be/VB avoided/VBN in/IN connection/NN with/IN budesonide/NN administration/NN ./.


DrugDDI.d570
DrugDDI.d570.s0
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.

The/DT administration/NN of/IN local/JJ anesthetic/JJ solutions/NNS containing/VBG epinephrine/NN or/CC norepinephrine/NN to/TO patients/NNS receiving/VBG monoamine/NN oxidase/NN inhibitors/NNS or/CC tricyclic/JJ antidepressants/NNS may/MD produce/VB severe/JJ ,/, prolonged/JJ hypertension/NN ./.


DrugDDI.d570
DrugDDI.d570.s3
Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

Concurrent/JJ administration/NN of/IN vasopressor/JJ drugs/NNS and/CC of/IN ergot-type/JJ oxytocic/JJ drugs/NNS may/MD cause/VB severe/JJ ,/, persistent/JJ hypertension/NN or/CC cerebrovascular/JJ accidents/NN ./.


DrugDDI.d570
DrugDDI.d570.s4
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .

Phenothiazines/NNS and/CC butyrophenones/NNS may/MD reduce/VB or/CC reverse/VB the/DT pressor/JJ effect/NN of/IN epinephrine/NN ./.


DrugDDI.d223
DrugDDI.d223.s0
The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.

The/DT CNS/NN effects/NNS of/IN butalbital/NN may/MD be/VB enhanced/VBN by/IN monoamine/NN oxidase/NN (/-LRB- MAO/NN )/-RRB- inhibitors/NNS ./.


DrugDDI.d223
DrugDDI.d223.s1
Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS depressants , causing increased CNS depression.

Butalbital/NN ,/, acetaminophen/NN and/CC caffeine/NN may/MD enhance/VB the/DT effects/NNS of/IN :/: other/JJ narcotic/JJ analgesic/JJ s/NNS ,/, alcohol/NN ,/, general/JJ anesthetics/NNS ,/, tranquilizers/NNS such/JJ as/IN chlordiazepoxide/NN ,/, sedative-hypnotics/NN ,/, or/CC other/JJ CNS/NN depressants/NNS ,/, causing/VBG increased/VBN CNS/NN depression/NN ./.


DrugDDI.d223
DrugDDI.d223.s2
Drug /Laboratory Test Interactions Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid .

Drug/NN /Laboratory/NN Test/NN Interactions/NNS Acetaminophen/NN may/MD produce/VB false-positive/JJ test/NN results/NNS for/IN urinary/JJ 5-hydroxyindoleacetic/JJ acid/NN ./.


DrugDDI.d38
DrugDDI.d38.s0
Interactions may occur with the following: adrenocorticoids ( cortisone -like medicine ), anticoagulants ( blood thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines ), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control ).

Interactions/NNS may/MD occur/VB with/IN the/DT following/NN :/: adrenocorticoids/NNS (/-LRB- cortisone/NN -like/JJ medicine/NN )/-RRB- ,/, anticoagulants/NNS (/-LRB- blood/NN thinner/NN s/NNS )/-RRB- ,/, carbamazepine/NN ,/, corticotropin/NN (/-LRB- barbiturates/NNS may/MD decrease/VB the/DT effects/NNS of/IN these/DT medicines/NNS )/-RRB- ,/, central/JJ nervous/JJ system/NN (/-LRB- CNS/NN )/-RRB- depressants/NNS (/-LRB- using/VBG these/DT medicines/NNS with/IN barbiturates/NNS may/MD result/VB in/IN increased/VBN CNS/NN depressant/NN effects/NNS )/-RRB- ,/, divalproex/NN sodium/NN ,/, valproic/JJ acid/NN (/-LRB- using/VBG these/DT medicines/NNS with/IN barbiturates/NNS may/MD change/VB the/DT amount/NN of/IN either/DT medicine/NN that/WDT you/RB need/VBP to/TO take/VB )/-RRB- ,/, and/CC oral/JJ contraceptives/NNS containing/VBG estrogens/NNS (/-LRB- barbiturates/NNS may/MD decrease/VB the/DT effectiveness/NN of/IN these/DT oral/JJ contraceptives/NNS ,/, and/CC you/RB may/MD need/VBP to/TO change/NN to/TO a/DT different/JJ type/NN of/IN birth/NN control/NN )/-RRB- ./.


DrugDDI.d218
DrugDDI.d218.s0
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines , butyrophenones , thioxanthines, or metoclopramide .

DOSTINEX/NN should/MD not/RB be/VB administered/VBN concurrently/RB with/IN D2-antagonists/NNS ,/, such/JJ as/IN phenothiazines/NNS ,/, butyrophenones/NNS ,/, thioxanthines/NNS ,/, or/CC metoclopramide/NN ./.


DrugDDI.d349
DrugDDI.d349.s0
No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).

No/DT significant/JJ drug/NN interactions/NNS have/VBP been/VBN reported/VBN in/IN studies/NNS of/IN candesartan/NN cilexetil/NN given/VBN with/IN other/JJ drugs/NNS such/JJ as/IN glyburide/NN ,/, nifedipine/NN ,/, digoxin/NN ,/, warfarin/NN ,/, hydrochlorothiazide/NN ,/, and/CC oral/JJ contraceptives/NNS in/IN healthy/JJ volunteers/NNS ,/, or/CC given/VBN with/IN enalapril/NN to/TO patients/NNS with/IN heart/NN failure/NN (/-LRB- NYHA/NN class/NN II/CD and/CC III/CD )./NN


DrugDDI.d349
DrugDDI.d349.s1
Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.

Because/IN candesartan/NN is/VBZ not/RB significantly/RB metabolized/VBN by/IN the/DT cytochrome/NN P450/NN system/NN and/CC at/IN therapeutic/JJ concentrations/NNS has/VBZ no/DT effects/NNS on/IN P450/NN enzymes/NNS ,/, interactions/NNS with/IN drugs/NNS that/WDT inhibit/VBP or/CC are/VBP metabolized/VBN by/IN those/DT enzymes/NNS would/MD not/RB be/VB expected/VBN ./.


DrugDDI.d349
DrugDDI.d349.s2
Lithium@ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors , and with some angiotensin II receptor antagonists .

Lithium/NN @/NN Reversible/JJ increases/NNS in/IN serum/NN lithium/NN concentrations/NNS and/CC toxicity/NN have/VBP been/VBN reported/VBN during/IN concomitant/JJ administration/NN of/IN lithium/NN with/IN ACE/NN inhibitors/NNS ,/, and/CC with/IN some/DT angiotensin/NN II/CD receptor/NN antagonists/NNS ./.


DrugDDI.d349
DrugDDI.d349.s3
An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND , so careful monitoring of serum lithium levels is recommended during concomitant use.

An/DT increase/NN in/IN serum/NN lithium/NN concentration/NN has/VBZ been/VBN reported/VBN during/IN concomitant/JJ administration/NN of/IN lithium/NN with/IN ATACAND/NN ,/, so/IN careful/JJ monitoring/NN of/IN serum/NN lithium/NN levels/NNS is/VBZ recommended/VBN during/IN concomitant/JJ use/NN ./.


DrugDDI.d303
DrugDDI.d303.s0
Geocillin ( carbenicillin indanyl sodium ) blood levels may be increased and prolonged by concurrent administration of probenecid .

Geocillin/NN (/-LRB- carbenicillin/NN indanyl/NN sodium/NN )/-RRB- blood/NN levels/NNS may/MD be/VB increased/VBN and/CC prolonged/VBD by/IN concurrent/JJ administration/NN of/IN probenecid/NN ./.


DrugDDI.d156
DrugDDI.d156.s0
Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole .

Iodine/NN or/CC iodine/NN excess/NN may/MD decrease/VB the/DT effect/NN of/IN Carbimazole/NN ,/, and/CC an/DT iodine/NN deficiency/NN can/MD increase/VB the/DT effect/NN of/IN Carbimazole/NN ./.


DrugDDI.d156
DrugDDI.d156.s1
Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents .

Serum/NN concentration/NN of/IN digoxin/NN and/CC digitoxin/NN may/MD increase/VB when/WRB patients/NNS take/VBP antithyroid/JJ agents/NNS ./.


DrugDDI.d156
DrugDDI.d156.s3
Antithyroid agents may decrease thyroid al uptake of sodium iodide I131 , a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole .

Antithyroid/JJ agents/NNS may/MD decrease/VB thyroid/NN al/FW uptake/NN of/IN sodium/NN iodide/NN I131/CD ,/, a/DT rebound/NN in/IN uptake/NN may/MD occur/VB up/RB to/TO 5/CD days/NNS after/IN sudden/CD withdrawal/NN of/IN Carbimazole/NN ./.


DrugDDI.d156
DrugDDI.d156.s4
Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status.

Patients/NNS response/NN to/TO oral/JJ anticoagulants/NNS may/MD be/VB affected/VBN by/IN his/her/JJ thyroid/NN and/CC metabolic/JJ status/NN ./.


DrugDDI.d156
DrugDDI.d156.s5
An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended .

An/DT evaluation/NN of/IN prothrombin/NN time/NN and/CC an/DT adjustment/NN of/IN anticoagulant/JJ dosage/NN are/VBP recommended/VBN ./.


DrugDDI.d506
DrugDDI.d506.s0
The renal effects of nephrotoxic compounds may be potentiated by Carboplatin .

The/DT renal/JJ effects/NNS of/IN nephrotoxic/JJ compounds/NNS may/MD be/VB potentiated/VBN by/IN Carboplatin/NN ./.


DrugDDI.d348
DrugDDI.d348.s0
Inhibitors of CYP2D6 ; .

Inhibitors/NNS of/IN CYP2D6/NN ;/: ./.


DrugDDI.d348
DrugDDI.d348.s1
poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .

poor/JJ metabolizers/NNS of/IN debrisoquin/NN :/: Interactions/NNS of/IN carvedilol/NN with/IN strong/JJ inhibitors/NNS of/IN CYP2D6/NN (/-LRB- such/JJ as/IN quinidine/NN ,/, fluoxetine/NN ,/, paroxetine/NN ,/, and/CC propafenone/NN )/-RRB- have/VBP not/RB been/VBN studied/VBN ,/, but/CC these/DT drugs/NNS would/MD be/VB expected/VBN to/TO increase/VB blood/NN levels/NNS of/IN the/DT R/NN (/-LRB- +/CC )/-RRB- enantiomer/NN of/IN carvedilol/NN ./.


DrugDDI.d348
DrugDDI.d348.s2
Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer .

Retrospective/JJ analysis/NN of/IN side/JJ effects/NNS in/IN clinical/JJ trials/NNS showed/VBD that/IN poor/JJ 2D6/NN metabolizers/NNS had/VBD a/DT higher/JJR rate/NN of/IN dizziness/NN during/IN up-titration/NN ,/, presumably/RB resulting/VBG from/IN vasodilating/JJ effects/NNS of/IN the/DT higher/JJR concentrations/NNS of/IN the/DT a-blocking/JJ R/NN (/-LRB- +/CC )/-RRB- enantiomer/NN ./.


DrugDDI.d348
DrugDDI.d348.s3
Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors ) should be observed closely for signs of hypotension and/or severe bradycardia.

Catecholamine-depleting/JJ Agents/NNS :/: Patients/NNS taking/VBG both/DT agents/NNS with/IN b-blocking/JJ properties/NNS and/CC a/DT drug/NN that/WDT can/MD deplete/VB catecholamines/NNS (/-LRB- e.g./FW ,/, reserpine/NN and/CC monoamine/NN oxidase/NN inhibitors/NNS )/-RRB- should/MD be/VB observed/VBN closely/RB for/IN signs/NNS of/IN hypotension/NN and/or/CC severe/JJ bradycardia/NN ./.


DrugDDI.d348
DrugDDI.d348.s4
Clonidine : Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.

Clonidine/NN :/: Concomitant/JJ administration/NN of/IN clonidine/NN with/IN agents/NNS with/IN b-blocking/JJ properties/NNS may/MD potentiate/VB blood-pressure-/JJ and/CC heart-rate-lowering/JJ effects/NNS ./.


DrugDDI.d348
DrugDDI.d348.s5
When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.

When/WRB concomitant/JJ treatment/NN with/IN agents/NNS with/IN b-blocking/JJ properties/NNS and/CC clonidine/NN is/VBZ to/TO be/VB terminated/VBN ,/, the/DT b-blocking/JJ agent/NN should/MD be/VB discontinued/VBN first/RB ./.


DrugDDI.d348
DrugDDI.d348.s6
Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.

Clonidine/NN therapy/NN can/MD then/RB be/VB discontinued/VBN several/JJ days/NNS later/RB by/IN gradually/RB decreasing/VBG the/DT dosage/NN ./.


DrugDDI.d348
DrugDDI.d348.s7
Cyclosporine : Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.

Cyclosporine/NN :/: Modest/JJ increases/NNS in/IN mean/JJ trough/NN cyclosporine/NN concentrations/NNS were/VBD observed/VBN following/VBG initiation/NN of/IN carvedilol/NN treatment/NN in/IN 21/CD renal/JJ transplant/NN patients/NNS suffering/VBG from/IN chronic/JJ vascular/JJ rejection/NN ./.


DrugDDI.d348
DrugDDI.d348.s8
In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.

In/IN about/RB 30/CD %/NN of/IN patients/NNS ,/, the/DT dose/NN of/IN cyclosporine/NN had/VBD to/TO be/VB reduced/VBN in/IN order/NN to/TO maintain/VB cyclosporine/NN concentrations/NNS within/IN the/DT therapeutic/JJ range/NN ,/, while/IN in/IN the/DT remainder/NN no/DT adjustment/NN was/VBD needed/VBN ./.


DrugDDI.d348
DrugDDI.d348.s9
On the average for the group, the dose of cyclosporine was reduced about 20% in these patients.

On/IN the/DT average/NN for/IN the/DT group/NN ,/, the/DT dose/NN of/IN cyclosporine/NN was/VBD reduced/VBN about/RB 20/CD %/NN in/IN these/DT patients/NNS ./.


DrugDDI.d348
DrugDDI.d348.s10
Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.

Due/JJ to/TO wide/JJ interindividual/JJ variability/NN in/IN the/DT dose/NN adjustment/NN required/VBN ,/, it/PRP is/VBZ recommended/VBN that/IN cyclosporine/NN concentrations/NNS be/VB monitored/VBN closely/RB after/IN initiation/NN of/IN carvedilol/NN therapy/NN and/CC that/IN the/DT dose/NN of/IN cyclosporine/NN be/VB adjusted/VBN as/IN appropriate/JJ ./.


DrugDDI.d348
DrugDDI.d348.s11
Digoxin : Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.

Digoxin/NN :/: Digoxin/NN concentrations/NNS are/VBP increased/VBN by/IN about/RB 15/CD %/NN when/WRB digoxin/NN and/CC carvedilol/NN are/VBP administered/VBN concomitantly/RB ./.


DrugDDI.d348
DrugDDI.d348.s12
Both digoxin and COREG slow AV conduction.

Both/CC digoxin/NN and/CC COREG/NN slow/JJ AV/NN conduction/NN ./.


DrugDDI.d348
DrugDDI.d348.s13
Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG .

Therefore/RB ,/, increased/VBN monitoring/NN of/IN digoxin/NN is/VBZ recommended/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, or/CC discontinuing/VBG COREG/NN ./.


DrugDDI.d348
DrugDDI.d348.s14
Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.

Inducers/NNS and/CC Inhibitors/NNS of/IN Hepatic/JJ Metabolism/NN :/: Rifampin/NN reduced/VBD plasma/NN concentrations/NNS of/IN carvedilol/NN by/IN about/RB 70/CD %./NN


DrugDDI.d348
DrugDDI.d348.s15
Cimetidine increased AUC by about 30% but caused no change in Cmax.

Cimetidine/NN increased/VBD AUC/NN by/IN about/RB 30/CD %/NN but/CC caused/VBD no/DT change/NN in/IN Cmax/NN ./.


DrugDDI.d348
DrugDDI.d348.s16
Calcium Channel Blockers : Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem .

Calcium/NN Channel/NN Blockers/NNS :/: Isolated/VBN cases/NNS of/IN conduction/NN disturbance/NN (/-LRB- rarely/RB with/IN hemodynamic/JJ compromise/VB )/-RRB- have/VBP been/VBN observed/VBN when/WRB COREG/NN is/VBZ co-administered/VBN with/IN diltiazem/NN ./.


DrugDDI.d348
DrugDDI.d348.s17
As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.

As/IN with/IN other/JJ agents/NNS with/IN b-blocking/JJ properties/NNS ,/, if/IN COREG/NN is/VBZ to/TO be/VB administered/VBN orally/RB with/IN calcium/NN channel/NN blockers/NNS of/IN the/DT verapamil/NN or/CC diltiazem/NN type/NN ,/, it/PRP is/VBZ recommended/VBN that/IN ECG/NN and/CC blood/NN pressure/NN be/VB monitored/VBN ./.


DrugDDI.d348
DrugDDI.d348.s18
Insulin or Oral Hypoglycemics : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .

Insulin/NN or/CC Oral/JJ Hypoglycemics/NN :/: Agents/NNS with/IN b-blocking/JJ properties/NNS may/MD enhance/VB the/DT blood-sugar-reducing/JJ effect/NN of/IN insulin/NN and/CC oral/JJ hypoglycemics/NN ./.


DrugDDI.d348
DrugDDI.d348.s19
Therefore, in patients taking insulin or oral hypoglycemics , regular monitoring of blood glucose is recommended.

Therefore/RB ,/, in/IN patients/NNS taking/VBG insulin/NN or/CC oral/JJ hypoglycemics/NN ,/, regular/JJ monitoring/NN of/IN blood/NN glucose/NN is/VBZ recommended/VBN ./.


DrugDDI.d59
DrugDDI.d59.s0
Studies in vitro show that caspofungin acetate is not an inhibitor of any enzyme in the cytochrome P450 ( CYP ) system.

Studies/NNS in/FW vitro/FW show/VBP that/IN caspofungin/NN acetate/NN is/VBZ not/RB an/DT inhibitor/NN of/IN any/DT enzyme/NN in/IN the/DT cytochrome/NN P450/NN (/-LRB- CYP/NN )/-RRB- system/NN ./.


DrugDDI.d59
DrugDDI.d59.s1
In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs .

In/IN clinical/JJ studies/NNS ,/, caspofungin/NN did/VBD not/RB induce/VB the/DT CYP3A4/NN metabolism/NN of/IN other/JJ drugs/NNS ./.


DrugDDI.d59
DrugDDI.d59.s2
Caspofungin is not a substrate for P- glycoprotein and is a poor substrate for cytochrome P450 enzymes.

Caspofungin/NN is/VBZ not/RB a/DT substrate/NN for/IN P-/NN glycoprotein/NN and/CC is/VBZ a/DT poor/JJ substrate/NN for/IN cytochrome/NN P450/NN enzymes/NNS ./.


DrugDDI.d59
DrugDDI.d59.s3
Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole , amphotericin B , mycophenolate , nelfinavir , or tacrolimus .

Clinical/JJ studies/NNS in/IN healthy/JJ volunteers/NNS show/VBP that/IN the/DT pharmacokinetics/NNS of/IN CANCIDAS/NNS are/VBP not/RB altered/VBN by/IN itraconazole/NN ,/, amphotericin/NN B/NN ,/, mycophenolate/NN ,/, nelfinavir/NN ,/, or/CC tacrolimus/NN ./.


DrugDDI.d59
DrugDDI.d59.s4
CANCIDAS has no effect on the pharmacokinetics of itraconazole , amphotericin B , or the active metabolite of mycophenolate .

CANCIDAS/NN has/VBZ no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN itraconazole/NN ,/, amphotericin/NN B/NN ,/, or/CC the/DT active/JJ metabolite/NN of/IN mycophenolate/NN ./.


DrugDDI.d59
DrugDDI.d59.s5
CANCIDAS reduced the blood AUC0-12 of tacrolimus ( FK-506 , Prograf span class= c4 @3) by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.

CANCIDAS/NN reduced/VBD the/DT blood/NN AUC0-12/CD of/IN tacrolimus/NN (/-LRB- FK-506/NN ,/, Prograf/NN span/NN class=/NN c4/NN @/NN 3/CD )/-RRB- by/IN approximately/RB 20/CD %/NN ,/, peak/JJ blood/NN concentration/NN (/-LRB- Cmax/NN )/-RRB- by/IN 16/CD %/NN ,/, and/CC 12-hour/JJ blood/NN concentration/NN (/-LRB- C12hr/NN )/-RRB- by/IN 26/CD %/NN in/IN healthy/JJ subjects/NNS when/WRB tacrolimus/NN (/-LRB- 2/CD doses/NNS of/IN 0.1/CD mg/kg/NN 12/CD hours/NNS apart/RB )/-RRB- was/VBD administered/VBN on/IN the/DT 10th/JJ day/NN of/IN CANCIDAS/NN 70/CD mg/NN daily/RB ,/, as/IN compared/VBN to/TO results/NNS from/IN a/DT control/NN period/NN in/IN which/WDT tacrolimus/NN was/VBD administered/VBN alone/RB ./.


DrugDDI.d59
DrugDDI.d59.s6
For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.

For/IN patients/NNS receiving/VBG both/DT therapies/NNS ,/, standard/JJ monitoring/NN of/IN tacrolimus/NN blood/NN concentrations/NNS and/CC appropriate/JJ tacrolimus/NN dosage/NN adjustments/NNS are/VBP recommended/VBN ./.


DrugDDI.d59
DrugDDI.d59.s7
In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.

In/IN two/CD clinical/JJ studies/NNS ,/, cyclosporine/NN (/-LRB- one/CD 4/CD mg/kg/NN dose/NN or/CC two/CD 3/CD mg/kg/NN doses/NNS )/-RRB- increased/VBD the/DT AUC/NN of/IN caspofungin/NN by/IN approximately/RB 35/CD %./NN


DrugDDI.d59
DrugDDI.d59.s8
CANCIDAS did not increase the plasma levels of cyclosporine .

CANCIDAS/NN did/VBD not/RB increase/VB the/DT plasma/NN levels/NNS of/IN cyclosporine/NN ./.


DrugDDI.d59
DrugDDI.d59.s9
There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.

There/EX were/VBD transient/JJ increases/NNS in/IN liver/NN ALT/NN and/CC AST/NN when/WRB CANCIDAS/NN and/CC cyclosporine/NN were/VBD co-administered/VBN ./.


DrugDDI.d59
DrugDDI.d59.s10
A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.

A/DT drug-drug/JJ interaction/NN study/NN with/IN rifampin/NN in/IN healthy/JJ volunteers/NNS has/VBZ shown/VBN a/DT 30/CD %/NN decrease/NN in/IN caspofungin/NN trough/NN concentrations/NNS ./.


DrugDDI.d59
DrugDDI.d59.s11
Patients on rifampin should receive 70 mg of CANCIDAS daily.

Patients/NNS on/IN rifampin/NN should/MD receive/VBP 70/CD mg/NN of/IN CANCIDAS/NNS daily/RB ./.


DrugDDI.d59
DrugDDI.d59.s12
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.

In/IN addition/NN ,/, results/NNS from/IN regression/NN analyses/NNS of/IN patient/NN pharmacokinetic/JJ data/NNS suggest/VBP that/IN co-administration/NN of/IN other/JJ inducers/NNS of/IN drug/NN clearance/NN (/-LRB- efavirenz/NN ,/, nevirapine/NN ,/, phenytoin/NN ,/, dexamethasone/NN ,/, or/CC carbamazepine/NN )/-RRB- with/IN CANCIDAS/NN may/MD result/VB in/IN clinically/RB meaningful/JJ reductions/NNS in/IN caspofungin/NN concentrations/NNS ./.


DrugDDI.d59
DrugDDI.d59.s13
It is not known which drug clearance mechanism involved in caspofungin disposition may be inducible.

It/PRP is/VBZ not/RB known/VBN which/WDT drug/NN clearance/NN mechanism/NN involved/VBN in/IN caspofungin/NN disposition/NN may/MD be/VB inducible/JJ ./.


DrugDDI.d59
DrugDDI.d59.s14
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of 70 mg of CANCIDAS should be considered .

When/WRB CANCIDAS/NN is/VBZ co-administered/VBN with/IN inducers/NNS of/IN drug/NN clearance/NN ,/, such/JJ as/IN efavirenz/NN ,/, nevirapine/NN ,/, phenytoin/NN ,/, dexamethasone/NN ,/, or/CC carbamazepine/NN ,/, use/NN of/IN a/DT daily/JJ dose/NN of/IN 70/CD mg/NN of/IN CANCIDAS/NN should/MD be/VB considered/VBN ./.


DrugDDI.d67
DrugDDI.d67.s0
Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.

Probenecid/NN may/MD decrease/VB renal/JJ tubular/JJ secretion/NN of/IN cephalosporins/NNS when/WRB used/VBN concurrently/RB ,/, resulting/VBG in/IN increased/VBN and/CC more/RBR prolonged/JJ cephalosporin/NN blood/NN levels/NNS ./.


DrugDDI.d67
DrugDDI.d67.s1
Drug /Laboratory Test Interactions : A false positive reaction for glucose in the urine may occur with Benedicts solution, Fehlings solution or with CLINITEST@ tablets, but not with enzyme-based tests such as CLINISTIX@.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: A/DT false/JJ positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN may/MD occur/VB with/IN Benedicts/NN solution/NN ,/, Fehlings/NN solution/NN or/CC with/IN CLINITEST/NN @/NN tablets/NNS ,/, but/CC not/RB with/IN enzyme-based/JJ tests/NNS such/JJ as/IN CLINISTIX/JJ @./NNS


DrugDDI.d67
DrugDDI.d67.s2
Positive direct and indirect antiglobulin (Coombs) tests have occurred; .

Positive/JJ direct/JJ and/CC indirect/JJ antiglobulin/NN (/-LRB- Coombs/NN )/-RRB- tests/NNS have/VBP occurred/VBN ;/: ./.


DrugDDI.d67
DrugDDI.d67.s3
these may also occur in neonates whose mothers received cephalosporins before delivery.

these/DT may/MD also/RB occur/VB in/IN neonates/NNS whose/WP$ mothers/NNS received/VBD cephalosporins/NN before/IN delivery/NN ./.


DrugDDI.d152
DrugDDI.d152.s0
Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol , the estrogenic component in most oral contraceptives .

Oral/JJ Contraceptives/NN Multiple/JJ doses/NNS of/IN cefditoren/CD pivoxil/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN ethinyl/NN estradiol/NN ,/, the/DT estrogenic/JJ component/NN in/IN most/JJS oral/JJ contraceptives/NNS ./.


DrugDDI.d152
DrugDDI.d152.s1
Antacids Co-administration of a single dose of an antacid which contained both magnesium (800 mg) and aluminum (900 mg) hydroxides reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 14% decrease in mean Cmax and an 11% decrease in mean AUC.

Antacids/NNS Co-administration/NN of/IN a/DT single/JJ dose/NN of/IN an/DT antacid/JJ which/WDT contained/VBD both/CC magnesium/NN (/-LRB- 800/CD mg/NN )/-RRB- and/CC aluminum/NN (/-LRB- 900/CD mg/NN )/-RRB- hydroxides/NNS reduced/VBD the/DT oral/JJ absorption/NN of/IN a/DT single/JJ 400/CD mg/NN dose/NN of/IN cefditoren/CD pivoxil/NN administered/VBN following/VBG a/DT meal/NN ,/, as/IN evidenced/VBN by/IN a/DT 14/CD %/NN decrease/NN in/IN mean/JJ Cmax/NN and/CC an/DT 11/CD %/NN decrease/NN in/IN mean/JJ AUC/NN ./.


DrugDDI.d152
DrugDDI.d152.s2
Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids .

Although/IN the/DT clinical/JJ significance/NN is/VBZ not/RB known/VBN ,/, it/PRP is/VBZ not/RB recommended/VBN that/IN cefditoren/CD pivoxil/NN be/VB taken/VBN concomitantly/RB with/IN antacids/NNS ./.


DrugDDI.d152
DrugDDI.d152.s3
H2-Receptor Antagonists Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.

H2-Receptor/JJ Antagonists/NNS Co-administration/NN of/IN a/DT single/JJ dose/NN of/IN intravenously/RB administered/VBN famotidine/NN (/-LRB- 20/CD mg/NN )/-RRB- reduced/VBD the/DT oral/JJ absorption/NN of/IN a/DT single/JJ 400/CD mg/NN dose/NN of/IN cefditoren/CD pivoxil/NN administered/VBN following/VBG a/DT meal/NN ,/, as/IN evidenced/VBN by/IN a/DT 27/CD %/NN decrease/NN in/IN mean/JJ Cmax/NN and/CC a/DT 22/CD %/NN decrease/NN in/IN mean/JJ AUC/NN ./.


DrugDDI.d152
DrugDDI.d152.s4
Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.

Although/IN the/DT clinical/JJ significance/NN is/VBZ not/RB known/VBN ,/, it/PRP is/VBZ not/RB recommended/VBN that/IN cefditoren/CD pivoxil/NN be/VB taken/VBN concomitantly/RB with/IN H2/NN receptor/NN antagonists/NNS ./.


DrugDDI.d152
DrugDDI.d152.s5
Probenecid : As with other b-lactam antibiotics , co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.

Probenecid/NN :/: As/IN with/IN other/JJ b-lactam/NN antibiotics/NNS ,/, co-administration/NN of/IN probenecid/NN with/IN cefditoren/CD pivoxil/NN resulted/VBD in/IN an/DT increase/NN in/IN the/DT plasma/NN exposure/NN of/IN cefditoren/NN ,/, with/IN a/DT 49/CD %/NN increase/NN in/IN mean/NN Cmax/NN ,/, a/DT 122/CD %/NN increase/NN in/IN mean/JJ AUC/NN ,/, and/CC a/DT 53/CD %/NN increase/NN in/IN half-life/NN ./.


DrugDDI.d152
DrugDDI.d152.s6
Drug /Laboratory Test Interactions Cephalosporins are known to occasionally induce a positive direct Coombs test.

Drug/NN /Laboratory/JJ Test/NN Interactions/NNS Cephalosporins/NNS are/VBP known/VBN to/TO occasionally/RB induce/VB a/DT positive/JJ direct/JJ Coombs/NN test/NN ./.


DrugDDI.d152
DrugDDI.d152.s7
A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedicts or Fehlings solution or with CLINITEST tablets), but not with enzyme-based tests for glycosuria (e.g., CLINISTIX, TES-TAPE).

A/DT false-positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN may/MD occur/VB with/IN copper/NN reduction/NN tests/NNS (/-LRB- Benedicts/NNP or/CC Fehlings/NNP solution/NN or/CC with/IN CLINITEST/JJ tablets/NNS )/-RRB- ,/, but/CC not/RB with/IN enzyme-based/JJ tests/NNS for/IN glycosuria/NN (/-LRB- e.g./FW ,/, CLINISTIX/NN ,/, TES-TAPE/JJ )./NN


DrugDDI.d152
DrugDDI.d152.s8
As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefditoren pivoxil .

As/IN a/DT false-negative/JJ result/NN may/MD occur/VB in/IN the/DT ferricyanide/NN test/NN ,/, it/PRP is/VBZ recommended/VBN that/IN either/CC the/DT glucose/NN oxidase/NN or/CC hexokinase/NN method/NN be/VB used/VBN to/TO determine/VB blood/plasma/NN glucose/NN levels/NNS in/IN patients/NNS receiving/VBG cefditoren/NN pivoxil/NN ./.


DrugDDI.d373
DrugDDI.d373.s0
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics .

Increased/VBN nephrotoxicity/NN has/VBZ been/VBN reported/VBN following/VBG concomitant/JJ administration/NN of/IN cephalosporins/NNS and/CC aminoglycoside/NN antibiotics/NNS ./.


DrugDDI.d373
DrugDDI.d373.s1
Drug /Laboratory Test Interactions : As with cephalothin , high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff@ reaction, and produce false increases of modest degree in the levels of creatinine reported.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: As/IN with/IN cephalothin/NN ,/, high/JJ concentrations/NNS of/IN cefoxitin/NN (/-LRB- 100/CD micrograms/mL/NNS )/-RRB- may/MD interfere/VB with/IN measurement/NN of/IN serum/NN and/CC urine/NN creatinine/NN levels/NNS by/IN the/DT Jaff/NN @/NN reaction/NN ,/, and/CC produce/VBP false/JJ increases/NNS of/IN modest/JJ degree/NN in/IN the/DT levels/NNS of/IN creatinine/NN reported/VBD ./.


DrugDDI.d373
DrugDDI.d373.s2
Serum samples from patients treated with cefoxitin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.

Serum/NN samples/NNS from/IN patients/NNS treated/VBN with/IN cefoxitin/NN should/MD not/RB be/VB analyzed/VBN for/IN creatinine/NN if/IN withdrawn/VBN within/IN 2/CD hours/NNS of/IN drug/NN administration/NN ./.


DrugDDI.d373
DrugDDI.d373.s3
High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy- corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.

High/JJ concentrations/NNS of/IN cefoxitin/NN in/IN the/DT urine/NN may/MD interfere/VB with/IN measurement/NN of/IN urinary/JJ 17-hydroxy-/JJ corticosteroids/NNS by/IN the/DT Porter-Silber/NN reaction/NN ,/, and/CC produce/VB false/JJ increases/NNS of/IN modest/JJ degree/NN in/IN the/DT levels/NNS reported/VBN ./.


DrugDDI.d373
DrugDDI.d373.s4
A false-positive reaction for glucose in the urine may occur.

A/DT false-positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN may/MD occur/VB ./.


DrugDDI.d373
DrugDDI.d373.s7
@ Registered trademark of Ame s Company, Division of Miles Laboratories, Inc.

@/NN Registered/JJ trademark/NN of/IN Ame/NN s/NN Company/NN ,/, Division/NN of/IN Miles/NN Laboratories/NNS ,/, Inc./NNP ./.


DrugDDI.d169
DrugDDI.d169.s0
Immunosuppressive Drugs, Fibric Acid Derivatives , Niacin ( Nicotinic Acid , Erythromycin , Azole Antifungals : Skeletal Muscle.

Immunosuppressive/JJ Drugs/NNS ,/, Fibric/JJ Acid/NN Derivatives/NNS ,/, Niacin/NN (/-LRB- Nicotinic/JJ Acid/NN ,/, Erythromycin/NN ,/, Azole/JJ Antifungals/NNS :/: Skeletal/JJ Muscle/NN ./.


DrugDDI.d169
DrugDDI.d169.s1
ANTACID ( Magnesium-Aluminum Hydroxide ): Cerivastatin plasma concentrations were not affected by co-administration of antacid .

ANTACID/JJ (/-LRB- Magnesium-Aluminum/NN Hydroxide/NN )/-RRB- :/: Cerivastatin/NN plasma/NN concentrations/NNS were/VBD not/RB affected/VBN by/IN co-administration/NN of/IN antacid/JJ ./.


DrugDDI.d169
DrugDDI.d169.s2
CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine .

CIMETlDINE/NN :/: Cerivastatin/NN plasma/NN concentrations/NNS were/VBD not/RB affected/VBN by/IN co-administration/NN of/IN cimetidine/NN ./.


DrugDDI.d169
DrugDDI.d169.s3
CHOLESTYRAMINE : The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.

CHOLESTYRAMINE/NN :/: The/DT influence/NN of/IN the/DT bile-acidsequestering/JJ agent/NN cholestyramine/NN on/IN the/DT pharmacokinetits/NNS of/IN cerivastatin/NN sodium/NN was/VBD evaluated/VBN in/IN 12/CD healthy/JJ males/NNS in/IN 2/CD separate/JJ randomized/JJ crossover/NN studies/NNS ./.


DrugDDI.d169
DrugDDI.d169.s4
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.

In/IN the/DT first/JJ study/NN ,/, concomitant/JJ administration/NN of/IN 0.2/CD mg/NN cerivastatin/NN sodium/NN and/CC 12/CD g/NN cholestyramine/NN resulted/VBD in/IN decreases/NNS of/IN more/JJR than/IN 22/CD %/NN for/IN AUC/NN and/CC 40/CD %/NN for/IN Cmax/NN when/WRB compared/VBN to/TO dosing/NN cerivastatin/NN sodium/NN alone/RB ./.


DrugDDI.d169
DrugDDI.d169.s5
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.

However/RB ,/, in/IN the/DT second/JJ study/NN ,/, administration/NN of/IN 12/CD g/NN cholestyramine/NN 1/CD hour/NN before/IN the/DT evening/NN meal/NN and/CC 0.3/CD mg/NN cerivastatin/NN sodium/NN approximately/RB 4/CD hours/NNS after/IN the/DT same/JJ evening/NN meal/NN resulted/VBD in/IN a/DT decrease/NN in/IN the/DT cerivastatin/NN AUC/NN of/IN less/JJR than/IN 8/CD %/NN ,/, and/CC a/DT decrease/NN in/IN Cmax/NN of/IN about/RB 30/CD %/NN when/WRB compared/VBN to/TO dosing/NN cerivastatin/NN sodium/NN alone/RB ./.


DrugDDI.d169
DrugDDI.d169.s6
Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium .

Therefore/RB ,/, it/PRP would/MD be/VB expected/VBN that/IN a/DT dosing/NN schedule/NN of/IN cerivastatin/NN sodium/NN given/VBN at/IN bedtime/NN and/CC cholestyramine/NN given/VBN before/IN the/DT evening/NN meal/NN would/MD not/RB result/VB in/IN a/DT significant/JJ decrease/NN in/IN the/DT clinical/JJ effect/NN of/IN cerivastatin/NN sodium/NN ./.


DrugDDI.d169
DrugDDI.d169.s7
DIGOXIN : Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium .

DIGOXIN/NN :/: Plasma/NN digoxin/NN levels/NNS and/CC digoxin/NN clearance/NN at/IN steady-state/NN were/VBD not/RB affected/VBN by/IN co-administration/NN of/IN 0.2/CD mg/NN cerivastatin/NN sodium/NN ./.


DrugDDI.d169
DrugDDI.d169.s8
Cerivastatin plasma concentrations were also not affected by co-administration of digoxin .

Cerivastatin/NN plasma/NN concentrations/NNS were/VBD also/RB not/RB affected/VBN by/IN co-administration/NN of/IN digoxin/NN ./.


DrugDDI.d169
DrugDDI.d169.s9
WARFARIN : Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.

WARFARIN/NN :/: Co-/NN administration/NN of/IN warfarin/NN and/CC cerivastatin/NN to/TO healthy/JJ volunteers/NNS did/VBD not/RB result/VB in/IN any/DT changes/NNS in/IN prothrombin/NN time/NN or/CC clotting/NN factor/NN VII/NN when/WRB compared/VBN to/TO co-administration/NN of/IN warfarin/NN and/CC placebo/NN ./.


DrugDDI.d169
DrugDDI.d169.s10
The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium .

The/DT AUC/NN and/CC Cmax/NN of/IN both/DT the/DT (/-LRB- R/NN )/-RRB- and/CC (/-LRB- S/NN )/-RRB- isomers/NNS of/IN warfarin/NN were/VBD unaffected/VBN by/IN concurrent/JJ dosing/NN of/IN 0.3/CD mg/NN cerivastatin/NN sodium/NN ./.


DrugDDI.d169
DrugDDI.d169.s11
Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium .

Co-administration/NN of/IN warfarin/NN and/CC cerivastatin/NN did/VBD not/RB alter/VB the/DT pharmacokinetics/NNS of/IN cerivastatin/NN sodium/NN ./.


DrugDDI.d169
DrugDDI.d169.s12
ERYTHROMYCIN : In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin , a known inhibitor of cytochrome P450 3A4 .

ERYTHROMYCIN/NN :/: In/IN hypercholesterolemic/JJ patients/NNS ,/, steady-state/JJ cerivastatin/NN AUC/NN and/CC Cmax/NN increased/VBD approximately/RB 50/CD %/NN and/CC 24/CD %/NN respectively/RB after/IN 10/CD days/NNS with/IN co-administration/NN of/IN erythromycin/NN ,/, a/DT known/JJ inhibitor/NN of/IN cytochrome/NN P450/NN 3A4/NN ./.


DrugDDI.d169
DrugDDI.d169.s13
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions.

OTHER/JJ CONCOMITANT/JJ THERAPY/NN :/: Although/IN specific/JJ interaction/NN studies/NNS were/VBD not/RB performed/VBN ,/, in/IN clinical/JJ studies/NNS ,/, cerivastatin/NN sodium/NN was/VBD used/VBN concomitantly/RB with/IN angiotensin-/NN converting/NN enzyme/NN (/-LRB- ACE/NN )/-RRB- inhibitors/NNS ,/, betablockers/NNS ,/, calcium-channel/NN blockers/NNS ,/, diuretics/NN ,/, and/CC nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS (/-LRB- NSAIDs/NNS )/-RRB- without/IN evidence/NN of/IN clinically/RB significant/JJ adverse/JJ interactions/NNS ./.


DrugDDI.d125
DrugDDI.d125.s0
Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide .

Although/IN clinical/JJ studies/NNS have/VBP not/RB established/VBN a/DT cause/NN and/CC effect/NN relationship/NN ,/, physicians/NNS should/MD be/VB aware/NN that/IN variable/JJ effects/NNS an/DT blood/NN coagulation/NN have/VBP been/VBN reported/VBN very/RB rarely/RB in/IN patients/NNS receiving/VBG oral/JJ anticoagulants/NNS and/CC chlordiazepoxide/NN ./.


DrugDDI.d125
DrugDDI.d125.s1
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.

The/DT concomitant/JJ use/NN of/IN alcohol/NN or/CC other/JJ central/JJ nervous/JJ system/NN depressants/NNS may/MD have/VB an/DT additive/JJ effect/NN ./.


DrugDDI.d261
DrugDDI.d261.s0
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors , tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.

The/DT administration/NN of/IN local/JJ anesthetic/JJ solutions/NNS containing/VBG epinephrine/NN or/CC norepinephrine/NN to/TO patients/NNS receiving/VBG monoamine/NN oxidase/NN inhibitors/NNS ,/, tricyclic/JJ antidepressants/NNS or/CC phenothiazines/NNS may/MD produce/VB severe/JJ ,/, prolonged/JJ hypotension/NN or/CC hypertension/NN ./.


DrugDDI.d261
DrugDDI.d261.s3
Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

Concurrent/JJ administration/NN of/IN vasopressor/JJ drugs/NNS (/-LRB- for/IN the/DT treatment/NN of/IN hypotension/NN related/JJ to/TO obstetric/JJ blocks/NNS )/-RRB- and/CC ergot-type/JJ oxytocic/JJ drugs/NNS may/MD cause/VB severe/JJ ,/, persistent/JJ hypertension/NN or/CC cerebrovascular/JJ accidents/NN ./.


DrugDDI.d261
DrugDDI.d261.s4
The para-aminobenzoic acid metabolite of chloroprocaine inhibits the action of sulfonamides .

The/DT para-aminobenzoic/JJ acid/NN metabolite/NN of/IN chloroprocaine/NN inhibits/VBZ the/DT action/NN of/IN sulfonamides/NNS ./.


DrugDDI.d261
DrugDDI.d261.s5
Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.

Therefore/RB ,/, chloroprocaine/NN should/MD not/RB be/VB used/VBN in/IN any/DT condition/NN in/IN which/WDT a/DT sulfonamide/NN drug/NN is/VBZ being/VBG employed/VBN ./.


DrugDDI.d354
DrugDDI.d354.s0
When given concurrently the following drugs may interact with thiazide diuretics .

When/WRB given/VBN concurrently/RB the/DT following/JJ drugs/NNS may/MD interact/VB with/IN thiazide/NN diuretics/NNS ./.


DrugDDI.d354
DrugDDI.d354.s1
- Alcohol , barbiturates , or narcotics : Potentiation of otthostatic hypotension may occur .

-/CC Alcohol/NN ,/, barbiturates/NNS ,/, or/CC narcotics/NNS :/: Potentiation/NN of/IN otthostatic/JJ hypotension/NN may/MD occur/VB ./.


DrugDDI.d354
DrugDDI.d354.s3
- Antidiabetic drugs : (Oral agents and insulin ) Dosage adjustment of the antidiabetic drug may be required .

-/CC Antidiabetic/JJ drugs/NNS :/: (/-LRB- Oral/JJ agents/NNS and/CC insulin/NN )/-RRB- Dosage/NN adjustment/NN of/IN the/DT antidiabetic/JJ drug/NN may/MD be/VB required/VBN ./.


DrugDDI.d354
DrugDDI.d354.s5
- Other antihypertensive drugs : Additive effect or potentiation .

-/CC Other/JJ antihypertensive/JJ drugs/NNS :/: Additive/JJ effect/NN or/CC potentiation/NN ./.


DrugDDI.d354
DrugDDI.d354.s7
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract .

-/CC Cholestyramine/NN and/CC colestipol/NN resins/NNS :/: Cholestytamine/NN and/CC colestipol/NN resins/NNS have/VBP the/DT potential/NN of/IN binding/NN thiazide/NN diuretics/NNS and/CC reducing/VBG diuretic/JJ absorption/NN from/IN the/DT gastrointestinal/JJ tract/NN ./.


DrugDDI.d354
DrugDDI.d354.s9
- Corticosteroids , ACTH : Intensified electrolyte depletion, particularly hypokalemia .

-/: Corticosteroids/NNS ,/, ACTH/NN :/: Intensified/JJ electrolyte/NN depletion/NN ,/, particularly/RB hypokalemia/NN ./.


DrugDDI.d354
DrugDDI.d354.s11
- Pressor amines (e.g., norepinephrine ): Possible decreased response to pressor amines but not sufficient to preclude their use .

-/CC Pressor/NN amines/NNS (/-LRB- e.g./FW ,/, norepinephrine/NN )/-RRB- :/: Possible/JJ decreased/VBD response/NN to/TO pressor/JJ amines/NNS but/CC not/RB sufficient/JJ to/TO preclude/VB their/PRP$ use/NN ./.


DrugDDI.d354
DrugDDI.d354.s13
- Skeletal muscle relaxants , nondepolarizing (e.g., tubocurarine ): Possible increased responsiveness to the muscle relaxant .

-/CC Skeletal/JJ muscle/NN relaxants/NNS ,/, nondepolarizing/JJ (/-LRB- e.g./FW ,/, tubocurarine/NN )/-RRB- :/: Possible/JJ increased/VBN responsiveness/NN to/TO the/DT muscle/NN relaxant/NN ./.


DrugDDI.d354
DrugDDI.d354.s15
- Lithium : Generally should not be given with diuretics .

-/CC Lithium/NN :/: Generally/RB should/MD not/RB be/VB given/VBN with/IN diuretics/NN ./.


DrugDDI.d354
DrugDDI.d354.s16
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.

Diuretic/JJ agents/NNS reduce/VBP the/DT renal/JJ clearance/NN of/IN lithium/NN and/CC add/VBP a/DT high/JJ risk/NN of/IN lithium/NN toxicity/NN ./.


DrugDDI.d354
DrugDDI.d354.s17
Refer to the package insert for lithium preparation s before use of such preparations with chlorothiazide .

Refer/VBP to/TO the/DT package/JJ insert/NN for/IN lithium/NN preparation/NN s/NNS before/IN use/NN of/IN such/JJ preparations/NNS with/IN chlorothiazide/NN ./.


DrugDDI.d354
DrugDDI.d354.s19
- Non-steroidal Anti-inflammatory Drugs : In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium -sparing and thiazide diuretics .

-/CC Non-steroidal/JJ Anti-inflammatory/JJ Drugs/NNS :/: In/IN some/DT patients/NNS ,/, the/DT administration/NN of/IN a/DT non-steroidal/JJ anti-inflammatory/JJ agent/NN can/MD reduce/VB the/DT diuretic/JJ ,/, natriuretic/JJ ,/, and/CC antihypertensive/JJ effects/NNS of/IN loop/NN ,/, potassium/NN -sparing/NN and/CC thiazide/NN diuretics/NNS ./.


DrugDDI.d354
DrugDDI.d354.s20
Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained .

Therefore/RB ,/, when/WRB chlorothiazide/NN and/CC non-steroidal/JJ anti-inflammatory/JJ agents/NNS are/VBP used/VBN concomitantly/RB ,/, the/DT patient/NN should/MD be/VB observed/VBN closely/RB to/TO determine/VB if/IN the/DT desired/JJ effect/NN of/IN the/DT diuretic/NN is/VBZ obtained/VBN ./.


DrugDDI.d354
DrugDDI.d354.s22
- Drug /Laboratory Test Interactions: Thiazides should be discontinued before carrying out tests for parathyroid function.

-/CC Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: Thiazides/NNS should/MD be/VB discontinued/VBN before/IN carrying/VBG out/RP tests/NNS for/IN parathyroid/JJ function/NN ./.


DrugDDI.d113
DrugDDI.d113.s0
Interactions for vitamin D analogues ( Vitamin D2 , Vitamin D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; .

Interactions/NNS for/IN vitamin/NN D/NN analogues/NNS (/-LRB- Vitamin/NN D2/NN ,/, Vitamin/NN D3/NN ,/, Calcitriol/NN ,/, and/CC Calcidiol/NN )/-RRB- :/: Cholestyramine/NN :/: Cholestyramine/NN has/VBZ been/VBN reported/VBN to/TO reduce/VB intestinal/JJ absorption/NN of/IN fat/JJ soluble/JJ vitamins/NNS ;/: ./.


DrugDDI.d113
DrugDDI.d113.s1
as such it may impair intestinal absorption of any of vitamin D .

as/IN such/JJ it/PRP may/MD impair/VB intestinal/JJ absorption/NN of/IN any/DT of/IN vitamin/NN D/NN ./.


DrugDDI.d113
DrugDDI.d113.s2
Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism.

Phenytoin/NN //: Phenobarbital/NN :/: The/DT coadministration/NN of/IN phenytoin/NN or/CC phenobarbital/NN will/MD not/RB affect/VB plasma/NN concentrations/NNS of/IN vitamin/NN D/NN ,/, but/CC may/MD reduce/VB endogenous/JJ plasma/NN levels/NNS of/IN calcitriol/NN /ergocalcitriol/NN by/IN accelerating/VBG metabolism/NN ./.


DrugDDI.d113
DrugDDI.d113.s3
Since blood level of calcitriol /ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.

Since/IN blood/NN level/NN of/IN calcitriol/NN /ergocalcitriol/NN will/MD be/VB reduced/VBN ,/, higher/JJR doses/NNS of/IN Rocaltrol/NN may/MD be/VB necessary/JJ if/IN these/DT drugs/NNS are/VBP administered/VBN simultaneously/RB ./.


DrugDDI.d113
DrugDDI.d113.s4
Thiazides : Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.

Thiazides/NNS :/: Thiazides/NNS are/VBP known/VBN to/TO induce/VB hypercalcemia/NN by/IN the/DT reduction/NN of/IN calcium/NN excretion/NN in/IN urine/NN ./.


DrugDDI.d113
DrugDDI.d113.s5
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.

Some/DT reports/NNS have/VBP shown/VBN that/IN the/DT concomitant/JJ administration/NN of/IN thiazides/NNS with/IN vitamin/NN D/NN causes/VBZ hypercalcemia/NN ./.


DrugDDI.d113
DrugDDI.d113.s7
Digitalis : Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis , as hypercalcemia in such patients may precipitate cardiac arrhythmias.

Digitalis/NN :/: Vitamin/NN D/NN dosage/NN must/MD be/VB determined/VBN with/IN care/NN in/IN patients/NNS undergoing/VBG treatment/NN with/IN digitalis/NN ,/, as/IN hypercalcemia/NN in/IN such/JJ patients/NNS may/MD precipitate/VB cardiac/JJ arrhythmias/NNS ./.


DrugDDI.d113
DrugDDI.d113.s8
Ketoconazole : Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D .

Ketoconazole/NN :/: Ketoconazole/NN may/MD inhibit/VBP both/CC synthetic/JJ and/CC catabolic/JJ enzymes/NNS of/IN vitamin/NN D/NN ./.


DrugDDI.d113
DrugDDI.d113.s9
Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.

Reductions/NNS in/IN serum/NN endogenous/JJ vitamin/NN D/NN concentrations/NNS have/VBP been/VBN observed/VBN following/VBG the/DT administration/NN of/IN 300/CD mg/day/NN to/TO 1200/CD mg/day/NN ketoconazole/NN for/IN a/DT week/NN to/TO healthy/JJ men/NNS ./.


DrugDDI.d113
DrugDDI.d113.s10
However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.

However/RB ,/, in/FW vivo/FW drug/NN interaction/NN studies/NNS of/IN ketoconazole/NN with/IN vitamin/NN D/NN have/VBP not/RB been/VBN investigated/VBN ./.


DrugDDI.d113
DrugDDI.d113.s11
Corticosteroids : A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids , which inhibit calcium absorption.

Corticosteroids/NNS :/: A/DT relationship/NN of/IN functional/JJ antagonism/NN exists/VBZ between/IN vitamin/NN D/NN analogues/NNS ,/, which/WDT promote/VBP calcium/NN absorption/NN ,/, and/CC corticosteroids/NNS ,/, which/WDT inhibit/VBP calcium/NN absorption/NN ./.


DrugDDI.d113
DrugDDI.d113.s12
Phosphate-Binding Agents : Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.

Phosphate-Binding/JJ Agents/NNS :/: Since/IN vitamin/NN D/NN also/RB has/VBZ an/DT effect/NN on/IN phosphate/NN transport/NN in/IN the/DT intestine/NN ,/, kidneys/NN and/CC bones/NN ,/, the/DT dosage/NN of/IN phosphate-binding/JJ agents/NNS must/MD be/VB adjusted/VBN in/IN accordance/NN with/IN the/DT serum/NN phosphate/NN concentration/NN ./.


DrugDDI.d113
DrugDDI.d113.s13
Vitamin D : The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.

Vitamin/NN D/NN :/: The/DT coadministration/NN of/IN any/DT of/IN the/DT vitamin/NN D/NN analogues/NNS should/MD be/VB avoided/VBN as/IN this/DT could/MD create/VB possible/JJ additive/JJ effects/NNS and/CC hypercalcemia/NN ./.


DrugDDI.d113
DrugDDI.d113.s14
Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.

Calcium/NN Supplements/NNS :/: Uncontrolled/JJ intake/NN of/IN additional/JJ calcium-containing/JJ preparations/NNS should/MD be/VB avoided/VBN ./.


DrugDDI.d113
DrugDDI.d113.s15
Magnesium : Magnesium-containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.

Magnesium/NN :/: Magnesium-containing/JJ preparations/NNS (/-LRB- eg/FW ,/, antacids/NNS )/-RRB- may/MD cause/VB hypermagnesemia/NN and/CC should/MD therefore/RB not/RB be/VB taken/VBN during/IN therapy/NN with/IN vitamin/NN D/NN by/IN patients/NNS on/IN chronic/JJ renal/JJ dialysis/NN ./.


DrugDDI.d462
DrugDDI.d462.s0
Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones .

Elevated/JJ plasma/NN levels/NNS of/IN theophylline/NN have/VBP been/VBN reported/VBN with/IN concomitant/JJ use/NN of/IN some/DT quinolones/NNS ./.


DrugDDI.d462
DrugDDI.d462.s1
There have been reports of theophylline -related side-effects in patients on concomitant theophylline -quinolone therapy.

There/EX have/VBP been/VBN reports/NNS of/IN theophylline/NN -related/JJ side-effects/NNS in/IN patients/NNS on/IN concomitant/JJ theophylline/NN -quinolone/NN therapy/NN ./.


DrugDDI.d462
DrugDDI.d462.s2
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.

Therefore/RB ,/, monitoring/NN of/IN theophylline/NN plasma/NN levels/NNS should/MD be/VB considered/VBN and/CC dosage/NN of/IN theophylline/NN adjusted/VBN as/IN required/VBN ./.


DrugDDI.d462
DrugDDI.d462.s3
Quinolones have also been shown to interfere with the metabolism of caffeine .

Quinolones/NNS have/VBP also/RB been/VBN shown/VBN to/TO interfere/VB with/IN the/DT metabolism/NN of/IN caffeine/NN ./.


DrugDDI.d462
DrugDDI.d462.s4
This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.

This/DT may/MD lead/VB to/TO reduced/VBN clearance/NN of/IN caffeine/NN and/CC a/DT prolongation/NN of/IN its/PRP$ plasma/NN half-life/NN ./.


DrugDDI.d462
DrugDDI.d462.s5
Although this interaction has not been reported with cinoxacin , caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.

Although/IN this/DT interaction/NN has/VBZ not/RB been/VBN reported/VBN with/IN cinoxacin/NN ,/, caution/NN should/MD be/VB exercised/VBN when/WRB cinoxacin/NN is/VBZ given/VBN concomitantly/RB with/IN caffeine-containing/JJ products/NNS ./.


DrugDDI.d462
DrugDDI.d462.s6
Antacids or sucralfate substantially interfere with the absorption of some quinolones , resulting in low urine levels.

Antacids/NNS or/CC sucralfate/NN substantially/RB interfere/VBP with/IN the/DT absorption/NN of/IN some/DT quinolones/NNS ,/, resulting/VBG in/IN low/JJ urine/NN levels/NNS ./.


DrugDDI.d462
DrugDDI.d462.s7
Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/ buffer ed tablets or the pediatric powder for oral solution may result in low urine levels.

Also/RB ,/, concomitant/JJ administration/NN of/IN quinolones/NNS with/IN products/NNS containing/VBG iron/NN ,/, multivitamins/NN containing/NN zinc/NN ,/, or/CC Videx/NN (/-LRB- didanosine/NN )/-RRB- chewable//NN buffer/NN ed/NN tablets/NNS or/CC the/DT pediatric/JJ powder/NN for/IN oral/JJ solution/NN may/MD result/VB in/IN low/JJ urine/NN levels/NNS ./.


DrugDDI.d462
DrugDDI.d462.s8
Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives .

Quinolones/NNS ,/, including/VBG cinoxacin/NN ,/, may/MD enhance/VB the/DT effects/NNS of/IN oral/JJ anticoagulants/NNS ,/, such/JJ as/IN warfarin/NN or/CC its/PRP$ derivatives/NNS ./.


DrugDDI.d462
DrugDDI.d462.s10
Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.

Seizures/NNS have/VBP been/VBN reported/VBN in/IN patients/NNS taking/VBG another/DT quinolone/NN class/NN antimicrobial/NN and/CC the/DT nonsteroidal/JJ anti-inflammatory/JJ drug/NN fenbufen/VBN concurrently/RB ./.


DrugDDI.d462
DrugDDI.d462.s11
Animal studies also suggest an increased potential for seizures when these 2 drugs are given concomitantly.

Animal/NN studies/NNS also/RB suggest/VBP an/DT increased/VBN potential/NN for/IN seizures/NNS when/WRB these/DT 2/CD drugs/NNS are/VBP given/VBN concomitantly/RB ./.


DrugDDI.d462
DrugDDI.d462.s12
Fenbufen is not approved in the United States at this time.

Fenbufen/NN is/VBZ not/RB approved/JJ in/IN the/DT United/JJ States/NNS at/IN this/DT time/NN ./.


DrugDDI.d462
DrugDDI.d462.s13
Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.

Physicians/NNS are/VBP provided/VBN this/DT information/NN to/TO increase/VB awareness/NN of/IN the/DT potential/NN for/IN serious/JJ interactions/NNS when/WRB cinoxacin/NN and/CC certain/JJ nonsteroidal/JJ anti-inflammatory/JJ agents/NNS are/VBP administered/VBN concomitantly/RB ./.


DrugDDI.d462
DrugDDI.d462.s14
Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine .

Elevated/JJ cyclosporine/NN serum/NN levels/NNS have/VBP been/VBN reported/VBN with/IN the/DT concomitant/JJ use/NN of/IN quinolones/NN and/CC cyclosporine/NN ./.


DrugDDI.d12
DrugDDI.d12.s0
Plasma levels of anticonvulsant agent s may become subtherapeutic during cisplatin therapy.

Plasma/NN levels/NNS of/IN anticonvulsant/JJ agent/NN s/NNS may/MD become/VB subtherapeutic/JJ during/IN cisplatin/NN therapy/NN ./.


DrugDDI.d12
DrugDDI.d12.s1
In a randomized trial in advanced ovarian cancer, response duration was adversely affected when pyridoxine was used in combination with altretamine ( hexamethylmelamine ) and cisplatin .1 .

In/IN a/DT randomized/JJ trial/NN in/IN advanced/JJ ovarian/JJ cancer/NN ,/, response/NN duration/NN was/VBD adversely/RB affected/VBN when/WRB pyridoxine/NN was/VBD used/VBN in/IN combination/NN with/IN altretamine/NN (/-LRB- hexamethylmelamine/NN )/-RRB- and/CC cisplatin/NN .1/NN ./.


DrugDDI.d430
DrugDDI.d430.s0
Central nervous system depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications , muscle relaxants , narcotics , sedatives , sleeping pills and tranquilizers .

Central/JJ nervous/JJ system/NN depressant/JJ (/-LRB- CNS/NN )/-RRB- drugs/NNS including/VBG alcohol/NN ,/, antidepressants/NNS ,/, antihistamines/NNS ,/, antipsychotics/NNS ,/, blood/NN pressure/NN medications/NNS (/-LRB- reserpine/NN ,/, methyldopa/NN ,/, beta-blockers/NN )/-RRB- ,/, motion/NN sickness/NN medications/NNS ,/, muscle/NN relaxants/NNS ,/, narcotics/NNS ,/, sedatives/NNS ,/, sleeping/JJ pills/NNS and/CC tranquilizers/NNS ./.


DrugDDI.d425
DrugDDI.d425.s0
Amantadine , tricyclic antidepressants , and MAOIs may increase anticholinergic effect of clidinium .

Amantadine/NN ,/, tricyclic/JJ antidepressants/NNS ,/, and/CC MAOIs/NN may/MD increase/VB anticholinergic/JJ effect/NN of/IN clidinium/NN ./.


DrugDDI.d425
DrugDDI.d425.s1
Clidinium may decrease the effect of phenothiazines , levodopa , and ketoconazole .

Clidinium/NN may/MD decrease/VB the/DT effect/NN of/IN phenothiazines/NNS ,/, levodopa/NN ,/, and/CC ketoconazole/NN ./.


DrugDDI.d40
DrugDDI.d40.s0
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents .

Clindamycin/NN has/VBZ been/VBN shown/VBN to/TO have/VBP neuromuscular/JJ blocking/NN properties/NNS that/WDT may/MD enhance/VB the/DT action/NN of/IN other/JJ neuromuscular/NN blocking/VBG agents/NNS ./.


DrugDDI.d40
DrugDDI.d40.s2
Antagonism has been demonstrated between clindamycin and erythromycin in vitro.

Antagonism/NN has/VBZ been/VBN demonstrated/VBN between/IN clindamycin/NN and/CC erythromycin/NN in/FW vitro/FW ./.


DrugDDI.d40
DrugDDI.d40.s3
Because of possible clinical significance, these two drugs should not be administered concurrently.

Because/IN of/IN possible/JJ clinical/JJ significance/NN ,/, these/DT two/CD drugs/NNS should/MD not/RB be/VB administered/VBN concurrently/RB ./.


DrugDDI.d119
DrugDDI.d119.s0
Alcohol (increases bioavailability by 50%), cimetidine , and valproates.

Alcohol/NN (/-LRB- increases/VBZ bioavailability/NN by/IN 50/CD %/NN )/-RRB- ,/, cimetidine/NN ,/, and/CC valproates/NN ./.


DrugDDI.d118
DrugDDI.d118.s0
Although no clinical drug-drug interaction studies have been conducted to date, on the basis of the in vitro studies, cytochrome p450 inhibitors and inducers are unlikely to affect the metabolism of clofarabine .

Although/IN no/DT clinical/JJ drug-drug/JJ interaction/NN studies/NNS have/VBP been/VBN conducted/VBN to/TO date/NN ,/, on/IN the/DT basis/NN of/IN the/DT in/FW vitro/FW studies/NNS ,/, cytochrome/NN p450/NN inhibitors/NNS and/CC inducers/NNS are/VBP unlikely/JJ to/TO affect/VB the/DT metabolism/NN of/IN clofarabine/NN ./.


DrugDDI.d118
DrugDDI.d118.s1
The effect of clofarabine on the metabolism of cytochrome p450 substrates has not been studied.

The/DT effect/NN of/IN clofarabine/NN on/IN the/DT metabolism/NN of/IN cytochrome/NN p450/NN substrates/NNS has/VBZ not/RB been/VBN studied/VBN ./.


DrugDDI.d118
DrugDDI.d118.s2
Drug /Laboratory Tests Interactions : There are no known clinically significant interactions of CLOLAR@ with other medications or laboratory tests.

Drug/NN /Laboratory/NN Tests/NNS Interactions/NNS :/: There/EX are/VBP no/RB known/VBN clinically/RB significant/JJ interactions/NNS of/IN CLOLAR/NN @/NN with/IN other/JJ medications/NNS or/CC laboratory/NN tests/NNS ./.


DrugDDI.d118
DrugDDI.d118.s3
No formal drug /laboratory test interaction studies have been conducted with CLOLAR@ .

No/DT formal/JJ drug/NN /laboratory/NN test/NN interaction/NN studies/NNS have/VBP been/VBN conducted/VBN with/IN CLOLAR/JJ @/NN ./.


DrugDDI.d558
DrugDDI.d558.s0
Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.

Preliminary/JJ data/NNS which/WDT suggest/VBP that/IN dapsone/NN may/MD inhibit/VB the/DT anti-inflammatory/JJ activity/NN of/IN Lamprene/NN have/VBP not/RB been/VBN confirmed/VBN ./.


DrugDDI.d558
DrugDDI.d558.s1
If leprosy -associated inflammatory reactions develop in patients being treated with dapsone and clofazimine , it is still advisable to continue treatment with both drugs .

If/IN leprosy/NN -associated/JJ inflammatory/JJ reactions/NNS develop/VBP in/IN patients/NNS being/VBG treated/VBN with/IN dapsone/NN and/CC clofazimine/NN ,/, it/PRP is/VBZ still/RB advisable/JJ to/TO continue/VBP treatment/NN with/IN both/DT drugs/NNS ./.


DrugDDI.d467
DrugDDI.d467.s0
Tablet : If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants , the effect of clonidine may be reduced, thus necessitating an increase in dosage.

Tablet/NN :/: If/IN a/DT patient/NN receiving/VBG clonidine/NN hydrochloride/NN is/VBZ also/RB taking/VBG tricyclic/JJ antidepressants/NNS ,/, the/DT effect/NN of/IN clonidine/NN may/MD be/VB reduced/VBN ,/, thus/RB necessitating/VBG an/DT increase/NN in/IN dosage/NN ./.


DrugDDI.d467
DrugDDI.d467.s1
Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol , barbiturates or other sedatives .

Clonidine/NN hydrochloride/NN may/MD enhance/VB the/DT CNS-depressive/JJ effects/NNS of/IN alcohol/NN ,/, barbiturates/NNS or/CC other/JJ sedatives/NNS ./.


DrugDDI.d467
DrugDDI.d467.s2
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating drugs .

Amitriptyline/NN in/IN combination/NN with/IN clonidine/NN enhances/VBZ the/DT manifestation/NN of/IN corneal/NN lesions/NNS in/IN rats/NNS Epidural/JJ Injection/NN Clonidine/NN may/MD potentiate/VB the/DT CNS-depressive/JJ effect/NN of/IN alcohol/NN ,/, barbiturates/NNS or/CC other/JJ sedating/JJ drugs/NNS ./.


DrugDDI.d467
DrugDDI.d467.s3
Narcotic analgesics may potentiate the hypotensive effects of clonidine .

Narcotic/JJ analgesics/NNS may/MD potentiate/VB the/DT hypotensive/JJ effects/NNS of/IN clonidine/NN ./.


DrugDDI.d467
DrugDDI.d467.s4
Tricyclic antidepressants may antagonize the hypotensive effects of clonidine .

Tricyclic/JJ antidepressants/NNS may/MD antagonize/VB the/DT hypotensive/JJ effects/NNS of/IN clonidine/NN ./.


DrugDDI.d467
DrugDDI.d467.s5
The effects of tricyclic antidepressants on clonidine s analgesic actions are not known.

The/DT effects/NNS of/IN tricyclic/JJ antidepressants/NNS on/IN clonidine/NN s/NN analgesic/JJ actions/NNS are/VBP not/RB known/VBN ./.


DrugDDI.d467
DrugDDI.d467.s6
Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.

Beta/NN blockers/NNS may/MD exacerbate/VB the/DT hypertensive/JJ response/NN seen/VBN with/IN clonidine/NN withdrawl/NN ./.


DrugDDI.d467
DrugDDI.d467.s7
Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis , calcium channel blockers , and beta-blockers .) .

Also/RB ,/, due/JJ to/TO the/DT potential/NN for/IN additive/JJ effects/NNS such/JJ as/IN bradycardia/NN and/CC AV/NN block/NN ,/, caution/NN is/VBZ warranted/VBN in/IN patients/NNS receiving/VBG clonidine/NN with/IN agents/NNS known/VBN to/TO affect/VB sinus/NN node/NN function/NN or/CC AV/NN nodal/JJ conduction/NN (/-LRB- e.g./FW ,/, digitalis/NN ,/, calcium/NN channel/NN blockers/NNS ,/, and/CC beta-blockers/NNS ./. )/-RRB- ./.


DrugDDI.d467
DrugDDI.d467.s8
There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine .

There/EX is/VBZ one/CD reported/VBN case/NN of/IN a/DT patient/NN with/IN acute/JJ delirium/NN associated/VBN with/IN the/DT simultaneous/JJ use/NN of/IN fluphenazine/NN and/CC oral/JJ clonidine/NN ./.


DrugDDI.d467
DrugDDI.d467.s9
Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine .

Symptoms/NNS resolved/VBN when/WRB clonidine/NN was/VBD withdrawn/VBN and/CC recurred/VBN when/WRB the/DT patient/NN was/VBD rechallenged/VBN with/IN clonidine/NN ./.


DrugDDI.d467
DrugDDI.d467.s10
Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics , including both sensory and motor blockade.

Epidural/JJ clonidine/NN may/MD prolong/VB the/DT duration/NN of/IN pharmacologic/JJ effects/NNS of/IN epidural/JJ local/JJ anesthetics/NN ,/, including/VBG both/CC sensory/NN and/CC motor/NN blockade/NN ./.


DrugDDI.d474
DrugDDI.d474.s0
Colchicine is inhibited by acidifying agents .

Colchicine/NN is/VBZ inhibited/VBN by/IN acidifying/JJ agents/NNS ./.


DrugDDI.d474
DrugDDI.d474.s1
The action of colchicine is potentiated by alkalinizing agents .

The/DT action/NN of/IN colchicine/NN is/VBZ potentiated/VBN by/IN alkalinizing/NN agents/NNS ./.


DrugDDI.d474
DrugDDI.d474.s2
Colchicine may increase sensitivity to the CNS depressants .

Colchicine/NN may/MD increase/VB sensitivity/NN to/TO the/DT CNS/NN depressants/NNS ./.


DrugDDI.d474
DrugDDI.d474.s3
Response to sympathomimetic agents may be enhanced by colchicine .

Response/NN to/TO sympathomimetic/JJ agents/NNS may/MD be/VB enhanced/VBN by/IN colchicine/NN ./.


DrugDDI.d469
DrugDDI.d469.s0
Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.

Corticotropin/NN may/MD accentuate/VB the/DT electrolyte/NN loss/NN associated/VBN with/IN diuretic/JJ therapy/NN ./.


DrugDDI.d191
DrugDDI.d191.s1
Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.

Drugs/NNS that/WDT induce/VBP hepatic/JJ enzymes/NNS such/JJ as/IN phenobarbital/NN ,/, phenytoin/NN and/CC rifampin/NN may/MD increase/VB the/DT clearance/NN of/IN corticosteroids/NNS and/CC may/MD require/VB increases/NNS in/IN corticosteroid/NN dose/NN to/TO achieve/VB the/DT desired/JJ response/NN ./.


DrugDDI.d191
DrugDDI.d191.s2
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.

Drugs/NNS such/JJ as/IN troleandomycin/NN and/CC ketoconazole/NN may/MD inhibit/VB the/DT metabolism/NN of/IN corticosteroids/NNS and/CC thus/RB decrease/VB their/PRP$ clearance/NN ./.


DrugDDI.d191
DrugDDI.d191.s3
Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity.

Therefore/RB ,/, the/DT dose/NN of/IN corticosteroid/NN should/MD be/VB titrated/VBN to/TO avoid/VB steroid/NN toxicity/NN ./.


DrugDDI.d191
DrugDDI.d191.s4
Corticosteroids may increase the clearance of chronic high dose aspirin .

Corticosteroids/NNS may/MD increase/VB the/DT clearance/NN of/IN chronic/JJ high/JJ dose/NN aspirin/NN ./.


DrugDDI.d191
DrugDDI.d191.s5
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.

This/DT could/MD lead/VB to/TO decreased/VBN salicylate/NN serum/NN levels/NNS or/CC increase/VBP the/DT risk/NN of/IN salicylate/NN toxicity/NN when/WRB corticosteroid/NN is/VBZ withdrawn/VBN ./.


DrugDDI.d191
DrugDDI.d191.s6
Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.

Aspirin/NN should/MD be/VB used/VBN cautiously/RB in/IN conjunction/NN with/IN cortico-steroids/NNS in/IN patients/NNS suffering/VBG from/IN hypopro-thrombinemia/NN ./.


DrugDDI.d191
DrugDDI.d191.s7
The effect of corticosteroids on oral anticoagulants is variable.

The/DT effect/NN of/IN corticosteroids/NNS on/IN oral/JJ anticoagulants/NNS is/VBZ variable/NN ./.


DrugDDI.d191
DrugDDI.d191.s8
There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids .

There/EX are/VBP reports/NNS of/IN enhanced/VBN as/RB well/RB as/IN diminished/VBN effects/NNS of/IN anticoagulants/NNS when/WRB given/VBN concurrently/RB with/IN corticosteroids/NNS ./.


DrugDDI.d25
DrugDDI.d25.s0
Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.

Drug/NN Interaction/NN During/IN Pregnancy/NN :/: Cromolyn/NN sodium/NN and/CC isoproterenol/NN were/VBD studied/VBN following/VBG subcutaneous/JJ injections/NNS in/IN pregnant/JJ mice/NNS ./.


DrugDDI.d25
DrugDDI.d25.s1
Cromolyn sodium alone in doses up to 540 mg/kg/day (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) did not cause significant increases in resorptions or major malformations.

Cromolyn/NN sodium/NN alone/RB in/IN doses/NNS up/RB to/TO 540/CD mg/kg/day/NN (/-LRB- approximately/RB 340/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/JJ basis/NN )/-RRB- did/VBD not/RB cause/VB significant/JJ increases/NNS in/IN resorptions/NNS or/CC major/JJ malformations/NNS ./.


DrugDDI.d25
DrugDDI.d25.s2
Isoproterenol alone at a dose of 2.7 mg/kg/day (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) increased both resorptions and malformations.

Isoproterenol/NN alone/RB at/IN a/DT dose/NN of/IN 2.7/CD mg/kg/day/NN (/-LRB- approximately/RB 7/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/JJ basis/NN )/-RRB- increased/VBD both/CC resorptions/NNS and/CC malformations/NNS ./.


DrugDDI.d25
DrugDDI.d25.s3
The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.

The/DT addition/NN of/IN 540/CD mg/kg/day/NN of/IN cromolyn/NN sodium/NN (/-LRB- approximately/RB 340/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/NN basis/NN )/-RRB- to/TO 2.7/CD mg/kg/day/NN of/IN isoproterenol/NN (/-LRB- approximately/RB 7/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/NN basis/NN )/-RRB- appears/VBZ to/TO have/VB increased/VBD the/DT incidence/NN of/IN both/CC resorptions/NNS and/CC malformations/NNS ./.


DrugDDI.d230
DrugDDI.d230.s0
May interact with wthionamide ( Trecator-SC ) and isoniazid ( Nydrazid ).

May/MD interact/VB with/IN wthionamide/NN (/-LRB- Trecator-SC/NN )/-RRB- and/CC isoniazid/NN (/-LRB- Nydrazid/NN )/-RRB- ./.


DrugDDI.d168
DrugDDI.d168.s0
Warfarin Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug , and the INR was not significantly altered.

Warfarin/JJ Concomitant/JJ administration/NN of/IN daptomycin/NN (/-LRB- 6/CD mg/kg/NN once/RB every/DT 24/CD hours/NNS for/IN 5/CD days/NNS )/-RRB- and/CC warfarin/NN (/-LRB- 25/CD mg/NN single/JJ oral/JJ dose/NN )/-RRB- had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN either/DT drug/NN ,/, and/CC the/DT INR/NN was/VBD not/RB significantly/RB altered/VBN ./.


DrugDDI.d168
DrugDDI.d168.s1
As experience with the concomitant administration of daptomycin and warfarin is limited to volunteer studies, anticoagulant activity in patients receiving daptomycin and warfarin should be monitored for the first several days after initiating therapy with Fentanyl .

As/IN experience/VBP with/IN the/DT concomitant/JJ administration/NN of/IN daptomycin/NN and/CC warfarin/NN is/VBZ limited/JJ to/TO volunteer/NN studies/NNS ,/, anticoagulant/JJ activity/NN in/IN patients/NNS receiving/VBG daptomycin/NN and/CC warfarin/NN should/MD be/VB monitored/VBN for/IN the/DT first/JJ several/JJ days/NNS after/IN initiating/VBG therapy/NN with/IN Fentanyl/NN ./.


DrugDDI.d168
DrugDDI.d168.s2
HMG-CoA Reductase Inhibitors Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.

HMG-CoA/NN Reductase/NN Inhibitors/NNS Inhibitors/NNS of/IN HMG-CoA/NN reductase/NN may/MD cause/VB myopathy/NN ,/, which/WDT is/VBZ manifested/VBN as/IN muscle/NN pain/NN or/CC weakness/NN associated/VBN with/IN elevated/JJ levels/NNS of/IN CPK/NN ./.


DrugDDI.d168
DrugDDI.d168.s3
There were no reports of skeletal myopathy in a placebo-controlled Phase : I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.

There/EX were/VBD no/DT reports/NNS of/IN skeletal/JJ myopathy/NN in/IN a/DT placebo-controlled/JJ Phase/NN :/: I/NN trial/NN in/IN which/WDT 10/CD healthy/JJ subjects/NNS on/IN stable/JJ simvastatin/NN therapy/NN were/VBD treated/VBN concurrently/RB with/IN daptomycin/NN (/-LRB- 4/CD mg/kg/NN once/RB every/DT 24/CD hours/NNS )/-RRB- for/IN 14/CD days/NNS ./.


DrugDDI.d168
DrugDDI.d168.s4
Experience with co-administration of HMG-CoA reduc-tase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl .

Experience/VBP with/IN co-administration/NN of/IN HMG-CoA/NN reduc-tase/NN inhibitors/NNS and/CC Fentanyl/NN in/IN patients/NNS is/VBZ limited/VBN ,/, therefore/RB ,/, consideration/NN should/MD be/VB given/VBN to/TO temporarily/RB suspending/JJ use/NN of/IN HMG-CoA/NN reductase/NN inhibitors/NNS in/IN patients/NNS receiving/VBG Fentanyl/NN ./.


DrugDDI.d51
DrugDDI.d51.s0
Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.

Use/NN of/IN Cerubidine/NN in/IN a/DT patient/NN who/WP has/VBZ previously/RB received/VBN doxorubicin/NN increases/VBZ the/DT risk/NN of/IN cardiotoxicity/NN ./.


DrugDDI.d51
DrugDDI.d51.s1
Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine .

Cerubidine/NN should/MD not/RB be/VB used/VBN in/IN patients/NNS who/WP have/VBP previously/RB received/VBN the/DT recommended/VBN maximum/JJ cumulative/JJ doses/NNS of/IN doxorubicin/NN or/CC Cerubidine/NN ./.


DrugDDI.d51
DrugDDI.d51.s2
Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.

Cyclophosphamide/NN used/VBN concurrently/RB with/IN Cerubidine/NN may/MD also/RB result/VB in/IN increased/VBN cardiotoxicity/NN ./.


DrugDDI.d51
DrugDDI.d51.s3
Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.

Dosage/JJ reduction/NN of/IN Cerubidine/NN may/MD be/VB required/VBN when/WRB used/VBN concurrently/RB with/IN other/JJ myelosuppressive/JJ agents/NNS ./.


DrugDDI.d51
DrugDDI.d51.s4
Hepatotoxic medications , such as high-dose methotrexate , may impair liver function and increase the risk of toxicity.

Hepatotoxic/JJ medications/NNS ,/, such/JJ as/IN high-dose/JJ methotrexate/NN ,/, may/MD impair/VB liver/NN function/NN and/CC increase/VB the/DT risk/NN of/IN toxicity/NN ./.


DrugDDI.d157
DrugDDI.d157.s0
Drug interaction studies with decitabine have not been conducted.

Drug/NN interaction/NN studies/NNS with/IN decitabine/NN have/VBP not/RB been/VBN conducted/VBN ./.


DrugDDI.d157
DrugDDI.d157.s1
In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes.

In/FW vitro/FW studies/NNS in/IN human/JJ liver/NN microsomes/NNS suggest/VBP that/IN decitabine/NN is/VBZ unlikely/JJ to/TO inhibit/VB or/CC induce/VB cytochrome/NN P450/NN enzymes/NNS ./.


DrugDDI.d157
DrugDDI.d157.s2
In vitro metabolism studies have suggested that decitabine is not a substrate for the human liver cytochrome P450 enzyme s.

In/FW vitro/FW metabolism/NN studies/NNS have/VBP suggested/VBN that/IN decitabine/NN is/VBZ not/RB a/DT substrate/NN for/IN the/DT human/JJ liver/NN cytochrome/NN P450/NN enzyme/NN s/NN ./.


DrugDDI.d157
DrugDDI.d157.s3
As plasma protein binding of decitabine is negligible ( 1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.

As/IN plasma/NN protein/NN binding/NN of/IN decitabine/NN is/VBZ negligible/JJ (/-LRB- 1/CD %/NN )/-RRB- ,/, interactions/NNS due/JJ to/TO displacement/NN of/IN more/RBR highly/RB protein/NN bound/JJ drugs/NNS from/IN plasma/NN proteins/NNS are/VBP not/RB expected/VBN ./.


DrugDDI.d492
DrugDDI.d492.s0
Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Because/IN the/DT tetracyclines/NNS have/VBP been/VBN shown/VBN to/TO depress/VB plasma/NN prothrombin/NN activity/NN ,/, patients/NNS who/WP are/VBP on/IN anticoagulant/NN therapy/NN may/MD require/VB downward/JJ adjustment/NN of/IN their/PRP$ anticoagulant/JJ dosage/NN ./.


DrugDDI.d492
DrugDDI.d492.s1
Since bacteriostat ic drugs, such as the tetracycline class of antibiotics , may interfere with the bactericidal action of penicillins , it is not advisable to administer these drugs concomitantly.

Since/IN bacteriostat/NN ic/NN drugs/NNS ,/, such/JJ as/IN the/DT tetracycline/NN class/NN of/IN antibiotics/NNS ,/, may/MD interfere/VB with/IN the/DT bactericidal/JJ action/NN of/IN penicillins/NNS ,/, it/PRP is/VBZ not/RB advisable/JJ to/TO administer/VB these/DT drugs/NNS concomitantly/RB ./.


DrugDDI.d492
DrugDDI.d492.s2
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effect ive.

Concurrent/JJ use/NN of/IN tetracyclines/NNS with/IN oral/JJ contraceptives/NNS may/MD render/VB oral/JJ contraceptives/NNS less/CC effect/VB ive/NN ./.


DrugDDI.d392
DrugDDI.d392.s1
Drugs Metabolized by P450 2D6 : The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 ( debrisoquin hydroxylase ) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); .

Drugs/NNS Metabolized/VBN by/IN P450/NN 2D6/NN :/: The/DT biochemical/JJ activity/NN of/IN the/DT drug/NN metabolizing/NN isozyme/NN cytochrome/NN P450/NN 2D6/NN (/-LRB- debrisoquin/NN hydroxylase/NN )/-RRB- is/VBZ reduced/VBN in/IN a/DT subset/NN of/IN the/DT caucasian/NN population/NN (/-LRB- about/RB 7/CD to/TO 10/CD %/NN of/IN caucasians/NNS are/VBP so/RB called/VBN poor/JJ metabolizers/NNS )/-RRB- ;/: ./.


DrugDDI.d392
DrugDDI.d392.s2
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.

reliable/JJ estimates/NNS of/IN the/DT prevalence/NN of/IN reduced/VBN P450/NN 2D6/NN isozyme/NN activity/NN among/IN Asian/JJ ,/, African/JJ and/CC other/JJ populations/NNS are/VBP not/RB yet/RB available/JJ ./.


DrugDDI.d392
DrugDDI.d392.s3
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

Poor/JJ metabolizers/NNS have/VBP higher/JJR than/IN expected/VBN plasma/NN concentrations/NNS of/IN tricyclic/JJ antidepressants/NNS (/-LRB- TCAs/NNS )/-RRB- when/WRB given/VBN usual/JJ doses/NNS ./.


DrugDDI.d392
DrugDDI.d392.s4
Depending on the traction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).

Depending/VBG on/IN the/DT traction/NN of/IN drug/NN metabolized/VBN by/IN P450/NN 2D6/NN ,/, the/DT increase/NN in/IN plasma/NN concentration/NN may/MD be/VB small/JJ ,/, or/CC quite/RB large/JJ (/-LRB- 8/CD fold/JJ increase/NN in/IN plasma/NN AUC/NN of/IN the/DT TCA/NN )./NN


DrugDDI.d392
DrugDDI.d392.s5
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.

In/IN addition/NN ,/, certain/JJ drugs/NNS inhibit/VB the/DT activity/NN of/IN this/DT isozyme/NN and/CC make/VB normal/JJ metabolizers/NNS resemble/VBP p.o./NN


DrugDDI.d392
DrugDDI.d392.s7
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

An/DT individual/JJ who/WP is/VBZ stable/JJ on/IN a/DT given/JJ dose/NN of/IN TCA/NN may/MD become/VB abruptly/RB toxic/JJ when/WRB given/VBN one/CD of/IN these/DT inhibiting/JJ drugs/NNS as/IN concomitant/JJ therapy/NN ./.


DrugDDI.d392
DrugDDI.d392.s8
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme ( quinidine ; .

The/DT drugs/NNS that/WDT inhibit/VBP cytochrome/NN P450/NN 2D6/NN include/VBP some/DT that/WDT are/VBP not/RB metabolized/VBN by/IN the/DT enzyme/NN (/-LRB- quinidine/NN ;/: ./.


DrugDDI.d392
DrugDDI.d392.s9
cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythrnics propatenone and flecainide ).

cimetidine/NN )/-RRB- and/CC many/JJ that/WDT are/VBP substrates/NNS for/IN P450/NN 2D6/NN (/-LRB- many/JJ other/JJ antidepressants/NNS ,/, phenothiazines/NNS ,/, and/CC the/DT Type/NN 1C/NN antiarrhythrnics/NNS propatenone/NN and/CC flecainide/NN )/-RRB- ./.


DrugDDI.d392
DrugDDI.d392.s10
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine , seriraline, and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition.

While/IN all/PDT the/DT selective/JJ serotonin/NN reuptake/NN inhibitors/NNS (/-LRB- SSRIs/NN )/-RRB- ,/, e.g./FW ,/, fluoxetine/NN ,/, seriraline/NN ,/, and/CC paroxetine/NN ,/, inhibit/VBP P450/NN 2D6/NN ,/, they/PRP may/MD vary/VB in/IN the/DT extent/NN of/IN inhibition/NN ./.


DrugDDI.d392
DrugDDI.d392.s12
Nevertheless, caution is indicated in the co-administration of T .A. with any of the SSRIs and also in switching from one class to the other.

Nevertheless/RB ,/, caution/NN is/VBZ indicated/VBN in/IN the/DT co-administration/NN of/IN T/NN .A./NNS with/IN any/DT of/IN the/DT SSRIs/NNS and/CC also/RB in/IN switching/NN from/IN one/CD class/NN to/TO the/DT other/JJ ./.


DrugDDI.d392
DrugDDI.d392.s13
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

Of/IN particular/JJ importance/NN ,/, sufficient/JJ time/NN must/MD elapse/VB before/IN initiating/VBG TCA/NN treatment/NN in/IN a/DT patient/NN being/VBG withdrawn/NN from/IN fluoxetine/NN ,/, given/IN the/DT long/JJ half-life/NN of/IN the/DT parent/JJ and/CC active/JJ metabolite/NN (/-LRB- at/IN least/JJS 5/CD weeks/NNS may/MD be/VB necessary/JJ )./NN


DrugDDI.d392
DrugDDI.d392.s14
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

Concomitant/JJ use/NN of/IN tricyclic/JJ antidepressants/NNS with/IN drugs/NNS that/WDT can/MD inhibit/VB cytochrome/NN P450/NN 2D6/NN may/MD require/VB lower/JJR doses/NNS than/IN usually/RB prescribed/VBN for/IN either/CC the/DT tricyclic/JJ antidepressant/JJ or/CC the/DT other/JJ drug/NN ./.


DrugDDI.d392
DrugDDI.d392.s15
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.

Furthermore/RB ,/, whenever/RB one/CD of/IN these/DT other/JJ drugs/NNS is/VBZ withdrawn/VBN from/IN co-therapy/NN ,/, an/DT increased/VBN dose/NN of/IN tricyclic/JJ antidepressant/JJ may/MD be/VB required/VBN ./.


DrugDDI.d392
DrugDDI.d392.s16
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6 .

It/PRP is/VBZ desirable/JJ to/TO monitor/VB TCA/NN plasma/NN levels/NNS whenever/RB a/DT TCA/NN is/VBZ going/JJ to/TO be/VB co-administered/VBN with/IN another/DT drug/NN known/VBN to/TO be/VB an/DT inhibitor/NN of/IN P450/NN 2D6/NN ./.


DrugDDI.d392
DrugDDI.d392.s18
Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs .

Close/JJ supervision/NN and/CC careful/JJ adjustment/NN of/IN dosage/NN are/VBP required/VBN when/WRB this/DT drug/NN is/VBZ given/VBN concomitantly/RB with/IN anticholinergic/JJ or/CC sympathomimetic/JJ drugs/NNS ./.


DrugDDI.d392
DrugDDI.d392.s20
Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited.

Clinical/JJ experience/VBP in/IN the/DT concurrent/JJ administration/NN of/IN ECT/NN and/CC antidepressant/JJ drugs/NNS is/VBZ limited/VBN ./.


DrugDDI.d392
DrugDDI.d392.s23
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam ) are additive.

If/IN desipramine/NN hydrochloride/NN is/VBZ to/TO be/VB combined/VBN with/IN other/JJ psychotropic/JJ agents/NNS such/JJ as/IN tranquilizers/NNS or/CC sedative/JJ //: hypnotics/NNS ,/, careful/JJ consideration/NN should/MD be/VB given/VBN to/TO the/DT pharmacology/NN of/IN the/DT agents/NNS employed/VBN since/IN the/DT sedative/JJ effects/NNS of/IN desipramine/NN and/CC benzodiazepines/NN (/-LRB- e.g./FW ,/, chlordiazepoxide/NN or/CC diazepam/NN )/-RRB- are/VBP additive/JJ ./.


DrugDDI.d392
DrugDDI.d392.s24
Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine .

Both/CC the/DT sedative/JJ and/CC anticholinergic/JJ effects/NNS of/IN the/DT major/JJ tranquilizers/NNS are/VBP also/RB additive/JJ to/TO those/DT of/IN desipramine/NN ./.


DrugDDI.d392
DrugDDI.d392.s26
Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants .

Concurrent/JJ administration/NN of/IN cimetidine/NN and/CC tricyclic/JJ antidepressants/NNS can/MD produce/VBP clinically/RB significant/JJ increases/NNS in/IN the/DT plasma/NN levels/NNS of/IN the/DT tricyclic/JJ antidepressants/NNS ./.


DrugDDI.d392
DrugDDI.d392.s27
Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.

Conversely/RB ,/, decreases/NNS in/IN plasma/NN levels/NNS of/IN the/DT tricyclic/JJ antidepressants/NNS have/VBP been/VBN reported/VBN upon/IN discontinuation/NN of/IN cimetidine/NN which/WDT may/MD result/VB in/IN the/DT loss/NN of/IN the/DT therapeutic/JJ efficacy/NN of/IN the/DT tricyclic/JJ antidepressant/JJ 6/CD ./.


DrugDDI.d392
DrugDDI.d392.s28
There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.

There/EX have/VBP been/VBN greater/JJR than/IN two-fold/JJ increases/NNS of/IN previously/RB stable/JJ plasma/NN levels/NNS of/IN tricyclic/JJ antidepressants/NNS when/WRB fluoxetine/NN has/VBZ been/VBN administered/VBN in/IN combination/NN with/IN these/DT agents/NNS ./.


DrugDDI.d298
DrugDDI.d298.s0
General : In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450-mediated drug interactions that are likely to be of clinical relevance.

General/JJ :/: In/FW vitro/FW studies/NNS in/IN human/JJ liver/NN microsomes/NNS demonstrated/VBD no/DT evidence/NN of/IN cytochrome/NN P450-mediated/JJ drug/NN interactions/NNS that/WDT are/VBP likely/JJ to/TO be/VB of/IN clinical/JJ relevance/NN ./.


DrugDDI.d298
DrugDDI.d298.s1
Anesthetics / Sedatives / Hypnotics / Opioids Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects.

Anesthetics/NNS //: Sedatives/NNS //: Hypnotics/NNS //: Opioids/NNS Co-administration/NN of/IN PRECEDEX/NN with/IN anesthetics/NNS ,/, sedatives/NNS ,/, hypnotics/NNS ,/, and/CC opioids/NNS is/VBZ likely/JJ to/TO lead/VB to/TO an/DT enhancement/NN of/IN effects/NNS ./.


DrugDDI.d298
DrugDDI.d298.s2
Specific studies have confirmed these effects with sevoflurane , isoflurane , propofol , alfentanil , and midazolam .

Specific/JJ studies/NNS have/VBP confirmed/VBN these/DT effects/NNS with/IN sevoflurane/NN ,/, isoflurane/NN ,/, propofol/NN ,/, alfentanil/NN ,/, and/CC midazolam/NN ./.


DrugDDI.d298
DrugDDI.d298.s3
No pharmacokinetic interactions between dexmedetomidine and isoflurane , propofol , alfentanil , and midazolam have been demonstrated.

No/DT pharmacokinetic/JJ interactions/NNS between/IN dexmedetomidine/NN and/CC isoflurane/NN ,/, propofol/NN ,/, alfentanil/NN ,/, and/CC midazolam/NN have/VBP been/VBN demonstrated/VBN ./.


DrugDDI.d298
DrugDDI.d298.s4
However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative, hypnotic or opioid may be required.

However/RB ,/, due/IN to/TO possible/JJ pharmacodynamic/JJ interactions/NNS ,/, when/WRB co-administered/VBN with/IN PRECEDEX/NN ,/, a/DT reduction/NN in/IN dosage/NN of/IN PRECEDEX/NN on/IN the/DT concomitant/JJ anesthetic/NN ,/, sedative/JJ ,/, hypnotic/JJ or/CC opioid/JJ may/MD be/VB required/VBN ./.


DrugDDI.d298
DrugDDI.d298.s5
Neuromuscular Blockers : In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.

Neuromuscular/JJ Blockers/NNS :/: In/IN one/CD study/NN of/IN 10/CD healthy/JJ volunteers/NNS ,/, administration/NN of/IN PRECEDEX/NN for/IN 45/CD minutes/NNS at/IN a/DT plasma/NN concentration/NN of/IN 1/CD (/-LRB- one/CD )/-RRB- ng/mL/NN resulted/VBD in/IN no/DT clinically/RB meaningful/JJ increases/NNS in/IN the/DT magnitude/NN or/CC neuromuscular/JJ blockade/NN associated/VBN with/IN rocuronium/NN administration/NN ./.


DrugDDI.d15
DrugDDI.d15.s0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids ).

May/MD interact/VB anticoagulants/NNS (/-LRB- altered/JJ hypo-prothrombinemic/JJ effect/NN )/-RRB- ,/, barbiturates/NNS ,/, rifampin/NN and/CC other/JJ inducers/NNS of/IN hepatic/JJ microsomal/JJ enzyme/NN oxidation/NN system/NN (/-LRB- decreased/VBN effect/NN of/IN diethylstilbestrol/NN )/-RRB- ,/, corticosteroids/NNS (/-LRB- increased/VBN effect/NN of/IN corticosteroids/NNS )/-RRB- ./.


DrugDDI.d62
DrugDDI.d62.s0
Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.

Administration/NN of/IN thiazide/NN diuretics/NNS to/TO hypoparathyroid/JJ patients/NNS who/WP are/VBP concurrently/RB being/VBG treated/VBN with/IN dihydrotachysterol/NN may/MD cause/VB hypercalcemia/NN ./.


DrugDDI.d337
DrugDDI.d337.s0
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants ( hypnotics , sedatives , tranquilizers , etc).

Diphenhydramine/NN hydrochloride/NN has/VBZ additive/JJ effects/NNS with/IN alcohol/NN and/CC other/JJ CNS/NN depressants/NNS (/-LRB- hypnotics/NN ,/, sedatives/NNS ,/, tranquilizers/NNS ,/, etc/NN )./CD


DrugDDI.d337
DrugDDI.d337.s1
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines .

MAO/NN inhibitors/NNS prolong/VBP and/CC intensify/VB the/DT anticholinergic/JJ (/-LRB- drying/NN )/-RRB- effects/NNS of/IN antihistamines/NNS ./.


DrugDDI.d189
DrugDDI.d189.s0
CNS depression@producing medications - concurrent use may potentiate the effects of either these medications or diphenidol ; .

CNS/NN depression/NN @/NN producing/NN medications/NNS -/CC concurrent/JJ use/NN may/MD potentiate/VB the/DT effects/NNS of/IN either/CC these/DT medications/NNS or/CC diphenidol/NN ;/: ./.


DrugDDI.d189
DrugDDI.d189.s1
anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol ; .

anticholinergics/NN or/CC other/JJ medications/NNS with/IN anticholinergic/JJ activity/NN -/CC anticholinergic/JJ effects/NNS may/MD be/VB potentiated/VBN when/WRB these/DT medications/NNS are/VBP used/VBN concurrently/RB with/IN diphenidol/NN ;/: ./.


DrugDDI.d189
DrugDDI.d189.s2
apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.

apomorphine/NN -/CC prior/JJ ingestion/NN of/IN diphenidol/NN may/MD decrease/VB the/DT emetic/JJ response/NN to/TO apomorphine/NN in/IN the/DT treatment/NN of/IN poisoning/NN ./.


DrugDDI.d448
DrugDDI.d448.s0
Known drug interactions include barbiturates , tranquilizers , and alcohol .

Known/JJ drug/NN interactions/NNS include/VBP barbiturates/NNS ,/, tranquilizers/NNS ,/, and/CC alcohol/NN ./.


DrugDDI.d448
DrugDDI.d448.s1
Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.

Diphenoxylate/NN HCl/NN and/CC atropine/NN sulfate/NN may/MD interact/VB with/IN MAO/NN inhibitors/NNS In/IN studies/NNS with/IN male/JJ rats/NNS ,/, diphenoxylate/NN hydrochloride/NN was/VBD found/VBN to/TO inhibit/VB the/DT hepatic/JJ microsomal/JJ enzyme/NN system/NN at/IN a/DT dose/NN of/IN 2/CD mg/kg/day/NN ./.


DrugDDI.d448
DrugDDI.d448.s2
Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.

Therefore/RB ,/, diphenoxylate/NN has/VBZ the/DT potential/NN to/TO prolong/VB the/DT biological/JJ half-lives/NNS of/IN drugs/NNS for/IN which/WDT the/DT rate/NN of/IN elimination/NN is/VBZ dependent/JJ on/IN the/DT microsomal/JJ drug/NN metabolizing/NN enzyme/NN system/NN ./.


DrugDDI.d383
DrugDDI.d383.s0
Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly.

Disulfiram/NN appears/VBZ to/TO decrease/VB the/DT rate/NN at/IN which/WDT certain/JJ drugs/NNS are/VBP metabolized/VBN and/CC therefore/RB may/MD increase/VB the/DT blood/NN levels/NNS and/CC the/DT possibility/NN of/IN clinical/JJ toxicity/NN of/IN drugs/NNS given/VBN concomitantly/RB ./.


DrugDDI.d383
DrugDDI.d383.s1
DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENER S.

DISULFIRAM/NN SHOULD/MD BE/VB USED/VBN WITH/IN CAUTION/NN IN/IN THOSE/DT PATIENTS/NNS REVEIVING/VBG PHENYTOIN/NN AND/CC ITS/PRP$ CONGENER/NN S/NNS ./.


DrugDDI.d383
DrugDDI.d383.s2
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.

SINCE/IN THE/DT CONCOMITANT/JJ ADMINISTRATION/NN OF/IN THESE/DT TWO/CD DRUGS/NNS CAN/MD LEAD/VB TO/TO PHENYTOIN/NN INTOXICATION/NN ,/, PRIOR/JJ TO/TO ADMINISTERING/VBG DISULFIRAM/NN TO/TO A/DT PATIENT/NN ON/IN PHENYTOIN/NN THERAPY/NN ,/, A/DT BASELINE/NN PHENYTOIN/NN SERUM/NN LEVEL/NN SHOULD/MD BE/VB OBTAINED/VBN ./.


DrugDDI.d383
DrugDDI.d383.s4
SERUM LEVELS OF PHENYTOIN SHOULD BE DETERMINED ON DIFFERENT DAYS FOR EVIDENCE OF AN INCREASE OR FOR A CONTINUING RISE IN LEVELS.

SERUM/NN LEVELS/NNS OF/IN PHENYTOIN/NN SHOULD/MD BE/VB DETERMINED/VBN ON/IN DIFFERENT/JJ DAYS/NNS FOR/IN EVIDENCE/NN OF/IN AN/DT INCREASE/NN OR/CC FOR/IN A/DT CONTINUING/VBG RISE/NN IN/IN LEVELS/NNS ./.


DrugDDI.d383
DrugDDI.d383.s6
It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram . since disulfiram may prolong prothrombin time.

It/PRP may/MD be/VB necessary/JJ to/TO adjust/VB the/DT dosage/NN of/IN oral/JJ anticoagulants/NNS upon/IN beginning/NN or/CC stopping/JJ disulfiram/NN ./. since/IN disulfiram/NN may/MD prolong/VB prothrombin/NN time/NN ./.


DrugDDI.d383
DrugDDI.d383.s7
Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status; .

Patients/NNS taking/VBG isoniazid/NN when/WRB disulfiram/NN is/VBZ given/VBN should/MD be/VB observed/VBN for/IN the/DT appearance/NN of/IN unsteady/NN gait/NN or/CC marked/JJ changes/NNS in/IN mental/JJ status/NN ;/: ./.


DrugDDI.d383
DrugDDI.d383.s8
the disulfiram should be discontinued if such signs appear.

the/DT disulfiram/NN should/MD be/VB discontinued/VBN if/IN such/JJ signs/NNS appear/VBP ./.


DrugDDI.d383
DrugDDI.d383.s9
In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.

In/IN rats/NNS ,/, simultaneous/JJ ingestion/NN of/IN disulfiram/NN and/CC nitrite/NN in/IN the/DT diet/NN for/IN 78/CD weeks/NNS has/VBZ been/VBN reported/VBN to/TO cause/VB tumors/NNS ,/, and/CC it/PRP has/VBZ been/VBN suggested/VBN that/IN disulfiram/NN may/MD react/VB with/IN nitrites/NNS in/IN the/DT rat/NN stomach/NN to/TO form/VB a/DT nitrosamine/NN ,/, which/WDT is/VBZ tumorigenic/JJ ./.


DrugDDI.d383
DrugDDI.d383.s10
Disulfiram alone in the rat@s diet did not lead to such tumors.

Disulfiram/NN alone/RB in/IN the/DT rat/NN @/NN s/NN diet/NN did/VBD not/RB lead/VB to/TO such/JJ tumors/NNS ./.


DrugDDI.d106
DrugDDI.d106.s0
There have been no formal clinical studies to evaluate the drug interactions of TAXOTERE with other medications .

There/EX have/VBP been/VBN no/DT formal/JJ clinical/JJ studies/NNS to/TO evaluate/VB the/DT drug/NN interactions/NNS of/IN TAXOTERE/NN with/IN other/JJ medications/NNS ./.


DrugDDI.d106
DrugDDI.d106.s1
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4 , such as cyclosporine , terfenadine , ketoconazole , erythromycin , and troleandomycin .

In/FW vitro/FW studies/NNS have/VBP shown/VBN that/IN the/DT metabolism/NN of/IN docetaxel/NN may/MD be/VB modified/VBN by/IN the/DT concomitant/JJ administration/NN of/IN compounds/NNS that/WDT induce/VBP ,/, inhibit/VBP ,/, or/CC are/VBP metabolized/VBN by/IN cytochrome/NN P450/NN 3A4/NN ,/, such/JJ as/IN cyclosporine/NN ,/, terfenadine/NN ,/, ketoconazole/NN ,/, erythromycin/NN ,/, and/CC troleandomycin/NN ./.


DrugDDI.d106
DrugDDI.d106.s2
Caution should be exercised with these drugs when treating patients receiving TAXOTERE as there is a potential for a significant interaction.

Caution/NN should/MD be/VB exercised/VBN with/IN these/DT drugs/NNS when/WRB treating/VBG patients/NNS receiving/VBG TAXOTERE/NN as/IN there/EX is/VBZ a/DT potential/NN for/IN a/DT significant/JJ interaction/NN ./.


DrugDDI.d212
DrugDDI.d212.s0
Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics , bronchodilators , enzyme supplements, vitamins , oral or inhaled corticosteroids , and analgesics .

Clinical/JJ trials/NNS have/VBP indicated/VBN that/IN Pulmozyme/NN can/MD be/VB effectively/RB and/CC safely/RB used/VBN in/IN conjunction/NN with/IN standard/JJ cystic/JJ fibrosis/NN therapies/NNS including/VBG oral/JJ ,/, inhaled/JJ and/or/CC parenteral/JJ antibiotics/NNS ,/, bronchodilators/NNS ,/, enzyme/NN supplements/NNS ,/, vitamins/NNS ,/, oral/JJ or/CC inhaled/JJ corticosteroids/NNS ,/, and/CC analgesics/NNS ./.


DrugDDI.d43
DrugDDI.d43.s0
Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX .

Prior/JJ administration/NN of/IN succinylcholine/NN has/VBZ no/DT clinically/RB important/JJ effect/NN on/IN the/DT neuromuscular/JJ blocking/NN action/NN of/IN NUROMAX/NN ./.


DrugDDI.d43
DrugDDI.d43.s1
The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.

The/DT use/NN of/IN NUROMAX/NN before/IN succinylcholine/NN to/TO attenuate/VB some/DT of/IN the/DT side/JJ effects/NNS of/IN succinylcholine/NN has/VBZ not/RB been/VBN studied/VBN ./.


DrugDDI.d43
DrugDDI.d43.s2
There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents .

There/EX are/VBP no/DT clinical/JJ data/NNS on/IN concomitant/JJ use/NN of/IN NUROMAX/NN and/CC other/JJ nondepolarizing/JJ neuromuscular/NN blocking/NN agents/NNS ./.


DrugDDI.d43
DrugDDI.d43.s3
Isoflurane , enflurane , and halothane decrease the ED50 of NUROMAX by 30% to 45%.

Isoflurane/NN ,/, enflurane/NN ,/, and/CC halothane/NN decrease/VBP the/DT ED50/NN of/IN NUROMAX/NN by/IN 30/CD %/NN to/TO 45/CD %./NN


DrugDDI.d43
DrugDDI.d43.s5
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agent s such as NUROMAX include certain antibiotics (e. g., aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate), magnesium salt s, lithium , local anesthetics , procainamide , and quinidine .

Other/JJ drugs/NNS which/WDT may/MD enhance/VB the/DT neuromuscular/JJ blocking/NN action/NN of/IN nondepolarizing/NN agent/NN s/NNS such/JJ as/IN NUROMAX/NN include/VBP certain/JJ antibiotics/NNS (/-LRB- e./FW g./FW ,/, aminoglycosides/NNS ,/, tetracyclines/NNS ,/, bacitracin/NN ,/, polymyxins/NNS ,/, lincomycin/NN ,/, clindamycin/NN ,/, colistin/NN ,/, and/CC sodium/NN colistimethate/NN )/-RRB- ,/, magnesium/NN salt/NN s/NNS ,/, lithium/NN ,/, local/JJ anesthetics/NNS ,/, procainamide/NN ,/, and/CC quinidine/NN ./.


DrugDDI.d43
DrugDDI.d43.s6
As with some other nondepolarizing neuromuscular blocking agents , the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine .

As/IN with/IN some/DT other/JJ nondepolarizing/JJ neuromuscular/JJ blocking/NN agents/NNS ,/, the/DT time/NN of/IN onset/NN of/IN neuromuscular/JJ block/NN induced/VBN by/IN NUROMAX/NN is/VBZ lengthened/VBN and/CC the/DT duration/NN of/IN block/NN is/VBZ shortened/VBD in/IN patients/NNS receiving/VBG phenytoin/NN or/CC carbamazepine/NN ./.


DrugDDI.d55
DrugDDI.d55.s0
Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .

Administration/NN of/IN doxapram/NN to/TO patients/NNS who/WP are/VBP receiving/VBG sympathomimetic/NN or/CC monoamine/NN oxidase/NN inhibiting/NN drugs/NNS may/MD result/VB in/IN an/DT additive/JJ pressor/JJ effect/NN ./.


DrugDDI.d55
DrugDDI.d55.s1
In patients who have received muscle relaxants , doxapram may temporarily mask the residual effects of muscle relaxant drugs .

In/IN patients/NNS who/WP have/VBP received/VBN muscle/NN relaxants/NNS ,/, doxapram/NN may/MD temporarily/RB mask/VB the/DT residual/JJ effects/NNS of/IN muscle/NN relaxant/NN drugs/NNS ./.


DrugDDI.d55
DrugDDI.d55.s2
In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation.

In/IN patients/NNS who/WP have/VBP received/VBN general/JJ anesthesia/NN utilizing/VBG a/DT volatile/JJ agent/NN known/VBN to/TO sensitize/VB the/DT myocardium/NN to/TO catecholamines/NNS ,/, administration/NN of/IN doxapram/NN should/MD be/VB delayed/VBN until/IN the/DT volatile/JJ agent/NN has/VBZ been/VBN excreted/VBN in/IN order/NN to/TO lessen/VB the/DT potential/NN for/IN arrhythmias/NNS ,/, including/VBG ventricular/JJ tachycardia/NN and/CC ventricular/JJ fibrillation/NN ./.


DrugDDI.d93
DrugDDI.d93.s0
Drug interaction studies with Xigris have not been performed in patients with severe sepsis.

Drug/NN interaction/NN studies/NNS with/IN Xigris/NN have/VBP not/RB been/VBN performed/VBN in/IN patients/NNS with/IN severe/JJ sepsis/NN ./.


DrugDDI.d93
DrugDDI.d93.s1
However, since there is an increased risk of bleeding with Xigris , caution should be employed when Xigris is used with other drugs that affect hemostasis.

However/RB ,/, since/IN there/EX is/VBZ an/DT increased/VBN risk/NN of/IN bleeding/JJ with/IN Xigris/NN ,/, caution/NN should/MD be/VB employed/VBN when/WRB Xigris/NN is/VBZ used/VBN with/IN other/JJ drugs/NNS that/WDT affect/VBP hemostasis/NN ./.


DrugDDI.d93
DrugDDI.d93.s2
Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin ( unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.

Approximately/RB 2/3/CD of/IN the/DT patients/NNS in/IN the/DT Phase/NN 3/CD study/NN received/VBD either/DT prophylactic/JJ low/JJ dose/NN heparin/NN (/-LRB- unfractionated/JJ heparin/NN up/RB to/TO 15,000/CD units/day/NN )/-RRB- or/CC prophylactic/JJ doses/NNS of/IN low/JJ molecular/JJ weight/NN heparins/NNS as/IN indicated/VBN in/IN the/DT prescribing/JJ information/NN for/IN the/DT specific/JJ products/NNS ./.


DrugDDI.d93
DrugDDI.d93.s3
Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.

Concomitant/JJ use/NN of/IN prophylactic/JJ low/JJ dose/NN heparin/NN did/VBD not/RB appear/VB to/TO affect/VB safety/NN ,/, however/RB ,/, its/PRP$ effects/NNS on/IN the/DT efficacy/NN of/IN Xigris/NN have/VBP not/RB been/VBN evaluated/VBN in/IN an/DT adequate/JJ and/CC well-controlled/JJ clinical/JJ trial/NN ./.


DrugDDI.d93
DrugDDI.d93.s4
Drug /Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII , IX, and XI assays).

Drug/NN /Laboratory/NN Test/NN Interaction/NN Because/IN Xigris/NN may/MD affect/VB the/DT APTT/NN assay/NN ,/, Xigris/NN present/NN in/IN plasma/NN samples/NNS may/MD interfere/VB with/IN one-stage/JJ coagulation/NN assays/NNS based/VBN on/IN the/DT APTT/NN (/-LRB- such/JJ as/IN factor/NN VIII/NN ,/, IX/NN ,/, and/CC XI/NN assays/NNS )./CD


DrugDDI.d93
DrugDDI.d93.s6
Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II , V, VII, and X assays).

Xigris/NN present/JJ in/IN plasma/NN samples/NNS does/VBZ not/RB interfere/VB with/IN one-stage/JJ factor/NN assays/NNS based/VBN on/IN the/DT PT/NN (/-LRB- such/JJ as/IN factor/NN II/CD ,/, V/NN ,/, VII/NN ,/, and/CC X/NN assays/NNS )./NN


DrugDDI.d522
DrugDDI.d522.s1
Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc . 7 .

Steroids/NNS enhance/VBP the/DT renal/JJ toxicity/NN of/IN edetate/NN calcium/NN disodium/NN in/IN animals./NN 7/CD Edetate/NN calcium/NN disodium/NN interferes/VBZ with/IN the/DT action/NN of/IN zinc/NN insulin/NN preparations/NNS by/IN chelating/NN the/DT zinc/NN ./. 7/CD ./.


DrugDDI.d496
DrugDDI.d496.s0
Efavirenz has been shown in vivo to induce CYP3A4 .

Efavirenz/NN has/VBZ been/VBN shown/VBN in/FW vivo/FW to/TO induce/VB CYP3A4/NN ./.


DrugDDI.d496
DrugDDI.d496.s1
Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA ( efavirenz ).

Other/JJ compounds/NNS that/WDT are/VBP substrates/NNS of/IN CYP3A4/NN may/MD have/VBP decreased/VBN plasma/NN concentrations/NNS when/WRB coadministered/VBN with/IN SUSTIVA/NN (/-LRB- efavirenz/NN )/-RRB- ./.


DrugDDI.d496
DrugDDI.d496.s2
In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.

In/FW vitro/FW studies/NNS have/VBP demonstrated/VBN that/IN efavirenz/NN inhibits/VBZ 2C9/NN ,/, 2C19/NN ,/, and/CC 3A4/NN isozymes/NNS in/IN the/DT range/NN of/IN observed/VBN efavirenz/NN plasma/NN concentrations/NNS ./.


DrugDDI.d496
DrugDDI.d496.s3
Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug .

Coadministration/NN of/IN efavirenz/NN with/IN drugs/NNS primarily/RB metabolized/VBN by/IN these/DT isozymes/NNS may/MD result/VB in/IN altered/JJ plasma/NN concentrations/NNS of/IN the/DT coadministered/JJ drug/NN ./.


DrugDDI.d496
DrugDDI.d496.s4
Therefore, appropriate dose adjustments may be necessary for these drugs .

Therefore/RB ,/, appropriate/JJ dose/NN adjustments/NNS may/MD be/VB necessary/JJ for/IN these/DT drugs/NNS ./.


DrugDDI.d496
DrugDDI.d496.s5
Drugs which induce CYP3A4 activity (eg, phenobarbital , rifampin , rifabutin ) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.

Drugs/NNS which/WDT induce/VBP CYP3A4/NN activity/NN (/-LRB- eg/NN ,/, phenobarbital/NN ,/, rifampin/NN ,/, rifabutin/NN )/-RRB- would/MD be/VB expected/VBN to/TO increase/VB the/DT clearance/NN of/IN efavirenz/NN resulting/VBG in/IN lowered/JJ plasma/NN concentrations/NNS ./.


DrugDDI.d496
DrugDDI.d496.s6
Drug interactions with SUSTIVA are summarized in Table 5.

Drug/NN interactions/NNS with/IN SUSTIVA/NN are/VBP summarized/VBN in/IN Table/NN 5/CD ./.


DrugDDI.d496
DrugDDI.d496.s7
Table 5a: Drugs That Should Not Be Coadministered With SUSTIVA .

Table/JJ 5a/NN :/: Drugs/NNS That/WDT Should/MD Not/RB Be/VB Coadministered/VBN With/IN SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s8
Drug Class .

Drug/NN Class/NN ./.


DrugDDI.d496
DrugDDI.d496.s9
Drugs Within Class Not To Be Coadministered With SUSTIVA .

Drugs/NNS Within/IN Class/NN Not/RB To/TO Be/VB Coadministered/VBN With/IN SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s10
Antihistamines Benzodiazepines GI Motility Agents Anti-Migraine Antifungal .

Antihistamines/NNS Benzodiazepines/NN GI/NN Motility/NN Agents/NNS Anti-Migraine/JJ Antifungal/JJ ./.


DrugDDI.d496
DrugDDI.d496.s11
astemizole midazolam, triazolam cisapride ergot derivatives voriconazole .

astemizole/NN midazolam/NNS ,/, triazolam/NN cisapride/NN ergot/NN derivatives/NNS voriconazole/NN ./.


DrugDDI.d496
DrugDDI.d496.s14
Drug Name .

Drug/NN Name/NN ./.


DrugDDI.d496
DrugDDI.d496.s17
Atazanavir .

Atazanavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s19
When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).

When/WRB coadministered/VBN with/IN SUSTIVA/NN in/IN treatment-naive/JJ patients/NNS ,/, the/DT recommended/VBN dose/NN of/IN atazanavir/NN is/VBZ 300/CD mg/NN with/IN ritonavir/NN 100/CD mg/NN and/CC SUSTIVA/NN 600/CD mg/NN (/-LRB- all/DT once/RB daily/JJ )./NN


DrugDDI.d496
DrugDDI.d496.s20
Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.

Dosing/NN recommendations/NNS for/IN SUSTIVA/NN and/CC atazanavir/NN in/IN treatment-experienced/JJ patients/NNS have/VBP not/RB been/VBN established/VBN ./.


DrugDDI.d496
DrugDDI.d496.s22
Drug Name .

Drug/NN Name/NN ./.


DrugDDI.d496
DrugDDI.d496.s25
Clarithromycin .

Clarithromycin/NN ./.


DrugDDI.d496
DrugDDI.d496.s26
@@ clarithromycin concentration .

@/NN @/NN clarithromycin/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s27
Plasma concentrations decreased by SUSTIVA ; .

Plasma/NN concentrations/NNS decreased/VBD by/IN SUSTIVA/NN ;/: ./.


DrugDDI.d496
DrugDDI.d496.s29
In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin .

In/IN uninfected/JJ volunteers/NNS ,/, 46/CD %/NN developed/VBD rash/NN while/IN receiving/VBG SUSTIVA/NN and/CC clarithromycin/NN ./.


DrugDDI.d496
DrugDDI.d496.s30
No dose adjustment of SUSTIVA is recommended when given with clarithromycin .

No/DT dose/NN adjustment/NN of/IN SUSTIVA/NN is/VBZ recommended/VBN when/WRB given/VBN with/IN clarithromycin/NN ./.


DrugDDI.d496
DrugDDI.d496.s31
Alternatives to clarithromycin , such as azithromycin , should be considered.

Alternatives/NNS to/TO clarithromycin/NN ,/, such/JJ as/IN azithromycin/NN ,/, should/MD be/VB considered/VBN ./.


DrugDDI.d496
DrugDDI.d496.s32
Other macrolide antibiotics , such as erythromycin , have not been studied in combination with SUSTIVA .

Other/JJ macrolide/NN antibiotics/NNS ,/, such/JJ as/IN erythromycin/NN ,/, have/VBP not/RB been/VBN studied/VBN in/IN combination/NN with/IN SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s35
Indinavir .

Indinavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s36
@@ indinavir concentration .

@/NN @/NN indinavir/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s37
The optimal dose of indinavir , when given in combination with SUSTIVA , is not known.

The/DT optimal/JJ dose/NN of/IN indinavir/NN ,/, when/WRB given/VBN in/IN combination/NN with/IN SUSTIVA/NN ,/, is/VBZ not/RB known/VBN ./.


DrugDDI.d496
DrugDDI.d496.s38
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA .

Increasing/VBG the/DT indinavir/NN dose/NN to/TO 1000/CD mg/NN every/DT 8/CD hours/NNS does/VBZ not/RB compensate/VB for/IN the/DT increased/VBN indinavir/NN metabolism/NN due/JJ to/TO SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s39
When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.

When/WRB indinavir/NN at/IN an/DT increased/VBN dose/NN (/-LRB- 1000/CD mg/NN every/DT 8/CD hours/NNS )/-RRB- was/VBD given/VBN with/IN SUSTIVA/NN (/-LRB- 600/CD mg/NN once/RB daily/JJ )/-RRB- ,/, the/DT indinavir/JJ AUC/NN and/CC Cmin/NN were/VBD decreased/VBN on/IN average/NN by/IN 33-46/CD %/NN and/CC 39-57/CD %/NN ,/, respectively/RB ,/, compared/VBN to/TO when/WRB indinavir/NN (/-LRB- 800/CD mg/NN every/DT 8/CD hours/NNS )/-RRB- was/VBD given/VBN alone/RB ./.


DrugDDI.d496
DrugDDI.d496.s40
Lopinavir / ritonavir .

Lopinavir/NN //: ritonavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s41
@@ lopinavir concentration .

@/NN @/NN lopinavir/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s42
A dose increase of lopinavir / ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA .

A/DT dose/NN increase/NN of/IN lopinavir/NN //: ritonavir/NN to/TO 533/133/CD mg/NN (/-LRB- 4/CD capsules/NNS or/CC 6.5/CD mL/NN )/-RRB- twice/RB daily/RB taken/VBN with/IN food/NN is/VBZ recommended/VBN when/WRB used/VBN in/IN combination/NN with/IN SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s43
Methadone .

Methadone/NN ./.


DrugDDI.d496
DrugDDI.d496.s44
@@ methadone concentration .

@/NN @/NN methadone/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s45
Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.

Coadministration/NN in/IN HIV-infected/JJ individuals/NNS with/IN a/DT history/NN of/IN injection/NN drug/NN use/NN resulted/VBD in/IN decreased/VBN plasma/NN levels/NNS of/IN methadone/NN and/CC signs/NNS of/IN opiate/NN withdrawal/NN ./.


DrugDDI.d496
DrugDDI.d496.s48
Ethinyl estradiol .

Ethinyl/NN estradiol/NN ./.


DrugDDI.d496
DrugDDI.d496.s49
@@ ethinyl estradiol concentration .

@/NN @/NN ethinyl/NN estradiol/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s50
Plasma concentrations increased by SUSTIVA ( efavirenz ); .

Plasma/NN concentrations/NNS increased/VBD by/IN SUSTIVA/NN (/-LRB- efavirenz/NN )/-RRB- ;/: ./.


DrugDDI.d496
DrugDDI.d496.s52
Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives .

Because/IN the/DT potential/JJ interaction/NN of/IN efavirenz/NN with/IN oral/JJ contraceptives/NNS has/VBZ not/RB been/VBN fully/RB characterized/VBN ,/, a/DT reliable/JJ method/NN of/IN barrier/NN contraception/NN should/MD be/VB used/VBN in/IN addition/NN to/TO oral/JJ contraceptives/NNS ./.


DrugDDI.d496
DrugDDI.d496.s53
Rifabutin .

Rifabutin/NN ./.


DrugDDI.d496
DrugDDI.d496.s54
@@ rifabutin concentration .

@/NN @/NN rifabutin/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s55
Increase daily dose of rifabutin by 50%.

Increase/NN daily/JJ dose/NN of/IN rifabutin/NN by/IN 50/CD %./NN


DrugDDI.d496
DrugDDI.d496.s56
Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.

Consider/VB doubling/VBG the/DT rifabutin/NN dose/NN in/IN regimens/NNS where/WRB rifabutin/NN is/VBZ given/VBN 2/CD or/CC 3/CD times/NNS a/DT week/NN ./.


DrugDDI.d496
DrugDDI.d496.s57
Rifampin .

Rifampin/NN ./.


DrugDDI.d496
DrugDDI.d496.s58
@@ efavirenz concentration .

@/NN @/NN efavirenz/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s59
Clinical significance of reduced efavirenz concentrations unknown.

Clinical/JJ significance/NN of/IN reduced/VBN efavirenz/NN concentrations/NNS unknown/JJ ./.


DrugDDI.d496
DrugDDI.d496.s60
Ritonavir .

Ritonavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s61
@@ ritonavir concentration .

@/NN @/NN ritonavir/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s63
Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir .

Monitoring/NN of/IN liver/NN enzymes/NNS is/VBZ recommended/VBN when/WRB SUSTIVA/NN is/VBZ used/VBN in/IN combination/NN with/IN ritonavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s64
@@ efavirenz concentration .

@/NN @/NN efavirenz/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s65
Saquinavir .

Saquinavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s66
@@ saquinavir concentration .

@/NN @/NN saquinavir/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s67
Should not be used as sole protease inhibitor in combination with SUSTIVA .

Should/MD not/RB be/VB used/VBN as/IN sole/JJ protease/NN inhibitor/NN in/IN combination/NN with/IN SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s68
Sertraline .

Sertraline/NN ./.


DrugDDI.d496
DrugDDI.d496.s69
@@ sertraline concentration .

@/NN @/NN sertraline/NN concentration/NN ./.


DrugDDI.d496
DrugDDI.d496.s71
Other Potentially Clinically Significant Drug or Herbal Product Interactions With SUSTIVAb .

Other/JJ Potentially/RB Clinically/RB Significant/JJ Drug/NN or/CC Herbal/NN Product/NN Interactions/NNS With/IN SUSTIVAb/NN ./.


DrugDDI.d496
DrugDDI.d496.s72
Anticoagulants : Warfarin .

Anticoagulants/NNS :/: Warfarin/NN ./.


DrugDDI.d496
DrugDDI.d496.s73
Plasma concentrations and effects potentially increased or decreased by SUSTIVA .

Plasma/NN concentrations/NNS and/CC effects/NNS potentially/RB increased/VBN or/CC decreased/VBN by/IN SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s74
Anticonvulsants : Phenytoin Phenobarbital Carbamazepine .

Anticonvulsants/NNS :/: Phenytoin/NN Phenobarbital/NN Carbamazepine/NN ./.


DrugDDI.d496
DrugDDI.d496.s75
Potential for reduction in anticonvulsant and/or efavirenz plasma levels; .

Potential/JJ for/IN reduction/NN in/IN anticonvulsant/JJ and/or/CC efavirenz/NN plasma/NN levels/NNS ;/: ./.


DrugDDI.d496
DrugDDI.d496.s76
periodic monitoring of anticonvulsant plasma levels should be conducted.

periodic/JJ monitoring/NN of/IN anticonvulsant/JJ plasma/NN levels/NNS should/MD be/VB conducted/VBN ./.


DrugDDI.d496
DrugDDI.d496.s77
Antifungals : Itraconazole Ketoconazole .

Antifungals/NNS :/: Itraconazole/NN Ketoconazole/NN ./.


DrugDDI.d496
DrugDDI.d496.s78
Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.

Drug/NN interaction/NN studies/NNS with/IN SUSTIVA/NNP and/CC these/DT imidazole/JJ and/CC triazole/JJ antifungals/NNS have/VBP not/RB been/VBN conducted/VBN ./.


DrugDDI.d496
DrugDDI.d496.s79
SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole .

SUSTIVA/NN has/VBZ the/DT potential/NN to/TO decrease/NN plasma/NN concentrations/NNS of/IN itraconazole/NN and/CC ketoconazole/NN ./.


DrugDDI.d496
DrugDDI.d496.s80
Anti-HIV protease inhibitors : Saquinavir / ritonavir combination .

Anti-HIV/NN protease/NN inhibitors/NNS :/: Saquinavir/NN //: ritonavir/NN combination/NN ./.


DrugDDI.d496
DrugDDI.d496.s82
Amprenavir .

Amprenavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s83
SUSTIVAhas the potential to decrease serum concentrations of amprenavir .

SUSTIVAhas/NNS the/DT potential/NN to/TO decrease/NN serum/NN concentrations/NNS of/IN amprenavir/NN ./.


DrugDDI.d496
DrugDDI.d496.s84
Non-nucleoside reverse transcriptase inhibitors .

Non-nucleoside/JJ reverse/NN transcriptase/NN inhibitors/NNS ./.


DrugDDI.d496
DrugDDI.d496.s86
St. John@s wort ( Hypericum perforatum ) .

St./NN John/NN @/NN s/NN wort/NN (/-LRB- Hypericum/NN perforatum/NN )/-RRB- ./.


DrugDDI.d496
DrugDDI.d496.s87
Expected to substantially decrease plasma levels of efavirenz ;has not been studied in combination with SUSTIVA .

Expected/VBN to/TO substantially/RB decrease/VB plasma/NN levels/NNS of/IN efavirenz/NN ;/: has/VBZ not/RB been/VBN studied/VBN in/IN combination/NN with/IN SUSTIVA/NN ./.


DrugDDI.d496
DrugDDI.d496.s90
Other Drugs : Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA ( efavirenz ) is given with the following: aluminum/ magnesium hydroxide antacids, azithromycin , cetirizine , famotidine , fluconazole , lamivudine , lorazepam , nelfinavir , paroxetine , and zidovudine .

Other/JJ Drugs/NNS :/: Based/NN on/IN the/DT results/NNS of/IN drug/NN interaction/NN studies/NNS ,/, no/DT dosage/JJ adjustment/NN is/VBZ recommended/VBN when/WRB SUSTIVA/NN (/-LRB- efavirenz/NN )/-RRB- is/VBZ given/VBN with/IN the/DT following/NN :/: aluminum//NN magnesium/NN hydroxide/NN antacids/NNS ,/, azithromycin/NN ,/, cetirizine/NN ,/, famotidine/NN ,/, fluconazole/NN ,/, lamivudine/NN ,/, lorazepam/NN ,/, nelfinavir/NN ,/, paroxetine/NN ,/, and/CC zidovudine/NN ./.


DrugDDI.d496
DrugDDI.d496.s91
Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine .

Specific/JJ drug/NN interaction/NN studies/NNS have/VBP not/RB been/VBN performed/VBN with/IN SUSTIVA/NN and/CC NRTIs/NN other/JJ than/IN lamivudine/NN and/CC zidovudine/NN ./.


DrugDDI.d496
DrugDDI.d496.s92
Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.

Clinically/RB significant/JJ interactions/NNS would/MD not/RB be/VB expected/VBN since/IN the/DT NRTIs/NNS are/VBP metabolized/VBN via/IN a/DT different/JJ route/NN than/IN efavirenz/NN and/CC would/MD be/VB unlikely/JJ to/TO compete/VB for/IN the/DT same/JJ metabolic/JJ enzymes/NNS and/CC elimination/NN pathways/NNS ./.


DrugDDI.d578
DrugDDI.d578.s0
Inhibitors of CYP3A4 -Eplerenone metabolism is predominantly mediated via CYP3A4 .

Inhibitors/NNS of/IN CYP3A4/NN -Eplerenone/NN metabolism/NN is/VBZ predominantly/RB mediated/VBN via/IN CYP3A4/NN ./.


DrugDDI.d578
DrugDDI.d578.s1
A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone .

A/DT pharmacokinetic/JJ study/NN evaluating/VBG the/DT administration/NN of/IN a/DT single/JJ dose/NN of/IN INSPRA/NN 100/CD mg/NN with/IN ketoconazole/NN 200/CD mg/NN BID/NN ,/, a/DT potent/JJ inhibitor/NN of/IN the/DT CYP3A4/NN pathway/NN ,/, showed/VBD a/DT 1.7-fold/JJ increase/NN in/IN Cmax/NN of/IN eplerenone/NN and/CC a/DT 5.4-fold/JJ increase/NN in/IN AUC/NN of/IN eplerenone/NN ./.


DrugDDI.d578
DrugDDI.d578.s2
INSPRA should not be used with drugs described as strong inhibitors of CYP3A4 in their labeling.

INSPRA/NN should/MD not/RB be/VB used/VBN with/IN drugs/NNS described/VBN as/IN strong/JJ inhibitors/NNS of/IN CYP3A4/NN in/IN their/PRP$ labeling/NN ./.


DrugDDI.d578
DrugDDI.d578.s3
Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.

Administration/NN of/IN eplerenone/NN with/IN other/JJ CYP3A4/JJ inhibitors/NNS (/-LRB- e.g./FW ,/, erythromycin/NN 500/CD mg/NN BID/NN ,/, verapamil/NN 240/NN mg/NN QD/NN ,/, saquinavir/NN 1200/CD mg/NN TID/NN ,/, fluconazole/NN 200/CD mg/NN QD/NN )/-RRB- resulted/VBD in/IN increases/NNS in/IN Cmax/NN of/IN eplerenone/NN ranging/VBG from/IN 1.4-/NN to/TO 1.6-/JJ fold/NN and/CC AUC/NN from/IN 2.0-/NN to/TO 2.9-/NN fold/NN ./.


DrugDDI.d578
DrugDDI.d578.s4
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).

ACE/NN Inhibitors/NNS and/CC Angiotensin/NN II/NN Receptor/NN Antagonists/NNS (/-LRB- Congestive/JJ Heart/NN Failure/NN Post-Myocardial/JJ Infarction/NN )/-RRB- -/: In/FW EPHESUS/FW ,/, 3020/CD (/-LRB- 91/CD %/NN )/-RRB- patients/NNS receiving/VBG INSPRA/FW 25/CD to/TO 50/CD mg/NN also/RB received/VBD ACE/NN inhibitors/NNS or/CC angiotensin/NN II/NN receptor/NN antagonists/NNS (/-LRB- ACEI/ARB)./CD


DrugDDI.d578
DrugDDI.d578.s6
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).

ACE/NN Inhibitors/NNS and/CC Angiotensin/NN II/NN Receptor/NN Antagonists/NNS (/-LRB- Hypertension/NN )/-RRB- -/: In/IN clinical/JJ studies/NNS of/IN patients/NNS with/IN hypertension/NN ,/, the/DT addition/NN of/IN INSPRA/NN 50/CD to/TO 100/CD mg/NN to/TO ACE/NN inhibitors/NNS and/CC angiotensin/NN II/NN receptor/NN antagonists/NNS increased/VBD mean/NN serum/NN potassium/NN slightly/RB (/-LRB- about/RB 0.09-0.13/CD mEq/L/NN )./NN


DrugDDI.d578
DrugDDI.d578.s7
In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium 5.5 mEq/L) from 17% on enalapril alone to 38%.

In/IN a/DT study/NN in/IN diabetics/NNS with/IN microalbuminuria/NN INSPRA/NN 200/CD mg/NN combined/VBN with/IN the/DT ACE/NN inhibitor/NN enalapril/NN 10/CD mg/NN increased/VBD the/DT frequency/NN of/IN hyperkalemia/NN (/-LRB- serum/NN potassium/NN 5.5/CD mEq/L/NN )/-RRB- from/IN 17/CD %/NN on/IN enalapril/NN alone/RB to/TO 38/CD %./NN


DrugDDI.d578
DrugDDI.d578.s8
Lithium -A drug interaction study of eplerenone with lithium has not been conducted.

Lithium/NN -A/NN drug/NN interaction/NN study/NN of/IN eplerenone/NN with/IN lithium/NN has/VBZ not/RB been/VBN conducted/VBN ./.


DrugDDI.d578
DrugDDI.d578.s9
Lithium toxicity has been reported in patients receiving lithium concomitantly with diuretics and ACE inhibitors .

Lithium/NN toxicity/NN has/VBZ been/VBN reported/VBN in/IN patients/NNS receiving/VBG lithium/NN concomitantly/RB with/IN diuretics/NNS and/CC ACE/NN inhibitors/NNS ./.


DrugDDI.d578
DrugDDI.d578.s10
Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium .

Serum/NN lithium/NN levels/NNS should/MD be/VB monitored/VBN frequently/RB if/IN INSPRA/NN is/VBZ administered/VBN concomitantly/RB with/IN lithium/NN ./.


DrugDDI.d578
DrugDDI.d578.s11
Nonsteroidal Anti-Inflammatory Drugs ( NSAIDs )-A drug interaction study of eplerenone with an NSAID has not been conducted.

Nonsteroidal/JJ Anti-Inflammatory/JJ Drugs/NNS (/-LRB- NSAIDs/NNS )/-RRB- -A/NN drug/NN interaction/NN study/NN of/IN eplerenone/NN with/IN an/DT NSAID/NN has/VBZ not/RB been/VBN conducted/VBN ./.


DrugDDI.d578
DrugDDI.d578.s12
The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.

The/DT administration/NN of/IN other/JJ potassium-sparing/JJ antihypertensives/NNS with/IN NSAIDs/NNS has/VBZ been/VBN shown/VBN to/TO reduce/VB the/DT antihypertensive/JJ effect/NN in/IN some/DT patients/NNS and/CC result/VB in/IN severe/JJ hyperkalemia/NN in/IN patients/NNS with/IN impaired/JJ renal/JJ function/NN ./.


DrugDDI.d578
DrugDDI.d578.s13
Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.

Therefore/RB ,/, when/WRB INSPRA/NN and/CC NSAIDs/NN are/VBP used/VBN concomitantly/RB ,/, patients/NNS should/MD be/VB observed/VBN to/TO determine/VB whether/IN the/DT desired/JJ effect/NN on/IN blood/NN pressure/NN is/VBZ obtained/VBN ./.


DrugDDI.d145
DrugDDI.d145.s0
Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.

Co-treatment/NN with/IN the/DT potent/JJ CYP3A4/NN inhibitor/NN ketoconazole/NN increases/VBZ erlotinib/NN AUC/NN by/IN 2/3/CD ./.


DrugDDI.d145
DrugDDI.d145.s1
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin ( TAO ), and voriconazole .

Caution/NN should/MD be/VB used/VBN when/WRB administering/VBG or/CC taking/VBG TARCEVA/NN with/IN ketoconazole/NN and/CC other/JJ strong/JJ CYP3A4/NN inhibitors/NNS such/JJ as/IN ,/, but/CC not/RB limited/JJ to/TO ,/, atazanavir/NN ,/, clarithromycin/NN ,/, indinavir/NN ,/, itraconazole/NN ,/, nefazodone/NN ,/, nelfinavir/NN ,/, ritonavir/NN ,/, saquinavir/NN ,/, telithromycin/NN ,/, troleandomycin/NN (/-LRB- TAO/CD )/-RRB- ,/, and/CC voriconazole/NN ./.


DrugDDI.d145
DrugDDI.d145.s2
Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.

Pre-treatment/NN with/IN the/DT CYP3A4/NN inducer/NN rifampicin/NN decreased/VBD erlotinib/NN AUC/NN by/IN about/RB 2/3/CD ./.


DrugDDI.d145
DrugDDI.d145.s3
Alternate treatments lacking CYP3A4 inducing activity should be considered.

Alternate/JJ treatments/NNS lacking/VBG CYP3A4/NN inducing/NN activity/NN should/MD be/VB considered/VBN ./.


DrugDDI.d145
DrugDDI.d145.s4
If an alternative treatment is unavailable, a TARCEVA dose greater than 150 mg should be considered for NSCLC patients, and greater than 100 mg considered for pancreatic cancer patients.

If/IN an/DT alternative/JJ treatment/NN is/VBZ unavailable/JJ ,/, a/DT TARCEVA/NN dose/NN greater/JJR than/IN 150/CD mg/NN should/MD be/VB considered/VBN for/IN NSCLC/NN patients/NNS ,/, and/CC greater/JJR than/IN 100/CD mg/NN considered/VBN for/IN pancreatic/JJ cancer/NN patients/NNS ./.


DrugDDI.d145
DrugDDI.d145.s5
If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.

If/IN the/DT TARCEVA/NN dose/NN is/VBZ adjusted/VBN upward/NN ,/, the/DT dose/NN will/MD need/VBP to/TO be/VB reduced/VBN upon/IN discontinuation/NN of/IN rifampicin/NN or/CC other/JJ inducers/NNS ./.


DrugDDI.d145
DrugDDI.d145.s6
Other CYP3A4 inducers include, but are not limited to, rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital and St. Johns Wort .

Other/JJ CYP3A4/NN inducers/NNS include/VBP ,/, but/CC are/VBP not/RB limited/JJ to/TO ,/, rifabutin/NN ,/, rifapentine/NN ,/, phenytoin/NN ,/, carbamazepine/NN ,/, phenobarbital/NN and/CC St./NN Johns/NNP Wort/NNP ./.


DrugDDI.d145
DrugDDI.d145.s7
Hepatotoxicity Asymptomatic increases in liver transaminases have been observed in TARCEVA treated patients; .

Hepatotoxicity/NN Asymptomatic/JJ increases/NNS in/IN liver/NN transaminases/NNS have/VBP been/VBN observed/VBN in/IN TARCEVA/NN treated/JJ patients/NNS ;/: ./.


DrugDDI.d145
DrugDDI.d145.s8
therefore, periodic liver function testing ( transaminases , bilirubin , and alkaline phosphatase ) should be considered.

therefore/RB ,/, periodic/JJ liver/NN function/NN testing/NN (/-LRB- transaminases/NN ,/, bilirubin/NN ,/, and/CC alkaline/NN phosphatase/NN )/-RRB- should/MD be/VB considered/VBN ./.


DrugDDI.d145
DrugDDI.d145.s9
Dose reduction or interruption of TARCEVA should be considered if changes in liver function are severe.

Dose/NN reduction/NN or/CC interruption/NN of/IN TARCEVA/NN should/MD be/VB considered/VBN if/IN changes/NNS in/IN liver/NN function/NN are/VBP severe/JJ ./.


DrugDDI.d145
DrugDDI.d145.s10
Patients with Hepatic Impairment : In vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver .

Patients/NNS with/IN Hepatic/JJ Impairment/NN :/: In/FW vitro/FW and/CC in/FW vivo/FW evidence/NN suggest/VBP that/IN erlotinib/NN is/VBZ cleared/VBN primarily/RB by/IN the/DT liver/NN ./.


DrugDDI.d145
DrugDDI.d145.s11
Therefore, erlotinib exposure may be increased in patients with hepatic dysfunction.

Therefore/RB ,/, erlotinib/NN exposure/NN may/MD be/VB increased/VBN in/IN patients/NNS with/IN hepatic/JJ dysfunction/NN ./.


DrugDDI.d145
DrugDDI.d145.s12
Elevated International Normalized Ratio and Potential Bleeding International Normalized Ratio (INR) elevations and infrequent reports of bleeding events including gastrointestinal and non-gastrointestinal bleedings have been reported in clinical studies, some associated with concomitant warfarin administration.

Elevated/JJ International/NNP Normalized/VBN Ratio/NN and/CC Potential/JJ Bleeding/JJ International/NNP Normalized/VBN Ratio/NN (/-LRB- INR/NN )/-RRB- elevations/NNS and/CC infrequent/JJ reports/NNS of/IN bleeding/JJ events/NNS including/VBG gastrointestinal/JJ and/CC non-gastrointestinal/JJ bleedings/NNS have/VBP been/VBN reported/VBN in/IN clinical/JJ studies/NNS ,/, some/DT associated/VBN with/IN concomitant/JJ warfarin/NN administration/NN ./.


DrugDDI.d145
DrugDDI.d145.s13
Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR .

Patients/NNS taking/VBG warfarin/NN or/CC other/JJ coumarin-derivative/JJ anticoagulants/NNS should/MD be/VB monitored/VBN regularly/RB for/IN changes/NNS in/IN prothrombin/NN time/NN or/CC INR/NN ./.


DrugDDI.d124
DrugDDI.d124.s0
When ertapenem is co-administered with probenecid ( 500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem .

When/WRB ertapenem/NN is/VBZ co-administered/VBN with/IN probenecid/NN (/-LRB- 500/CD mg/NN p.o./NN every/DT 6/CD hours/NNS )/-RRB- ,/, probenecid/NN competes/VBZ for/IN active/JJ tubular/JJ secretion/NN and/CC reduces/VBZ the/DT renal/JJ clearance/NN of/IN ertapenem/NN ./.


DrugDDI.d124
DrugDDI.d124.s1
Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.

Based/VBN on/IN total/JJ ertapenem/NN concentrations/NNS ,/, probenecid/NN increased/VBD the/DT AUC/NN by/IN 25/CD %/NN and/CC reduced/VBD the/DT plasma/NN and/CC renal/JJ clearances/NNS by/IN 20/CD %/NN and/CC 35/CD %/NN ,/, respectively/RB ./.


DrugDDI.d124
DrugDDI.d124.s3
Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.

Because/IN of/IN the/DT small/JJ effect/NN on/IN half-life/NN ,/, the/DT coadministration/NN with/IN probenecid/NN to/TO extend/VB the/DT half-life/NN of/IN ertapenem/NN is/VBZ not/RB recommended/VBN ./.


DrugDDI.d124
DrugDDI.d124.s4
In vitro studies indicate that ertapenem does not inhibit P- glycoprotein -mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P- glycoprotein -mediated transport.

In/FW vitro/FW studies/NNS indicate/VBP that/IN ertapenem/NN does/VBZ not/RB inhibit/VB P-/NN glycoprotein/NN -mediated/JJ transport/NN of/IN digoxin/NN or/CC vinblastine/NN and/CC that/IN ertapenem/NN is/VBZ not/RB a/DT substrate/NN for/IN P-/NN glycoprotein/NN -mediated/JJ transport/NN ./.


DrugDDI.d124
DrugDDI.d124.s5
In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following six cytochrome p450 ( CYP ) isoforms : 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.

In/FW vitro/FW studies/NNS in/IN human/JJ liver/NN microsomes/NNS indicate/VBP that/IN ertapenem/NN does/VBZ not/RB inhibit/VB metabolism/NN mediated/VBN by/IN any/DT of/IN the/DT following/JJ six/CD cytochrome/NN p450/NN (/-LRB- CYP/NN )/-RRB- isoforms/NNS :/: 1A2/NN ,/, 2C9/NN ,/, 2C19/NN ,/, 2D6/NN ,/, 2E1/NN and/CC 3A4/NN ./.


DrugDDI.d124
DrugDDI.d124.s6
Drug interactions caused by inhibition of P- glycoprotein -mediated drug clearance or CYP -mediated drug clearance with the listed isoforms are unlikely.

Drug/NN interactions/NNS caused/VBN by/IN inhibition/NN of/IN P-/NN glycoprotein/NN -mediated/JJ drug/NN clearance/NN or/CC CYP/NN -mediated/JJ drug/NN clearance/NN with/IN the/DT listed/JJ isoforms/NNS are/VBP unlikely/JJ ./.


DrugDDI.d124
DrugDDI.d124.s7
Other than with probenecid , no specific clinical drug interaction studies have been conducted .

Other/JJ than/IN with/IN probenecid/NN ,/, no/DT specific/JJ clinical/JJ drug/NN interaction/NN studies/NNS have/VBP been/VBN conducted/VBN ./.


DrugDDI.d388
DrugDDI.d388.s1
Drug and Laboratory Test Interactions 1.

Drug/NN and/CC Laboratory/NN Test/NN Interactions/NNS 1/CD ./.


DrugDDI.d388
DrugDDI.d388.s4
increased factors II , VII antigen , VIII antigen , VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin ; .

increased/VBN factors/NNS II/CD ,/, VII/NN antigen/NN ,/, VIII/NN antigen/NN ,/, VIII/NN coagulant/NN activity/NN ,/, IX/NN ,/, X/NN ,/, XII/NN ,/, VII-X/NN complex/NN ,/, II-VII-X/NN complex/NN ,/, and/CC beta-thromboglobulin/NN ;/: ./.


DrugDDI.d388
DrugDDI.d388.s5
decreased levels of anti-factor Xa and antithrombin III , decreased antithrombin III activity; .

decreased/VBN levels/NNS of/IN anti-factor/NN Xa/NN and/CC antithrombin/NN III/CD ,/, decreased/VBD antithrombin/NN III/CD activity/NN ;/: ./.


DrugDDI.d388
DrugDDI.d388.s6
increased levels of fibrinogen and fibrinogen activity; .

increased/VBN levels/NNS of/IN fibrinogen/NN and/CC fibrinogen/NN activity/NN ;/: ./.


DrugDDI.d388
DrugDDI.d388.s9
Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.

Increased/VBN thyroid-binding/JJ globulin/NN (/-LRB- TBG/NN )/-RRB- leading/VBG to/TO increased/VBN circulating/JJ total/JJ thyroid/NN hormone/NN levels/NNS ,/, as/IN measured/VBN by/IN protein-bound/JJ iodine/NN (/-LRB- PBI/NN )/-RRB- ,/, T4/NN levels/NNS (/-LRB- by/IN column/NN or/CC by/IN radioimmunoassay/NN )/-RRB- or/CC T3/NN levels/NNS by/IN radioimmunoassay/NN ./.


DrugDDI.d388
DrugDDI.d388.s11
Free T4 and T3 concentrations are unaltered.

Free/JJ T4/NN and/CC T3/NN concentrations/NNS are/VBP unaltered/JJ ./.


DrugDDI.d388
DrugDDI.d388.s12
Patients on thyroid replacement therapy may require higher doses of thyroid hormone .

Patients/NNS on/IN thyroid/NN replacement/NN therapy/NN may/MD require/VBP higher/JJR doses/NNS of/IN thyroid/NN hormone/NN ./.


DrugDDI.d388
DrugDDI.d388.s14
Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin ( CBG ), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.

Other/JJ binding/NN proteins/NNS may/MD be/VB elevated/VBN in/IN serum/NN ,/, i.e./FW ,/, corticosteroid/NN binding/NN globulin/NN (/-LRB- CBG/NN )/-RRB- ,/, sex/NN hormone-binding/NN globulin/NN (/-LRB- SHBG/NN )/-RRB- ,/, leading/VBG to/TO increased/VBN total/JJ circulating/JJ corticosteroids/NNS and/CC sex/NN steroids/NNS ,/, respectively/RB ./.


DrugDDI.d388
DrugDDI.d388.s16
Other plasma proteins may be increased ( angiotensinogen /renin substrate , alpha-1-antitrypsin , ceruloplasmin ).

Other/JJ plasma/NN proteins/NNS may/MD be/VB increased/VBN (/-LRB- angiotensinogen/NN /renin/NN substrate/NN ,/, alpha-1-antitrypsin/JJ ,/, ceruloplasmin/NN )/-RRB- ./.


DrugDDI.d388
DrugDDI.d388.s18
Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.

Increased/VBN plasma/NN HDL/NN and/CC HDL2/NN cholesterol/NN subfraction/NN concentrations/NNS ,/, reduced/VBD LDL/NN cholesterol/NN concentration/NN ,/, increased/VBD triglyceride/NN levels/NNS ./.


DrugDDI.d217
DrugDDI.d217.s1
However, it was observed that the pharmacokinetics of ENBREL@ was unaltered by concomitant methotrexate in rheumatoid arthritis patients.

However/RB ,/, it/PRP was/VBD observed/VBN that/IN the/DT pharmacokinetics/NNS of/IN ENBREL/NN @/NN was/VBD unaltered/JJ by/IN concomitant/JJ methotrexate/NN in/IN rheumatoid/JJ arthritis/NN patients/NNS ./.


DrugDDI.d217
DrugDDI.d217.s2
In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL@ and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL@ alone (0%).

In/IN a/DT study/NN in/IN which/WDT patients/NNS with/IN active/JJ RA/NN were/VBD treated/VBN for/IN up/RB to/TO 24/CD weeks/NNS with/IN concurrent/JJ ENBREL/NN @/NN and/CC anakinra/NN therapy/NN ,/, a/DT 7/CD %/NN rate/NN of/IN serious/JJ infections/NNS was/VBD observed/VBN ,/, which/WDT was/VBD higher/JJR than/IN that/DT observed/VBN with/IN ENBREL/NN @/NN alone/RB (/-LRB- 0%)./JJ


DrugDDI.d217
DrugDDI.d217.s3
Two percent of patients treated concurrently with ENBREL@ and anakinra developed neutropenia ( ANC 1 x 109/L ).

Two/CD percent/NN of/IN patients/NNS treated/VBN concurrently/RB with/IN ENBREL/NN @/NN and/CC anakinra/NN developed/VBD neutropenia/NN (/-LRB- ANC/NN 1/CD x/NN 109/L/NN )/-RRB- ./.


DrugDDI.d217
DrugDDI.d217.s4
Patients in a clinical study who were on established therapy with sulfasalazine , to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.

Patients/NNS in/IN a/DT clinical/JJ study/NN who/WP were/VBD on/IN established/JJ therapy/NN with/IN sulfasalazine/NN ,/, to/TO which/WDT ENBREL/NN was/VBD added/VBN ,/, were/VBD noted/VBN to/TO develop/VB a/DT mild/JJ decrease/NN in/IN mean/NN neutrophil/NN counts/NNS in/IN comparison/NN to/TO groups/NNS treated/VBN with/IN either/CC ENBREL/NN CI/CD or/CC sulfasalazine/NN alone/RB ./.


DrugDDI.d174
DrugDDI.d174.s0
Dicumarol and warfarin may decrease hypoprothrombinemic effect.

Dicumarol/NN and/CC warfarin/NN may/MD decrease/VB hypoprothrombinemic/JJ effect/NN ./.


DrugDDI.d174
DrugDDI.d174.s1
Other depressasnts such as alcohol , barbiturates , and MAOIs may enhance CNS depression when administered with ethchlorvynol .

Other/JJ depressasnts/NNS such/JJ as/IN alcohol/NN ,/, barbiturates/NNS ,/, and/CC MAOIs/NNS may/MD enhance/VB CNS/NN depression/NN when/WRB administered/VBN with/IN ethchlorvynol/NN ./.


DrugDDI.d9
DrugDDI.d9.s0
Certain endocrine and liver function tests may be affected by estrogen -containing oral contraceptives .

Certain/JJ endocrine/NN and/CC liver/NN function/NN tests/NNS may/MD be/VB affected/VBN by/IN estrogen/NN -containing/JJ oral/JJ contraceptives/NNS ./.


DrugDDI.d9
DrugDDI.d9.s1
The following similar changes may be expected with larger doses of estrogen : Increased sulfobromophthalein retention; .

The/DT following/JJ similar/JJ changes/NNS may/MD be/VB expected/VBN with/IN larger/JJR doses/NNS of/IN estrogen/NN :/: Increased/VBN sulfobromophthalein/NN retention/NN ;/: ./.


DrugDDI.d9
DrugDDI.d9.s2
increased prothrombin and factors VII , VIII, IX, and X; .

increased/VBN prothrombin/NN and/CC factors/NNS VII/NN ,/, VIII/NN ,/, IX/NN ,/, and/CC X/NN ;/: ./.


DrugDDI.d9
DrugDDI.d9.s3
decreased antithrombin 3; .

decreased/VBN antithrombin/NN 3/CD ;/: ./.


DrugDDI.d9
DrugDDI.d9.s4
increased norepinephrine -induced platel et aggregation; .

increased/VBN norepinephrine/NN -induced/JJ platel/NNP et/FW aggregation/NN ;/: ./.


DrugDDI.d9
DrugDDI.d9.s5
increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone , as measured by PBI, T4 by column, or T4 by radioimmunoassay.

increased/VBN thyroid/NN binding/NN globulin/NN (/-LRB- TBG/NN )/-RRB- leading/VBG to/TO increased/VBN circulating/VBG total/JJ thyroid/NN hormone/NN ,/, as/IN measured/VBN by/IN PBI/NN ,/, T4/NN by/IN column/NN ,/, or/CC T4/NN by/IN radioimmunoassay/NN ./.


DrugDDI.d9
DrugDDI.d9.s11
increased serum triglyceride and phospholipid concentration.

increased/VBN serum/NN triglyceride/NN and/CC phospholipid/NN concentration/NN ./.


DrugDDI.d132
DrugDDI.d132.s0
Ethinyl estradiol : Substrate of CYP3A4 (major), 3A5-7 (minor); .

Ethinyl/NN estradiol/NN :/: Substrate/NN of/IN CYP3A4/NN (/-LRB- major/JJ )/-RRB- ,/, 3A5-7/NN (/-LRB- minor/JJ )/-RRB- ;/: ./.


DrugDDI.d132
DrugDDI.d132.s1
Inhibits CYP1A2 (weak), 2B6 (weak), 2C19 (weak), 3A4 (weak).

Inhibits/VBZ CYP1A2/NN (/-LRB- weak/JJ )/-RRB- ,/, 2B6/NN (/-LRB- weak/JJ )/-RRB- ,/, 2C19/NN (/-LRB- weak/JJ )/-RRB- ,/, 3A4/NN (/-LRB- weak)./NN


DrugDDI.d132
DrugDDI.d132.s2
Acetaminophen : May increase plasma concentration of synthetic estrogens , possibly by inhibiting conjugation.

Acetaminophen/NN :/: May/MD increase/VB plasma/NN concentration/NN of/IN synthetic/JJ estrogens/NNS ,/, possibly/RB by/IN inhibiting/VBG conjugation/NN ./.


DrugDDI.d132
DrugDDI.d132.s3
Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen .

Combination/NN hormonal/JJ contraceptives/NNS may/MD also/RB decrease/VB the/DT plasma/NN concentration/NN of/IN acetaminophen/NN ./.


DrugDDI.d132
DrugDDI.d132.s4
Acitretin : Interferes with the contraceptive effect of microdosed progestin -containing minipill preparations.

Acitretin/NN :/: Interferes/VBZ with/IN the/DT contraceptive/JJ effect/NN of/IN microdosed/JJ progestin/NN -containing/JJ minipill/NN preparations/NNS ./.


DrugDDI.d132
DrugDDI.d132.s5
The effect on other progestational contraceptives (eg, implants, injectables) is unknown.

The/DT effect/NN on/IN other/JJ progestational/JJ contraceptives/NNS (/-LRB- eg/FW ,/, implants/NNS ,/, injectables/NNS )/-RRB- is/VBZ unknown/JJ ./.


DrugDDI.d132
DrugDDI.d132.s6
Aminoglutethimide : May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.

Aminoglutethimide/NN :/: May/MD increase/VBP CYP/NN metabolism/NN of/IN progestins/NNS leading/VBG to/TO possible/JJ decrease/NN in/IN contraceptive/JJ effectiveness/NN ./.


DrugDDI.d132
DrugDDI.d132.s7
Use of a nonhormonal contraceptive product is recommended.

Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.


DrugDDI.d132
DrugDDI.d132.s8
Antibiotics ( ampicillin , tetracycline ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.

Antibiotics/NNS (/-LRB- ampicillin/NN ,/, tetracycline/NN )/-RRB- :/: Pregnancy/NN has/VBZ been/VBN reported/VBN following/VBG concomitant/JJ use/NN ,/, however/RB ,/, pharmacokinetic/JJ studies/NNS have/VBP not/RB shown/VBN consistent/JJ effects/NNS with/IN these/DT antibiotics/NNS on/IN plasma/NN concentrations/NNS of/IN synthetic/JJ steroids/NNS ./.


DrugDDI.d132
DrugDDI.d132.s9
Use of a nonhormonal contraceptive product is recommended.

Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.


DrugDDI.d132
DrugDDI.d132.s10
Anticoagulants : Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.

Anticoagulants/NNS :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB or/CC decrease/VB the/DT effects/NNS of/IN coumarin/NN derivatives/NNS ./.


DrugDDI.d132
DrugDDI.d132.s11
Combination hormonal contraceptives may also increase risk of thromboembolic disorders.

Combination/NN hormonal/JJ contraceptives/NNS may/MD also/RB increase/VB risk/NN of/IN thromboembolic/JJ disorders/NNS ./.


DrugDDI.d132
DrugDDI.d132.s12
Anticonvulsants ( carbamazepine , felbamate , phenobarbital , phenytoin , topiramate ): Increase the metabolism of ethinyl estradiol and/or some progestins , leading to possible decrease in contraceptive effectiveness.

Anticonvulsants/NNS (/-LRB- carbamazepine/NN ,/, felbamate/NN ,/, phenobarbital/NN ,/, phenytoin/NN ,/, topiramate/NN )/-RRB- :/: Increase/NN the/DT metabolism/NN of/IN ethinyl/NN estradiol/NN and/or/CC some/DT progestins/NNS ,/, leading/VBG to/TO possible/JJ decrease/NN in/IN contraceptive/JJ effectiveness/NN ./.


DrugDDI.d132
DrugDDI.d132.s13
Use of a nonhormonal contraceptive product is recommended.

Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.


DrugDDI.d132
DrugDDI.d132.s14
Ascorbic acid : Doses of ascorbic acid ( vitamin C ) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation; .

Ascorbic/JJ acid/NN :/: Doses/NNS of/IN ascorbic/JJ acid/NN (/-LRB- vitamin/NN C/NN )/-RRB- 1/CD g/day/NN have/VBP been/VBN reported/VBN to/TO increase/VB plasma/NN concentration/NN of/IN synthetic/JJ estrogens/NNS by/IN ~47/CD %/NN ,/, possibly/RB by/IN inhibiting/VBG conjugation/NN ;/: ./.


DrugDDI.d132
DrugDDI.d132.s16
Atorvastatin : Atorvastatin increases the AUC for norethindrone and ethinyl estradiol .

Atorvastatin/NN :/: Atorvastatin/NN increases/VBZ the/DT AUC/NN for/IN norethindrone/NN and/CC ethinyl/NN estradiol/NN ./.


DrugDDI.d132
DrugDDI.d132.s17
Benzodiazepines : Combination hormonal contraceptives may decrease the clearance of some benzodiazepines ( alprazolam , chlordiazepoxide , diazepam ) and increase the clearance of others ( lorazepam , oxazepam , temazepam ).

Benzodiazepines/NNS :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD decrease/VB the/DT clearance/NN of/IN some/DT benzodiazepines/NNS (/-LRB- alprazolam/NN ,/, chlordiazepoxide/NN ,/, diazepam/NN )/-RRB- and/CC increase/VB the/DT clearance/NN of/IN others/NNS (/-LRB- lorazepam/NN ,/, oxazepam/NN ,/, temazepam/NN )/-RRB- ./.


DrugDDI.d132
DrugDDI.d132.s18
Clofibric acid : Combination hormonal contraceptives may increase the clearance of clofibric acid .

Clofibric/JJ acid/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT clearance/NN of/IN clofibric/JJ acid/NN ./.


DrugDDI.d132
DrugDDI.d132.s19
Cyclosporine : Combination hormonal contraceptives may inhibit the metabolism of cyclosporine , leading to increased plasma concentrations; .

Cyclosporine/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD inhibit/VB the/DT metabolism/NN of/IN cyclosporine/NN ,/, leading/VBG to/TO increased/VBN plasma/NN concentrations/NNS ;/: ./.


DrugDDI.d132
DrugDDI.d132.s20
monitor cyclosporine levels.

monitor/VB cyclosporine/NN levels/NNS ./.


DrugDDI.d132
DrugDDI.d132.s21
CYP3A4 inducers: CYP3A4 inducers may decrease the levels/effects of ethinyl estradiol .

CYP3A4/JJ inducers/NNS :/: CYP3A4/NN inducers/NNS may/MD decrease/VB the/DT levels/effects/NNS of/IN ethinyl/NN estradiol/NN ./.


DrugDDI.d132
DrugDDI.d132.s22
Example inducers include aminoglutethimide , carbamazepine , nafcillin , nevirapine , phenobarbital , phenytoin , and rifamycins .

Example/NN inducers/NNS include/VBP aminoglutethimide/NN ,/, carbamazepine/NN ,/, nafcillin/NN ,/, nevirapine/NN ,/, phenobarbital/NN ,/, phenytoin/NN ,/, and/CC rifamycins/NN ./.


DrugDDI.d132
DrugDDI.d132.s23
Griseofulvin : Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes; .

Griseofulvin/NN :/: Griseofulvin/NN may/MD induce/VB the/DT metabolism/NN of/IN combination/NN hormonal/JJ contraceptives/NNS causing/VBG menstrual/JJ changes/NNS ;/: ./.


DrugDDI.d132
DrugDDI.d132.s25
Use of barrier form of contraception is suggested while on griseofulvin therapy.

Use/NN of/IN barrier/NN form/NN of/IN contraception/NN is/VBZ suggested/VBN while/IN on/IN griseofulvin/NN therapy/NN ./.


DrugDDI.d132
DrugDDI.d132.s26
Morphine : Combination hormonal contraceptives may increase the clearance of morphine .

Morphine/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT clearance/NN of/IN morphine/NN ./.


DrugDDI.d132
DrugDDI.d132.s27
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives ; .

Non-nucleoside/JJ reverse/NN transcriptase/NN inhibitors/NNS (/-LRB- NNRTIs/NN )/-RRB- :/: Nevirapine/NN may/MD decrease/VB plasma/NN levels/NNS of/IN combination/NN hormonal/JJ contraceptives/NNS ;/: ./.


DrugDDI.d132
DrugDDI.d132.s28
use of a nonhormonal contraceptive product is recommended.

use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.


DrugDDI.d132
DrugDDI.d132.s29
No data for delavirdine ; .

No/NN data/NNS for/IN delavirdine/NN ;/: ./.


DrugDDI.d132
DrugDDI.d132.s30
incomplete data for efavirenz .

incomplete/JJ data/NNS for/IN efavirenz/NN ./.


DrugDDI.d132
DrugDDI.d132.s31
Prednisolone : Ethinyl estradiol may inhibit the metabolism of prednisolone , leading to increased plasma concentrations.

Prednisolone/NN :/: Ethinyl/NN estradiol/NN may/MD inhibit/VB the/DT metabolism/NN of/IN prednisolone/NN ,/, leading/VBG to/TO increased/VBN plasma/NN concentrations/NNS ./.


DrugDDI.d132
DrugDDI.d132.s32
Protease inhibitors : Amprenavir , lopinavir , nelfinavir , and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives ; .

Protease/NN inhibitors/NNS :/: Amprenavir/NN ,/, lopinavir/NN ,/, nelfinavir/NN ,/, and/CC ritonavir/NN have/VBP been/VBN shown/VBN to/TO decrease/VB plasma/NN levels/NNS of/IN combination/NN hormonal/JJ contraceptives/NNS ;/: ./.


DrugDDI.d132
DrugDDI.d132.s33
use of a nonhormonal contraceptive product is recommended.

use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.


DrugDDI.d132
DrugDDI.d132.s34
Indinavir has been shown to increase plasma levels of combination hormonal contraceptives .

Indinavir/NN has/VBZ been/VBN shown/VBN to/TO increase/VB plasma/NN levels/NNS of/IN combination/NN hormonal/JJ contraceptives/NNS ./.


DrugDDI.d132
DrugDDI.d132.s35
No data for saquinavir .

No/DT data/NNS for/IN saquinavir/NN ./.


DrugDDI.d132
DrugDDI.d132.s36
Rifampin : Rifampin increases the metabolism of ethinyl estradiol and some progestins ( norethindrone ) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.

Rifampin/NN :/: Rifampin/NN increases/VBZ the/DT metabolism/NN of/IN ethinyl/NN estradiol/NN and/CC some/DT progestins/NNS (/-LRB- norethindrone/NN )/-RRB- resulting/VBG in/IN decreased/VBN contraceptive/JJ effectiveness/NN and/CC increased/VBN menstrual/JJ irregularities/NNS ./.


DrugDDI.d132
DrugDDI.d132.s37
Use of a nonhormonal contraceptive product is recommended.

Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.


DrugDDI.d132
DrugDDI.d132.s38
Salicylic acid : Combination hormonal contraceptives may increase the clearance of salicylic acid .

Salicylic/JJ acid/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT clearance/NN of/IN salicylic/JJ acid/NN ./.


DrugDDI.d132
DrugDDI.d132.s39
Selegiline : Combination hormonal contraceptives may increase the serum concentration of selegiline .

Selegiline/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT serum/NN concentration/NN of/IN selegiline/NN ./.


DrugDDI.d132
DrugDDI.d132.s40
Theophylline : Ethinyl estradiol may inhibit the metabolism of theophylline , leading to increased plasma concentrations.

Theophylline/NN :/: Ethinyl/NN estradiol/NN may/MD inhibit/VB the/DT metabolism/NN of/IN theophylline/NN ,/, leading/VBG to/TO increased/VBN plasma/NN concentrations/NNS ./.


DrugDDI.d132
DrugDDI.d132.s41
Tricyclic antidepressants ( amitriptyline , imipramine , nortriptyline ): Metabolism may be inhibited by combination hormonal contraceptives , increasing plasma levels of antidepressant ; .

Tricyclic/JJ antidepressants/NNS (/-LRB- amitriptyline/NN ,/, imipramine/NN ,/, nortriptyline/NN )/-RRB- :/: Metabolism/NN may/MD be/VB inhibited/VBN by/IN combination/NN hormonal/JJ contraceptives/NNS ,/, increasing/VBG plasma/NN levels/NNS of/IN antidepressant/JJ ;/: ./.


DrugDDI.d132
DrugDDI.d132.s43
ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine .

ETHANOL/NN //: NUTRITION/NN //: HERB/NN INTERACTIONS/NNS :/: Food/NN :/: CNS/NN effects/NNS of/IN caffeine/NN may/MD be/VB enhanced/VBN if/IN combination/NN hormonal/JJ contraceptives/NNS are/VBP used/VBN concurrently/RB with/IN caffeine/NN ./.


DrugDDI.d132
DrugDDI.d132.s44
Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; .

Grapefruit/NN juice/NN increases/VBZ ethinyl/NN estradiol/NN concentrations/NNS and/CC would/MD be/VB expected/VBN to/TO increase/VB progesterone/NN serum/NN levels/NNS as/IN well/NN ;/: ./.


DrugDDI.d132
DrugDDI.d132.s46
Herb/Nutraceutical: St Johns wort may decrease the effectiveness of combination hormonal contraceptives by inducing hepatic enzymes.

Herb/Nutraceutical/NN :/: St/JJ Johns/NNP wort/NN may/MD decrease/VB the/DT effectiveness/NN of/IN combination/NN hormonal/JJ contraceptives/NNS by/IN inducing/VBG hepatic/JJ enzymes/NNS ./.


DrugDDI.d132
DrugDDI.d132.s47
Avoid dong quai and black cohosh (have estrogen activity).

Avoid/VB dong/JJ quai/NN and/CC black/JJ cohosh/NN (/-LRB- have/VB estrogen/NN activity/NN )./RB


DrugDDI.d132
DrugDDI.d132.s48
Avoid saw palmetto , red clover , ginseng .

Avoid/VB saw/VB palmetto/NN ,/, red/JJ clover/NN ,/, ginseng/NN ./.


DrugDDI.d411
DrugDDI.d411.s0
CYP3A4 Inhibitors@Felodipine is metabolized by CYP3A4 .

CYP3A4/JJ Inhibitors/NNS @/NN Felodipine/NN is/VBZ metabolized/VBN by/IN CYP3A4/NN ./.


DrugDDI.d411
DrugDDI.d411.s1
Co-administration of CYP3A4 inhibitors (eg, ketoconazole , itraconazole , erythromycin , grapefruit juice, cimetidine ) with felodipine may lead to several- fold increases in the plasma levels of felodipine , either due to an increase in bioavailability or due to a decrease in metabolism.

Co-administration/NN of/IN CYP3A4/JJ inhibitors/NNS (/-LRB- eg/NN ,/, ketoconazole/NN ,/, itraconazole/NN ,/, erythromycin/NN ,/, grapefruit/NN juice/NN ,/, cimetidine/NN )/-RRB- with/IN felodipine/NN may/MD lead/VB to/TO several-/JJ fold/JJ increases/NNS in/IN the/DT plasma/NN levels/NNS of/IN felodipine/NN ,/, either/CC due/JJ to/TO an/DT increase/NN in/IN bioavailability/NN or/CC due/JJ to/TO a/DT decrease/NN in/IN metabolism/NN ./.


DrugDDI.d411
DrugDDI.d411.s3
These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).

These/DT effects/NNS have/VBP been/VBN observed/VBN with/IN co-administration/NN of/IN itraconazole/NN (/-LRB- a/DT potent/JJ CYP3A4/NN inhibitor/NN )./NN


DrugDDI.d411
DrugDDI.d411.s4
Caution should be used when CYP3A4 inhibitors are co-administered with felodipine .

Caution/NN should/MD be/VB used/VBN when/WRB CYP3A4/JJ inhibitors/NNS are/VBP co-administered/VBN with/IN felodipine/NN ./.


DrugDDI.d411
DrugDDI.d411.s5
A conservative approach to dosing felodipine should be taken.

A/DT conservative/JJ approach/NN to/TO dosing/NN felodipine/NN should/MD be/VB taken/VBN ./.


DrugDDI.d411
DrugDDI.d411.s6
The following specific interactions have been reported: Itraconazole@Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine .

The/DT following/JJ specific/JJ interactions/NNS have/VBP been/VBN reported/VBN :/: Itraconazole/NN @/NN Co-administration/NN of/IN another/DT extended/VBN release/NN formulation/NN of/IN felodipine/NN with/IN itraconazole/NN resulted/VBD in/IN approximately/RB 8-fold/JJ increase/NN in/IN the/DT AUC/NN ,/, more/JJR than/IN 6-/CD fold/NN increase/NN in/IN the/DT Cmax/NN ,/, and/CC 2-fold/JJ prolongation/NN in/IN the/DT half-/JJ life/NN of/IN felodipine/NN ./.


DrugDDI.d411
DrugDDI.d411.s7
Erythromycin@Co-administration of felodipine ( PLENDIL ) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine .

Erythromycin/NN @/NN Co-administration/NN of/IN felodipine/NN (/-LRB- PLENDIL/NN )/-RRB- with/IN erythromycin/NN resulted/VBD in/IN approximately/RB 2.5-/CD fold/JJ increase/NN in/IN the/DT AUC/NN and/CC Cmax/NN ,/, and/CC about/RB 2-/CD fold/NN prolongation/NN in/IN the/DT half-/JJ life/NN of/IN felodipine/NN ./.


DrugDDI.d411
DrugDDI.d411.s8
Grapefruit juice@Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine .

Grapefruit/NN juice/NN @/NN Co-administration/NN of/IN felodipine/NN with/IN grapefruit/NN juice/NN resulted/VBD in/IN more/JJR than/IN 2-fold/JJ increase/NN in/IN the/DT AUC/NN and/CC Cmax/NN ,/, but/CC no/DT prolongation/NN in/IN the/DT half-/JJ life/NN of/IN felodipine/NN ./.


DrugDDI.d411
DrugDDI.d411.s9
Cimetidine@Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine .

Cimetidine/NN @/NN Co-administration/NN of/IN felodipine/NN with/IN cimetidine/NN (/-LRB- a/DT non-specific/JJ CYP-450/NN inhibitor/NN )/-RRB- resulted/VBD in/IN an/DT increase/NN of/IN approximately/RB 50/CD %/NN in/IN the/DT AUC/NN and/CC the/DT Cmax/NN ,/, of/IN felodipine/NN ./.


DrugDDI.d411
DrugDDI.d411.s10
Beta-Blocking Agents@ : A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine .

Beta-Blocking/JJ Agents/NNS @/NN :/: A/DT pharmacokinetic/JJ study/NN of/IN felodipine/NN in/IN conjunction/NN with/IN metoprolol/NN demonstrated/VBD no/DT significant/JJ effects/NNS on/IN the/DT pharmacokinetics/NNS of/IN felodipine/NN ./.


DrugDDI.d411
DrugDDI.d411.s11
The AUC and Cmax of metoprolol , however, were increased approximately 31 and 38%, respectively.

The/DT AUC/NN and/CC Cmax/NN of/IN metoprolol/NN ,/, however/RB ,/, were/VBD increased/VBN approximately/RB 31/CD and/CC 38/CD %/NN ,/, respectively/RB ./.


DrugDDI.d411
DrugDDI.d411.s12
In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.

In/IN controlled/JJ clinical/JJ trials/NNS ,/, however/RB ,/, beta/NN blockers/NNS including/VBG metoprolol/NN were/VBD concurrently/RB administered/VBN with/IN felodipine/NN and/CC were/VBD well/RB tolerated/VBN ./.


DrugDDI.d411
DrugDDI.d411.s13
Digoxin@ : When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.

Digoxin/NN @/NN :/: When/WRB given/VBN concomitantly/RB with/IN PLENDIL/NN the/DT pharmacokinetics/NNS of/IN digoxin/NN in/IN patients/NNS with/IN heart/NN failure/NN were/VBD not/RB significantly/RB altered/VBN ./.


DrugDDI.d411
DrugDDI.d411.s14
Anticonvulsants@ : In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin , carbamazepine , or phenobarbital ) than in healthy volunteers.

Anticonvulsants/NNS @/NN :/: In/IN a/DT pharmacokinetic/JJ study/NN ,/, maximum/JJ plasma/NN concentrations/NNS of/IN felodipine/NN were/VBD considerably/RB lower/JJR in/IN epileptic/JJ patients/NNS on/IN long-term/JJ anticonvulsant/JJ therapy/NN (/-LRB- eg/NN ,/, phenytoin/NN ,/, carbamazepine/NN ,/, or/CC phenobarbital/NN )/-RRB- than/IN in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d411
DrugDDI.d411.s15
In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers.

In/IN such/JJ patients/NNS ,/, the/DT mean/JJ area/NN under/IN the/DT felodipine/NN plasma/NN concentration-time/NN curve/NN was/VBD also/RB reduced/VBN to/TO approximately/RB 6/CD %/NN of/IN that/DT observed/VBN in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d411
DrugDDI.d411.s16
Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.

Since/IN a/DT clinically/RB significant/JJ interaction/NN may/MD be/VB anticipated/VBN ,/, alternative/JJ antihypertensive/JJ therapy/NN should/MD be/VB considered/VBN in/IN these/DT patients/NNS ./.


DrugDDI.d411
DrugDDI.d411.s17
Tacrolimus@ Felodipine may increase the blood concentration of tacrolimus .

Tacrolimus/NN @/NN Felodipine/NN may/MD increase/VB the/DT blood/NN concentration/NN of/IN tacrolimus/NN ./.


DrugDDI.d411
DrugDDI.d411.s18
When given concomitantly with felodipine , the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.

When/WRB given/VBN concomitantly/RB with/IN felodipine/NN ,/, the/DT tacrolimus/NN blood/NN concentration/NN should/MD be/VB followed/VBN and/CC the/DT tacrolimus/NN dose/NN may/MD need/VBP to/TO be/VB adjusted/VBN ./.


DrugDDI.d411
DrugDDI.d411.s19
Other Concomitant Therapy@ : In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone .

Other/JJ Concomitant/JJ Therapy/NN @/NN :/: In/IN healthy/JJ subjects/NNS there/EX were/VBD no/DT clinically/RB significant/JJ interactions/NNS when/WRB felodipine/NN was/VBD given/VBN concomitantly/RB with/IN indomethacin/NN or/CC spironolactone/NN ./.


DrugDDI.d210
DrugDDI.d210.s0
Fenfluramine may increase slightly the effect of antihypertensive drugs , e.g., guanethidine , methyldopa , reserpine .

Fenfluramine/NN may/MD increase/VB slightly/RB the/DT effect/NN of/IN antihypertensive/JJ drugs/NNS ,/, e.g./FW ,/, guanethidine/NN ,/, methyldopa/NN ,/, reserpine/NN ./.


DrugDDI.d210
DrugDDI.d210.s1
Other CNS depressant drugs should be used with caution in patients taking fenfluramine , since the effects may be additive.

Other/JJ CNS/NN depressant/NN drugs/NNS should/MD be/VB used/VBN with/IN caution/NN in/IN patients/NNS taking/VBG fenfluramine/NN ,/, since/IN the/DT effects/NNS may/MD be/VB additive/JJ ./.


DrugDDI.d199
DrugDDI.d199.s0
Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANT S ARE GIVEN IN CONJUNCTION WITH TRICOR .

Oral/JJ Anticoagulants/NNS CAUTION/NN SHOULD/MD BE/VB EXERCISED/VBN WHEN/WRB COUMARIN/NN ANTICOAGULANT/NN S/NNS ARE/VBP GIVEN/VBN IN/IN CONJUNCTION/NN WITH/IN TRICOR/NN ./.


DrugDDI.d199
DrugDDI.d199.s1
THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS.

THE/DT DOSAGE/NN OF/IN THE/DT ANTICOAGULANTS/NNS SHOULD/MD BE/VB REDUCED/VBN TO/TO MAINTAIN/VB THE/DT PROTHROMBIN/NN TIME/INR/NN AT/IN THE/DT DESIRED/JJ LEVEL/NN TO/TO PREVENT/VB BLEEDING/JJ COMPLICATIONS/NNS ./.


DrugDDI.d199
DrugDDI.d199.s3
HMG-CoA reductase inhibitors The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.

HMG-CoA/NN reductase/NN inhibitors/NNS The/DT combined/JJ use/NN of/IN TRICOR/NN and/CC HMG-CoA/NN reductase/NN inhibitors/NNS should/MD be/VB avoided/VBN unless/IN the/DT benefit/NN of/IN further/JJ alterations/NNS in/IN lipid/NN levels/NNS is/VBZ likely/JJ to/TO outweigh/VB the/DT increased/VBN risk/NN of/IN this/DT drug/NN combination/NN ./.


DrugDDI.d199
DrugDDI.d199.s4
Resins : Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.

Resins/NNS :/: Since/IN bile/JJ acid/NN sequestrants/NNS may/MD bind/VB other/JJ drugs/NNS given/VBN concurrently/RB ,/, patients/NNS should/MD take/VB TRICOR/NN at/IN least/JJS 1/CD hour/NN before/IN or/CC 4-6/CD hours/NNS after/IN a/DT bile/JJ acid/NN binding/NN resin/NN to/TO avoid/VB impeding/VBG its/PRP$ absorption/NN ./.


DrugDDI.d199
DrugDDI.d199.s5
Cyclosporine : Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR , there is a risk that an interaction will lead to deterioration.

Cyclosporine/NN :/: Because/IN cyclosporine/NN can/MD produce/VB nephrotoxicity/NN with/IN decreases/NNS in/IN creatinine/NN clearance/NN and/CC rises/VBZ in/IN serum/NN creatinine/NN ,/, and/CC because/IN renal/JJ excretion/NN is/VBZ the/DT primary/JJ elimination/NN route/NN of/IN fibrate/JJ drugs/NNS including/VBG TRICOR/NN ,/, there/EX is/VBZ a/DT risk/NN that/IN an/DT interaction/NN will/MD lead/VB to/TO deterioration/NN ./.


DrugDDI.d199
DrugDDI.d199.s6
The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed .

The/DT benefits/NNS and/CC risks/NNS of/IN using/VBG TRICOR/NN with/IN immunosuppressants/NNS and/CC other/JJ potentially/RB nephrotoxic/JJ agents/NNS should/MD be/VB carefully/RB considered/VBN ,/, and/CC the/DT lowest/JJS effective/JJ dose/NN employed/VBN ./.


DrugDDI.d199
DrugDDI.d199.s8
@ Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome ( CYP ) P450 isoforms CYP3A4, CYP2D6 , CYP2E1 , or CYP1A2 .

@/NN Drug-drug/JJ interactions/NNS In/FW vitro/FW studies/NNS using/VBG human/JJ liver/NN microsomes/NNS indicate/VBP that/IN fenofibrate/NN and/CC fenofibric/JJ acid/NN are/VBP not/RB inhibitors/NNS of/IN cytochrome/NN (/-LRB- CYP/NN )/-RRB- P450/NN isoforms/NNS CYP3A4/NN ,/, CYP2D6/NN ,/, CYP2E1/NN ,/, or/CC CYP1A2/NN ./.


DrugDDI.d199
DrugDDI.d199.s9
They are weak inhibitors of CYP2C19 and CYP2A6 , and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.

They/PRP are/VBP weak/JJ inhibitors/NNS of/IN CYP2C19/NN and/CC CYP2A6/NN ,/, and/CC mild-to-moderate/JJ inhibitors/NNS of/IN CYP2C9/NN at/IN therapeutic/JJ concentrations/NNS ./.


DrugDDI.d199
DrugDDI.d199.s10
Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.

Potentiation/NN of/IN coumarin-type/NN anticoagulants/NNS has/VBZ been/VBN observed/VBN with/IN prolongation/NN of/IN the/DT prothrombin/NN time/INR/NN ./.


DrugDDI.d199
DrugDDI.d199.s11
Bile acid sequestrants have been shown to bind other drugs given concurrently.

Bile/JJ acid/NN sequestrants/NNS have/VBP been/VBN shown/VBN to/TO bind/VB other/JJ drugs/NNS given/VBN concurrently/RB ./.


DrugDDI.d199
DrugDDI.d199.s12
Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .

Therefore/RB ,/, fenofibrate/NN should/MD be/VB taken/VBN at/IN least/JJS 1/CD hour/NN before/IN or/CC 4-6/CD hours/NNS after/IN a/DT bile/JJ acid/NN binding/NN resin/NN to/TO avoid/VB impeding/VBG its/PRP$ absorption/NN ./.


DrugDDI.d199
DrugDDI.d199.s13
Concomitant administration of fenofibrate (equivalent to 145mg TRICOR ) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3@-hydroxy-iso- pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.

Concomitant/JJ administration/NN of/IN fenofibrate/NN (/-LRB- equivalent/JJ to/TO 145mg/NN TRICOR/NN )/-RRB- with/IN pravastatin/NN (/-LRB- 40/CD mg/NN )/-RRB- once/RB daily/JJ for/IN 10/CD days/NNS has/VBZ been/VBN shown/VBN to/TO increase/VB the/DT mean/NN Cmax/NN and/CC AUC/NN values/NNS for/IN pravastatin/NN by/IN 36/CD %/NN (/-LRB- range/NN from/IN 69/CD %/NN decrease/NN to/TO 321/CD %/NN increase/NN )/-RRB- and/CC 28/CD %/NN (/-LRB- range/NN from/IN 54/CD %/NN decrease/NN to/TO 128/CD %/NN increase/NN )/-RRB- ,/, respectively/RB ,/, and/CC for/IN 3/CD @/NN -hydroxy-iso-/JJ pravastatin/NN by/IN 55/CD %/NN (/-LRB- range/NN from/IN 32/CD %/NN decrease/NN to/TO 314/CD %/NN increase/NN )/-RRB- and/CC 39/CD %/NN (/-LRB- range/NN from/IN 24/CD %/NN decrease/NN to/TO 261/CD %/NN increase/NN )/-RRB- ,/, respectively/RB in/IN 23/CD healthy/JJ adults/NNS ./.


DrugDDI.d199
DrugDDI.d199.s14
A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid .

A/DT single/JJ dose/NN of/IN pravastatin/NN had/VBD no/DT clinically/RB important/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN fenofibric/JJ acid/NN ./.


DrugDDI.d199
DrugDDI.d199.s15
Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR ) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.

Concomitant/JJ administration/NN of/IN fenofibrate/NN (/-LRB- equivalent/JJ to/TO 145/CD mg/NN TRICOR/NN )/-RRB- with/IN atorvastatin/NN (/-LRB- 20/CD mg/NN )/-RRB- once/RB daily/RB for/IN 10/CD days/NNS resulted/VBD in/IN approximately/RB 17/CD %/NN decrease/NN (/-LRB- range/NN from/IN 67/CD %/NN decrease/NN to/TO 44/CD %/NN increase/NN )/-RRB- in/IN atorvastatin/NN AUC/NN values/NNS in/IN 22/CD healthy/JJ males/NNS ./.


DrugDDI.d199
DrugDDI.d199.s16
The atorvastatin Cmax values were not significantly affected by fenofibrate .

The/DT atorvastatin/NN Cmax/NN values/NNS were/VBD not/RB significantly/RB affected/VBN by/IN fenofibrate/NN ./.


DrugDDI.d199
DrugDDI.d199.s17
The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin .

The/DT pharmacokinetics/NNS of/IN fenofibric/JJ acid/NN were/VBD not/RB significantly/RB affected/VBN by/IN atorvastatin/NN ./.


DrugDDI.d95
DrugDDI.d95.s0
Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.

Drug/NN Interaction/NN with/IN Erythromycin/NN and/CC Ketoconazole/NN Fexofenadine/NN has/VBZ been/VBN shown/VBN to/TO exhibit/VB minimal/JJ (/-LRB- ca./FW 5/CD %/NN )/-RRB- metabolism/NN ./.


DrugDDI.d95
DrugDDI.d95.s1
However, co@ administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine .

However/RB ,/, co/NN @/NN administration/NN of/IN fexofenadine/NN hydrochloride/NN with/IN either/CC ketoconazole/NN or/CC erythromycin/NN led/VBD to/TO increased/VBN plasma/NN concentrations/NNS of/IN fexofenadine/NN ./.


DrugDDI.d95
DrugDDI.d95.s2
Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole .

Fexofenadine/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN either/CC erythromycin/NN or/CC ketoconazole/NN ./.


DrugDDI.d95
DrugDDI.d95.s3
In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).

In/IN 2/CD separate/JJ studies/NNS ,/, fexofenadine/NN hydrochloride/NN 120/CD mg/NN twice/RB daily/RB (/-LRB- 240/CD mg/NN total/JJ daily/JJ dose/NN )/-RRB- was/VBD co-administered/VBN with/IN either/CC erythromycin/NN 500/CD mg/NN every/DT 8/CD hours/NNS or/CC ketoconazole/NN 400/CD mg/NN once/RB daily/JJ under/IN steady-state/JJ conditions/NNS to/TO healthy/JJ volunteers/NNS (/-LRB- n=24/NN ,/, each/DT study/NN )./NN


DrugDDI.d95
DrugDDI.d95.s4
No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole .

No/DT differences/NNS in/IN adverse/JJ events/NNS or/CC QTc/NN interval/NN were/VBD observed/VBN when/WRB subjects/NNS were/VBD administered/VBN fexofenadine/NN hydrochloride/NN alone/RB or/CC in/IN combination/NN with/IN either/CC erythromycin/NN or/CC ketoconazole/NN ./.


DrugDDI.d95
DrugDDI.d95.s5
The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24) .

The/DT findings/NNS of/IN these/DT studies/NNS are/VBP summarized/VBN in/IN the/DT following/VBG table/NN :/: Effects/NNS on/IN steady-state/JJ fexofenadine/NN pharmacokinetics/NNS after/IN 7/CD days/NNS of/IN co-administration/NN with/IN fexofenadine/NN hydrochloride/NN 120/CD mg/NN every/DT 12/CD hours/NNS (/-LRB- two/CD times/NNS the/DT recommended/VBN twice/RB daily/JJ dose/NN )/-RRB- in/IN healthy/JJ volunteers/NNS (/-LRB- n=24/NN )/-RRB- ./.


DrugDDI.d95
DrugDDI.d95.s6
Concomitant Drug .

Concomitant/JJ Drug/NN ./.


DrugDDI.d95
DrugDDI.d95.s9
Erythromycin (500 mg every 8 hrs) .

Erythromycin/NN (/-LRB- 500/CD mg/NN every/DT 8/CD hrs/NNS )/-RRB- ./.


DrugDDI.d95
DrugDDI.d95.s12
Ketoconazole (400 mg once daily) .

Ketoconazole/NN (/-LRB- 400/CD mg/NN once/RB daily/JJ )/-RRB- ./.


DrugDDI.d95
DrugDDI.d95.s17
These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.

These/DT studies/NNS indicate/VBP that/IN ketoconazole/NN or/CC erythromycin/NN co-administration/NN enhances/VBZ fexofenadine/NN gastrointestinal/JJ absorption/NN ./.


DrugDDI.d95
DrugDDI.d95.s18
This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p- glycoprotein . in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.

This/DT observed/VBN increase/NN in/IN the/DT bioavailability/NN of/IN fexofenadine/NN may/MD be/VB due/JJ to/TO transport-related/JJ effects/NNS ,/, such/JJ as/IN p-/NN glycoprotein/NN ./. in/FW vivo/FW animal/NN studies/NNS also/RB suggest/VBP that/IN in/IN addition/NN to/TO enhancing/VBG absorption/NN ,/, ketoconazole/NN decreases/VBZ fexofenadine/NN gastrointestinal/JJ secretion/NN ,/, while/IN erythromycin/NN may/MD also/RB decrease/VB biliary/JJ excretion/NN ./.


DrugDDI.d95
DrugDDI.d95.s19
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox@) decreased fexofenadine AUC by 41% and cmax by 43%.

Drug/NN Interactions/NNS with/IN Antacids/NNS Administration/NN of/IN 120/CD mg/NN of/IN fexofenadine/NN hydrochloride/NN (/-LRB- 2/CD x/CC 60/CD mg/NN capsule/JJ )/-RRB- within/IN 15/CD minutes/NNS of/IN an/DT aluminum/NN and/CC magnesium/NN containing/VBG antacid/JJ (/-LRB- Maalox/NN @/NN )/-RRB- decreased/VBN fexofenadine/NN AUC/NN by/IN 41/CD %/NN and/CC cmax/NN by/IN 43/CD %./NN


DrugDDI.d95
DrugDDI.d95.s20
ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids .

ALLEGRA/NN should/MD not/RB be/VB taken/VBN closely/RB in/IN time/NN with/IN aluminum/NN and/CC magnesium/NN containing/VBG antacids/NNS ./.


DrugDDI.d95
DrugDDI.d95.s21
Interactions with Fruit Juices Fruit juices such as grapefruit , orange and apple may reduce the bioavailability and exposure of fexofenadine .

Interactions/NNS with/IN Fruit/NN Juices/NNS Fruit/NN juices/NNS such/JJ as/IN grapefruit/NN ,/, orange/NN and/CC apple/NN may/MD reduce/VB the/DT bioavailability/NN and/CC exposure/NN of/IN fexofenadine/NN ./.


DrugDDI.d95
DrugDDI.d95.s23
The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water .

The/DT size/NN of/IN wheal/NN and/CC flare/NN were/VBD significantly/RB larger/JJR when/WRB fexofenadine/NN hydrochloride/NN was/VBD administered/VBN with/IN either/CC grapefruit/NN or/CC orange/NN juices/NNS compared/VBN to/TO water/NN ./.


DrugDDI.d95
DrugDDI.d95.s26
In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.

In/IN addition/NN ,/, based/VBN on/IN the/DT population/NN pharmacokinetics/NNS analysis/NN of/IN the/DT combined/JJ data/NNS from/IN grapefruit/NN and/CC orange/NN juices/NNS studies/NNS with/IN the/DT data/NNS from/IN a/DT bioequivalence/NN study/NN ,/, the/DT bioavailability/NN of/IN fexofenadine/NN was/VBD reduced/VBN by/IN 36/CD %./NN


DrugDDI.d95
DrugDDI.d95.s27
Therefore, to maximize the effects of fexofenadine , it is recommended that ALLEGRA should be taken with water .

Therefore/RB ,/, to/TO maximize/VB the/DT effects/NNS of/IN fexofenadine/NN ,/, it/PRP is/VBZ recommended/VBN that/IN ALLEGRA/NN should/MD be/VB taken/VBN with/IN water/NN ./.


DrugDDI.d433
DrugDDI.d433.s0
Androgens may increase sensitivity to oral anticoagulahts.

Androgens/NNS may/MD increase/VB sensitivity/NN to/TO oral/JJ anticoagulahts/NNS ./.


DrugDDI.d433
DrugDDI.d433.s1
Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.

Dosage/NN of/IN the/DT anticoagulant/NN may/MD require/VB reduction/NN in/IN order/NN to/TO maintain/VB satisfactory/JJ therapeutic/JJ hypoprothrombinemia/NN ./.


DrugDDI.d433
DrugDDI.d433.s2
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone .

Concurrent/JJ administration/NN of/IN oxyphenbutazone/NN and/CC androgens/NNS may/MD result/VB in/IN elevated/JJ serum/NN levels/NNS of/IN oxyphenbutazone/NN ./.


DrugDDI.d433
DrugDDI.d433.s3
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.

In/IN diabetic/JJ patients/NNS ,/, the/DT metabolic/JJ effects/NNS of/IN androgens/NNS may/MD decrease/VB blood/NN glucose/NN and/CC therefore/RB ,/, insulin/NN requirements/NNS ./.


DrugDDI.d332
DrugDDI.d332.s0
Antacids : Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).

Antacids/NNS :/: Administration/NN of/IN flurbiprofen/NN to/TO volunteers/NNS under/IN fasting/JJ conditions/NNS ,/, or/CC with/IN antacid/JJ suspension/NN yielded/VBD similar/JJ serum/NN flurbiprofen/NN time/NN profiles/NNS in/IN young/JJ subjects/NNS (/-LRB- n=12)./NN


DrugDDI.d332
DrugDDI.d332.s1
In geriatric subjects ( n=7 ) there was a reduction in the rate but not the extent of flurbiprofen absorption.

In/IN geriatric/JJ subjects/NNS (/-LRB- n=7/NN )/-RRB- there/EX was/VBD a/DT reduction/NN in/IN the/DT rate/NN but/CC not/RB the/DT extent/NN of/IN flurbiprofen/NN absorption/NN ./.


DrugDDI.d332
DrugDDI.d332.s2
Anticoagulants : Flurbiprofen like other nonsteroidal anti-inflammatory drugs , has been shown to affect bleeding parameters in patients receiving anti-coagulants , and serious clinical bleeding has been reported.

Anticoagulants/NNS :/: Flurbiprofen/NN like/IN other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS ,/, has/VBZ been/VBN shown/VBN to/TO affect/VB bleeding/JJ parameters/NNS in/IN patients/NNS receiving/VBG anti-coagulants/NNS ,/, and/CC serious/JJ clinical/JJ bleeding/JJ has/VBZ been/VBN reported/VBN ./.


DrugDDI.d332
DrugDDI.d332.s3
The physician should be cautious when administering flurbiprofen to patients taking anticoagulants .

The/DT physician/NN should/MD be/VB cautious/JJ when/WRB administering/VBG flurbiprofen/NN to/TO patients/NNS taking/VBG anticoagulants/NNS ./.


DrugDDI.d332
DrugDDI.d332.s4
Aspirin : Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.

Aspirin/NN :/: Concurrent/JJ administration/NN of/IN aspirin/NN and/CC flurbiprofen/NN resulted/VBD in/IN 50/CD %/NN lower/JJR serum/NN flurbiprofen/NN concentrations/NNS ./.


DrugDDI.d332
DrugDDI.d332.s5
This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).

This/DT effect/NN of/IN aspirin/NN (/-LRB- which/WDT also/RB lowers/VBZ serum/NN concentrations/NNS of/IN other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS given/VBN with/IN it/PRP )/-RRB- has/VBZ been/VBN demonstrated/VBN in/IN patients/NNS with/IN rheumatoid/JJ arthritis/NN (/-LRB- n=/NN 15/CD )/-RRB- as/RB well/RB as/IN normal/JJ volunteers/NNS (/-LRB- n=/NN 16/CD )./NN


DrugDDI.d332
DrugDDI.d332.s6
Concurrent use of flurbiprofen and aspirin is therefore not recommended.

Concurrent/JJ use/NN of/IN flurbiprofen/NN and/CC aspirin/NN is/VBZ therefore/RB not/RB recommended/VBN ./.


DrugDDI.d332
DrugDDI.d332.s7
Beta-adrenergic Blocking Agents : The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).

Beta-adrenergic/JJ Blocking/NN Agents/NNS :/: The/DT effect/NN of/IN flurbiprofen/NN on/IN blood/NN pressure/NN response/NN to/TO propranolol/NN and/CC atenolol/NN was/VBD evaluated/VBN in/IN men/NNS with/IN mild/JJ uncomplicated/JJ hypertension/NN (/-LRB- n/NN =/JJ 10/CD )./NN


DrugDDI.d332
DrugDDI.d332.s8
Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol .

Flurbiprofen/NN pretreatment/NN attenuated/VBD the/DT hypotensive/JJ effect/NN of/IN a/DT single/JJ dose/NN of/IN propranolol/NN but/CC not/RB atenolol/NN ./.


DrugDDI.d332
DrugDDI.d332.s9
Flurbiprofen did not appear to affect the beta-blocker -mediated reduction in heart rate.

Flurbiprofen/NN did/VBD not/RB appear/VB to/TO affect/VB the/DT beta-blocker/JJ -mediated/JJ reduction/NN in/IN heart/NN rate/NN ./.


DrugDDI.d332
DrugDDI.d332.s10
Flurbiprofen did not affect the pharmacokinetic profile of either drug , and the mechanism under lying the interference with propranolol s hypotensive effect is unknown.

Flurbiprofen/NN did/VBD not/RB affect/VB the/DT pharmacokinetic/JJ profile/NN of/IN either/DT drug/NN ,/, and/CC the/DT mechanism/NN under/IN lying/VBG the/DT interference/NN with/IN propranolol/NN s/NN hypotensive/JJ effect/NN is/VBZ unknown/JJ ./.


DrugDDI.d332
DrugDDI.d332.s11
Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.

Patients/NNS taking/VBG both/CC flurbiprofen/NN and/CC a/DT beta-blocker/NN should/MD be/VB monitored/VBN to/TO ensure/VB that/IN a/DT satisfactory/JJ hypotensive/JJ effect/NN is/VBZ achieved/VBN ./.


DrugDDI.d332
DrugDDI.d332.s12
Cimetidine , Ranitidine : In normal volunteers ( n=9 ), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine .

Cimetidine/NN ,/, Ranitidine/NN :/: In/IN normal/JJ volunteers/NNS (/-LRB- n=9/NN )/-RRB- ,/, pretreatment/NN with/IN cimetidine/NN or/CC ranitidine/NN did/VBD not/RB affect/VB flurbiprofen/NN pharmacokinetics/NNS except/IN that/IN a/DT small/JJ (/-LRB- 13/CD %/NN )/-RRB- but/CC statistically/RB significant/JJ increase/NN in/IN the/DT area/NN under/IN the/DT serum/NN concentration/NN curve/NN of/IN flurbiprofen/NN resulted/VBD with/IN cimetidine/NN ./.


DrugDDI.d332
DrugDDI.d332.s13
Digoxin : Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug .

Digoxin/NN :/: Studies/NNS of/IN concomitant/JJ administration/NN of/IN flurbiprofen/NN and/CC digoxin/NN to/TO healthy/JJ men/NNS (/-LRB- n=/NN 14/CD )/-RRB- did/VBD not/RB show/VB a/DT change/NN in/IN the/DT steady/JJ state/NN serum/NN levels/NNS of/IN either/DT drug/NN ./.


DrugDDI.d332
DrugDDI.d332.s14
Diuretics : Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs , can interfere with the effects of furosemide .

Diuretics/NN :/: Studies/NNS in/IN normal/JJ volunteers/NNS have/VBP shown/VBN that/IN flurbiprofen/NN like/IN other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS ,/, can/MD interfere/VB with/IN the/DT effects/NNS of/IN furosemide/NN ./.


DrugDDI.d332
DrugDDI.d332.s15
Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis , natriuresis, and kaliuresis.

Although/IN results/NNS have/VBP varied/VBD from/IN study/NN to/TO study/NN ,/, effects/NNS have/VBP been/VBN shown/VBN on/IN furosemide-stimulated/JJ diuresis/NN ,/, natriuresis/NN ,/, and/CC kaliuresis/NN ./.


DrugDDI.d332
DrugDDI.d332.s16
Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics .

Other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS that/WDT inhibit/VBP prostaglandin/NN synthesis/NN have/VBP been/VBN shown/VBN to/TO interfere/VB with/IN thiazide/NN diuretics/NNS in/IN some/DT studies/NNS and/CC with/IN potassium-sparing/JJ diuretics/NN ./.


DrugDDI.d332
DrugDDI.d332.s17
Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.

Patients/NNS receiving/VBG flurbiprofen/NN and/CC furosemide/NN or/CC other/JJ diuretics/NNS should/MD be/VB observed/VBN closely/RB to/TO determine/VB if/IN the/DT desired/JJ effect/NN is/VBZ obtained/VBN ./.


DrugDDI.d332
DrugDDI.d332.s18
Oral Hypoglycemic Agents : In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin ( n= 3 ) or glyburide with phenformin (n=6).

Oral/JJ Hypoglycemic/JJ Agents/NNS :/: In/IN one/CD study/NN ,/, flurbiprofen/NN was/VBD given/VBN to/TO adult/JJ diabetics/NNS who/WP were/VBD already/RB receiving/VBG glyburide/NN (/-LRB- n=4/NN )/-RRB- ,/, metformin/NN (/-LRB- n=2/NN )/-RRB- chlorpropamide/NN with/IN phenformin/NN (/-LRB- n=/NN 3/CD )/-RRB- or/CC glyburide/NN with/IN phenformin/NN (/-LRB- n=6)./CD


DrugDDI.d332
DrugDDI.d332.s19
Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents , there were no signs or symptoms of hypoglycemia.

Although/IN there/EX was/VBD a/DT slight/JJ reduction/NN in/IN blood/NN sugar/NN concentrations/NNS during/IN concomitant/JJ administration/NN of/IN flurbiprofen/NN and/CC hypoglycemic/JJ agents/NNS ,/, there/EX were/VBD no/DT signs/NNS or/CC symptoms/NNS of/IN hypoglycemia/NN ./.


DrugDDI.d561
DrugDDI.d561.s0
Diuretics : Patients on diuretics , especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium .

Diuretics/NN :/: Patients/NNS on/IN diuretics/NN ,/, especially/RB those/DT with/IN intravascular/JJ volume/NN depletion/NN ,/, may/MD occasionally/RB experience/VBP an/DT excessive/JJ reduction/NN of/IN blood/NN pressure/NN after/IN initiation/NN of/IN therapy/NN with/IN fosinopril/NN sodium/NN ./.


DrugDDI.d561
DrugDDI.d561.s1
The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium .

The/DT possibility/NN of/IN hypotensive/JJ effects/NNS can/MD be/VB minimized/VBN by/IN either/CC discontinuing/VBG the/DT diuretic/JJ or/CC increasing/VBG salt/NN intake/NN prior/RB to/TO initiation/NN of/IN treatment/NN with/IN fosinopril/NN sodium/NN ./.


DrugDDI.d561
DrugDDI.d561.s3
Potassium Supplement s and Potassium-Sparing Diuretics : Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics .

Potassium/NN Supplement/NN s/NNS and/CC Potassium-Sparing/JJ Diuretics/NNS :/: Fosinopril/NN sodium/NN can/MD attenuate/VB potassium/NN loss/NN caused/VBN by/IN thiazide/NN diuretics/NNS ./.


DrugDDI.d561
DrugDDI.d561.s4
Potassium-sparing diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplement s can increase the risk of hyperkalemia.

Potassium-sparing/JJ diuretics/NNS (/-LRB- spironolactone/NN ,/, amiloride/NN ,/, triamterene/NN ,/, and/CC others/NNS )/-RRB- or/CC potassium/NN supplement/NN s/NNS can/MD increase/VB the/DT risk/NN of/IN hyperkalemia/NN ./.


DrugDDI.d561
DrugDDI.d561.s6
Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium .

Lithium/NN :/: Increased/VBN serum/NN lithium/NN levels/NNS and/CC symptoms/NNS of/IN lithium/NN toxicity/NN have/VBP been/VBN reported/VBN in/IN patients/NNS receiving/VBG ACE/NN inhibitors/NNS during/IN therapy/NN with/IN lithium/NN ./.


DrugDDI.d561
DrugDDI.d561.s7
These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.

These/DT drugs/NNS should/MD be/VB coadministered/VBN with/IN caution/NN ,/, and/CC frequent/JJ monitoring/NN of/IN serum/NN lithium/NN levels/NNS is/VBZ recommended/VBN ./.


DrugDDI.d561
DrugDDI.d561.s8
If a diuretic is also used, the risk of lithium toxicity may be increased.

If/IN a/DT diuretic/NN is/VBZ also/RB used/VBN ,/, the/DT risk/NN of/IN lithium/NN toxicity/NN may/MD be/VB increased/VBN ./.


DrugDDI.d561
DrugDDI.d561.s9
Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril .

Antacids/NNS :/: In/IN a/DT clinical/JJ pharmacology/NN study/NN ,/, coadministration/NN of/IN an/DT antacid/JJ (/-LRB- aluminum/NN hydroxide/NN ,/, magnesium/NN hydroxide/NN ,/, and/CC simethicone/NN )/-RRB- with/IN fosinopril/NN reduced/VBD serum/NN levels/NNS and/CC urinary/JJ excretion/NN of/IN fosinoprilat/NN as/IN compared/VBN with/IN fosinopril/NN administered/VBN alone/RB ,/, suggesting/VBG that/IN antacids/NNS may/MD impair/VB absorption/NN of/IN fosinopril/NN ./.


DrugDDI.d561
DrugDDI.d561.s11
Other: Neither fosinopril sodium nor its metabolites have been found to interact with food.

Other/JJ :/: Neither/CC fosinopril/NN sodium/NN nor/CC its/PRP$ metabolites/NNS have/VBP been/VBN found/VBN to/TO interact/VB with/IN food/NN ./.


DrugDDI.d561
DrugDDI.d561.s12
In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs .

In/IN separate/JJ single/JJ or/CC multiple/JJ dose/NN pharmacokinetic/JJ interaction/NN studies/NNS with/IN chlorthalidone/NN ,/, nifedipine/NN ,/, propanolol/NN ,/, hydrochlorothiazide/NN ,/, cimetidine/NN ,/, metoclopramide/NN ,/, propantheline/NN ,/, digoxin/NN ,/, and/CC warfarin/NN ,/, the/DT bioavailability/NN of/IN fosinoprilat/NN was/VBD not/RB altered/VBN by/IN coadministration/NN of/IN fosinopril/NN with/IN any/DT one/CD of/IN these/DT drugs/NNS ./.


DrugDDI.d561
DrugDDI.d561.s13
In a study with concomitant administration of aspirin and fosinopril sodium , the bioavailability of unbound fosinoprilat was not altered.

In/IN a/DT study/NN with/IN concomitant/JJ administration/NN of/IN aspirin/NN and/CC fosinopril/NN sodium/NN ,/, the/DT bioavailability/NN of/IN unbound/JJ fosinoprilat/NN was/VBD not/RB altered/VBN ./.


DrugDDI.d561
DrugDDI.d561.s14
In a pharmacokinetic interaction study with warfarin , bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.

In/IN a/DT pharmacokinetic/JJ interaction/NN study/NN with/IN warfarin/NN ,/, bioavailability/NN parameters/NNS ,/, the/DT degree/NN of/IN protein/NN binding/NN ,/, and/CC the/DT anticoagulant/JJ effect/NN (/-LRB- measured/VBN by/IN prothrombin/NN time/NN )/-RRB- of/IN warfarin/NN were/VBD not/RB significantly/RB changed/VBN ./.


DrugDDI.d561
DrugDDI.d561.s15
Drug /Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab@ RIA Kit for Digoxin .

Drug/NN /Laboratory/NN Test/NN Interaction/NN Fosinopril/NN may/MD cause/VB a/DT false/JJ low/JJ measurement/NN of/IN serum/NN digoxin/NN levels/NNS with/IN the/DT Digi-/NN Tab/NN @/NN RIA/NN Kit/NN for/IN Digoxin/NN ./.


DrugDDI.d466
DrugDDI.d466.s0
No drugs are known to interfere with the conversion of fosphenytoin to phenytoin .

No/DT drugs/NNS are/VBP known/VBN to/TO interfere/VB with/IN the/DT conversion/NN of/IN fosphenytoin/NN to/TO phenytoin/NN ./.


DrugDDI.d466
DrugDDI.d466.s1
Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin .

Conversion/NN could/MD be/VB affected/VBN by/IN alterations/NNS in/IN the/DT level/NN of/IN phosphatase/NN activity/NN ,/, but/CC given/IN the/DT abundance/NN and/CC wide/JJ distribution/NN of/IN phosphatases/NNS in/IN the/DT body/NN it/PRP is/VBZ unlikely/JJ that/IN drugs/NNS would/MD affect/VB this/DT activity/NN enough/RB to/TO affect/VB conversion/NN of/IN fosphenytoin/NN to/TO phenytoin/NN ./.


DrugDDI.d466
DrugDDI.d466.s2
Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin .

Drugs/NNS highly/RB bound/VBN to/TO albumin/NN could/MD increase/VB the/DT unbound/JJ fraction/NN of/IN fosphenytoin/NN ./.


DrugDDI.d466
DrugDDI.d466.s3
Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering Cerebyx with other drugs that significantly bind to serum albumin .

Although/IN ,/, it/PRP is/VBZ unknown/JJ whether/IN this/DT could/MD result/VB in/IN clinically/RB significant/JJ effects/NNS ,/, caution/NN is/VBZ advised/VBN when/WRB administering/VBG Cerebyx/NN with/IN other/JJ drugs/NNS that/WDT significantly/RB bind/VBP to/TO serum/NN albumin/NN ./.


DrugDDI.d466
DrugDDI.d466.s4
The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.

The/DT pharmacokinetics/NNS and/CC protein/NN binding/NN of/IN fosphenytoin/NN ,/, phenytoin/NN ,/, and/CC diazepam/NN were/VBD not/RB altered/VBN when/WRB diazepam/NN and/CC Cerebyx/NN were/VBD concurrently/RB administered/VBN in/IN single/JJ submaximal/JJ doses/NNS ./.


DrugDDI.d466
DrugDDI.d466.s5
The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin .

The/DT most/RBS significant/JJ drug/NN interactions/NNS following/VBG administration/NN of/IN Cerebyx/NN are/VBP expected/VBN to/TO occur/VB with/IN drugs/NNS that/WDT interact/VBP with/IN phenytoin/NN ./.


DrugDDI.d466
DrugDDI.d466.s6
Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement.

Phenytoin/NN is/VBZ extensively/RB bound/VBN to/TO serum/NN plasma/NN proteins/NNS and/CC is/VBZ prone/JJ to/TO competitive/JJ displacement/NN ./.


DrugDDI.d466
DrugDDI.d466.s7
Phenytoin is metabolized by hepatic cytochrome P450 enzyme s and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism.

Phenytoin/NN is/VBZ metabolized/VBN by/IN hepatic/JJ cytochrome/NN P450/NN enzyme/NN s/NN and/CC is/VBZ particularly/RB susceptible/JJ to/TO inhibitory/JJ drug/NN interactions/NNS because/IN it/PRP is/VBZ subject/JJ to/TO saturable/JJ metabolism/NN ./.


DrugDDI.d466
DrugDDI.d466.s8
Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.

Inhibition/NN of/IN metabolism/NN may/MD produce/VB significant/JJ increases/NNS in/IN circulating/VBG phenytoin/NN concentrations/NNS and/CC enhance/VB the/DT risk/NN of/IN drug/NN toxicity/NN ./.


DrugDDI.d466
DrugDDI.d466.s9
Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.

Phenytoin/NN is/VBZ a/DT potent/JJ inducer/NN of/IN hepatic/JJ drug-metabolizing/JJ enzymes/NNS ./.


DrugDDI.d466
DrugDDI.d466.s10
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists, halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone .

The/DT most/RBS commonly/RB occurring/VBG drug/NN interactions/NNS are/VBP listed/VBN below/IN :/: -/CC Drugs/NNS that/WDT may/MD increase/VB plasma/NN phenytoin/NN concentrations/NNS include/VBP :/: acute/JJ alcohol/NN intake/NN ,/, amiodarone/NN ,/, chboramphenicol/NN ,/, chlordiazepoxide/NN ,/, cimetidine/NN ,/, diazepam/NN ,/, dicumarol/NN ,/, disulfiram/NN ,/, estrogens/NNS ,/, ethosuximide/NN ,/, fluoxetine/NN ,/, H2-antagonists/NN ,/, halothane/NN ,/, isoniazid/NN ,/, methylphenidate/NN ,/, phenothiazines/NNS ,/, phenylbutazone/NN ,/, salicylates/NNS ,/, succinimides/NNS ,/, sulfonamides/NNS ,/, tolbutamide/NN ,/, trazodone/NN ./.


DrugDDI.d466
DrugDDI.d466.s12
- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine .

-/CC Drugs/NNS that/WDT may/MD decrease/VB plasma/NN phenytoin/NN concentrations/NNS include/VBP :/: carbamazepine/NN ,/, chronic/JJ alcohol/NN abuse/NN ,/, reserpine/NN ./.


DrugDDI.d466
DrugDDI.d466.s14
- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital , vaiproic acid, and sodium valproate .

-/CC Drugs/NNS that/WDT may/MD either/RB increase/VB or/CC decrease/VB plasma/NN phenytoin/NN concentrations/NNS include/VBP :/: phenobarbital/NN ,/, vaiproic/JJ acid/NN ,/, and/CC sodium/NN valproate/NN ./.


DrugDDI.d466
DrugDDI.d466.s15
Similarly, the effects of phenytoin on phenobarbital , valproic acid and sodium plasma valproate concentrations are unpredictable .

Similarly/RB ,/, the/DT effects/NNS of/IN phenytoin/NN on/IN phenobarbital/NN ,/, valproic/JJ acid/NN and/CC sodium/NN plasma/NN valproate/NN concentrations/NNS are/VBP unpredictable/JJ ./.


DrugDDI.d466
DrugDDI.d466.s17
- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted .

-/CC Although/IN not/RB a/DT true/JJ drug/NN interaction/NN ,/, tricyclic/JJ antidepressants/NNS may/MD precipitate/VB seizures/NNS in/IN susceptible/JJ patients/NNS and/CC Cerebyx/NN dosage/NN may/MD need/VBP to/TO be/VB adjusted/VBN ./.


DrugDDI.d466
DrugDDI.d466.s19
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin D .

-/CC Drugs/NNS whose/WP$ efficacy/NN is/VBZ impaired/VBN by/IN phenytoin/NN include/VBP :/: anticoagulants/NNS ,/, corticosteroids/NNS ,/, coumarin/NN ,/, digitoxin/NN ,/, doxycycline/NN ,/, estrogens/NNS ,/, furosemide/NN ,/, oral/JJ contraceptives/NNS ,/, rifampin/NN ,/, quinidine/NN ,/, theophylline/NN ,/, vitamin/NN D/NN ./.


DrugDDI.d466
DrugDDI.d466.s20
Monitoring of plasma phenytoin concentrations may be helpful when possible drug interactions are suspected.

Monitoring/NN of/IN plasma/NN phenytoin/NN concentrations/NNS may/MD be/VB helpful/JJ when/WRB possible/JJ drug/NN interactions/NNS are/VBP suspected/VBN ./.


DrugDDI.d466
DrugDDI.d466.s21
Drug /Laboratory Test Interactions Phenytoin may decrease serum concentrations of 14.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS Phenytoin/NN may/MD decrease/VB serum/NN concentrations/NNS of/IN 14/CD ./.


DrugDDI.d466
DrugDDI.d466.s22
It may also produce artifactually low results in dexamethasone or metyrapone tests.

It/PRP may/MD also/RB produce/VB artifactually/RB low/JJ results/NNS in/IN dexamethasone/NN or/CC metyrapone/NN tests/NNS ./.


DrugDDI.d466
DrugDDI.d466.s23
Phenytoin may also cause increased serum concentrations of glucose , alkaline phosphatase , and gamma glutamyl transpeptidase (GGT).

Phenytoin/NN may/MD also/RB cause/VB increased/VBN serum/NN concentrations/NNS of/IN glucose/NN ,/, alkaline/NN phosphatase/NN ,/, and/CC gamma/NN glutamyl/NN transpeptidase/NN (/-LRB- GGT)./NN


DrugDDI.d466
DrugDDI.d466.s24
Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.

Care/NN should/MD be/VB taken/VBN when/WRB using/VBG immunoanalytical/JJ methods/NNS to/TO measure/VB plasma/NN phenytoin/NN concentrations/NNS following/VBG Cerebyx/NN administration/NN ./.


DrugDDI.d281
DrugDDI.d281.s0
No drug interactions have been observed with the Vitrasert Implant.

No/DT drug/NN interactions/NNS have/VBP been/VBN observed/VBN with/IN the/DT Vitrasert/JJ Implant/NN ./.


DrugDDI.d281
DrugDDI.d281.s1
There is limited experience with use of retinal tamponades in conjunction with the Vitrasert Implant.

There/EX is/VBZ limited/VBN experience/VBP with/IN use/NN of/IN retinal/JJ tamponades/NNS in/IN conjunction/NN with/IN the/DT Vitrasert/NN Implant/NN ./.


DrugDDI.d178
DrugDDI.d178.s0
Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations.

Substances/NNS that/WDT are/VBP inducers/NNS of/IN CYP3A4/NN activity/NN increase/VBP the/DT metabolism/NN of/IN gefitinib/NN and/CC decrease/VBP its/PRP$ plasma/NN concentrations/NNS ./.


DrugDDI.d178
DrugDDI.d178.s1
In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin , a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).

In/IN patients/NNS receiving/VBG a/DT potent/JJ CYP3A4/NN inducer/NN such/JJ as/IN rifampicin/NN or/CC phenytoin/NN ,/, a/DT dose/NN increase/NN to/TO 500/CD mg/NN daily/RB should/MD be/VB considered/VBN in/IN the/DT absence/NN of/IN severe/JJ adverse/JJ drug/NN reaction/NN ,/, and/CC clinical/JJ response/NN and/CC adverse/JJ events/NNS should/MD be/VB carefully/RB monitored/VBN (/-LRB- see/VB CLINICAL/JJ PHARMACOLOGY-Pharmacokinetics-Drug-Drug/JJ Interactions/NNS and/CC DOSAGE/NN AND/CC ADMINISTRATION-Dosage/JJ Adjustment/JJ sections/NNS )./NN


DrugDDI.d178
DrugDDI.d178.s2
International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.

International/NNP Normalized/VBN Ratio/NN (/-LRB- INR/NN )/-RRB- elevations/NNS and/or/CC bleeding/JJ events/NNS have/VBP been/VBN reported/VBN in/IN some/DT patients/NNS taking/VBG warfarin/NN while/IN on/IN IRESSA/NN therapy/NN ./.


DrugDDI.d178
DrugDDI.d178.s3
Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR.

Patients/NNS taking/VBG warfarin/NN should/MD be/VB monitored/VBN regularly/RB for/IN changes/NNS in/IN prothrombin/NN time/NN or/CC INR/NN ./.


DrugDDI.d178
DrugDDI.d178.s4
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole ) decrease gefitinib metabolism and increase gefitinib plasma concentrations.

Substances/NNS that/WDT are/VBP potent/JJ inhibitors/NNS of/IN CYP3A4/NN activity/NN (/-LRB- eg/NN ,/, ketoconazole/NN and/CC itraconazole/NN )/-RRB- decrease/VBP gefitinib/NN metabolism/NN and/CC increase/VBP gefitinib/NN plasma/NN concentrations/NNS ./.


DrugDDI.d178
DrugDDI.d178.s6
therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA .

therefore/RB ,/, caution/NN should/MD be/VB used/VBN when/WRB administering/VBG CYP3A4/JJ inhibitors/NNS with/IN IRESSA/NN ./.


DrugDDI.d178
DrugDDI.d178.s7
Drugs that cause significant sustained elevation in gastric pH ( histamine H2-receptor antagonists such as ranitidine or cimetidine ) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.

Drugs/NNS that/WDT cause/VBP significant/JJ sustained/JJ elevation/NN in/IN gastric/JJ pH/NN (/-LRB- histamine/NN H2-receptor/NN antagonists/NNS such/JJ as/IN ranitidine/NN or/CC cimetidine/NN )/-RRB- may/MD reduce/VB plasma/NN concentrations/NNS of/IN IRESSA/NN and/CC therefore/RB potentially/RB may/MD reduce/VB efficacy/NN ./.


DrugDDI.d178
DrugDDI.d178.s8
Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine .

Phase/NN II/CD clinical/JJ trial/NN data/NNS ,/, where/WRB IRESSA/NN and/CC vinorelbine/NN have/VBP been/VBN used/VBN concomitantly/RB ,/, indicate/VBP that/IN IRESSA/NN may/MD exacerbate/VB the/DT neutropenic/JJ effect/NN of/IN vinorelbine/NN ./.


DrugDDI.d147
DrugDDI.d147.s1
For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.

For/IN information/NN on/IN the/DT pharmacokinetics/NNS of/IN Gemzar/NN and/CC cisplatin/NN in/IN combination/NN ,/, see/VB Drug/NN Interactions/NNS under/IN CLINICAL/JJ PHARMACOLOGY/NN section/NN ./.


DrugDDI.d57
DrugDDI.d57.s4
increased creatine .

increased/VBN creatine/NN ./.


DrugDDI.d57
DrugDDI.d57.s7
phosphokinase .

phosphokinase/NN ./.


DrugDDI.d57
DrugDDI.d57.s8
antibody .

antibody/NN ./.


DrugDDI.d57
DrugDDI.d57.s10
increased bilirubin .

increased/VBN bilirubin/NN ./.


DrugDDI.d57
DrugDDI.d57.s13
increased liver .

increased/VBD liver/NN ./.


DrugDDI.d57
DrugDDI.d57.s16
transaminases ( AST .

transaminases/NNS (/-LRB- AST/NN ./.


DrugDDI.d465
DrugDDI.d465.s0
Many other medicines may increase or decrease the effects of glimepiride or affect your condition.

Many/JJ other/JJ medicines/NNS may/MD increase/VB or/CC decrease/VB the/DT effects/NNS of/IN glimepiride/NN or/CC affect/VB your/NN condition/NN ./.


DrugDDI.d465
DrugDDI.d465.s1
Before taking glimepiride , tell your doctor if you are taking any of the following medicines : - aspirin or another salicylate such as magnesium / choline salicylate ( Trilisate ), salsalate ( Disalcid , others), choline salicylate ( Arthropan ), magnesium salicylate ( Magan ), or bismuth subsalicylate ( Pepto-Bismol ); .

Before/IN taking/VBG glimepiride/NN ,/, tell/NN your/NN doctor/NN if/IN you/NN are/VBP taking/VBG any/DT of/IN the/DT following/JJ medicines/NNS :/: -/CC aspirin/NN or/CC another/DT salicylate/NN such/JJ as/IN magnesium/NN //: choline/NN salicylate/NN (/-LRB- Trilisate/NN )/-RRB- ,/, salsalate/NN (/-LRB- Disalcid/NN ,/, others/NNS )/-RRB- ,/, choline/NN salicylate/NN (/-LRB- Arthropan/NNP )/-RRB- ,/, magnesium/NN salicylate/NN (/-LRB- Magan/NNP )/-RRB- ,/, or/CC bismuth/NN subsalicylate/NN (/-LRB- Pepto-Bismol/NN )/-RRB- ;/: ./.


DrugDDI.d465
DrugDDI.d465.s2
- a nonsteroidal anti-inflammatory drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve ); .

-/CC a/DT nonsteroidal/JJ anti-inflammatory/JJ drug/NN (/-LRB- NSAID/NN )/-RRB- such/JJ as/IN ibuprofen/NN (/-LRB- Motrin/NNP ,/, Advil/NNP ,/, Nuprin/NNP ,/, others/NNS )/-RRB- ,/, ketoprofen/NN (/-LRB- Orudis/NNP ,/, Orudis/NNP KT/NNP ,/, Oruvail/NNP )/-RRB- ,/, diclofenac/NN (/-LRB- Voltaren/NNP ,/, Cataflam/NNP )/-RRB- ,/, etodolac/NN (/-LRB- Lodine/NN )/-RRB- ,/, indomethacin/NN (/-LRB- Indocin/NNP )/-RRB- ,/, nabumetone/NN (/-LRB- Relafen/NNP )/-RRB- ,/, oxaprozin/NN (/-LRB- Daypro/NNP )/-RRB- ,/, and/CC naproxen/NN (/-LRB- Anaprox/NN ,/, Naprosyn/NNP ,/, Aleve/NNP )/-RRB- ;/: ./.


DrugDDI.d465
DrugDDI.d465.s3
- a sulfa-based drug such as sulfamethoxazole-trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine ); .

-/CC a/DT sulfa-based/JJ drug/NN such/JJ as/IN sulfamethoxazole-trimethoprim/NN (/-LRB- Bactrim/NNP ,/, Septra/NNP )/-RRB- ,/, sulfisoxazole/NN (/-LRB- Gantrisin/NN )/-RRB- ,/, or/CC sulfasalazine/NN (/-LRB- Azulfidine/NN )/-RRB- ;/: ./.


DrugDDI.d465
DrugDDI.d465.s4
- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ); .

-/CC a/DT monoamine/NN oxidase/NN inhibitor/NN (/-LRB- MAOI/NN )/-RRB- such/JJ as/IN isocarboxazid/NN (/-LRB- Marplan/NN )/-RRB- ,/, tranylcypromine/NN (/-LRB- Parnate/NN )/-RRB- ,/, or/CC phenelzine/NN (/-LRB- Nardil/NN )/-RRB- ;/: ./.


DrugDDI.d465
DrugDDI.d465.s5
- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others; .

-/CC a/DT beta-blocker/NN such/JJ as/IN propranolol/NN (/-LRB- Inderal/NN )/-RRB- ,/, atenolol/NN (/-LRB- Tenormin/NN )/-RRB- ,/, acebutolol/NN (/-LRB- Sectral/NN )/-RRB- ,/, metoprolol/NN (/-LRB- Lopressor/NN )/-RRB- ,/, and/CC others/NNS ;/: ./.


DrugDDI.d465
DrugDDI.d465.s6
- a diuretic ( water pill) such as hydrochlorothiazide ( HCTZ , Hydrodiuril ), chlorothiazide ( Diuril ), and others; .

-/CC a/DT diuretic/JJ (/-LRB- water/NN pill/NN )/-RRB- such/JJ as/IN hydrochlorothiazide/NN (/-LRB- HCTZ/NN ,/, Hydrodiuril/NN )/-RRB- ,/, chlorothiazide/NN (/-LRB- Diuril/NN )/-RRB- ,/, and/CC others/NNS ;/: ./.


DrugDDI.d465
DrugDDI.d465.s7
- a steroid medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others; .

-/CC a/DT steroid/NN medicine/NN such/JJ as/IN prednisone/NN (/-LRB- Deltasone/NNP ,/, Orasone/NNP ,/, others/NNS )/-RRB- ,/, methylprednisolone/NN (/-LRB- Medrol/NN ,/, others/NNS )/-RRB- ,/, prednisolone/NN (/-LRB- Prelone/NNP ,/, Pediapred/NNP ,/, others/NNS )/-RRB- ,/, and/CC others/NNS ;/: ./.


DrugDDI.d465
DrugDDI.d465.s8
- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others; .

-/CC a/DT phenothiazine/JJ such/JJ as/IN chlorpromazine/NN (/-LRB- Thorazine/NN )/-RRB- ,/, fluphenazine/NN (/-LRB- Prolixin/NNP ,/, Permitil/NNP )/-RRB- ,/, prochlorperazine/NN (/-LRB- Compazine/NN )/-RRB- ,/, promethazine/NN (/-LRB- Phenergan/NNP )/-RRB- ,/, and/CC others/NNS ;/: ./.


DrugDDI.d465
DrugDDI.d465.s9
- phenytoin ( Dilantin ); .

-/CC phenytoin/NN (/-LRB- Dilantin/NN )/-RRB- ;/: ./.


DrugDDI.d465
DrugDDI.d465.s10
- isoniazid ( Nydrazid ); .

-/CC isoniazid/NN (/-LRB- Nydrazid/NN )/-RRB- ;/: ./.


DrugDDI.d465
DrugDDI.d465.s11
- rifampin ( Rifadin , Rifamate ); .

-/CC rifampin/NN (/-LRB- Rifadin/NNP ,/, Rifamate/NNP )/-RRB- ;/: ./.


DrugDDI.d465
DrugDDI.d465.s12
or - over-the-counter cough, cold, allergy, or weight loss medications .

or/CC -/CC over-the-counter/JJ cough/NN ,/, cold/NN ,/, allergy/NN ,/, or/CC weight/NN loss/NN medications/NNS ./.


DrugDDI.d465
DrugDDI.d465.s13
You may require a dosage adjustment or special monitoring if you are taking any of the medicines listed above.

You/NN may/MD require/VB a/DT dosage/JJ adjustment/NN or/CC special/JJ monitoring/NN if/IN you/RB are/VBP taking/VBG any/DT of/IN the/DT medicines/NNS listed/VBN above/RB ./.


DrugDDI.d465
DrugDDI.d465.s14
Drugs other than those listed here may also interact with glimepiride or affect your condition.

Drugs/NNS other/JJ than/IN those/DT listed/VBN here/RB may/MD also/RB interact/VB with/IN glimepiride/NN or/CC affect/VB your/NN condition/NN ./.


DrugDDI.d465
DrugDDI.d465.s15
Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines , including herbal products.

Talk/NN to/TO your/NN doctor/NN and/CC pharmacist/VBP before/IN taking/VBG any/DT prescription/NN or/CC over-the-counter/NN medicines/NNS ,/, including/VBG herbal/JJ products/NNS ./.


DrugDDI.d244
DrugDDI.d244.s0
The use of codeine may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression.

The/DT use/NN of/IN codeine/NN may/MD result/VB in/IN additive/JJ CNS/NN depressant/NN effects/NNS when/WRB coadministered/VBN with/IN alcohol/NN ,/, antihistamines/NNS ,/, psychotropics/NNS or/CC other/JJ drugs/NNS that/WDT produce/VBP CNS/NN depression/NN ./.


DrugDDI.d244
DrugDDI.d244.s1
Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).

Serious/JJ toxicity/NN may/MD result/VB if/IN dextromethorphan/NN is/VBZ coadministered/VBN with/IN monoamine/NN oxidase/NN inhibitors/NNS (/-LRB- MAOIs)./NN


DrugDDI.d244
DrugDDI.d244.s2
The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression.

The/DT use/NN of/IN dextromethorphan/NN hydrobromide/NN may/MD result/VB in/IN additive/JJ CNS/NN depressant/NN effects/NNS when/WRB coadministered/VBN with/IN alcohol/NN ,/, antihistamines/NNS ,/, psychotropics/NNS or/CC other/JJ drugs/NNS that/WDT produce/VBP CNS/NN depression/NN ./.


DrugDDI.d184
DrugDDI.d184.s0
Calcium Supplements/ Antacids .

Calcium/NN Supplements//NN Antacids/NNS ./.


DrugDDI.d184
DrugDDI.d184.s1
Products containing calcium and other multivalent cations (such as aluminum, magnesium , iron ) are likely to interfere with absorption of Ibandronate .

Products/NNS containing/VBG calcium/NN and/CC other/JJ multivalent/JJ cations/NNS (/-LRB- such/JJ as/IN aluminum/NN ,/, magnesium/NN ,/, iron/NN )/-RRB- are/VBP likely/JJ to/TO interfere/VB with/IN absorption/NN of/IN Ibandronate/NN ./.


DrugDDI.d184
DrugDDI.d184.s2
Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids , supplements or vitamins ).

Ibandronate/NN should/MD be/VB taken/VBN at/IN least/JJS 60/CD minutes/NNS before/IN any/DT oral/JJ medications/NNS containing/VBG multivalent/JJ cations/NNS (/-LRB- including/VBG antacids/NNS ,/, supplements/NNS or/CC vitamins/NNS )/-RRB- ./.


DrugDDI.d184
DrugDDI.d184.s3
H2 Blockers and Proton Pump Inhibitors (PPIs) .

H2/NN Blockers/NNS and/CC Proton/NN Pump/NN Inhibitors/NNS (/-LRB- PPIs/NN )/-RRB- ./.


DrugDDI.d184
DrugDDI.d184.s4
Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).

Of/IN over/IN 3500/CD patients/NNS enrolled/VBN in/IN the/DT Ibandronate/JJ osteoporosis/NN Treatment/NN and/CC Prevention/NN Studies/NNS ,/, 15/CD %/NN used/VBN anti-peptic/JJ agents/NNS (/-LRB- primarily/RB H2/NN blockers/NN and/CC PPIs/NN )./NN


DrugDDI.d184
DrugDDI.d184.s5
Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients.

Among/IN these/DT patients/NNS ,/, the/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ adverse/JJ experiences/NNS in/IN the/DT patients/NNS treated/VBN with/IN Ibandronate/NN was/VBD similar/JJ to/TO that/DT in/IN placebo-treated/JJ patients/NNS ./.


DrugDDI.d184
DrugDDI.d184.s6
Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate , 14% of patients used anti-peptic agents .

Similarly/RB ,/, of/IN over/IN 1600/CD patients/NNS enrolled/VBN in/IN a/DT study/NN comparing/VBG once-monthly/JJ with/IN daily/JJ dosing/NN regimens/NNS of/IN ibandronate/NN ,/, 14/CD %/NN of/IN patients/NNS used/VBN anti-peptic/JJ agents/NNS ./.


DrugDDI.d184
DrugDDI.d184.s7
Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.

Among/IN these/DT patients/NNS ,/, the/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ adverse/JJ experiences/NNS in/IN the/DT patients/NNS treated/VBN with/IN Ibandronate/NN 150/CD mg/NN once/RB monthly/RB was/VBD similar/JJ to/TO that/DT in/IN patients/NNS treated/VBN with/IN Ibandronate/NN 2.5/CD mg/NN once/RB daily/RB ./.


DrugDDI.d184
DrugDDI.d184.s8
Aspirin / Nonsteroidal Antiinflammatory Drug s ( NSAIDs ) .

Aspirin/NN //: Nonsteroidal/JJ Antiinflammatory/JJ Drug/NN s/NNS (/-LRB- NSAIDs/NNS )/-RRB- ./.


DrugDDI.d184
DrugDDI.d184.s9
In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.

In/IN the/DT large/JJ ,/, placebo-controlled/JJ osteoporosis/NN Treatment/NN Study/NN ,/, aspirin/NN and/CC nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS were/VBD taken/VBN by/IN 62/CD %/NN of/IN the/DT 2946/CD patients/NNS ./.


DrugDDI.d184
DrugDDI.d184.s10
Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).

Among/IN aspirin/NN or/CC NSAID/NN users/NNS ,/, the/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ adverse/JJ events/NNS in/IN patients/NNS treated/VBN with/IN ibandronate/NN 2.5/CD mg/NN daily/RB (/-LRB- 28.9/CD %/NN )/-RRB- was/VBD similar/JJ to/TO that/DT in/IN placebo-treated/JJ patients/NNS (/-LRB- 30.7%)./NN


DrugDDI.d184
DrugDDI.d184.s11
Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.

Similarly/RB ,/, in/IN the/DT 1-year/JJ monthly/JJ comparison/NN study/NN ,/, aspirin/NN and/CC nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS were/VBD taken/VBN by/IN 39/CD %/NN of/IN the/DT 1602/CD patients/NNS ./.


DrugDDI.d184
DrugDDI.d184.s12
The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).

The/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ events/NNS in/IN patients/NNS concomitantly/RB taking/VBG aspirin/NN or/CC NSAIDs/NN was/VBD similar/JJ in/IN patients/NNS taking/VBG ibandronate/NN 2.5/CD mg/NN daily/RB (/-LRB- 21.7/CD %/NN )/-RRB- and/CC 150/CD mg/NN once/RB monthly/RB (/-LRB- 22.0%)./CD


DrugDDI.d184
DrugDDI.d184.s13
However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate .

However/RB ,/, since/IN aspirin/NN ,/, NSAIDs/NN ,/, and/CC bisphosphonates/NNS are/VBP all/DT associated/VBN with/IN gastrointestinal/JJ irritation/NN ,/, caution/NN should/MD be/VB exercised/VBN in/IN the/DT concomitant/JJ use/NN of/IN aspirin/NN or/CC NSAIDs/NN with/IN Ibandronate/NN ./.


DrugDDI.d184
DrugDDI.d184.s14
Drug /Laboratory Test Interactions .

Drug/NN /Laboratory/NN Test/NN Interactions/NNS ./.


DrugDDI.d184
DrugDDI.d184.s15
Bisphosphonates are known to interfere with the use of bone-imaging agents.

Bisphosphonates/NNS are/VBP known/VBN to/TO interfere/VB with/IN the/DT use/NN of/IN bone-imaging/JJ agents/NNS ./.


DrugDDI.d184
DrugDDI.d184.s16
Specific studies with ibandronate have not been performed.

Specific/JJ studies/NNS with/IN ibandronate/NN have/VBP not/RB been/VBN performed/VBN ./.


DrugDDI.d246
DrugDDI.d246.s1
No evaluation of EXTRANEAL s effects on the cytochrome P450 system was conducted.

No/DT evaluation/NN of/IN EXTRANEAL/JJ s/NN effects/NNS on/IN the/DT cytochrome/NN P450/NN system/NN was/VBD conducted/VBN ./.


DrugDDI.d246
DrugDDI.d246.s2
As with other dialysis solutions , blood concentrations of dialyzable drugs may be reduced by dialysis.

As/IN with/IN other/JJ dialysis/NN solutions/NNS ,/, blood/NN concentrations/NNS of/IN dialyzable/JJ drugs/NNS may/MD be/VB reduced/VBN by/IN dialysis/NN ./.


DrugDDI.d246
DrugDDI.d246.s3
Dosage adjustment of concomitant medications may be necessary.

Dosage/JJ adjustment/NN of/IN concomitant/JJ medications/NNS may/MD be/VB necessary/JJ ./.


DrugDDI.d246
DrugDDI.d246.s4
In patients using cardiac glycosides ( digoxin and others), plasma levels of calcium , potassium and magnesium must be carefully monitored.

In/IN patients/NNS using/VBG cardiac/JJ glycosides/NNS (/-LRB- digoxin/NN and/CC others/NNS )/-RRB- ,/, plasma/NN levels/NNS of/IN calcium/NN ,/, potassium/NN and/CC magnesium/NN must/MD be/VB carefully/RB monitored/VBN ./.


DrugDDI.d246
DrugDDI.d246.s5
Insulin : A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .

Insulin/NN :/: A/DT clinical/JJ study/NN in/IN 6/CD insulin-dependent/JJ diabetic/JJ patients/NNS demonstrated/VBD no/DT effect/NN of/IN EXTRANEAL/NN on/IN insulin/NN absorption/NN from/IN the/DT peritoneal/JJ cavity/NN or/CC on/IN insulin/NN s/NN ability/NN to/TO control/VB blood/NN glucose/NN when/WRB insulin/NN was/VBD administered/VBN intraperitoneally/RB with/IN EXTRANEAL/NN ./.


DrugDDI.d246
DrugDDI.d246.s6
However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.

However/RB ,/, appropriate/JJ monitoring/NN of/IN blood/NN glucose/NN should/MD be/VB performed/VBN when/WRB initiating/VBG EXTRANEAL/NN in/IN diabetic/JJ patients/NNS and/CC insulin/NN dosage/NN should/MD be/VB adjusted/VBN if/IN needed/VBN ./.


DrugDDI.d246
DrugDDI.d246.s7
Heparin : No human drug interaction studies with heparin were conducted.

Heparin/NN :/: No/DT human/JJ drug/NN interaction/NN studies/NNS with/IN heparin/NN were/VBD conducted/VBN ./.


DrugDDI.d246
DrugDDI.d246.s8
In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL .

In/FW vitro/FW studies/NNS demonstrated/VBD no/DT evidence/NN of/IN incompatibility/NN of/IN heparin/NN with/IN EXTRANEAL/NN ./.


DrugDDI.d246
DrugDDI.d246.s9
Antibiotics : No human drug interaction studies with antibiotics were conducted.

Antibiotics/NNS :/: No/DT human/JJ drug/NN interaction/NN studies/NNS with/IN antibiotics/NNS were/VBD conducted/VBN ./.


DrugDDI.d246
DrugDDI.d246.s10
In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL .

In/FW vitro/FW studies/NNS evaluating/VBG the/DT minimum/JJ inhibitory/JJ concentration/NN (/-LRB- MIC/NN )/-RRB- of/IN vancomycin/NN ,/, cefazolin/NN ,/, ampicillin/NN ,/, ampicillin/NN /flucoxacillin/NN ,/, ceftazidime/NN ,/, gentamicin/NN ,/, and/CC amphotericin/NN demonstrated/VBD no/DT evidence/NN of/IN incompatibility/NN of/IN these/DT antibiotics/NNS with/IN EXTRANEAL/NN ./.


DrugDDI.d246
DrugDDI.d246.s11
Drug /Laboratory Test Interactions Blood Glucose Blood glucose measurement must be done with a glucose -specific method to prevent maltose interference with test results.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS Blood/NN Glucose/NN Blood/NN glucose/NN measurement/NN must/MD be/VB done/VBN with/IN a/DT glucose/NN -specific/JJ method/NN to/TO prevent/VB maltose/NN interference/NN with/IN test/NN results/NNS ./.


DrugDDI.d246
DrugDDI.d246.s12
Since falsely elevated glucose levels have been observed with blood glucose monitoring devices and test strips that use glucose dehydrogenase pyrroloquinolinequinone ( GDH PQQ)-based methods, GDH PQQ-based methods should not be used to measure glucose levels in patients administered EXTRANEAL ..

Since/IN falsely/RB elevated/JJ glucose/NN levels/NNS have/VBP been/VBN observed/VBN with/IN blood/NN glucose/NN monitoring/NN devices/NNS and/CC test/NN strips/NNS that/WDT use/VBP glucose/NN dehydrogenase/NN pyrroloquinolinequinone/NN (/-LRB- GDH/CD PQQ/NN )/-RRB- -based/JJ methods/NNS ,/, GDH/CD PQQ-based/JJ methods/NNS should/MD not/RB be/VB used/VBN to/TO measure/VB glucose/NN levels/NNS in/IN patients/NNS administered/VBN EXTRANEAL/NN ./. ./.


DrugDDI.d246
DrugDDI.d246.s13
Serum Amylase : An apparent decrease in serum amylase activity has been observed in patients administered EXTRANEAL .

Serum/NN Amylase/NN :/: An/DT apparent/JJ decrease/NN in/IN serum/NN amylase/NN activity/NN has/VBZ been/VBN observed/VBN in/IN patients/NNS administered/VBN EXTRANEAL/NN ./.


DrugDDI.d246
DrugDDI.d246.s14
Preliminary investigations indicate that icodextrin and its metabolites interfere with enzymatic-based amylase assays, resulting in inaccurately low values.

Preliminary/JJ investigations/NNS indicate/VBP that/IN icodextrin/NN and/CC its/PRP$ metabolites/NNS interfere/VBP with/IN enzymatic-based/JJ amylase/NN assays/NNS ,/, resulting/VBG in/IN inaccurately/RB low/JJ values/NNS ./.


DrugDDI.d246
DrugDDI.d246.s15
This should be taken into account when evaluating serum amylase levels for diagnosis or monitoring of pancreatitis in patients using EXTRANEAL .

This/DT should/MD be/VB taken/VBN into/IN account/NN when/WRB evaluating/VBG serum/NN amylase/NN levels/NNS for/IN diagnosis/NN or/CC monitoring/NN of/IN pancreatitis/NN in/IN patients/NNS using/VBG EXTRANEAL/NN ./.


DrugDDI.d470
DrugDDI.d470.s0
The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs , including other cytotoxic drugs .

The/DT physician/NN should/MD be/VB alert/JJ for/IN possible/JJ combined/JJ drug/NN actions/NNS ,/, desirable/JJ or/CC undesirable/JJ ,/, involving/VBG ifosfamide/NN even/RB though/IN ifosfamide/NN has/VBZ been/VBN used/VBN successfully/RB concurrently/RB with/IN other/JJ drugs/NNS ,/, including/VBG other/JJ cytotoxic/JJ drugs/NNS ./.


DrugDDI.d188
DrugDDI.d188.s0
In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine -like effects may become more pronounced (e.g., paralytic ileus).

In/IN occasional/JJ susceptible/JJ patients/NNS or/CC in/IN those/DT receiving/VBG anticholinergic/JJ drugs/NNS (/-LRB- including/VBG antiparkinsonism/NN agents/NNS )/-RRB- in/IN addition/NN ,/, the/DT atropine/JJ -like/JJ effects/NNS may/MD become/VB more/RBR pronounced/JJ (/-LRB- e.g./FW ,/, paralytic/JJ ileus/NN )./NN


DrugDDI.d188
DrugDDI.d188.s1
Close supervision and careful adjustment of dosage is required when this drug is administered concomitantly with anticholinergic drugs .

Close/JJ supervision/NN and/CC careful/JJ adjustment/NN of/IN dosage/NN is/VBZ required/VBN when/WRB this/DT drug/NN is/VBZ administered/VBN concomitantly/RB with/IN anticholinergic/JJ drugs/NNS ./.


DrugDDI.d188
DrugDDI.d188.s2
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine , norepinephrine ), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.

Avoid/VB the/DT use/NN of/IN preparations/NNS such/JJ as/IN decongestants/NNS and/CC local/JJ anesthetics/NNS which/WDT contain/VBP any/DT sympathomimetic/JJ amine/NN (/-LRB- e.g./FW ,/, epinephrine/NN ,/, norepinephrine/NN )/-RRB- ,/, since/IN it/PRP has/VBZ been/VBN reported/VBN that/IN tricyclic/JJ antidepressants/NNS can/MD potentiate/VB the/DT effects/NNS of/IN catecholamines/NNS ./.


DrugDDI.d188
DrugDDI.d188.s3
Caution should be exercised when imipramine hydrochloride is used with agents that lower blood pressure.

Caution/NN should/MD be/VB exercised/VBN when/WRB imipramine/NN hydrochloride/NN is/VBZ used/VBN with/IN agents/NNS that/IN lower/JJR blood/NN pressure/NN ./.


DrugDDI.d188
DrugDDI.d188.s4
Imipramine hydrochloride may potentiate the effects of CNS depressant drugs .

Imipramine/NN hydrochloride/NN may/MD potentiate/VB the/DT effects/NNS of/IN CNS/NN depressant/NN drugs/NNS ./.


DrugDDI.d188
DrugDDI.d188.s5
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary.

The/DT plasma/NN concentration/NN of/IN imipramine/NN may/MD increase/VB when/WRB the/DT drug/NN is/VBZ given/VBN concomitantly/RB with/IN hepatic/JJ enzyme/NN inhibitors/NNS (/-LRB- e.g./FW ,/, cimetidine/NN ,/, fluoxetine/NN )/-RRB- and/CC decrease/VB by/IN concomitant/JJ administration/NN of/IN hepatic/JJ enzyme/NN inducers/NNS (/-LRB- e.g./FW ,/, barbiturates/NNS ,/, phenytoin/NN )/-RRB- ,/, and/CC adjustment/NN of/IN the/DT dosage/NN of/IN imipramine/NN may/MD therefore/RB be/VB necessary/JJ ./.


DrugDDI.d188
DrugDDI.d188.s6
Drugs Metabolized by P450 2D6 : The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 ( debrisoquin hydroxylase ) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); .

Drugs/NNS Metabolized/VBN by/IN P450/NN 2D6/NN :/: The/DT biochemical/JJ activity/NN of/IN the/DT drug/NN metabolizing/NN isozyme/NN cytochrome/NN P450/NN 2D6/NN (/-LRB- debrisoquin/NN hydroxylase/NN )/-RRB- is/VBZ reduced/VBN in/IN a/DT subset/NN of/IN the/DT caucasian/NN population/NN (/-LRB- about/RB 7/CD to/TO 10/CD %/NN of/IN caucasians/NNS are/VBP so/RB called/VBN poor/JJ metabolizers/NNS )/-RRB- ;/: ./.


DrugDDI.d188
DrugDDI.d188.s7
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.

reliable/JJ estimates/NNS of/IN the/DT prevalence/NN of/IN reduced/VBN P450/NN 2D6/NN isozyme/NN activity/NN among/IN Asian/JJ ,/, African/JJ and/CC other/JJ populations/NNS are/VBP not/RB yet/RB available/JJ ./.


DrugDDI.d188
DrugDDI.d188.s8
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

Poor/JJ metabolizers/NNS have/VBP higher/JJR than/IN expected/VBN plasma/NN concentrations/NNS of/IN tricyclic/JJ antidepressants/NNS (/-LRB- TCAs/NNS )/-RRB- when/WRB given/VBN usual/JJ doses/NNS ./.


DrugDDI.d188
DrugDDI.d188.s9
Depending on the fraction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).

Depending/VBG on/IN the/DT fraction/NN of/IN drug/NN metabolized/VBN by/IN P450/NN 2D6/NN ,/, the/DT increase/NN in/IN plasma/NN concentration/NN may/MD be/VB small/JJ ,/, or/CC quite/RB large/JJ (/-LRB- 8-fold/JJ increase/NN in/IN plasma/NN AUC/NN of/IN the/DT TCA/NN )./NN


DrugDDI.d188
DrugDDI.d188.s10
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.

In/IN addition/NN ,/, certain/JJ drugs/NNS inhibit/VB the/DT activity/NN of/IN this/DT isozyme/NN and/CC make/VB normal/JJ metabolizers/NNS resemble/VBP p.o./NN


DrugDDI.d188
DrugDDI.d188.s12
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

An/DT individual/JJ who/WP is/VBZ stable/JJ on/IN a/DT given/JJ dose/NN of/IN TCA/NN may/MD become/VB abruptly/RB toxic/JJ when/WRB given/VBN one/CD of/IN these/DT inhibiting/JJ drugs/NNS as/IN concomitant/JJ therapy/NN ./.


DrugDDI.d188
DrugDDI.d188.s13
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme ( quinidine ; .

The/DT drugs/NNS that/WDT inhibit/VBP cytochrome/NN P450/NN 2D6/NN include/VBP some/DT that/WDT are/VBP not/RB metabolized/VBN by/IN the/DT enzyme/NN (/-LRB- quinidine/NN ;/: ./.


DrugDDI.d188
DrugDDI.d188.s14
cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and flecainide ).

cimetidine/NN )/-RRB- and/CC many/JJ that/WDT are/VBP substrates/NNS for/IN P450/NN 2D6/NN (/-LRB- many/JJ other/JJ antidepressants/NNS ,/, phenothiazines/NNS ,/, and/CC the/DT Type/NN 1C/NN antiarrhythmics/NNS propafenone/NN and/CC flecainide/NN )/-RRB- ./.


DrugDDI.d188
DrugDDI.d188.s15
While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition.

While/IN all/PDT the/DT selective/JJ serotonin/NN reuptake/NN inhibitors/NNS (/-LRB- SSRIs/NN )/-RRB- ,/, e./FW g./FW ,/, fluoxetine/NN ,/, sertraline/NN ,/, and/CC paroxetine/NN ,/, inhibit/VBP P450/NN 2D6/NN ,/, they/PRP may/MD vary/VB in/IN the/DT extent/NN of/IN inhibition/NN ./.


DrugDDI.d188
DrugDDI.d188.s18
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

Of/IN particular/JJ importance/NN ,/, sufficient/JJ time/NN must/MD elapse/VB before/IN initiating/VBG TCA/NN treatment/NN in/IN a/DT patient/NN being/VBG withdrawn/NN from/IN fluoxetine/NN ,/, given/IN the/DT long/JJ half-life/NN of/IN the/DT parent/JJ and/CC active/JJ metabolite/NN (/-LRB- at/IN least/JJS 5/CD weeks/NNS may/MD be/VB necessary/JJ )./NN


DrugDDI.d188
DrugDDI.d188.s19
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

Concomitant/JJ use/NN of/IN tricyclic/JJ antidepressants/NNS with/IN drugs/NNS that/WDT can/MD inhibit/VB cytochrome/NN P450/NN 2D6/NN may/MD require/VB lower/JJR doses/NNS than/IN usually/RB prescribed/VBN for/IN either/CC the/DT tricyclic/JJ antidepressant/JJ or/CC the/DT other/JJ drug/NN ./.


DrugDDI.d188
DrugDDI.d188.s20
Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required.

Furthermore/RB ,/, whenever/RB one/CD of/IN these/DT other/JJ drugs/NNS is/VBZ withdrawn/VBN from/IN cotherapy/NN ,/, an/DT increased/VBN dose/NN of/IN tricyclic/JJ antidepressant/JJ may/MD be/VB required/VBN ./.


DrugDDI.d188
DrugDDI.d188.s21
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6 .

It/PRP is/VBZ desirable/JJ to/TO monitor/VB TCA/NN plasma/NN levels/NNS whenever/RB a/DT TCA/NN is/VBZ going/JJ to/TO be/VB co-administered/VBN with/IN another/DT drug/NN known/VBN to/TO be/VB an/DT inhibitor/NN of/IN P450/NN 2D6/NN ./.


DrugDDI.d83
DrugDDI.d83.s0
In normal volunteers receiving indomethacin , the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin .

In/IN normal/JJ volunteers/NNS receiving/VBG indomethacin/NN ,/, the/DT administration/NN of/IN diflunisal/NN decreased/VBD the/DT renal/JJ clearance/NN and/CC significantly/RB increased/VBD the/DT plasma/NN levels/NNS of/IN indomethacin/NN ./.


DrugDDI.d83
DrugDDI.d83.s1
In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.

In/IN some/DT patients/NNS ,/, combined/JJ use/NN of/IN INDOCIN/NN and/CC diflunisal/NN has/VBZ been/VBN associated/VBN with/IN fatal/JJ gastrointestinal/JJ hemorrhage/NN ./.


DrugDDI.d83
DrugDDI.d83.s2
Therefore, diflunisal and INDOCIN should not be used concomitantly.

Therefore/RB ,/, diflunisal/NN and/CC INDOCIN/NN should/MD not/RB be/VB used/VBN concomitantly/RB ./.


DrugDDI.d83
DrugDDI.d83.s3
In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.

In/IN a/DT study/NN in/IN normal/JJ volunteers/NNS ,/, it/PRP was/VBD found/VBN that/IN chronic/JJ concurrent/JJ administration/NN of/IN 3.6/CD g/NN of/IN aspirin/NN per/IN day/NN decreases/VBZ indomethacin/NN blood/NN levels/NNS approximately/RB 20/CD %./NN


DrugDDI.d83
DrugDDI.d83.s4
The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.

The/DT concomitant/JJ use/NN of/IN INDOCIN/NN with/IN other/JJ NSAIDs/NNS is/VBZ not/RB recommended/VBN due/JJ to/TO the/DT increased/VBN possibility/NN of/IN gastrointestinal/JJ toxicity/NN ,/, with/IN little/JJ or/CC no/DT increase/NN in/IN efficacy/NN ./.


DrugDDI.d83
DrugDDI.d83.s5
Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants .

Clinical/JJ studies/NNS have/VBP shown/VBN that/IN INDOCIN/NN does/VBZ not/RB influence/VB the/DT hypoprothrombinemia/NN produced/VBN by/IN anticoagulants/NNS ./.


DrugDDI.d83
DrugDDI.d83.s6
However, when any additional drug , including INDOCIN , is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.

However/RB ,/, when/WRB any/DT additional/JJ drug/NN ,/, including/VBG INDOCIN/NN ,/, is/VBZ added/VBN to/TO the/DT treatment/NN of/IN patients/NNS on/IN anticoagulant/NN therapy/NN ,/, the/DT patients/NNS should/MD be/VB observed/VBN for/IN alterations/NNS of/IN the/DT prothrombin/NN time/NN ./.


DrugDDI.d83
DrugDDI.d83.s7
In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN .

In/IN post-marketing/JJ experience/VBP ,/, bleeding/JJ has/VBZ been/VBN reported/VBN in/IN patients/NNS on/IN concomitant/JJ treatment/NN with/IN anticoagulants/NNS and/CC INDOCIN/NN ./.


DrugDDI.d83
DrugDDI.d83.s8
Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.

Caution/NN should/MD be/VB exercised/VBN when/WRB INDOCIN/NN and/CC anticoagulants/NNS are/VBP administered/VBN concomitantly/RB ./.


DrugDDI.d83
DrugDDI.d83.s9
When INDOCIN is given to patients receiving probenecid , the plasma levels of indomethacin are likely to be increased.

When/WRB INDOCIN/NN is/VBZ given/VBN to/TO patients/NNS receiving/VBG probenecid/NN ,/, the/DT plasma/NN levels/NNS of/IN indomethacin/NN are/VBP likely/JJ to/TO be/VB increased/VBN ./.


DrugDDI.d83
DrugDDI.d83.s10
Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect.

Therefore/RB ,/, a/DT lower/RBR total/JJ daily/JJ dosage/NN of/IN INDOCIN/NN may/MD produce/VB a/DT satisfactory/JJ therapeutic/JJ effect/NN ./.


DrugDDI.d83
DrugDDI.d83.s11
When increases in the dose of INDOCIN are made, they should be made carefully and in small increments.

When/WRB increases/NNS in/IN the/DT dose/NN of/IN INDOCIN/NN are/VBP made/VBN ,/, they/PRP should/MD be/VB made/VBN carefully/RB and/CC in/IN small/JJ increments/NNS ./.


DrugDDI.d83
DrugDDI.d83.s12
Caution should be used if INDOCIN is administered simultaneously with methotrexate .

Caution/NN should/MD be/VB used/VBN if/IN INDOCIN/NN is/VBZ administered/VBN simultaneously/RB with/IN methotrexate/NN ./.


DrugDDI.d83
DrugDDI.d83.s13
INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.

INDOCIN/NN has/VBZ been/VBN reported/VBN to/TO decrease/VB the/DT tubular/JJ secretion/NN of/IN methotrexate/NN and/CC to/TO potentiate/VB its/PRP$ toxicity/NN ./.


DrugDDI.d83
DrugDDI.d83.s14
Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin .

Administration/NN of/IN non-steroidal/JJ anti-inflammatory/JJ drugs/NNS concomitantly/RB with/IN cyclosporine/NN has/VBZ been/VBN associated/VBN with/IN an/DT increase/NN in/IN cyclosporine-induced/JJ toxicity/NN ,/, possibly/RB due/JJ to/TO decreased/VBN synthesis/NN of/IN renal/JJ prostacyclin/NN ./.


DrugDDI.d83
DrugDDI.d83.s15
NSAIDs should be used with caution in patients taking cyclosporine , and renal function should be carefully monitored.

NSAIDs/NN should/MD be/VB used/VBN with/IN caution/NN in/IN patients/NNS taking/VBG cyclosporine/NN ,/, and/CC renal/JJ function/NN should/MD be/VB carefully/RB monitored/VBN ./.


DrugDDI.d83
DrugDDI.d83.s16
Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.

Capsules/NNS INDOCIN/NN 50/CD mg/NN t.i.d./RB produced/VBD a/DT clinically/RB relevant/JJ elevation/NN of/IN plasma/NN lithium/NN and/CC reduction/NN in/IN renal/JJ lithium/NN clearance/NN in/IN psychiatric/JJ patients/NNS and/CC normal/JJ subjects/NNS with/IN steady/JJ state/NN plasma/NN lithium/NN concentrations/NNS ./.


DrugDDI.d83
DrugDDI.d83.s17
This effect has been attributed to inhibition of prostaglandin synthesis.

This/DT effect/NN has/VBZ been/VBN attributed/VBN to/TO inhibition/NN of/IN prostaglandin/NN synthesis/NN ./.


DrugDDI.d83
DrugDDI.d83.s18
As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.

As/IN a/DT consequence/NN ,/, when/WRB INDOCIN/NN and/CC lithium/NN are/VBP given/VBN concomitantly/RB ,/, the/DT patient/NN should/MD be/VB carefully/RB observed/VBN for/IN signs/NNS of/IN lithium/NN toxicity/NN ./.


DrugDDI.d83
DrugDDI.d83.s19
(Read circulars for lithium preparation s before use of such concomitant therapy.) .

(/-LRB- Read/VBN circulars/NNS for/IN lithium/NN preparation/NN s/NNS before/IN use/NN of/IN such/JJ concomitant/JJ therapy./NN )/-RRB- ./.


DrugDDI.d83
DrugDDI.d83.s20
In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.

In/IN addition/NN ,/, the/DT frequency/NN of/IN monitoring/VBG serum/NN lithium/NN concentration/NN should/MD be/VB increased/VBN at/IN the/DT outset/NN of/IN such/JJ combination/NN drug/NN treatment/NN ./.


DrugDDI.d83
DrugDDI.d83.s21
INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin .

INDOCIN/NN given/VBN concomitantly/RB with/IN digoxin/NN has/VBZ been/VBN reported/VBN to/TO increase/VB the/DT serum/NN concentration/NN and/CC prolong/VB the/DT half-life/NN of/IN digoxin/NN ./.


DrugDDI.d83
DrugDDI.d83.s22
Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.

Therefore/RB ,/, when/WRB INDOCIN/NN and/CC digoxin/NN are/VBP used/VBN concomitantly/RB ,/, serum/NN digoxin/NN levels/NNS should/MD be/VB closely/RB monitored/VBN ./.


DrugDDI.d83
DrugDDI.d83.s23
In some patients, the administration of INDOCIN can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium -sparing, and thiazide diuretics .

In/IN some/DT patients/NNS ,/, the/DT administration/NN of/IN INDOCIN/NN can/MD reduce/VB the/DT diuretic/JJ ,/, natriuretic/JJ ,/, and/CC antihypertensive/JJ effects/NNS of/IN loop/NN ,/, potassium/NN -sparing/NN ,/, and/CC thiazide/NN diuretics/NNS ./.


DrugDDI.d83
DrugDDI.d83.s24
Therefore, when INDOCIN and INDOCIN .

Therefore/RB ,/, when/IN INDOCIN/NN and/CC INDOCIN/NN ./.


DrugDDI.d83
DrugDDI.d83.s25
( Indomethacin ) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

(/-LRB- Indomethacin/NN )/-RRB- diuretics/NNS are/VBP used/VBN concomitantly/RB ,/, the/DT patient/NN should/MD be/VB observed/VBN closely/RB to/TO determine/VB if/IN the/DT desired/JJ effect/NN of/IN the/DT diuretic/NN is/VBZ obtained/VBN ./.


DrugDDI.d83
DrugDDI.d83.s26
INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.

INDOCIN/NN reduces/VBZ basal/JJ plasma/NN renin/NN activity/NN (/-LRB- PRA/NN )/-RRB- ,/, as/RB well/RB as/IN those/DT elevations/NNS of/IN PRA/NN induced/VBN by/IN furosemide/NN administration/NN ,/, or/CC salt/NN or/CC volume/NN depletion/NN ./.


DrugDDI.d83
DrugDDI.d83.s28
It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.

It/PRP has/VBZ been/VBN reported/VBN that/IN the/DT addition/NN of/IN triamterene/NN to/TO a/DT maintenance/NN schedule/NN of/IN INDOCIN/NN resulted/VBD in/IN reversible/JJ acute/JJ renal/JJ failure/NN in/IN two/CD of/IN four/CD healthy/JJ volunteers/NNS ./.


DrugDDI.d83
DrugDDI.d83.s29
INDOCIN and triamterene should not be administered together.

INDOCIN/NN and/CC triamterene/NN should/MD not/RB be/VB administered/VBN together/RB ./.


DrugDDI.d83
DrugDDI.d83.s30
INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.

INDOCIN/NN and/CC potassium-sparing/JJ diuretics/NNS each/DT may/MD be/VB associated/VBN with/IN increased/VBN serum/NN potassium/NN levels/NNS ./.


DrugDDI.d83
DrugDDI.d83.s31
The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.

The/DT potential/JJ effects/NNS of/IN INDOCIN/JJ and/CC potassium-sparing/JJ diuretics/NNS on/IN potassium/NN kinetics/NNS and/CC renal/JJ function/NN should/MD be/VB considered/VBN when/WRB these/DT agents/NNS are/VBP administered/VBN concurrently/RB ./.


DrugDDI.d83
DrugDDI.d83.s32
Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN .

Most/JJS of/IN the/DT above/JJ effects/NNS concerning/VBG diuretics/NNS have/VBP been/VBN attributed/VBN ,/, at/IN least/JJS in/IN part/NN ,/, to/TO mechanisms/NNS involving/VBG inhibition/NN of/IN prostaglandin/NN synthesis/NN by/IN INDOCIN/NN ./.


DrugDDI.d83
DrugDDI.d83.s33
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agent s by non-steroidal antiinflammatory drugs including INDOCIN has been reported.

Blunting/NN of/IN the/DT antihypertensive/JJ effect/NN of/IN beta-adrenoceptor/NN blocking/NN agent/NN s/NNS by/IN non-steroidal/JJ antiinflammatory/JJ drugs/NNS including/VBG INDOCIN/NN has/VBZ been/VBN reported/VBN ./.


DrugDDI.d83
DrugDDI.d83.s35
INDOCIN can reduce the antihypertensive effects of captopril and losartan .

INDOCIN/NN can/MD reduce/VB the/DT antihypertensive/JJ effects/NNS of/IN captopril/NN and/CC losartan/NN ./.


DrugDDI.d83
DrugDDI.d83.s36
False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported.

False-negative/JJ results/NNS in/IN the/DT dexamethasone/NN suppression/NN test/NN (/-LRB- DST/NN )/-RRB- in/IN patients/NNS being/VBG treated/VBN with/IN INDOCIN/NN have/VBP been/VBN reported/VBN ./.


DrugDDI.d395
DrugDDI.d395.s0
A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.

A/DT number/NN of/IN substances/NNS affect/VBP glucose/NN metabolism/NN and/CC may/MD require/VBP insulin/NN dose/NN adjustment/NN and/CC particularly/RB close/JJ monitoring/NN ./.


DrugDDI.d395
DrugDDI.d395.s1
@@ @ The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase (MAO) inhibitors, propoxyphene , salicylates , somatostatin analog (e.g., octreotide ), sulfonamide antibiotics.

@/NN @/NN @/NN The/DT following/NN are/VBP examples/NNS of/IN substances/NNS that/WDT may/MD increase/VB the/DT blood-glucose-lowering/JJ effect/NN and/CC susceptibility/NN to/TO hypoglycemia/NN :/: oral/JJ antidiabetic/JJ products/NNS ,/, ACE/NN inhibitors/NNS ,/, disopyramide/NN ,/, fibrates/NNS ,/, fluoxetine/NN ,/, monoamine/NN oxidase/NN (/-LRB- MAO/NN )/-RRB- inhibitors/NNS ,/, propoxyphene/NN ,/, salicylates/NNS ,/, somatostatin/NN analog/NN (/-LRB- e.g./FW ,/, octreotide/NN )/-RRB- ,/, sulfonamide/NN antibiotics/NNS ./.


DrugDDI.d395
DrugDDI.d395.s2
@@ @ The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic agents (e.g., epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens (e.g., in oral contraceptives ).

@/NN @/NN @/NN The/DT following/VBG are/VBP examples/NNS of/IN substances/NNS that/WDT may/MD reduce/VB the/DT blood-glucose-lowering/JJ effect/NN :/: corticosteroids/NNS ,/, niacin/NN ,/, danazol/NN ,/, diuretics/NN ,/, sympathomimetic/JJ agents/NNS (/-LRB- e.g./FW ,/, epinephrine/NN ,/, salbutamol/NN ,/, terbutaline/NN )/-RRB- ,/, isoniazid/NN ,/, phenothiazine/JJ derivatives/NNS ,/, somatropin/NN ,/, thyroid/NN hormones/NNS ,/, estrogens/NNS ,/, progestogens/NNS (/-LRB- e.g./FW ,/, in/IN oral/JJ contraceptives/NNS )/-RRB- ./.


DrugDDI.d395
DrugDDI.d395.s3
@@ @ Beta-blockers , clonidine , lithium salt s, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin .

@/NN @/NN @/NN Beta-blockers/NN ,/, clonidine/NN ,/, lithium/NN salt/NN s/NN ,/, and/CC alcohol/NN may/MD either/CC potentiate/VB or/CC weaken/VB the/DT blood-glucose-lowering/JJ effect/NN of/IN insulin/NN ./.


DrugDDI.d395
DrugDDI.d395.s4
Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.

Pentamidine/NN may/MD cause/VB hypoglycemia/NN ,/, which/WDT may/MD sometimes/RB be/VB followed/VBN by/IN hyperglycemia/NN ./.


DrugDDI.d395
DrugDDI.d395.s5
@@ @ : In addition, under the influence of sympatholytic medicinal products such as beta-blockers , clonidine , guanethidine , and reserpine , the signs of hypoglycemia may be reduced or absent.

@/NN @/NN @/NN :/: In/IN addition/NN ,/, under/IN the/DT influence/NN of/IN sympatholytic/JJ medicinal/NN products/NNS such/JJ as/IN beta-blockers/NN ,/, clonidine/NN ,/, guanethidine/NN ,/, and/CC reserpine/NN ,/, the/DT signs/NNS of/IN hypoglycemia/NN may/MD be/VB reduced/VBN or/CC absent/JJ ./.


DrugDDI.d395
DrugDDI.d395.s6
Mixing of Insulins .

Mixing/NN of/IN Insulins/NNS ./.


DrugDDI.d395
DrugDDI.d395.s7
@@ @ : A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog , but that the time to peak and the total bioavailability of NovoLog were not significantly affected.

@/NN @/NN @/NN :/: A/DT clinical/JJ study/NN in/IN healthy/JJ male/JJ volunteers/NNS (/-LRB- n=24/NN )/-RRB- demonstrated/VBD that/IN mixing/NN NovoLog/NN with/IN NPH/NN human/JJ insulin/NN immediately/RB before/IN injection/NN produced/VBD some/DT attenuation/NN in/IN the/DT peak/JJ concentration/NN of/IN NovoLog/NN ,/, but/CC that/IN the/DT time/NN to/TO peak/NN and/CC the/DT total/JJ bioavailability/NN of/IN NovoLog/NN were/VBD not/RB significantly/RB affected/VBN ./.


DrugDDI.d395
DrugDDI.d395.s8
If NovoLog is mixed with NPH human insulin , NovoLog should be drawn into the syringe first.

If/IN NovoLog/NN is/VBZ mixed/VBN with/IN NPH/NN human/JJ insulin/NN ,/, NovoLog/NN should/MD be/VB drawn/VBN into/IN the/DT syringe/NN first/JJ ./.


DrugDDI.d395
DrugDDI.d395.s10
Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparation s, NovoLog should not be mixed with these preparations.

Because/IN there/EX are/VBP no/DT data/NNS on/IN the/DT compatibility/NN of/IN NovoLog/NN and/CC crystalline/JJ zinc/NN insulin/NN preparation/NN s/NNS ,/, NovoLog/NN should/MD not/RB be/VB mixed/VBN with/IN these/DT preparations/NNS ./.


DrugDDI.d395
DrugDDI.d395.s11
@@ @ : The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .

@/NN @/NN @/NN :/: The/DT effects/NNS of/IN mixing/JJ NovoLog/NN with/IN insulins/NNS of/IN animal/NN source/NN or/CC insulin/NN preparations/NNS produced/VBN by/IN other/JJ manufacturers/NNS have/VBP not/RB been/VBN studied/VBN ./.


DrugDDI.d395
DrugDDI.d395.s13
@@ @ : When used in external subcutaneous infusion pumps for insulin , NovoLog should not be mixed with any other insulins or diluent.

@/NN @/NN @/NN :/: When/WRB used/VBN in/IN external/JJ subcutaneous/JJ infusion/NN pumps/VBZ for/IN insulin/NN ,/, NovoLog/NN should/MD not/RB be/VB mixed/VBN with/IN any/DT other/JJ insulins/NNS or/CC diluent/NN ./.


DrugDDI.d396
DrugDDI.d396.s0
No significant drug -drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide , digoxin , warfarin , and nifedipine .

No/DT significant/JJ drug/NN -drug/NN pharmacokinetic/JJ (/-LRB- or/CC pharmacodynamic/JJ )/-RRB- interactions/NNS have/VBP been/VBN found/VBN in/IN interaction/NN studies/NNS with/IN hydrochlorothiazide/NN ,/, digoxin/NN ,/, warfarin/NN ,/, and/CC nifedipine/NN ./.


DrugDDI.d396
DrugDDI.d396.s1
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine .

In/FW vitro/FW studies/NNS show/VBP significant/JJ inhibition/NN of/IN the/DT formation/NN of/IN oxidized/VBN irbesartan/NN metabolites/NNS with/IN the/DT known/JJ cytochrome/NN CYP/NN 2C9/NN substrates/inhibitors/NN sulphenazole/NN ,/, tolbutamide/NN and/CC nifedipine/NN ./.


DrugDDI.d396
DrugDDI.d396.s2
However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.

However/RB ,/, in/IN clinical/JJ studies/NNS the/DT consequences/NNS of/IN concomitant/JJ irbesartan/NN on/IN the/DT pharmacodynamics/NNS of/IN warfarin/NN were/VBD negligible/JJ ./.


DrugDDI.d396
DrugDDI.d396.s3
Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1 , 1A2,2A6,2B6,2D6,2E1,or 3A4.

Based/VBN on/IN in/FW vitro/FW data/NNS ,/, no/DT interaction/NN would/MD be/VB expected/VBN with/IN drugs/NNS whose/WP$ metabolism/NN is/VBZ dependent/JJ upon/IN cytochrome/NN P450/NN isozymes/NNS 1A1/NN ,/, 1A2,2A6,2B6,2D6,2E1/NN ,/, or/CC 3A4/NN ./.


DrugDDI.d396
DrugDDI.d396.s4
In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin .

In/IN separate/JJ studies/NNS of/IN patients/NNS receiving/VBG maintenance/NN doses/NNS of/IN warfarin/NN ,/, hydrochlorothiazide/NN ,/, or/CC digoxin/NN ,/, irbesartan/NN administration/NN for/IN 7/CD days/NNS had/VBD no/DT effect/NN on/IN the/DT pharmacodynamics/NNS of/IN warfarin/NN (/-LRB- prothrombin/NN time/NN )/-RRB- or/CC pharmacokinetics/NNS of/IN digoxin/NN ./.


DrugDDI.d396
DrugDDI.d396.s5
The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide .

The/DT pharmacokinetics/NNS of/IN irbesartan/NN were/VBD not/RB affected/VBN by/IN coadministration/NN of/IN nifedipine/NN or/CC hydrochlorothiazide/NN ./.


DrugDDI.d177
DrugDDI.d177.s0
The adverse effects of CAMPTOSAR , such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.

The/DT adverse/JJ effects/NNS of/IN CAMPTOSAR/NN ,/, such/JJ as/IN myelosuppression/NN and/CC diarrhea/NN ,/, would/MD be/VB expected/VBN to/TO be/VB exacerbated/JJ by/IN other/JJ antineoplastic/JJ agents/NNS having/VBG similar/JJ adverse/JJ effects/NNS ./.


DrugDDI.d177
DrugDDI.d177.s1
Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR .

Patients/NNS who/WP have/VBP previously/RB received/VBN pelvic//NN abdominal/JJ irradiation/NN are/VBP at/IN increased/VBN risk/NN of/IN severe/JJ myelosuppression/NN following/VBG the/DT administration/NN of/IN CAMPTOSAR/NN ./.


DrugDDI.d177
DrugDDI.d177.s2
The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.

The/DT concurrent/JJ administration/NN of/IN CAMPTOSAR/NN with/IN irradiation/NN has/VBZ not/RB been/VBN adequately/RB studied/VBN and/CC is/VBZ not/RB recommended/VBN ./.


DrugDDI.d177
DrugDDI.d177.s3
Lymphocytopenia has been reported in patients receiving CAMPTOSAR , and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.

Lymphocytopenia/NN has/VBZ been/VBN reported/VBN in/IN patients/NNS receiving/VBG CAMPTOSAR/NN ,/, and/CC it/PRP is/VBZ possible/JJ that/IN the/DT administration/NN of/IN dexamethasone/NN as/IN antiemetic/JJ prophylaxis/NNS may/MD have/VB enhanced/VBD the/DT likelihood/NN of/IN this/DT effect/NN ./.


DrugDDI.d177
DrugDDI.d177.s5
Hyperglycemia has also been reported in patients receiving CAMPTOSAR .

Hyperglycemia/NN has/VBZ also/RB been/VBN reported/VBN in/IN patients/NNS receiving/VBG CAMPTOSAR/NN ./.


DrugDDI.d177
DrugDDI.d177.s6
Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR .

Usually/RB ,/, this/DT has/VBZ been/VBN observed/VBN in/IN patients/NNS with/IN a/DT history/NN of/IN diabetes/NN mellitus/NN or/CC evidence/NN of/IN glucose/NN intolerance/NN prior/JJ to/TO administration/NN of/IN CAMPTOSAR/NN ./.


DrugDDI.d177
DrugDDI.d177.s7
It is probable that dexamethasone , given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.

It/PRP is/VBZ probable/JJ that/IN dexamethasone/NN ,/, given/VBN as/IN antiemetic/NN prophylaxis/NN ,/, contributed/VBD to/TO hyperglycemia/NN in/IN some/DT patients/NNS ./.


DrugDDI.d177
DrugDDI.d177.s8
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).

The/DT incidence/NN of/IN akathisia/NN in/IN clinical/JJ trials/NNS of/IN the/DT weekly/JJ dosage/NN schedule/NN was/VBD greater/JJR (/-LRB- 8.5/CD %/NN ,/, 4/47/CD patients/NNS )/-RRB- when/WRB prochlorperazine/NN was/VBD administered/VBN on/IN the/DT same/JJ day/NN as/IN CAMPTOSAR/NN than/IN when/WRB these/DT drugs/NNS were/VBD given/VBN on/IN separate/JJ days/NNS (/-LRB- 1.3/CD %/NN ,/, 1/80/NN patients/NNS )./CD


DrugDDI.d177
DrugDDI.d177.s9
The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.

The/DT 8.5/CD %/NN incidence/NN of/IN akathisia/NN ,/, however/RB ,/, is/VBZ within/IN the/DT range/NN reported/VBN for/IN use/NN of/IN prochlorperazine/NN when/WRB given/VBN as/IN a/DT premedication/NN for/IN other/JJ chemotherapies/NNS ./.


DrugDDI.d177
DrugDDI.d177.s10
It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.

It/PRP would/MD be/VB expected/VBN that/IN laxative/JJ use/NN during/IN therapy/NN with/IN CAMPTOSAR/NN would/MD worsen/VB the/DT incidence/NN or/CC severity/NN of/IN diarrhea/NN ,/, but/CC this/DT has/VBZ not/RB been/VBN studied/VBN ./.


DrugDDI.d177
DrugDDI.d177.s11
In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR , the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.

In/IN view/NN of/IN the/DT potential/JJ risk/NN of/IN dehydration/NN secondary/JJ to/TO vomiting/NN and/or/CC diarrhea/NN induced/VBN by/IN CAMPTOSAR/NN ,/, the/DT physician/NN may/MD wish/VB to/TO withhold/JJ diuretics/NNS during/IN dosing/NN with/IN CAMPTOSAR/NN and/CC ,/, certainly/RB ,/, during/IN periods/NNS of/IN active/JJ vomiting/NN or/CC diarrhea/NN ./.


DrugDDI.d177
DrugDDI.d177.s12
Drug-Laboratory Test Interactions : There are no known interactions between CAMPTOSAR and laboratory tests.

Drug-Laboratory/JJ Test/NN Interactions/NNS :/: There/EX are/VBP no/DT known/JJ interactions/NNS between/IN CAMPTOSAR/NN and/CC laboratory/NN tests/NNS ./.


DrugDDI.d171
DrugDDI.d171.s0
Isoflurane potentiates the muscle relaxant effect of all muscle relaxants , most notably nondepolarizing muscle relaxants , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N span class= c13 2O.

Isoflurane/NN potentiates/VBZ the/DT muscle/NN relaxant/JJ effect/NN of/IN all/DT muscle/NN relaxants/NNS ,/, most/RBS notably/RB nondepolarizing/VBG muscle/NN relaxants/NNS ,/, and/CC MAC/NN (/-LRB- minimum/JJ alveolar/JJ concentration/NN )/-RRB- is/VBZ reduced/VBN by/IN concomitant/JJ administration/NN of/IN N/NN span/NN class=/NN c13/NN 2O/NN ./.


DrugDDI.d250
DrugDDI.d250.s0
The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators .

The/DT vasodilating/JJ effects/NNS of/IN isosorbide/NN dinitrate/NN may/MD be/VB additive/JJ with/IN those/DT of/IN other/JJ vasodilators/NNS ./.


DrugDDI.d250
DrugDDI.d250.s1
Alcohol , in particular, has been found to exhibit additive effects of this variety.

Alcohol/NN ,/, in/IN particular/JJ ,/, has/VBZ been/VBN found/VBN to/TO exhibit/VBP additive/JJ effects/NNS of/IN this/DT variety/NN ./.


DrugDDI.d347
DrugDDI.d347.s0
The following drug interactions were studied with ketoprofen doses of 200 mg/day.

The/DT following/JJ drug/NN interactions/NNS were/VBD studied/VBN with/IN ketoprofen/NN doses/NNS of/IN 200/CD mg/day/NN ./.


DrugDDI.d347
DrugDDI.d347.s1
The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.

The/DT possibility/NN of/IN increased/VBN interaction/NN should/MD be/VB kept/VBN in/IN mind/NN when/WRB Orudis/NN doses/NNS greater/JJR than/IN 50/CD mg/NN as/IN a/DT single/JJ dose/NN or/CC 200/CD mg/NN of/IN ketoprofen/NN per/IN day/NN are/VBP used/VBN concomitantly/RB with/IN highly/RB bound/VBN drugs/NNS ./.


DrugDDI.d347
DrugDDI.d347.s3
Antacids : Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .

Antacids/NNS :/: Concomitant/JJ administration/NN of/IN magnesium/NN hydroxide/NN and/CC aluminum/NN hydroxide/NN does/VBZ not/RB interfere/VB with/IN the/DT rate/NN or/CC extent/NN of/IN the/DT absorption/NN of/IN ketoprofen/NN administered/VBN as/IN Orudis/NN ./.


DrugDDI.d347
DrugDDI.d347.s5
Aspirin : Ketoprofen does not alter aspirin absorption; .

Aspirin/NN :/: Ketoprofen/NN does/VBZ not/RB alter/VB aspirin/NN absorption/NN ;/: ./.


DrugDDI.d347
DrugDDI.d347.s6
however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin .

however/RB ,/, in/IN a/DT study/NN of/IN 12/CD normal/JJ subjects/NNS ,/, concurrent/JJ administration/NN of/IN aspirin/NN decreased/VBD ketoprofen/NN protein/NN binding/NN and/CC increased/VBN ketoprofen/NN plasma/NN clearance/NN from/IN 0.07/CD L/kg/h/NN without/IN aspirin/NN to/TO 0.11/NN L/kg/h/NN with/IN aspirin/NN ./.


DrugDDI.d347
DrugDDI.d347.s8
Therefore, concurrent use of aspirin and ketoprofen is not recommended.

Therefore/RB ,/, concurrent/JJ use/NN of/IN aspirin/NN and/CC ketoprofen/NN is/VBZ not/RB recommended/VBN ./.


DrugDDI.d347
DrugDDI.d347.s10
Diuretic : Hydrochlorothiazide , given concomitantly with ketoprofen , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.

Diuretic/JJ :/: Hydrochlorothiazide/NN ,/, given/VBN concomitantly/RB with/IN ketoprofen/NN ,/, produces/VBZ a/DT reduction/NN in/IN urinary/JJ potassium/NN and/CC chloride/NN excretion/NN compared/VBN to/TO hydrochlorothiazide/NN alone/RB ./.


DrugDDI.d347
DrugDDI.d347.s11
Patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.

Patients/NNS taking/VBG diuretics/NNS are/VBP at/IN a/DT greater/JJR risk/NN of/IN developing/VBG renal/JJ failure/NN secondary/JJ to/TO a/DT decrease/NN in/IN renal/JJ blood/NN flow/NN caused/VBN by/IN prostaglandin/NN inhibition/NN ./.


DrugDDI.d347
DrugDDI.d347.s13
Digoxin : In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin .

Digoxin/NN :/: In/IN a/DT study/NN in/IN 12/CD patients/NNS with/IN congestive/JJ heart/NN failure/NN where/WRB ketoprofen/NN and/CC digoxin/NN were/VBD concomitantly/RB administered/VBN ,/, ketoprofen/NN did/VBD not/RB alter/VB the/DT serum/NN levels/NNS of/IN digoxin/NN ./.


DrugDDI.d347
DrugDDI.d347.s15
Warfarin : In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.

Warfarin/NN :/: In/IN a/DT short-term/JJ controlled/JJ study/NN in/IN 14/CD normal/JJ volunteers/NNS ,/, ketoprofen/NN did/VBD not/RB significantly/RB interfere/VB with/IN the/DT effect/NN of/IN warfarin/NN on/IN prothrombin/NN time/NN ./.


DrugDDI.d347
DrugDDI.d347.s16
Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.

Bleeding/JJ from/IN a/DT number/NN of/IN sites/NNS may/MD be/VB a/DT complication/NN of/IN warfarin/NN treatment/NN and/CC GI/JJ bleeding/JJ a/DT complication/NN of/IN ketoprofen/NN treatment/NN ./.


DrugDDI.d347
DrugDDI.d347.s17
Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs .

Because/IN prostaglandina/NNS play/VBP an/DT important/JJ role/NN in/IN hemostasis/NN and/CC ketoprofen/NN has/VBZ an/DT effect/NN on/IN platelet/NN function/NN as/IN well/NN ,/, concurent/JJ therapy/NN with/IN ketoprofen/NN and/CC warfarin/NN requires/VBZ close/JJ monitoring/NN of/IN patients/NNS on/IN both/DT drugs/NNS ./.


DrugDDI.d347
DrugDDI.d347.s19
Probenecid : Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.

Probenecid/NN :/: Probenecid/NN increases/VBZ both/CC free/JJ and/CC bound/JJ ketoprofen/NN by/IN reducing/VBG the/DT plasma/NN clearance/NN of/IN ketoprofen/NN to/TO about/RB one-third/CD ,/, as/RB well/RB as/IN decreasing/VBG its/PRP$ protein/NN binding/NN ./.


DrugDDI.d347
DrugDDI.d347.s20
Therefore, the combination of ketoprofen and probenecid is not recommended.

Therefore/RB ,/, the/DT combination/NN of/IN ketoprofen/NN and/CC probenecid/NN is/VBZ not/RB recommended/VBN ./.


DrugDDI.d347
DrugDDI.d347.s22
Methotrexate : Ketoprofen , like other NSAIDs , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.

Methotrexate/NN :/: Ketoprofen/NN ,/, like/IN other/JJ NSAIDs/NNS ,/, may/MD cause/VB changes/NNS in/IN the/DT elimination/NN of/IN methotrexate/NN leading/VBG to/TO elevated/JJ serum/NN levels/NNS of/IN the/DT drug/NN and/CC increased/VBN toxicity/NN ./.


DrugDDI.d347
DrugDDI.d347.s24
Lithium : Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.

Lithium/NN :/: Nonsteroidal/JJ anti-inflammatory/JJ agents/NNS have/VBP been/VBN reported/VBN to/TO increase/VB steadystate/JJ plasma/NN lithium/NN levels/NNS ./.


DrugDDI.d347
DrugDDI.d347.s25
It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium .

It/PRP is/VBZ recommended/VBN that/IN plasma/NN lithium/NN levels/NNS be/VB monitored/VBN when/WRB ketoprofen/NN is/VBZ coadministered/VBN with/IN lithium/NN ./.


DrugDDI.d347
DrugDDI.d347.s26
DRUG /LABORATORY TEST INTERACTIONS: EFFECT ON BLOOD COAGULATION Ketoprofen decreases platelet adhesion and aggregation.

DRUG/NN /LABORATORY/NN TEST/NN INTERACTIONS/NNS :/: EFFECT/NN ON/IN BLOOD/NN COAGULATION/NN Ketoprofen/NN decreases/VBZ platelet/NN adhesion/NN and/CC aggregation/NN ./.


DrugDDI.d334
DrugDDI.d334.s0
Ketorolac is highly bound to human plasma protein (mean 99.2%).

Ketorolac/NN is/VBZ highly/RB bound/VBN to/TO human/JJ plasma/NN protein/NN (/-LRB- mean/NN 99.2/CD %)./NN


DrugDDI.d334
DrugDDI.d334.s1
Warfarin , Digoxin , Salicylate , and Heparin : The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.

Warfarin/NN ,/, Digoxin/NN ,/, Salicylate/NN ,/, and/CC Heparin/NN :/: The/DT in/FW vitro/FW binding/NN of/IN warfarin/NN to/TO plasma/NN proteins/NNS is/VBZ only/RB slightly/RB reduced/VBN by/IN ketorolac/NN tromethamine/NN (/-LRB- 99.5/CD %/NN control/NN vs/CC 99.3/CD %/NN )/-RRB- when/WRB ketorolac/NN plasma/NN concentrations/NNS reach/VBP 5/CD to10/CD m/NN g/mL/NN ./.


DrugDDI.d334
DrugDDI.d334.s2
Ketorolac does not alter digoxin protein binding.

Ketorolac/NN does/VBZ not/RB alter/VB digoxin/NN protein/NN binding/NN ./.


DrugDDI.d334
DrugDDI.d334.s3
In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.

In/FW vitro/FW studies/NNS indicate/VBP that/IN ,/, at/IN therapeutic/JJ concentrations/NNS of/IN salicylate/NN (/-LRB- 300/CD m/NN g/mL/NN )/-RRB- ,/, the/DT binding/NN of/IN ketorolac/NN was/VBD reduced/VBN from/IN approximately/RB 99.2/CD %/NN to/TO 97.5/CD %/NN ,/, representing/VBG a/DT potential/JJ twofold/JJ increase/NN in/IN unbound/JJ ketorolac/NN plasma/NN levels/NNS ./.


DrugDDI.d334
DrugDDI.d334.s4
Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.

Therapeutic/JJ concentrations/NNS of/IN digoxin/NN ,/, warfarin/NN ,/, ibuprofen/NN ,/, naproxen/NN ,/, piroxicam/NN ,/, acetaminophen/NN ,/, phenytoin/NN andtolbutamide/NN did/VBD not/RB alter/VB ketorolac/NN tromethamine/NN protein/NN binding/NN ./.


DrugDDI.d334
DrugDDI.d334.s5
In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin , causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin .

In/IN a/DT study/NN involving/VBG 12/CD adult/JJ volunteers/NNS ,/, TORADOLORAL/NN was/VBD coadministered/VBN with/IN a/DT single/JJ dose/NN of/IN 25/CD mg/NN warfarin/NN ,/, causing/VBG no/DT significant/JJ changes/NNS in/IN pharmacokinetics/NNS or/CC pharmacodynamics/NNS of/IN warfarin/NN ./.


DrugDDI.d334
DrugDDI.d334.s6
In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.

In/IN another/DT study/NN ,/, TORADOLIV/IM/NN was/VBD given/VBN with/IN two/CD doses/NNS of/IN 5000/CD U/NN of/IN heparin/NN to/TO 11/CD healthy/JJ volunteers/NNS ,/, resulting/VBG in/IN a/DT mean/NN template/NN bleeding/JJ time/NN of/IN 6.4/CD minutes/NNS (/-LRB- 3.2/CD to/TO 11.4/CD min/NN )/-RRB- compared/VBN to/TO a/DT mean/NN of/IN 6.0/CD minutes/NNS (/-LRB- 3.4/CD to/TO 7.5/CD min/NN )/-RRB- for/IN heparin/NN alone/RB and/CC 5.1/CD minutes/NNS (/-LRB- 3.5/CD to/TO 8.5/CD min/NN )/-RRB- for/IN placebo/NN ./.


DrugDDI.d334
DrugDDI.d334.s7
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.

Although/IN these/DT results/NNS do/VBP not/RB indicate/VB a/DT significant/JJ interaction/NN between/IN TORADOL/NN and/CC warfarin/NN or/CC heparin/NN ,/, the/DT administration/NN of/IN TORADOL/NN to/TO patients/NNS taking/VBG anticoagulants/NNS should/MD be/VB done/VBN extremely/RB cautiously/RB ,/, and/CC patients/NNS should/MD be/VB closely/RB monitored/VBN ./.


DrugDDI.d334
DrugDDI.d334.s8
Furosemide TORADOLIV /IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).

Furosemide/NN TORADOLIV/NN /IM/NN reduced/VBD the/DT diuretic/JJ response/NN to/TO furosemide/NN in/IN normovolemic/JJ healthy/JJ subjects/NNS by/IN approximately/RB 20/CD %/NN (/-LRB- mean/JJ sodium/NN and/CC urinary/JJ output/NN decreased/VBD 17/CD %)./NN


DrugDDI.d334
DrugDDI.d334.s9
Probenecid Concomitant administration of TORADOLORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.

Probenecid/NN Concomitant/JJ administration/NN of/IN TORADOLORAL/NN and/CC probenecid/NN resulted/VBD in/IN decreased/VBN clearance/NN of/IN ketorolac/NN and/CC significant/JJ increases/NNS in/IN ketorolac/NN plasma/NN levels/NNS (/-LRB- total/JJ AUC/NN increased/VBD approximately/RB threefold/RB from/IN 5.4/CD to/TO 17.8/CD m/NN g/h/mL/NN )/-RRB- and/CC terminal/JJ half-life/NN increased/VBD approximately/RB twofold/RB from/IN 6.6/CD to/TO 15.1/CD hours/NNS ./.


DrugDDI.d334
DrugDDI.d334.s10
Therefore, concomitant use of TORADOL and probenecid is contraindicated.

Therefore/RB ,/, concomitant/JJ use/NN of/IN TORADOL/NN and/CC probenecid/NN is/VBZ contraindicated/VBN ./.


DrugDDI.d334
DrugDDI.d334.s11
Lithium Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs .

Lithium/NN Inhibition/NN of/IN renal/JJ lithium/NN clearance/NN ,/, leading/VBG to/TO an/DT increase/NN in/IN plasma/NN lithium/NN concentration/NN ,/, has/VBZ been/VBN reported/VBN with/IN some/DT prostaglandin/NN synthesis-inhibiting/JJ drugs/NNS ./.


DrugDDI.d334
DrugDDI.d334.s12
The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.

The/DT effect/NN of/IN TORADOL/NN on/IN plasma/NN lithium/NN has/VBZ not/RB been/VBN studied/VBN ,/, but/CC cases/NNS of/IN increased/VBN lithium/NN plasma/NN levels/NNS during/IN TORADOL/NN therapy/NN have/VBP been/VBN reported/VBN ./.


DrugDDI.d334
DrugDDI.d334.s13
Methotrexate Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate , enhancing the toxicity of methotrexate .

Methotrexate/NN Concomitant/JJ administration/NN of/IN methotrexate/NN and/CC some/DT NSAIDs/NNS has/VBZ been/VBN reported/VBN to/TO reduce/VB the/DT clearance/NN of/IN methotrexate/NN ,/, enhancing/VBG the/DT toxicity/NN of/IN methotrexate/NN ./.


DrugDDI.d334
DrugDDI.d334.s14
The effect of TORADOL on methotrexate clearance has not been studied.

The/DT effect/NN of/IN TORADOL/NN on/IN methotrexate/NN clearance/NN has/VBZ not/RB been/VBN studied/VBN ./.


DrugDDI.d334
DrugDDI.d334.s15
Nondepolarizing Muscle Relaxants : In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.

Nondepolarizing/JJ Muscle/NN Relaxants/NNS :/: In/FW postmarketing/FW experience/VBP there/EX have/VBP been/VBN reports/NNS of/IN a/DT possible/JJ interaction/NN between/IN TORADOLIV/IM/NN and/CC nondepolarizing/JJ muscle/NN relaxants/NNS that/WDT resulted/VBD in/IN apnea/NN ./.


DrugDDI.d334
DrugDDI.d334.s16
The concurrent use of TORADOL with muscle relaxants has not been formally studied.

The/DT concurrent/JJ use/NN of/IN TORADOL/NN with/IN muscle/NN relaxants/NNS has/VBZ not/RB been/VBN formally/RB studied/VBN ./.


DrugDDI.d334
DrugDDI.d334.s17
ACE Inhibitors Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.

ACE/NN Inhibitors/NNS Concomitant/JJ use/NN of/IN ACE/NN inhibitors/NNS may/MD increase/VB the/DT risk/NN of/IN renal/JJ impairment/NN ,/, particularly/RB in/IN volume-depleted/JJ patients/NNS ./.


DrugDDI.d334
DrugDDI.d334.s18
Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs ( phenytoin , carbamazepine ).

Antiepileptic/JJ Drugs/NNS Sporadic/JJ cases/NNS of/IN seizures/NNS have/VBP been/VBN reported/VBN during/IN concomitant/JJ use/NN of/IN TORADOL/NN and/CC antiepileptic/JJ drugs/NNS (/-LRB- phenytoin/NN ,/, carbamazepine/NN )/-RRB- ./.


DrugDDI.d334
DrugDDI.d334.s19
Psychoactive Drugs Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs ( fluoxetine , thiothixene , alprazolam ).

Psychoactive/JJ Drugs/NNS Hallucinations/NNS have/VBP been/VBN reported/VBN when/WRB TORADOL/NN was/VBD used/VBN in/IN patients/NNS taking/VBG psychoactive/JJ drugs/NNS (/-LRB- fluoxetine/NN ,/, thiothixene/NN ,/, alprazolam/NN )/-RRB- ./.


DrugDDI.d334
DrugDDI.d334.s20
Morphine TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.

Morphine/NN TORADOLIV/IM/NN has/VBZ been/VBN administered/VBN concurrently/RB with/IN morphine/NN in/IN several/JJ clinical/JJ trials/NNS of/IN postoperative/JJ pain/NN without/IN evidence/NN of/IN adverse/JJ interactions/NNS ./.


DrugDDI.d334
DrugDDI.d334.s21
Do not mix TORADOL and morphine in the same syringe.

Do/VBP not/RB mix/NN TORADOL/NN and/CC morphine/NN in/IN the/DT same/JJ syringe/NN ./.


DrugDDI.d334
DrugDDI.d334.s22
There is no evidence in animal or human studies that TORADOL induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs .

There/EX is/VBZ no/DT evidence/NN in/IN animal/JJ or/CC human/JJ studies/NNS that/IN TORADOL/NN induces/VBZ or/CC inhibits/VBZ hepatic/JJ enzymes/NNS capable/JJ of/IN metabolizing/VBG itself/PRP or/CC other/JJ drugs/NNS ./.


DrugDDI.d415
DrugDDI.d415.s0
Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.

Medroxyprogesterone/NN Acetate/NN -/CC L-histidine/NN was/VBD observed/VBN to/TO enhance/VBP (/-LRB- in/IN tissue/NN culture/NN )/-RRB- the/DT effect/NN of/IN medroxyprogesterone/NN acetate/NN in/IN reducing/VBG the/DT number/NN of/IN human/JJ breast/NN cancer/NN cells/NNS that/WDT were/VBD in/IN the/DT S/NN phase/NN ./.


DrugDDI.d415
DrugDDI.d415.s1
H1 and H2 Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers .

H1/NN and/CC H2/NN Blockers/NNS -/: Although/IN not/RB reported/VBN ,/, L-histidine/NN ,/, via/IN its/PRP$ metabolism/NN to/TO histamine/NN ,/, might/MD decrease/VB the/DT efficacy/NN of/IN H1/NN and/CC H2/NN blockers/NN ./.


DrugDDI.d201
DrugDDI.d201.s0
Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.

Effects/NNS of/IN Lapatinib/NN on/IN Drug/NN Metabolizing/NN Enzymes/NNS and/CC Drug/NN Transport/NN Systems/NNS Lapatinib/NN inhibits/VBZ CYP3A4/NN and/CC CYP2C8/NN in/FW vitro/FW at/IN clinically/RB relevant/JJ concentrations/NNS ./.


DrugDDI.d201
DrugDDI.d201.s1
Caution should be exercised and dose reduction of the concomitant substrate drug should be considered when dosing lapatinib concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or CYP2C8 .

Caution/NN should/MD be/VB exercised/VBN and/CC dose/NN reduction/NN of/IN the/DT concomitant/JJ substrate/NN drug/NN should/MD be/VB considered/VBN when/IN dosing/NN lapatinib/NN concurrently/RB with/IN medications/NNS with/IN narrow/JJ therapeutic/JJ windows/NNS that/WDT are/VBP substrates/NNS of/IN CYP3A4/NN or/CC CYP2C8/NN ./.


DrugDDI.d201
DrugDDI.d201.s2
Lapatinib did not significantly inhibit the following enzymes in human liver microsomes: CYP1A2 , CYP2C9 , CYP2C19 , and CYP2D6 or UGT enzymes in vitro, however, the clinical significance is unknown.

Lapatinib/NN did/VBD not/RB significantly/RB inhibit/VB the/DT following/JJ enzymes/NNS in/IN human/JJ liver/NN microsomes/NNS :/: CYP1A2/NN ,/, CYP2C9/NN ,/, CYP2C19/NN ,/, and/CC CYP2D6/NN or/CC UGT/NN enzymes/NNS in/FW vitro/FW ,/, however/RB ,/, the/DT clinical/JJ significance/NN is/VBZ unknown/JJ ./.


DrugDDI.d201
DrugDDI.d201.s3
Lapatinib inhibits human P- glycoprotein .

Lapatinib/NN inhibits/VBZ human/JJ P-/NN glycoprotein/NN ./.


DrugDDI.d201
DrugDDI.d201.s4
If TYKERB is administered with drugs that are substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be exercised.

If/IN TYKERB/NN is/VBZ administered/VBN with/IN drugs/NNS that/WDT are/VBP substrates/NNS of/IN Pgp/NN ,/, increased/VBN concentrations/NNS of/IN the/DT substrate/JJ drug/NN are/VBP likely/JJ ,/, and/CC caution/NN should/MD be/VB exercised/VBN ./.


DrugDDI.d201
DrugDDI.d201.s5
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4 , and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.

Drugs/NNS that/WDT Inhibit/VBP or/CC Induce/VBP Cytochrome/NN P450/NN 3A4/NN Enzymes/NNS Lapatinib/NN undergoes/VBZ extensive/JJ metabolism/NN by/IN CYP3A4/NN ,/, and/CC concomitant/JJ administration/NN of/IN strong/JJ inhibitors/NNS or/CC inducers/NNS of/IN CYP3A4/NN alter/VB lapatinib/NN concentrations/NNS significantly/RB ./.


DrugDDI.d201
DrugDDI.d201.s6
Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.

Dose/NN adjustment/NN of/IN lapatinib/NN should/MD be/VB considered/VBN for/IN patients/NNS who/WP must/MD receive/VBP concomitant/JJ strong/JJ inhibitors/NNS or/CC concomitant/JJ strong/JJ inducers/NNS of/IN CYP3A4/JJ enzymes/NNS ./.


DrugDDI.d201
DrugDDI.d201.s7
Ketoconazole : In healthy subjects receiving ketoconazole , a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.

Ketoconazole/NN :/: In/IN healthy/JJ subjects/NNS receiving/VBG ketoconazole/NN ,/, a/DT CYP3A4/NN inhibitor/NN ,/, at/IN 200/CD mg/NN twice/RB daily/RB for/IN 7/CD days/NNS ,/, systemic/JJ exposure/NN (/-LRB- AUC/NN )/-RRB- to/TO lapatinib/NN was/VBD increased/VBN to/TO approximately/RB 3.6-fold/NN of/IN control/NN and/CC half-life/NN increased/VBD to/TO 1.7-fold/NN of/IN control/NN ./.


DrugDDI.d201
DrugDDI.d201.s8
Carbamazepine : In healthy subjects receiving the CYP3A4 inducer, carbamazepine , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.

Carbamazepine/NN :/: In/IN healthy/JJ subjects/NNS receiving/VBG the/DT CYP3A4/NN inducer/NN ,/, carbamazepine/NN ,/, at/IN 100/CD mg/NN twice/RB daily/JJ for/IN 3/CD days/NNS and/CC 200/CD mg/NN twice/RB daily/JJ for/IN 17/CD days/NNS ,/, systemic/JJ exposure/NN (/-LRB- AUC/NN )/-RRB- to/TO lapatinib/NN was/VBD decreased/VBN approximately/RB 72/CD %./NN


DrugDDI.d201
DrugDDI.d201.s9
Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1 ).

Drugs/NNS that/WDT Inhibit/VBP Drug/NN Transport/NN Systems/NNS Lapatinib/NN is/VBZ a/DT substrate/NN of/IN the/DT efflux/NN transporter/NN P-glycoprotein/NN (/-LRB- Pgp/NN ,/, ABCB1/NN )/-RRB- ./.


DrugDDI.d201
DrugDDI.d201.s10
If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.

If/IN TYKERB/NN is/VBZ administered/VBN with/IN drugs/NNS that/WDT inhibit/VBP Pgp/NN ,/, increased/VBN concentrations/NNS of/IN lapatinib/NN are/VBP likely/JJ ,/, and/CC caution/NN should/MD be/VB exercised/VBN ./.


DrugDDI.d201
DrugDDI.d201.s11
Other Chemotherapy Agents : In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine ).

Other/JJ Chemotherapy/NN Agents/NNS :/: In/IN a/DT separate/JJ study/NN ,/, concomitant/JJ administration/NN of/IN lapatinib/NN with/IN capecitabine/NN did/VBD not/RB meaningfully/RB alter/VB the/DT pharmacokinetics/NNS of/IN either/DT agent/NN (/-LRB- or/CC the/DT metabolites/NNS of/IN capecitabine/NN )/-RRB- ./.


DrugDDI.d581
DrugDDI.d581.s0
Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .

Cholestyramine/NN and/CC Charcoal/NN Administration/NN of/IN cholestyramine/NN or/CC activated/VBN charcoal/NN in/IN patients/NNS (/-LRB- n=13/NN )/-RRB- and/CC volunteers/NNS (/-LRB- n=96/CD )/-RRB- resulted/VBD in/IN a/DT rapid/JJ and/CC significant/JJ decrease/NN in/IN plasma/NN M1/NN (/-LRB- the/DT active/JJ metabolite/NN of/IN leflunomide/NN )/-RRB- concentration/NN ./.


DrugDDI.d581
DrugDDI.d581.s1
Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.

Hepatotoxic/JJ Drugs/NNS Increased/VBN side/NN effects/NNS may/MD occur/VB when/WRB leflunomide/NN is/VBZ given/VBN concomitantly/RB with/IN hepatotoxic/JJ substances/NNS ./.


DrugDDI.d581
DrugDDI.d581.s2
This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.

This/DT is/VBZ also/RB to/TO be/VB considered/VBN when/WRB leflunomide/NN treatment/NN is/VBZ followed/VBN by/IN such/JJ drugs/NNS without/IN a/DT drug/NN elimination/NN procedure/NN ./.


DrugDDI.d581
DrugDDI.d581.s3
In a small (n=30) combination study of ARAVA with methotrexate , a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.

In/IN a/DT small/JJ (/-LRB- n=30/NN )/-RRB- combination/NN study/NN of/IN ARAVA/NN with/IN methotrexate/NN ,/, a/DT 2-/CD to/TO 3-fold/JJ elevation/NN in/IN liver/NN enzymes/NNS was/VBD seen/VBN in/IN 5/CD of/IN 30/CD patients/NNS ./.


DrugDDI.d581
DrugDDI.d581.s4
All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

All/DT elevations/NNS resolved/VBN ,/, 2/CD with/IN continuation/NN of/IN both/DT drugs/NNS and/CC 3/CD after/IN discontinuation/NN of/IN leflunomide/NN ./.


DrugDDI.d581
DrugDDI.d581.s6
All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

All/DT of/IN these/DT also/RB resolved/VBN ,/, 2/CD with/IN continuation/NN of/IN both/DT drugs/NNS and/CC 3/CD after/IN discontinuation/NN of/IN leflunomide/NN ./.


DrugDDI.d581
DrugDDI.d581.s7
Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa).

Three/CD patients/NNS met/NN ACR/NN criteria/NNS for/IN liver/NN biopsy/NN (/-LRB- 1/CD :/: Roegnik/NNP Grade/NN I/CD ,/, 2/CD :/: Roegnik/NNP Grade/NN IIIa/NN )./NN


DrugDDI.d581
DrugDDI.d581.s9
NSAIDs : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.

NSAIDs/NNS :/: In/IN in/FW vitro/FW studies/NNS ,/, M1/NN was/VBD shown/VBN to/TO cause/VB increases/NNS ranging/VBG from/IN 13/CD -/CC 50/CD %/NN in/IN the/DT free/JJ fraction/NN of/IN diclofenac/NN and/CC ibuprofen/NN at/IN concentrations/NNS in/IN the/DT clinical/JJ range/NN ./.


DrugDDI.d581
DrugDDI.d581.s11
however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.

however/RB ,/, there/EX was/VBD extensive/JJ concomitant/JJ use/NN of/IN NSAIDs/NN in/IN clinical/JJ studies/NNS and/CC no/DT differential/JJ effect/NN was/VBD observed/VBN ./.


DrugDDI.d581
DrugDDI.d581.s12
Tolbutamide : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.

Tolbutamide/NN :/: In/IN in/FW vitro/FW studies/NNS ,/, M1/NN was/VBD shown/VBN to/TO cause/VB increases/NNS ranging/VBG from/IN 13/CD -/CC 50/CD %/NN in/IN the/DT free/JJ fraction/NN of/IN tolbutamide/NN at/IN concentrations/NNS in/IN the/DT clinical/JJ range/NN ./.


DrugDDI.d581
DrugDDI.d581.s14
Rifampin Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin , M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.

Rifampin/NN Following/VBG concomitant/JJ administration/NN of/IN a/DT single/JJ dose/NN of/IN ARAVA/NN to/TO subjects/NNS receiving/VBG multiple/JJ doses/NNS of/IN rifampin/NN ,/, M1/NN peak/NN levels/NNS were/VBD increased/VBN (/-LRB- ~40/CD %/NN )/-RRB- over/IN those/DT seen/VBN when/WRB ARAVA/NN was/VBD given/VBN alone/RB ./.


DrugDDI.d581
DrugDDI.d581.s15
Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin .

Because/IN of/IN the/DT potential/NN for/IN ARAVA/NN levels/NNS to/TO continue/VBP to/TO increase/VB with/IN multiple/JJ dosing/NN ,/, caution/NN should/MD be/VB used/VBN if/IN patients/NNS are/VBP to/TO be/VB receiving/VBG both/CC ARAVA/NN and/CC rifampin/NN ./.


DrugDDI.d581
DrugDDI.d581.s16
Warfarin Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.

Warfarin/JJ Increased/VBN INR/NN (/-LRB- International/NNP Normalized/VBN Ratio/NN )/-RRB- when/WRB ARAVA/NN and/CC warfarin/NN were/VBD co-administered/VBN has/VBZ been/VBN rarely/RB reported/VBN ./.


DrugDDI.d379
DrugDDI.d379.s0
Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.

Clinical/JJ interaction/NN studies/NNS with/IN cimetidine/NN and/CC warfarin/NN indicated/VBD that/IN the/DT coadministration/NN of/IN Femara/NN with/IN these/DT drugs/NNS does/VBZ not/RB result/VB in/IN clinically-/JJ significant/JJ drug/NN interactions/NNS ./.


DrugDDI.d379
DrugDDI.d379.s1
(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.

(/-LRB- See/VB CLINICAL/JJ PHARMACOLOGY/NN )/-RRB- Coadministration/NN of/IN Femara/NN and/CC tamoxifen/NN 20/CD mg/NN daily/RB resulted/VBD in/IN a/DT reduction/NN of/IN letrozole/NN plasma/NN levels/NNS by/IN 38/CD %/NN on/IN average/NN ./.


DrugDDI.d379
DrugDDI.d379.s2
There is no clinical experience to date on the use of Femara in combination with other anticancer agents.

There/EX is/VBZ no/DT clinical/JJ experience/VBP to/TO date/VB on/IN the/DT use/NN of/IN Femara/NN in/IN combination/NN with/IN other/JJ anticancer/JJ agents/NNS ./.


DrugDDI.d379
DrugDDI.d379.s3
Drug /Laboratory Test-Interactions None observed.

Drug/NN /Laboratory/NN Test-Interactions/NN None/NN observed/VBN ./.


DrugDDI.d341
DrugDDI.d341.s0
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients.

Folic/JJ acid/NN in/IN large/JJ amounts/NNS may/MD counteract/VB the/DT antiepileptic/JJ effect/NN of/IN phenobarbital/NN ,/, phenytoin/NN and/CC primidone/NN ,/, and/CC increase/VB the/DT frequency/NN of/IN seizures/NNS in/IN susceptible/JJ pediatric/JJ patients/NNS ./.


DrugDDI.d341
DrugDDI.d341.s1
Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.

Preliminary/JJ animal/JJ and/CC human/JJ studies/NNS have/VBP shown/VBN that/IN small/JJ quantities/NNS of/IN systemically/RB administered/VBN leucovorin/NN enter/VBP the/DT CSF/NN primarily/RB as/IN 5-methyltetrahydro-folate/NN and/CC ,/, in/IN humans/NNS ,/, remain/VBP 1/CD to/TO 3/CD orders/NNS of/IN magnitude/NN lower/JJR than/IN the/DT usual/JJ methotrexate/NN concentrations/NNS following/VBG intrathecal/JJ administration/NN ./.


DrugDDI.d341
DrugDDI.d341.s2
However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate .

However/RB ,/, high/JJ doses/NNS of/IN leucovorin/NN may/MD reduce/VB the/DT efficacy/NN of/IN intrathecally/RB administered/VBN methotrexate/NN ./.


DrugDDI.d341
DrugDDI.d341.s3
Leucovorin may enhance the toxicity of 5- fluorouracil .

Leucovorin/NN may/MD enhance/VB the/DT toxicity/NN of/IN 5-/CD fluorouracil/NN ./.


DrugDDI.d484
DrugDDI.d484.s0
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.

Although/IN BETAGAN/NN used/VBN alone/RB has/VBZ little/JJ or/CC no/DT effect/NN on/IN pupil/NN size/NN ,/, mydriasis/NNS resulting/VBG from/IN concomitant/JJ therapy/NN with/IN BETAGAN/NN and/CC epinephrine/NN may/MD occur/VB ./.


DrugDDI.d484
DrugDDI.d484.s1
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.

Close/JJ observation/NN of/IN the/DT patient/NN is/VBZ recommended/VBN when/WRB a/DT beta-blocker/NN is/VBZ administered/VBN to/TO patients/NNS receiving/VBG catecholamine-depleting/JJ drugs/NNS such/JJ as/IN reserpine/NN ,/, because/IN of/IN possible/JJ additive/JJ effects/NNS and/CC the/DT production/NN of/IN hypotension/NN and/or/CC marked/JJ bradycardia/NN ,/, which/WDT may/MD produce/VB vertigo/NN ,/, syncope/NN or/CC postural/JJ hypotension/NN ./.


DrugDDI.d484
DrugDDI.d484.s2
Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonist s should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.

Patients/NNS receiving/VBG beta-adrenergic/JJ blocking/NN agents/NNS along/IN with/IN either/CC oral/JJ or/CC intravenous/JJ calcium/NN antagonist/NN s/NN should/MD be/VB monitored/VBN for/IN possible/JJ atrioventricular/JJ conduction/NN disturbances/NNS ,/, left/JJ ventricular/NN failure/NN and/CC hypotension/NN ./.


DrugDDI.d484
DrugDDI.d484.s4
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonist s may have additive effects on prolonging atrioventricular conduction time.

The/DT concomitant/JJ use/NN of/IN beta-adrenergic/JJ blocking/NN agents/NNS with/IN digitalis/NN and/CC calcium/NN antagonist/NN s/NN may/MD have/VB additive/JJ effects/NNS on/IN prolonging/VBG atrioventricular/JJ conduction/NN time/NN ./.


DrugDDI.d484
DrugDDI.d484.s5
Phenothiazine -related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other@s metabolism.

Phenothiazine/JJ -related/JJ compounds/NNS and/CC beta-adrenergic/JJ blocking/NN agents/NNS may/MD have/VB additive/JJ hypotensite/JJ effects/NNS due/JJ to/TO the/DT inhibition/NN of/IN each/DT other/JJ @/NN s/NN metabolism/NN ./.


DrugDDI.d112
DrugDDI.d112.s0
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , digoxin , warfarin , cimetidine and phenobarbital .

No/DT significant/JJ drug-drug/JJ pharmacokinetic/JJ interactions/NNS have/VBP been/VBN found/VBN in/IN interaction/NN studies/NNS with/IN hydrochlorothiazide/NN ,/, digoxin/NN ,/, warfarin/NN ,/, cimetidine/NN and/CC phenobarbital/NN ./.


DrugDDI.d112
DrugDDI.d112.s1
Rifampin , an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite .

Rifampin/NN ,/, an/DT inducer/NN of/IN drug/NN metabolism/NN ,/, decreased/VBD the/DT concentrations/NNS of/IN losartan/NN and/CC its/PRP$ active/JJ metabolite/NN ./.


DrugDDI.d112
DrugDDI.d112.s2
In humans, two inhibitors of P450 3A4 have been studied.

In/IN humans/NNS ,/, two/CD inhibitors/NNS of/IN P450/NN 3A4/NN have/VBP been/VBN studied/VBN ./.


DrugDDI.d112
DrugDDI.d112.s3
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration.

Ketoconazole/NN did/VBD not/RB affect/VB the/DT conversion/NN of/IN losartan/NN to/TO the/DT active/JJ metabolite/NN after/IN intravenous/JJ administration/NN of/IN losartan/NN ,/, and/CC erythromycin/NN had/VBD no/DT clinically/RB significant/JJ effect/NN after/IN oral/JJ administration/NN ./.


DrugDDI.d112
DrugDDI.d112.s4
Fluconazole , an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.

Fluconazole/NN ,/, an/DT inhibitor/NN of/IN P450/NN 2C9/NNS ,/, decreased/VBD active/JJ metabolite/NN concentration/NN and/CC increased/VBD losartan/NN concentration/NN ./.


DrugDDI.d112
DrugDDI.d112.s5
The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.

The/DT pharmacodynamic/JJ consequences/NNS of/IN concomitant/JJ use/NN of/IN losartan/NN and/CC inhibitors/NNS of/IN P450/NN 2C9/NNS have/VBP not/RB been/VBN examined/VBN ./.


DrugDDI.d112
DrugDDI.d112.s6
Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9 .

Subjects/NNS who/WP do/VBP not/RB metabolize/VB losartan/NN to/TO active/JJ metabolite/NN have/VBP been/VBN shown/VBN to/TO have/VB a/DT specific/JJ ,/, rare/JJ defect/NN in/IN cytochrome/NN P450/NN 2C9/NN ./.


DrugDDI.d112
DrugDDI.d112.s7
These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4 .

These/DT data/NNS suggest/VBP that/IN the/DT conversion/NN of/IN losartan/NN to/TO its/PRP$ active/JJ metabolite/NN is/VBZ mediated/VBN primarily/RB by/IN P450/NN 2C9/NN and/CC not/RB P450/NN 3A4/NN ./.


DrugDDI.d112
DrugDDI.d112.s8
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone , triamterene , amiloride ), potassium supplement s, or salt substitutes containing potassium may lead to increases in serum potassium.

As/IN with/IN other/JJ drugs/NNS that/WDT block/VBP angiotensin/NN II/CD or/CC its/PRP$ effects/NNS ,/, concomitant/JJ use/NN of/IN potassium-sparing/JJ diuretics/NNS (/-LRB- e.g./FW ,/, spironolactone/NN ,/, triamterene/NN ,/, amiloride/NN )/-RRB- ,/, potassium/NN supplement/NN s/NNS ,/, or/CC salt/NN substitutes/VBZ containing/VBG potassium/NN may/MD lead/VB to/TO increases/NNS in/IN serum/NN potassium/NN ./.


DrugDDI.d112
DrugDDI.d112.s9
As with other antihypertensive agents , the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin .

As/IN with/IN other/JJ antihypertensive/JJ agents/NNS ,/, the/DT antihypertensive/JJ effect/NN of/IN losartan/NN may/MD be/VB blunted/VBN by/IN the/DT non-steroidal/JJ anti-inflammatory/JJ drug/NN indomethacin/NN ./.


DrugDDI.d464
DrugDDI.d464.s0
When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents : Anesthetics , general: exaggeration of the hypotension induced by general anesthetics .

When/WRB administered/VBN concurrently/RB ,/, the/DT following/VBG drugs/NNS may/MD interact/VB with/IN beta-adrenergic/JJ receptor/NN blocking/NN agents/NNS :/: Anesthetics/NN ,/, general/JJ :/: exaggeration/NN of/IN the/DT hypotension/NN induced/VBN by/IN general/JJ anesthetics/NNS ./.


DrugDDI.d464
DrugDDI.d464.s1
Antidiabetic drugs (oral agents and insulin ): hypoglycemia or hyperglycemia; .

Antidiabetic/JJ drugs/NNS (/-LRB- oral/JJ agents/NNS and/CC insulin/NN )/-RRB- :/: hypoglycemia/NN or/CC hyperglycemia/NN ;/: ./.


DrugDDI.d464
DrugDDI.d464.s2
adjust dosage of antidiabetic drug accordingly.

adjust/VB dosage/NN of/IN antidiabetic/JJ drug/NN accordingly/RB ./.


DrugDDI.d464
DrugDDI.d464.s3
Catecholamine-depleting drugs (e.g., reserpine ): additive effect; .

Catecholamine-depleting/JJ drugs/NNS (/-LRB- e.g./FW ,/, reserpine/NN )/-RRB- :/: additive/JJ effect/NN ;/: ./.


DrugDDI.d464
DrugDDI.d464.s5
Response to Treatment for Anaphylactic Reaction: While taking beta-blockers , patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.

Response/NN to/TO Treatment/NN for/IN Anaphylactic/JJ Reaction/NN :/: While/IN taking/VBG beta-blockers/NN ,/, patients/NNS with/IN a/DT history/NN of/IN severe/JJ anaphylactic/JJ reaction/NN to/TO a/DT variety/NN of/IN allergens/NNS may/MD be/VB more/RBR reactive/JJ to/TO repeated/JJ challenge/NN ,/, either/CC accidental/JJ ,/, diagnostic/JJ ,/, or/CC therapeutic/JJ ./.


DrugDDI.d464
DrugDDI.d464.s6
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

Such/JJ patients/NNS may/MD be/VB unresponsive/JJ to/TO the/DT usual/JJ doses/NNS of/IN epinephrine/NN used/VBN to/TO treat/VB allergic/JJ reaction/NN ./.


DrugDDI.d485
DrugDDI.d485.s0
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.

Elevated/JJ plasma/NN levels/NNS of/IN theophylline/NN have/VBP been/VBN reported/VBN with/IN concomitant/JJ quinolone/NN use/NN ./.


DrugDDI.d485
DrugDDI.d485.s1
There have been reports of theophylline -related side effects in patients on concomitant therapy with quinolones and theophylline .

There/EX have/VBP been/VBN reports/NNS of/IN theophylline/NN -related/JJ side/JJ effects/NNS in/IN patients/NNS on/IN concomitant/JJ therapy/NN with/IN quinolones/NNS and/CC theophylline/NN ./.


DrugDDI.d485
DrugDDI.d485.s2
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.

Therefore/RB ,/, monitoring/NN of/IN theophylline/NN plasma/NN levels/NNS should/MD be/VB considered/VBN and/CC dosage/NN of/IN theophylline/NN adjusted/VBN ,/, as/IN required/VBN ./.


DrugDDI.d485
DrugDDI.d485.s3
Quinolones have been shown to interfere with the metabolism of caffeine .

Quinolones/NNS have/VBP been/VBN shown/VBN to/TO interfere/VB with/IN the/DT metabolism/NN of/IN caffeine/NN ./.


DrugDDI.d485
DrugDDI.d485.s4
This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.

This/DT may/MD lead/VB to/TO reduced/VBN clearance/NN of/IN caffeine/NN and/CC the/DT prolongation/NN of/IN its/PRP$ plasma/NN half-life/NN ./.


DrugDDI.d485
DrugDDI.d485.s5
Quinolones , including nalidixic acid , may enhance the effects of the oral anticoagulant warfarin or its derivatives .

Quinolones/NNS ,/, including/VBG nalidixic/JJ acid/NN ,/, may/MD enhance/VB the/DT effects/NNS of/IN the/DT oral/JJ anticoagulant/NN warfarin/NN or/CC its/PRP$ derivatives/NNS ./.


DrugDDI.d485
DrugDDI.d485.s7
Nitrofurantoin interferes with the therapeutic action of nalidixic acid .

Nitrofurantoin/NN interferes/VBZ with/IN the/DT therapeutic/JJ action/NN of/IN nalidixic/JJ acid/NN ./.


DrugDDI.d485
DrugDDI.d485.s8
Antacids containing magnesium , aluminum, or calcium ; .

Antacids/NNS containing/VBG magnesium/NN ,/, aluminum/NN ,/, or/CC calcium/NN ;/: ./.


DrugDDI.d485
DrugDDI.d485.s9
sucralfate or divalent or trivalent cations such as iron ; .

sucralfate/VBP or/CC divalent/JJ or/CC trivalent/JJ cations/NNS such/JJ as/IN iron/NN ;/: ./.


DrugDDI.d485
DrugDDI.d485.s10
multivitamins containing zinc ; .

multivitamins/NNS containing/VBG zinc/NN ;/: ./.


DrugDDI.d485
DrugDDI.d485.s11
and Videx@, ( Didanosine ), chewable/ buffer ed tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones , resulting in systemic levels considerably lower than desired.

and/CC Videx/NN @/NN ,/, (/-LRB- Didanosine/NN )/-RRB- ,/, chewable//NN buffer/NN ed/NN tablets/NNS or/CC the/DT pediatric/JJ powder/NN for/IN oral/JJ solution/NN may/MD substantially/RB interfere/VB with/IN the/DT absorption/NN of/IN quinolones/NNS ,/, resulting/VBG in/IN systemic/JJ levels/NNS considerably/RB lower/JJR than/IN desired/VBN ./.


DrugDDI.d485
DrugDDI.d485.s12
These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.

These/DT agents/NNS should/MD not/RB be/VB taken/VBN within/IN the/DT two/CD hour/NN period/NN before/IN or/CC within/IN the/DT two-hour/JJ period/NN after/IN nalidixic/JJ acid/NN administration/NN ./.


DrugDDI.d485
DrugDDI.d485.s13
Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine .

Elevated/JJ serum/NN levels/NNS of/IN cyclosporine/NN have/VBP been/VBN reported/VBN with/IN the/DT concomitant/JJ use/NN of/IN some/DT quinolones/NN and/CC cyclosporine/NN ./.


DrugDDI.d485
DrugDDI.d485.s14
Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.

Therefore/RB ,/, cyclosporine/NN serum/NN levels/NNS should/MD be/VB monitored/VBN and/CC appropriate/JJ cyclosporine/NN dosage/NN adjustments/NNS made/VBD when/WRB these/DT drugs/NNS are/VBP used/VBN concomitantly/RB ./.


DrugDDI.d249
DrugDDI.d249.s0
In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).

In/FW vitro/FW drug/NN metabolism/NN studies/NNS indicate/VBP that/IN Starlix/NN is/VBZ predominantly/RB metabolized/VBN by/IN the/DT cytochrome/NN P450/NN isozyme/NN CYP2C9/NN (/-LRB- 70/CD %/NN )/-RRB- and/CC to/TO a/DT lesser/JJR extent/NN CYP3A4/NN (/-LRB- 30%)./NN


DrugDDI.d249
DrugDDI.d249.s1
Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide .

Starlix/NN is/VBZ a/DT potential/JJ inhibitor/NN of/IN the/DT CYP2C9/NN isoenzyme/NN in/FW vivo/FW as/IN indicated/VBN by/IN its/PRP$ ability/NN to/TO inhibit/VB the/DT in/FW vitro/FW metabolism/NN of/IN tolbutamide/NN ./.


DrugDDI.d249
DrugDDI.d249.s2
Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.

Inhibition/NN of/IN CYP3A4/JJ metabolic/JJ reactions/NNS was/VBD not/RB detected/VBN in/IN in/FW vitro/FW experiments/NNS ./.


DrugDDI.d249
DrugDDI.d249.s3
Glyburide : In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.

Glyburide/NN :/: In/IN a/DT randomized/JJ ,/, multiple-dose/JJ crossover/NN study/NN ,/, patients/NNS with/IN Type/NN 2/CD diabetes/NNS were/VBD administered/VBN 120/CD mg/NN Starlix/NN three/CD times/NNS a/DT day/NN before/IN meals/NN for/IN 1/CD day/NN in/IN combination/NN with/IN glyburide/NN 10/CD mg/NN daily/RB ./.


DrugDDI.d249
DrugDDI.d249.s5
Metformin : When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.

Metformin/NN :/: When/WRB Starlix/NN 120/CD mg/NN three/CD times/NNS daily/RB before/IN meals/NN was/VBD administered/VBN in/IN combination/NN with/IN metformin/NN 500/CD mg/NN three/CD times/NNS daily/JJ to/TO patients/NNS with/IN Type/NN 2/CD diabetes/NNS ,/, there/EX were/VBD no/DT clinically/RB relevant/JJ changes/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s6
Digoxin : When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.

Digoxin/NN :/: When/WRB Starlix/NN 120/CD mg/NN before/IN meals/NN was/VBD administered/VBN in/IN combination/NN with/IN a/DT single/JJ 1-mg/JJ dose/NN of/IN digoxin/NN to/TO healthy/JJ volunteers/NNS ,/, there/EX were/VBD no/DT clinically/RB relevant/JJ changes/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s7
Warfarin : When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.

Warfarin/NN :/: When/WRB healthy/JJ subjects/NNS were/VBD administered/VBN Starlix/NN 120/CD mg/NN three/CD times/NNS daily/RB before/IN meals/NN for/IN four/CD days/NNS in/IN combination/NN with/IN a/DT single/JJ dose/NN of/IN warfarin/NN 30/CD mg/NN on/IN day/NN 2/CD ,/, there/EX were/VBD no/DT alterations/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s9
Diclofenac : Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.

Diclofenac/NN :/: Administration/NN of/IN morning/NN and/CC lunch/NN doses/NNS of/IN Starlix/NN 120/CD mg/NN in/IN combination/NN with/IN a/DT single/JJ 75-mg/NN dose/NN of/IN diclofenac/NN in/IN healthy/JJ volunteers/NNS resulted/VBD in/IN no/DT significant/JJ changes/NNS to/TO the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s10
Nateglinide is highly bound to plasma proteins (98%), mainly albumin .

Nateglinide/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN proteins/NNS (/-LRB- 98/CD %/NN )/-RRB- ,/, mainly/RB albumin/NN ./.


DrugDDI.d249
DrugDDI.d249.s11
In vitro displacement studies with highly protein -bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding.

In/FW vitro/FW displacement/NN studies/NNS with/IN highly/RB protein/NN -bound/JJ drugs/NNS such/JJ as/IN furosemide/NN ,/, propranolol/NN ,/, captopril/NN ,/, nicardipine/NN ,/, pravastatin/NN ,/, glyburide/NN ,/, warfarin/NN ,/, phenytoin/NN ,/, acetylsalicylic/JJ acid/NN ,/, tolbutamide/NN ,/, and/CC metformin/NN showed/VBD no/DT influence/NN on/IN the/DT extent/NN of/IN nateglinide/JJ protein/NN binding/NN ./.


DrugDDI.d249
DrugDDI.d249.s12
Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic acid , and tolbutamide in vitro .

Similarly/RB ,/, nateglinide/NN had/VBD no/DT influence/NN on/IN the/DT serum/NN protein/NN binding/NN of/IN propranolol/NN ,/, glyburide/NN ,/, nicardipine/NN ,/, warfarin/NN ,/, phenytoin/NN ,/, acetylsalicylic/JJ acid/NN ,/, and/CC tolbutamide/NN in/FW vitro/FW ./.


DrugDDI.d249
DrugDDI.d249.s14
Certain drugs , including nonsteroidal anti-inflammatory agents ( NSAIDs ), salicylates , monoamine oxidase inhibitors , and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs .

Certain/JJ drugs/NNS ,/, including/VBG nonsteroidal/JJ anti-inflammatory/JJ agents/NNS (/-LRB- NSAIDs/NNS )/-RRB- ,/, salicylates/NNS ,/, monoamine/NN oxidase/NN inhibitors/NNS ,/, and/CC non-selective/JJ beta-adrenergic-blocking/JJ agents/NNS may/MD potentiate/VB the/DT hypoglycemic/JJ action/NN of/IN Starlix/NN and/CC other/JJ oral/JJ antidiabetic/JJ drugs/NNS ./.


DrugDDI.d249
DrugDDI.d249.s15
Certain drugs including thiazides , corticosteroids , thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs .

Certain/JJ drugs/NNS including/VBG thiazides/NNS ,/, corticosteroids/NNS ,/, thyroid/NN products/NNS ,/, and/CC sympathomimetics/NNS may/MD reduce/VB the/DT hypoglycemic/JJ action/NN of/IN Starlix/NN and/CC other/JJ oral/JJ antidiabetic/JJ drugs/NNS ./.


DrugDDI.d249
DrugDDI.d249.s16
When these drugs are administered to or withdrawn from patients receiving Starlix , the patient should be observed closely for changes in glycemic control.

When/WRB these/DT drugs/NNS are/VBP administered/VBN to/TO or/CC withdrawn/VBN from/IN patients/NNS receiving/VBG Starlix/NN ,/, the/DT patient/NN should/MD be/VB observed/VBN closely/RB for/IN changes/NNS in/IN glycemic/JJ control/NN ./.


DrugDDI.d312
DrugDDI.d312.s0
In clinical studies, Tilade has been co-administered with other anti-asthma medications , including inhaled and oral bronchodilators , and inhaled corticosteroids , with no evidence of increased frequency of adverse events or laboratory abnormalities.

In/IN clinical/JJ studies/NNS ,/, Tilade/NN has/VBZ been/VBN co-administered/VBN with/IN other/JJ anti-asthma/NN medications/NNS ,/, including/VBG inhaled/JJ and/CC oral/JJ bronchodilators/NNS ,/, and/CC inhaled/JJ corticosteroids/NNS ,/, with/IN no/DT evidence/NN of/IN increased/VBN frequency/NN of/IN adverse/JJ events/NNS or/CC laboratory/NN abnormalities/NNS ./.


DrugDDI.d336
DrugDDI.d336.s0
Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin .

Caution/NN should/MD be/VB taken/VBN in/IN concurrent/JJ or/CC serial/JJ use/NN of/IN other/JJ neurotoxic/JJ and//NN or/CC nephrotoxic/JJ drugs/NNS because/IN of/IN possible/JJ enhancement/NN of/IN the/DT nephrotoxicity/NN and/or/CC ototoxicity/NN of/IN neomycin/NN ./.


DrugDDI.d336
DrugDDI.d336.s1
Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin@s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate@s neuromuscular blocking effects.

Caution/NN should/MD also/RB be/VB taken/VBN in/IN concurrent/JJ or/CC serial/JJ use/NN of/IN other/JJ aminoglycosides/NNS and/CC polymyxins/NNS because/IN they/PRP may/MD enhance/VB neomycin/NN @/NN s/NN nephrotoxicity/NN and/or/CC ototoxicity/NN and/CC potentiate/VB neomycin/NN sulfate/NN @/NN s/NN neuromuscular/JJ blocking/VBG effects/NNS ./.


DrugDDI.d336
DrugDDI.d336.s2
Oral neomycin inhibits the gastrointestinal absorption of penicillin V , oral vitamin B-12 , methotrexate and 5-fluorouracil .

Oral/JJ neomycin/NN inhibits/VBZ the/DT gastrointestinal/JJ absorption/NN of/IN penicillin/NN V/NN ,/, oral/JJ vitamin/NN B-12/NN ,/, methotrexate/NN and/CC 5-fluorouracil/NN ./.


DrugDDI.d336
DrugDDI.d336.s3
The gastrointestinal absorption of digoxin also appears to be inhibited.

The/DT gastrointestinal/JJ absorption/NN of/IN digoxin/NN also/RB appears/VBZ to/TO be/VB inhibited/VBN ./.


DrugDDI.d336
DrugDDI.d336.s5
Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.

Oral/JJ neomycin/NN sulfate/NN may/MD enhance/VB the/DT effect/NN of/IN coumarin/NN in/IN anticoagulants/NNS by/IN decreasing/VBG vitamin/NN K/NN availability/NN ./.


DrugDDI.d266
DrugDDI.d266.s0
Beta-adrenergic Blocking Agents : Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agent s is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.

Beta-adrenergic/JJ Blocking/NN Agents/NNS :/: Experience/VBP in/IN over/IN 1400/CD patients/NNS in/IN a/DT non-comparative/JJ clinical/JJ trial/NN has/VBZ shown/VBN that/IN concomitant/JJ administration/NN of/IN nifedipine/NN and/CC beta-blocking/JJ agent/NN s/NNS is/VBZ usually/RB well/RB tolerated/VBN ,/, but/CC there/EX have/VBP been/VBN occasional/JJ literature/NN reports/NNS suggesting/VBG that/IN the/DT combination/NN may/MD increase/VBP the/DT likelihood/NN of/IN congestive/JJ heart/NN failure/NN ,/, severe/JJ hypotension/NN or/CC exacerbation/NN of/IN angina/NN ./.


DrugDDI.d266
DrugDDI.d266.s1
Long Acting Nitrates : Nifedipine may be safely co-administered with nitrates , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.

Long/JJ Acting/NN Nitrates/NNS :/: Nifedipine/NN may/MD be/VB safely/RB co-administered/VBN with/IN nitrates/NNS ,/, but/CC there/EX have/VBP been/VBN no/DT controlled/JJ studies/NNS to/TO evaluate/VB the/DT antianginal/JJ effectiveness/NN of/IN this/DT combination/NN ./.


DrugDDI.d266
DrugDDI.d266.s2
Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

Digitalis/NN :/: Immediate/JJ Release/NN Capsules/NNS :/: Since/IN there/EX have/VBP been/VBN isolated/VBN reports/NNS of/IN patients/NNS with/IN elevated/JJ digoxin/NN levels/NNS ,/, and/CC there/EX is/VBZ a/DT possible/JJ interaction/NN between/IN digoxin/NN and/CC nifedipine/NN ,/, it/PRP is/VBZ recommended/VBN that/IN digoxin/NN levels/NNS be/VB monitored/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, and/CC discontinuing/VBG nifedipine/NN to/TO avoid/VB possible/JJ over-/NN or/CC under-digitalization/NN ./.


DrugDDI.d266
DrugDDI.d266.s3
Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.

Extended/JJ Release/NN Tablets/NNS :/: Administration/NN of/IN nifedipine/NN with/IN digoxin/NN increased/VBD digoxin/NN levels/NNS in/IN 9/CD of/IN 12/CD normal/JJ volunteers/NNS ./.


DrugDDI.d266
DrugDDI.d266.s7
Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

Since/IN there/EX have/VBP been/VBN isolated/VBN reports/NNS of/IN patients/NNS with/IN elevated/JJ digoxin/NN levels/NNS ,/, it/PRP is/VBZ recommended/VBN that/IN digoxin/NN levels/NNS be/VB monitored/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, and/CC discontinuing/VBG nifedipine/NN to/TO avoid/VB possible/JJ over-/NN or/CC under-digitalization/NN ./.


DrugDDI.d266
DrugDDI.d266.s8
Quinidine : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine ).

Quinidine/NN :/: Immediate/JJ Release/NN Capsules/NNS :/: There/EX have/VBP been/VBN rare/JJ reports/NNS of/IN an/DT interaction/NN between/IN quinidine/NN and/CC nifedipine/NN (/-LRB- with/IN a/DT decreased/VBN plasma/NN level/NN of/IN quinidine/NN )/-RRB- ./.


DrugDDI.d266
DrugDDI.d266.s9
Coumarin Anticoagulant s: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulant s to whom nifedipine was administered.

Coumarin/NN Anticoagulant/NN s/NNS :/: There/EX have/VBP been/VBN rare/JJ reports/NNS of/IN increased/VBN prothrombin/NN time/NN in/IN patients/NNS taking/VBG coumarin/NN anticoagulant/NN s/NNS to/TO whom/WP nifedipine/NN was/VBD administered/VBN ./.


DrugDDI.d266
DrugDDI.d266.s10
However, the relationship to nifedipine therapy is uncertain.

However/RB ,/, the/DT relationship/NN to/TO nifedipine/NN therapy/NN is/VBZ uncertain/JJ ./.


DrugDDI.d266
DrugDDI.d266.s11
Cimetidine : A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.

Cimetidine/NN :/: A/DT study/NN in/IN 6/CD healthy/JJ volunteers/NNS has/VBZ shown/VBN a/DT significant/JJ increase/NN in/IN peak/NN nifedipine/NN plasma/NN levels/NNS (/-LRB- 80/CD %/NN )/-RRB- and/CC area-under-the-curve/JJ (/-LRB- 74/CD %/NN )/-RRB- after/IN a/DT 1/CD week/NN course/NN of/IN cimetidine/NN at/IN 1000/CD mg/NN per/IN day/NN and/CC nifedipine/NN at/IN 40/CD mg/NN per/IN day/NN ./.


DrugDDI.d266
DrugDDI.d266.s12
Ranitidine produced smaller, non-significant increases.

Ranitidine/NN produced/VBD smaller/JJR ,/, non-significant/JJ increases/NNS ./.


DrugDDI.d266
DrugDDI.d266.s13
The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450 , the enzyme system probably responsible for the first-pass metabolism of nifedipine .

The/DT effect/NN may/MD be/VB mediated/VBN by/IN the/DT known/JJ inhibition/NN of/IN cimetidine/NN on/IN hepatic/JJ cytochrome/NN P-450/NN ,/, the/DT enzyme/NN system/NN probably/RB responsible/JJ for/IN the/DT first-pass/NN metabolism/NN of/IN nifedipine/NN ./.


DrugDDI.d266
DrugDDI.d266.s14
If nifedipine therapy is initiated in a patient currently receiving cimetidine , cautious titration is advised.

If/IN nifedipine/NN therapy/NN is/VBZ initiated/VBN in/IN a/DT patient/NN currently/RB receiving/VBG cimetidine/NN ,/, cautious/JJ titration/NN is/VBZ advised/VBN ./.


DrugDDI.d234
DrugDDI.d234.s0
A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.

A/DT 30/CD to/TO 45/CD %/NN increase/NN in/IN AUC/NN and/CC Cmax/NN of/IN nisoldipine/NN was/VBD observed/VBN with/IN concomitant/JJ administration/NN of/IN cimetidine/NN 400/CD mg/NN twice/RB daily/RB ./.


DrugDDI.d234
DrugDDI.d234.s1
Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).

Ranitidine/NN 150/CD mg/NN twice/RB daily/RB did/VBD not/RB interact/VB significantly/RB with/IN nisoldipine/NN (/-LRB- AUC/NN was/VBD decreased/VBN by/IN 15-20/CD %/NN )./CD


DrugDDI.d234
DrugDDI.d234.s2
No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.

No/DT pharmacodynamic/JJ effects/NNS of/IN either/DT histamine/NN H2/NN receptor/NN antagonist/NN were/VBD observed/VBN ./.


DrugDDI.d234
DrugDDI.d234.s3
Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.

Coadministration/NN of/IN phenytoin/NN with/IN 40/CD mg/NN SULAR/NN tablets/NNS in/IN epileptic/JJ patients/NNS lowered/VBD the/DT nisoldipine/NN plasma/NN concentrations/NNS to/TO undetectable/JJ levels/NNS ./.


DrugDDI.d234
DrugDDI.d234.s4
Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.

Coadministration/NN of/IN SULAR/NN with/IN phenytoin/NN or/CC any/DT known/JJ CYP3A4/NN inducer/NN should/MD be/VB avoided/VBN and/CC alternative/JJ antihypertensive/JJ therapy/NN should/MD be/VB considered/VBN ./.


DrugDDI.d234
DrugDDI.d234.s5
Pharmacokinetic interactions between nisoldipine and beta-blockers ( atenolol , propranolol ) were variable and not significant.

Pharmacokinetic/JJ interactions/NNS between/IN nisoldipine/NN and/CC beta-blockers/NNS (/-LRB- atenolol/NN ,/, propranolol/NN )/-RRB- were/VBD variable/JJ and/CC not/RB significant/JJ ./.


DrugDDI.d234
DrugDDI.d234.s6
Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine .

Propranolol/NN attenuated/VBD the/DT heart/NN rate/NN increase/NN following/VBG administration/NN of/IN immediate/JJ release/NN nisoldipine/NN ./.


DrugDDI.d234
DrugDDI.d234.s7
The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.

The/DT blood/NN pressure/NN effect/NN of/IN SULAR/NN tended/VBD to/TO be/VB greater/JJR in/IN patients/NNS on/IN atenolol/NN than/IN in/IN patients/NNS on/IN no/DT other/JJ antihypertensive/JJ therapy/NN ./.


DrugDDI.d234
DrugDDI.d234.s8
Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.

Quinidine/NN at/IN 648/CD mg/NN bid/NN decreased/VBD the/DT bioavailability/NN (/-LRB- AUC/NN )/-RRB- of/IN nisoldipine/NN by/IN 26/CD %/NN ,/, but/CC not/RB the/DT peak/JJ concentration/NN ./.


DrugDDI.d234
DrugDDI.d234.s9
The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.

The/DT immediate/JJ release/NN ,/, but/CC not/RB the/DT coat-core/JJ formulation/NN of/IN nisoldipine/NN increased/VBD plasma/NN quinidine/NN concentrations/NNS by/IN about/RB 20/CD %./NN


DrugDDI.d234
DrugDDI.d234.s11
No significant interactions were found between nisoldipine and warfarin or digoxin .

No/DT significant/JJ interactions/NNS were/VBD found/VBN between/IN nisoldipine/NN and/CC warfarin/NN or/CC digoxin/NN ./.


DrugDDI.d306
DrugDDI.d306.s0
Tizoxanide is highly bound to plasma protein ( 99.9%).

Tizoxanide/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN protein/NN (/-LRB- 99.9/CD %)./NN


DrugDDI.d306
DrugDDI.d306.s1
Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin ).

Therefore/RB ,/, caution/NN should/MD be/VB used/VBN when/WRB administering/VBG nitazoxanide/NN concurrently/RB with/IN other/JJ highly/RB plasma/NN protein-bound/JJ drugs/NNS with/IN narrow/JJ therapeutic/JJ indices/NNS ,/, as/IN competition/NN for/IN binding/NN sites/NNS may/MD occur/VB (/-LRB- e.g./FW ,/, warfarin/NN )/-RRB- ./.


DrugDDI.d306
DrugDDI.d306.s2
In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.

In/FW vitro/FW metabolism/NN studies/NNS have/VBP demonstrated/VBN that/IN tizoxanide/NN has/VBZ no/DT significant/JJ inhibitory/JJ effect/NN on/IN cytochrome/NN P450/NN enzymes/NNS ./.


DrugDDI.d306
DrugDDI.d306.s3
Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.

Although/IN no/DT drug-drug/JJ interaction/NN studies/NNS have/VBP been/VBN conducted/VBN in/FW vivo/FW ,/, it/PRP is/VBZ expected/VBN that/IN no/DT significant/JJ interaction/NN would/MD occur/VB when/WRB nitazoxanide/NN is/VBZ co-administered/VBN with/IN drugs/NNS that/WDT either/RB are/VBP metabolized/VBN by/IN or/CC inhibit/VB cytochrome/NN P450/NN enzymes/NNS ./.


DrugDDI.d20
DrugDDI.d20.s0
Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4 /5 with potentially important effects on plasma concentrations of other drugs .

Oxcarbazepine/NN can/MD inhibit/VB CYP2C19/NN and/CC induce/VB CYP3A4/NN /5/NN with/IN potentially/RB important/JJ effects/NNS on/IN plasma/NN concentrations/NNS of/IN other/JJ drugs/NNS ./.


DrugDDI.d20
DrugDDI.d20.s1
In addition, several AED@s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.

In/IN addition/NN ,/, several/JJ AED/JJ @/NN s/NNS that/WDT are/VBP cytochrome/NN P450/NN inducers/NNS can/MD decrease/VB plasma/NN concentrations/NNS of/IN oxcarbazepine/NN and/CC MHD/NN ./.


DrugDDI.d20
DrugDDI.d20.s2
Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs .

Oxcarbazepine/NN was/VBD evaluated/VBN in/IN human/JJ liver/NN microsomes/NNS to/TO determine/VB its/PRP$ capacity/NN to/TO inhibit/VB the/DT major/JJ cytochrome/NN P450/NN enzymes/NNS responsible/JJ for/IN the/DT metabolism/NN of/IN other/JJ drugs/NNS ./.


DrugDDI.d20
DrugDDI.d20.s3
Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2D6 , CYP2E1 , CYP4A9 and CYP4A11 ) with the exception of CYP2C19 and CYP3A4 /5.

Results/NNS demonstrate/VBP that/IN oxcarbazepine/NN and/CC its/PRP$ pharmacologically/RB active/JJ 10-monohydroxy/NN metabolite/NN (/-LRB- MHD/NN )/-RRB- have/VBP little/JJ or/CC no/DT capacity/NN to/TO function/VB as/IN inhibitors/NNS for/IN most/JJS of/IN the/DT human/JJ cytochrome/NN P450/NN enzymes/NNS evaluated/VBN (/-LRB- CYP1A2/NN ,/, CYP2A6/NN ,/, CYP2C9/NN ,/, CYP2D6/NN ,/, CYP2E1/NN ,/, CYP4A9/NN and/CC CYP4A11/NN )/-RRB- with/IN the/DT exception/NN of/IN CYP2C19/NN and/CC CYP3A4/NN /5/NN ./.


DrugDDI.d20
DrugDDI.d20.s4
Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.

Although/IN inhibition/NN of/IN CYP/NN 3A4/5/NN by/IN OXC/NN and/CC MHD/NN did/VBD occur/VB at/IN high/JJ concentrations/NNS ,/, it/PRP is/VBZ not/RB likely/JJ to/TO be/VB of/IN clinical/JJ significance/NN ./.


DrugDDI.d20
DrugDDI.d20.s5
The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.

The/DT inhibition/NN of/IN CYP-2C19/NN by/IN OXC/NN and/CC MHD/NN ,/, however/RB ,/, is/VBZ clinically/RB relevant/JJ ./.


DrugDDI.d20
DrugDDI.d20.s6
In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme.

In/FW vitro/FW ,/, the/DT UDP-glucuronyl/JJ transferase/NN level/NN was/VBD increased/VBN ,/, indicating/VBG induction/NN of/IN this/DT enzyme/NN ./.


DrugDDI.d20
DrugDDI.d20.s7
Increases of 22% with MHD and 47% with oxcarbazepine were observed.

Increases/NNS of/IN 22/CD %/NN with/IN MHD/NN and/CC 47/CD %/NN with/IN oxcarbazepine/NN were/VBD observed/VBN ./.


DrugDDI.d20
DrugDDI.d20.s8
As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid , lamotrigine ).

As/IN MHD/NN ,/, the/DT predominant/JJ plasma/NN substrate/NN ,/, is/VBZ only/RB a/DT weak/JJ inducer/NN of/IN UDP-glucuronyl/NN transferase/NN ,/, it/PRP is/VBZ unlikely/JJ to/TO have/VB an/DT effect/NN on/IN drugs/NNS that/WDT are/VBP mainly/RB eliminated/VBN by/IN conjugation/NN through/IN UDP-glucuronyl/JJ transferase/NN (/-LRB- e.g./FW ,/, valproic/JJ acid/NN ,/, lamotrigine/NN )/-RRB- ./.


DrugDDI.d20
DrugDDI.d20.s9
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of dihydropyridine calcium antagonist s and oral contraceptives , resulting in a lower plasma concentration of these drugs .

In/IN addition/NN ,/, oxcarbazepine/NN and/CC MHD/NN induce/VBP a/DT subgroup/NN of/IN the/DT cytochrome/NN P450/NN 3A/NN family/NN (/-LRB- CYP3A4/NN and/CC CYP3A5/NN )/-RRB- responsible/JJ for/IN the/DT metabolism/NN of/IN dihydropyridine/NN calcium/NN antagonist/NN s/NN and/CC oral/JJ contraceptives/NNS ,/, resulting/VBG in/IN a/DT lower/JJR plasma/NN concentration/NN of/IN these/DT drugs/NNS ./.


DrugDDI.d20
DrugDDI.d20.s10
As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.

As/IN binding/NN of/IN MHD/NN to/TO plasma/NN proteins/NNS is/VBZ low/JJ (/-LRB- 40/CD %/NN )/-RRB- ,/, clinically/RB significant/JJ interactions/NNS with/IN other/JJ drugs/NNS through/IN competition/NN for/IN protein/NN binding/NN sites/NNS are/VBP unlikely/JJ ./.


DrugDDI.d20
DrugDDI.d20.s11
Antiepileptic drugs Potential interactions between Trileptal and other AEDs were assessed in clinical studies.

Antiepileptic/JJ drugs/NNS Potential/JJ interactions/NNS between/IN Trileptal/NNP and/CC other/JJ AEDs/NNS were/VBD assessed/VBN in/IN clinical/JJ studies/NNS ./.


DrugDDI.d20
DrugDDI.d20.s12
The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal .

The/DT effect/NN of/IN these/DT interactions/NNS on/IN mean/JJ AUCs/NNS and/CC Cmin/NN are/VBP summarized/VBN in/IN Table/NN 2/CD :/: Table/NN 2/CD :/: Summary/NN of/IN AED/JJ interactions/NNS with/IN Trileptal/NN ./.


DrugDDI.d20
DrugDDI.d20.s15
Trileptal dose (mg/day) .

Trileptal/JJ dose/NN (/-LRB- mg/day/NN )/-RRB- ./.


DrugDDI.d20
DrugDDI.d20.s16
Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval) .

Influence/NN of/IN Trileptal/NN on/IN AED/JJ Concentration/NN (/-LRB- Mean/NN change/NN ,/, 90/CD %/NN Confidence/NN Interval/NN )/-RRB- ./.


DrugDDI.d20
DrugDDI.d20.s18
Carbamazepine .

Carbamazepine/NN ./.


DrugDDI.d20
DrugDDI.d20.s22
Phenobarbital .

Phenobarbital/NN ./.


DrugDDI.d20
DrugDDI.d20.s26
Phenytoin .

Phenytoin/NN ./.


DrugDDI.d20
DrugDDI.d20.s31
Valproic acid .

Valproic/JJ acid/NN ./.


DrugDDI.d20
DrugDDI.d20.s35
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.

1-/CD nc/NN denotes/VBZ a/DT mean/JJ change/NN of/IN less/JJR than/IN 10/CD %/NN 2-/CD Pediatrics/NN 3-/CD Mean/NN increase/NN in/IN adults/NNS at/IN high/JJ Trileptal/NN doses/NNS In/FW vivo/FW ,/, the/DT plasma/NN levels/NNS of/IN phenytoin/NN increased/VBD by/IN up/RB to/TO 40/CD %/NN ,/, when/WRB Trileptal/NN was/VBD given/VBN at/IN doses/NNS above/IN 1200/CD mg/day/NN ./.


DrugDDI.d20
DrugDDI.d20.s36
Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.

Therefore/RB ,/, when/WRB using/VBG doses/NNS of/IN Trileptal/NN greater/JJR than/IN 1200/CD mg/day/NN during/IN adjunctive/JJ therapy/NN ,/, a/DT decrease/NN in/IN the/DT dose/NN of/IN phenytoin/NN may/MD be/VB required/VBN ./.


DrugDDI.d20
DrugDDI.d20.s37
The increase of phenobarbital level, however, is small (15%) when given with Trileptal .

The/DT increase/NN of/IN phenobarbital/NN level/NN ,/, however/RB ,/, is/VBZ small/JJ (/-LRB- 15/CD %/NN )/-RRB- when/WRB given/VBN with/IN Trileptal/NN ./.


DrugDDI.d20
DrugDDI.d20.s38
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine , phenytoin and phenobarbital ) have been shown to decrease the plasma levels of MHD (29-40%).

Strong/JJ inducers/NNS of/IN cytochrome/NN P450/NN enzymes/NNS (/-LRB- i.e./FW carbamazepine/NN ,/, phenytoin/NN and/CC phenobarbital/NN )/-RRB- have/VBP been/VBN shown/VBN to/TO decrease/VB the/DT plasma/NN levels/NNS of/IN MHD/NN (/-LRB- 29-40%)./NN


DrugDDI.d20
DrugDDI.d20.s39
No autoinduction has been observed with Trileptal .

No/DT autoinduction/NN has/VBZ been/VBN observed/VBN with/IN Trileptal/NN ./.


DrugDDI.d20
DrugDDI.d20.s40
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).

Hormonal/JJ contraceptives/NNS Co-administration/NN of/IN Trileptal/NN with/IN an/DT oral/JJ contraceptive/NN has/VBZ been/VBN shown/VBN to/TO influence/VB the/DT plasma/NN concentrations/NNS of/IN the/DT two/CD hormonal/JJ components/NNS ,/, ethinylestradiol/NN (/-LRB- EE/NN )/-RRB- and/CC levonorgestrel/NN (/-LRB- LNG)./NN


DrugDDI.d20
DrugDDI.d20.s43
Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.

Therefore/RB ,/, concurrent/JJ use/NN of/IN Trileptal/NN with/IN hormonal/JJ contraceptives/NNS may/MD render/VB these/DT contraceptives/NNS less/RBR effective/JJ ./.


DrugDDI.d20
DrugDDI.d20.s44
Studies with other oral or implant contraceptives have not been conducted.

Studies/NNS with/IN other/JJ oral/JJ or/CC implant/JJ contraceptives/NNS have/VBP not/RB been/VBN conducted/VBN ./.


DrugDDI.d20
DrugDDI.d20.s45
Calcium Antagonist s After repeated co-administration of Trileptal , the AUC of felodipine was lowered by 28% [90% CI: 20-33].

Calcium/NN Antagonist/NN s/NN After/IN repeated/JJ co-administration/NN of/IN Trileptal/NN ,/, the/DT AUC/NN of/IN felodipine/NN was/VBD lowered/VBN by/IN 28/CD %/NN [90/CD %/NN CI/NN :/: 20-33/CD ]./NN


DrugDDI.d20
DrugDDI.d20.s46
Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.

Verapamil/NN produced/VBD a/DT decrease/NN of/IN 20/CD %/NN [90/CD %/NN CI/CD :/: 18-27/CD ]/-RRB- of/IN the/DT plasma/NN levels/NNS of/IN MHD/NN ./.


DrugDDI.d20
DrugDDI.d20.s47
Other drug interactions Cimetidine , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.

Other/JJ drug/NN interactions/NNS Cimetidine/NN ,/, erythromycin/NN and/CC dextropropoxyphene/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN MHD/NN ./.


DrugDDI.d20
DrugDDI.d20.s48
Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal .

Results/NNS with/IN warfarin/NN wshow/VBP no/DT evidence/NN of/IN interaction/NN with/IN either/CC single/JJ or/CC repeated/JJ doses/NNS of/IN Trileptal/NN ./.


DrugDDI.d480
DrugDDI.d480.s0
In a Phase : I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin ).

In/IN a/DT Phase/NN :/: I/NN trial/NN using/VBG escalating/JJ doses/NNS of/IN TAXOL/NN (/-LRB- 110-200/CD mg/m2/NN )/-RRB- and/CC cisplatin/NN (/-LRB- 50/CD or/CC 75/CD mg/m2/NN )/-RRB- given/VBN as/IN sequential/JJ infusions/NNS ,/, myelosuppression/NN was/VBD more/RBR profound/JJ when/WRB TAXOL/NN was/VBD given/VBN after/IN cisplatin/NN than/IN with/IN the/DT alternate/JJ sequence/NN (/-LRB- ie/FW ,/, TAXOL/NN before/IN cisplatin/NN )/-RRB- ./.


DrugDDI.d480
DrugDDI.d480.s1
Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin .

Pharmacokinetic/JJ data/NNS from/IN these/DT patients/NNS demonstrated/VBD a/DT decrease/NN in/IN paclitaxel/NN clearance/NN of/IN approximately/RB 33/CD %/NN when/WRB TAXOL/NN was/VBD administered/VBN following/VBG cisplatin/NN ./.


DrugDDI.d480
DrugDDI.d480.s2
The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4 .

The/DT metabolism/NN of/IN TAXOL/NN is/VBZ catalyzed/VBN by/IN cytochrome/NN P450/NN isoen-zymes/NNS CYP2C8/NN and/CC CYP3A4/NN ./.


DrugDDI.d480
DrugDDI.d480.s3
In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4 .

In/IN the/DT absence/NN of/IN formal/JJ clinical/JJ drug/NN interaction/NN studies/NNS ,/, caution/NN should/MD be/VB exercised/VBN when/WRB administering/VBG TAXOL/NN concomitantly/RB with/IN known/JJ substrates/NNS or/CC inhibitors/NNS of/IN the/DT cytochrome/NN P450/NN isoenzymes/NNS CYP2C8/NN and/CC CYP3A4/NN ./.


DrugDDI.d480
DrugDDI.d480.s4
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials.

Potential/JJ interactions/NNS between/IN TAXOL/NN ,/, a/DT substrate/NN of/IN CYP3A4/NN ,/, and/CC protease/NN inhibitors/NNS (/-LRB- ritonavir/NN ,/, saquinavir/NN ,/, indinavir/NN ,/, and/CC nelfinavir/NN )/-RRB- ,/, which/WDT are/VBP substrates/NNS and/or/CC inhibitors/NNS of/IN CYP3A4/NN ,/, have/VBP not/RB been/VBN evaluated/VBN in/IN clinical/JJ trials/NNS ./.


DrugDDI.d480
DrugDDI.d480.s5
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.

Reports/NNS in/IN the/DT literature/NN suggest/VBP that/IN plasma/NN levels/NNS of/IN doxorubicin/NN (/-LRB- and/CC its/PRP$ active/JJ metabolite/NN doxorubicinol/NN )/-RRB- may/MD be/VB increased/VBN when/WRB paclitaxel/NN and/CC doxorubicin/NN are/VBP used/VBN in/IN combination/NN ./.


DrugDDI.d480
DrugDDI.d480.s6
Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.

Hematology/NNP :/: TAXOL/NN therapy/NN should/MD not/RB be/VB administered/VBN to/TO patients/NNS with/IN baseline/NN neutrophil/NN counts/NNS of/IN less/JJR than/IN 1,500/CD cells/mm3/NN ./.


DrugDDI.d480
DrugDDI.d480.s7
In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL .

In/IN order/NN to/TO monitor/VB the/DT occurrence/NN of/IN myelotoxicity/NN ,/, it/PRP is/VBZ recommended/VBN that/IN frequent/JJ peripheral/JJ blood/NN cell/NN counts/NNS be/VB performed/VBN on/IN all/DT patients/NNS receiving/VBG TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s8
Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level 1500 cells/mm3 and platelets recover to a level 100,000 cells/mm3.

Patients/NNS should/MD not/RB be/VB re-treated/VBN with/IN subsequent/JJ cycles/NNS of/IN TAXOL/NN until/IN neutrophils/NNS recover/VBP to/TO a/DT level/NN 1500/CD cells/mm3/NN and/CC platelets/NNS recover/VBP to/TO a/DT level/NN 100,000/CD cells/mm3/NN ./.


DrugDDI.d480
DrugDDI.d480.s9
In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.

In/IN the/DT case/NN of/IN severe/JJ neutropenia/NN (/-LRB- 500/CD cells/mm3/NN for/IN seven/CD days/NNS or/CC more/JJR )/-RRB- during/IN a/DT course/NN of/IN TAXOL/NN therapy/NN ,/, a/DT 20/CD %/NN reduction/NN in/IN dose/NN for/IN subsequent/JJ courses/NNS of/IN therapy/NN is/VBZ recommended/VBN ./.


DrugDDI.d480
DrugDDI.d480.s10
For patients with advanced HIV disease and poor-risk AIDS-related Kaposi@s sarcoma, TAXOL , at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.

For/IN patients/NNS with/IN advanced/JJ HIV/NN disease/NN and/CC poor-risk/JJ AIDS-related/JJ Kaposi/NN @/NN s/NN sarcoma/NN ,/, TAXOL/NN ,/, at/IN the/DT recommended/VBN dose/NN for/IN this/DT disease/NN ,/, can/MD be/VB initiated/VBN and/CC repeated/VBN if/IN the/DT neutrophil/NN count/NN is/VBZ at/IN least/JJS 1000/CD cells/mm3/NN ./.


DrugDDI.d480
DrugDDI.d480.s11
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor@ EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL .

Hypersensitivity/NN Reactions/NNS :/: Patients/NNS with/IN a/DT history/NN of/IN severe/JJ hypersensitivity/NN reactions/NNS to/TO products/NNS containing/VBG Cremophor/NN @/NN EL/NN (/-LRB- eg/NN ,/, cyclosporin/NN for/IN injection/NN concentrate/NN and/CC teniposide/NN for/IN injection/NN concentrate/NN )/-RRB- should/MD not/RB be/VB treated/VBN with/IN TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s12
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen -hydramine and H2 antagonists (such as cimetidine or ranitidine ).

In/IN order/NN to/TO avoid/VB the/DT occurrence/NN of/IN severe/JJ hypersensitivity/NN reactions/NNS ,/, all/DT patients/NNS treated/VBN with/IN TAXOL/NN should/MD be/VB premedicated/VBN with/IN corticosteroids/NNS (/-LRB- such/JJ as/IN dexamethasone/NN )/-RRB- ,/, diphen/NN -hydramine/NN and/CC H2/NN antagonists/NNS (/-LRB- such/JJ as/IN cimetidine/NN or/CC ranitidine/NN )/-RRB- ./.


DrugDDI.d480
DrugDDI.d480.s14
However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators , angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.

However/RB ,/, severe/JJ reactions/NNS ,/, such/JJ as/IN hypotension/NN requiring/VBG treatment/NN ,/, dyspnea/NN requiring/VBG bronchodilators/NNS ,/, angioedema/NN ,/, or/CC generalized/JJ urticaria/NN require/VBP immediate/JJ discontinuation/NN of/IN TAXOL/NN and/CC aggressive/JJ symptomatic/JJ therapy/NN ./.


DrugDDI.d480
DrugDDI.d480.s15
Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL .

Patients/NNS who/WP have/VBP developed/VBN severe/JJ hypersensitivity/NN reactions/NNS should/MD not/RB be/VB rechallenged/VBN with/IN TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s16
Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL , but generally do not require treatment.

Cardiovascular/NN :/: Hypotension/NN ,/, bradycardia/NN ,/, and/CC hypertension/NN have/VBP been/VBN observed/VBN during/IN administration/NN of/IN TAXOL/NN ,/, but/CC generally/RB do/VBP not/RB require/VB treatment/NN ./.


DrugDDI.d480
DrugDDI.d480.s17
Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.

Occasionally/RB TAXOL/NN infusions/NNS must/MD be/VB interrupted/VBN or/CC discontinued/VBD because/IN of/IN initial/JJ or/CC recurrent/JJ hypertension/NN ./.


DrugDDI.d480
DrugDDI.d480.s18
Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.

Frequent/JJ vital/JJ sign/NN monitoring/NN ,/, particularly/RB during/IN the/DT first/JJ hour/NN of/IN TAXOL/NN infusion/NN ,/, is/VBZ recommended/VBN ./.


DrugDDI.d480
DrugDDI.d480.s20
Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL .

Nervous/JJ System/NN :/: Although/IN the/DT occurrence/NN of/IN peripheral/JJ neuropathy/NN is/VBZ frequent/JJ ,/, the/DT development/NN of/IN severe/JJ symptomatology/NN is/VBZ unusual/JJ and/CC requires/VBZ a/DT dose/NN reduction/NN of/IN 20/CD %/NN for/IN all/DT subsequentcourses/NNS of/IN TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s21
TAXOL contains dehydrated alcohol USP , 396 mg/mL; .

TAXOL/NN contains/VBZ dehydrated/JJ alcohol/NN USP/NN ,/, 396/CD mg/mL/NN ;/: ./.


DrugDDI.d480
DrugDDI.d480.s22
consideration should be given to possible CNS and other effects of alcohol .

consideration/NN should/MD be/VB given/VBN to/TO possible/JJ CNS/NNS and/CC other/JJ effects/NNS of/IN alcohol/NN ./.


DrugDDI.d480
DrugDDI.d480.s23
Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin 2 times ULN.

Hepatic/JJ :/: There/EX is/VBZ limited/JJ evidence/NN that/IN the/DT myelotoxicity/NN of/IN TAXOL/NN may/MD be/VB exacerbated/JJ in/IN patients/NNS with/IN serum/NN total/JJ bilirubin/NN 2/CD times/NNS ULN/NN ./.


DrugDDI.d480
DrugDDI.d480.s24
Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.

Extreme/JJ caution/NN should/MD be/VB exercised/VBN when/WRB administering/VBG TAXOL/NN to/TO such/JJ patients/NNS ,/, with/IN dose/NN reduction/NN as/IN recommended/VBN in/IN DOSAGE/NN AND/CC ADMINISTRATION/NN ,/, Table/NN 17/CD ./.


DrugDDI.d480
DrugDDI.d480.s27
Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.

Recurrence/NN of/IN skin/NN reactions/NNS at/IN a/DT site/NN of/IN previous/JJ extravasation/NN following/VBG administration/NN of/IN TAXOL/NN at/IN a/DT different/JJ site/NN ,/, ie/FW ,/, recall/NN ,/, has/VBZ been/VBN reported/VBN rarely/RB ./.


DrugDDI.d480
DrugDDI.d480.s28
Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.

Rare/JJ reports/NNS of/IN more/RBR severe/JJ events/NNS such/JJ as/IN phlebitis/NN ,/, cellulitis/NN ,/, induration/NN ,/, skin/NN exfoliation/NN ,/, necrosis/NN ,/, and/CC fibrosis/NN have/VBP been/VBN received/VBN as/IN part/NN of/IN the/DT continuing/VBG surveillance/NN of/IN TAXOL/NN safety/NN ./.


DrugDDI.d235
DrugDDI.d235.s0
Aminoglycosides : The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside .

Aminoglycosides/NNS :/: The/DT mixing/NN of/IN piperacillin/NN with/IN an/DT aminoglycoside/NN in/IN vitro/FW can/MD result/VB in/IN substantial/JJ inactivation/NN of/IN the/DT aminoglycoside/NN ./.


DrugDDI.d235
DrugDDI.d235.s1
Vecuronium : When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium .

Vecuronium/NN :/: When/WRB used/VBN in/IN the/DT perioperative/JJ period/NN ,/, piperacillin/NN has/VBZ been/VBN implicated/VBN in/IN the/DT prolongation/NN of/IN the/DT neuromuscular/JJ blockade/NN of/IN vecuronium/NN ./.


DrugDDI.d235
DrugDDI.d235.s2
Caution is indicated when piperacillin is used perioperatively.

Caution/NN is/VBZ indicated/VBN when/WRB piperacillin/NN is/VBZ used/VBN perioperatively/NN ./.


DrugDDI.d235
DrugDDI.d235.s3
In one controlled clinical study, the ureidopenicillins, including piperacillin , were reported to prolong the action of vecuronium .

In/IN one/CD controlled/JJ clinical/JJ study/NN ,/, the/DT ureidopenicillins/NNS ,/, including/VBG piperacillin/NN ,/, were/VBD reported/VBN to/TO prolong/VB the/DT action/NN of/IN vecuronium/NN ./.


DrugDDI.d235
DrugDDI.d235.s4
Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin .

Due/JJ to/TO their/PRP$ similar/JJ mechanism/NN of/IN action/NN ,/, it/PRP is/VBZ expected/VBN that/IN the/DT neuromuscular/JJ blockade/NN produced/VBN by/IN any/DT of/IN the/DT non-depolarizing/JJ muscle/NN relaxants/NNS could/MD be/VB prolonged/VBD in/IN the/DT presence/NN of/IN piperacillin/NN ./.


DrugDDI.d235
DrugDDI.d235.s5
Probenecid : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.

Probenecid/NN :/: The/DT oral/JJ combination/NN of/IN probenecid/NN before/IN intramuscular/JJ injection/NN of/IN PIPRACIL/NN produces/VBZ an/DT increase/NN in/IN piperacillin/JJ peak/JJ serum/NN level/NN of/IN about/RB 30/CD %./NN


DrugDDI.d235
DrugDDI.d235.s6
Anticoagulants Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin , oral anticoagulants , or other drugs that may affect the blood coagulation system or the thrombocyte function.

Anticoagulants/NNS Coagulation/NN parameters/NNS should/MD be/VB tested/VBN more/RBR frequently/RB and/CC monitored/VBN regularly/RB during/IN simultaneous/JJ administration/NN of/IN high/JJ doses/NNS of/IN heparin/NN ,/, oral/JJ anticoagulants/NNS ,/, or/CC other/JJ drugs/NNS that/WDT may/MD affect/VB the/DT blood/NN coagulation/NN system/NN or/CC the/DT thrombocyte/JJ function/NN ./.


DrugDDI.d235
DrugDDI.d235.s7
Methotrexate Piperacillin sodium may reduce the excretion of methotrexate .

Methotrexate/NN Piperacillin/NN sodium/NN may/MD reduce/VB the/DT excretion/NN of/IN methotrexate/NN ./.


DrugDDI.d235
DrugDDI.d235.s8
Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.

Therefore/RB ,/, serum/NN levels/NNS of/IN methotrexate/NN should/MD be/VB monitored/VBN in/IN patients/NNS to/TO avoid/VB drug/NN toxicity/NN ./.


DrugDDI.d235
DrugDDI.d235.s9
Drug /Laboratory Test Interactions : As with other penicillins , the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper -reduction method.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: As/IN with/IN other/JJ penicillins/NNS ,/, the/DT administration/NN of/IN PIPRACIL/NN may/MD result/VB in/IN a/DT false-positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN using/VBG a/DT copper/NN -reduction/NN method/NN ./.


DrugDDI.d235
DrugDDI.d235.s10
It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

It/PRP is/VBZ recommended/VBN that/IN glucose/NN tests/NNS based/VBN on/IN enzymatic/JJ glucose/NN oxidase/NN reactions/NNS be/VB used/VBN ./.


DrugDDI.d235
DrugDDI.d235.s11
There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin / tazobactam injection who were subsequently found to be free of Aspergillus infection.

There/EX have/VBP been/VBN reports/NNS of/IN positive/JJ test/NN results/NNS using/VBG the/DT Bio-Rad/JJ Laboratories/NNS Platelia/NN Aspergillus/NN EIA/NN test/NN in/IN patients/NNS receiving/VBG piperacillin/NN //: tazobactam/NN injection/NN who/WP were/VBD subsequently/RB found/VBN to/TO be/VB free/JJ of/IN Aspergillus/JJ infection/NN ./.


DrugDDI.d235
DrugDDI.d235.s12
Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.

Cross-reactions/NNS with/IN non-Aspergillus/JJ polysaccharides/NNS and/CC polyfuranoses/NNS with/IN the/DT Bio-Rad/JJ Laboratories/NNS Platelia/FW Aspergillus/FW EIA/NN test/NN have/VBP been/VBN reported/VBN ./.


DrugDDI.d235
DrugDDI.d235.s13
Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.

Therefore/RB ,/, positive/JJ test/NN results/NNS in/IN patients/NNS receiving/VBG piperacillin/NN should/MD be/VB interpreted/VBN cautiously/RB and/CC confirmed/VBN by/IN other/JJ diagnostic/JJ methods/NNS ./.


DrugDDI.d253
DrugDDI.d253.s0
Effect of other drugs on Vardenafil .

Effect/NN of/IN other/JJ drugs/NNS on/IN Vardenafil/NN ./.


DrugDDI.d253
DrugDDI.d253.s1
In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 ( CYP ) isoforms 3A4/5, and to a lesser degree by CYP2C9 .

In/FW vitro/FW studies/NNS :/: Studies/NNS in/IN human/JJ liver/NN microsomes/NNS showed/VBD that/IN vardenafil/NN is/VBZ metabolized/VBN primarily/RB by/IN cytochrome/NN P450/NN (/-LRB- CYP/NN )/-RRB- isoforms/NNS 3A4/5/NN ,/, and/CC to/TO a/DT lesser/JJR degree/NN by/IN CYP2C9/NN ./.


DrugDDI.d253
DrugDDI.d253.s2
Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.

Therefore/RB ,/, inhibitors/NNS of/IN these/DT enzymes/NNS are/VBP expected/VBN to/TO reduce/VB vardenafil/NN clearance/NN ./.


DrugDDI.d253
DrugDDI.d253.s3
In vivo studies: Cytochrome P450 Inhibitors .

In/FW vivo/FW studies/NNS :/: Cytochrome/NN P450/NN Inhibitors/NNS ./.


DrugDDI.d253
DrugDDI.d253.s4
Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.

Cimetidine/NN (/-LRB- 400/CD mg/NN b.i.d./NN )/-RRB- had/VBD no/DT effect/NN on/IN vardenafil/NN bioavailability/NN (/-LRB- AUC/NN )/-RRB- and/CC maximum/NN concentration/NN (/-LRB- Cmax/NN )/-RRB- of/IN vardenafil/NN when/WRB co-administered/VBN with/IN 20/CD mg/NN Vardenafil/NN in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d253
DrugDDI.d253.s5
Erythromycin ( 500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.

Erythromycin/NN (/-LRB- 500/CD mg/NN t.i.d/CD )/-RRB- produced/VBD a/DT 4-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 3-fold/JJ increase/NN in/IN Cmax/NN when/WRB co-administered/VBN with/IN Vardenafil/NN 5/CD mg/NN in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d253
DrugDDI.d253.s6
It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin .

It/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 5/CD mg/NN dose/NN of/IN Vardenafil/NN in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN erythromycin/NN ./.


DrugDDI.d253
DrugDDI.d253.s7
Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.

Ketoconazole/NN (/-LRB- 200/CD mg/NN once/RB daily/JJ )/-RRB- produced/VBD a/DT 10-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 4-fold/JJ increase/NN in/IN Cmax/NN when/WRB co-administered/VBN with/IN Vardenafil/NN (/-LRB- 5/CD mg/NN )/-RRB- in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d253
DrugDDI.d253.s8
A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole .

A/DT 5-mg/JJ Vardenafil/NN dose/NN should/MD not/RB be/VB exceeded/VBD when/WRB used/VBN in/IN combination/NN with/IN 200/CD mg/NN once/IN daily/JJ ketoconazole/NN ./.


DrugDDI.d253
DrugDDI.d253.s9
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.

Since/IN higher/JJR doses/NNS of/IN ketoconazole/NN (/-LRB- 400/CD mg/NN daily/RB )/-RRB- may/MD result/VB in/IN higher/JJR increases/NNS in/IN Cmax/NN and/CC AUC/NN ,/, a/DT single/JJ 2.5/CD mg/NN dose/NN of/IN Vardenafil/NN should/MD not/RB be/VB exceeded/VBD in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN ketoconazole/NN 400/CD mg/NN daily/RB ./.


DrugDDI.d253
DrugDDI.d253.s10
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.

HIV/NN Protease/NN Inhibitors/NNS :/: Indinavir/NN (/-LRB- 800/CD mg/NN t.i.d./NN )/-RRB- co-administered/VBN with/IN Vardenafil/NN 10/CD mg/NN resulted/VBD in/IN a/DT 16-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN ,/, a/DT 7-fold/JJ increase/NN in/IN vardenafil/NN Cmax/NN and/CC a/DT 2-fold/JJ increase/NN in/IN vardenafil/NN half-life/NN ./.


DrugDDI.d253
DrugDDI.d253.s11
It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir .

It/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 2.5/CD mg/NN Vardenafil/NN dose/NN in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN indinavir/NN ./.


DrugDDI.d253
DrugDDI.d253.s12
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.

Ritonavir/NN (/-LRB- 600/CD mg/NN b.i.d./NN )/-RRB- co-administered/VBN with/IN Vardenafil/NN 5/CD mg/NN resulted/VBD in/IN a/DT 49-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 13-fold/RB increase/NN in/IN vardenafil/NN Cmax/NN ./.


DrugDDI.d253
DrugDDI.d253.s13
The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir , a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9 .

The/DT interaction/NN is/VBZ a/DT consequence/NN of/IN blocking/VBG hepatic/JJ metabolism/NN of/IN vardenafil/NN by/IN ritonavir/NN ,/, a/DT highly/RB potent/JJ CYP3A4/NN inhibitor/NN ,/, which/WDT also/RB inhibits/VBZ CYP2C9/NN ./.


DrugDDI.d253
DrugDDI.d253.s14
Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.

Ritonavir/NN significantly/RB prolonged/VBD the/DT half-life/NN of/IN vardenafil/NN to/TO 26/CD hours/NNS ./.


DrugDDI.d253
DrugDDI.d253.s15
Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir .

Consequently/RB ,/, it/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 2.5/CD mg/NN Vardenafil/NN dose/NN in/IN a/DT 72-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN ritonavir/NN ./.


DrugDDI.d253
DrugDDI.d253.s16
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs : glyburide , warfarin , digoxin , Maalox , and ranitidine .

Other/JJ Drug/NN Interactions/NNS :/: No/DT pharmacokinetic/JJ interactions/NNS were/VBD observed/VBN between/IN vardenafil/NN and/CC the/DT following/JJ drugs/NNS :/: glyburide/NN ,/, warfarin/NN ,/, digoxin/NN ,/, Maalox/NN ,/, and/CC ranitidine/NN ./.


DrugDDI.d253
DrugDDI.d253.s17
In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.

In/IN the/DT warfarin/JJ study/NN ,/, vardenafil/NN had/VBD no/DT effect/NN on/IN the/DT prothrombin/NN time/NN or/CC other/JJ pharmacodynamic/JJ parameters/NNS ./.


DrugDDI.d253
DrugDDI.d253.s18
Effects of Vardenafil on other drugs .

Effects/NNS of/IN Vardenafil/NN on/IN other/JJ drugs/NNS ./.


DrugDDI.d253
DrugDDI.d253.s19
In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2 , 2A6, and 2E1 ( Ki 100uM ).

In/FW vitro/FW studies/NNS :/: Vardenafil/NN and/CC its/PRP$ metabolites/NNS had/VBD no/DT effect/NN on/IN CYP1A2/NN ,/, 2A6/NN ,/, and/CC 2E1/NN (/-LRB- Ki/NN 100uM/NN )/-RRB- ./.


DrugDDI.d253
DrugDDI.d253.s20
Weak inhibitory effects toward other isoforms ( CYP2C8 , 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing.

Weak/JJ inhibitory/JJ effects/NNS toward/IN other/JJ isoforms/NNS (/-LRB- CYP2C8/NN ,/, 2C9/NN ,/, 2C19/NN ,/, 2D6/NN ,/, 3A4/NN )/-RRB- were/VBD found/VBN ,/, but/CC Ki/NN values/NNS were/VBD in/IN excess/NN of/IN plasma/NN concentrations/NNS achieved/VBN following/VBG dosing/NN ./.


DrugDDI.d253
DrugDDI.d253.s21
The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4 , which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.

The/DT most/RBS potent/JJ inhibitory/JJ activity/NN was/VBD observed/VBN for/IN vardenafil/NN metabolite/NN M1/NN ,/, which/WDT had/VBD a/DT Ki/NN of/IN 1.4/CD uM/NN toward/IN CYP3A4/NN ,/, which/WDT is/VBZ about/RB 20/CD times/NNS higher/JJR than/IN the/DT M1/NN Cmax/NN values/NNS after/IN an/DT 80/CD mg/NN Vardenafil/NN dose/NN ./.


DrugDDI.d253
DrugDDI.d253.s22
In vivo studies: Nitrates : The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.

In/FW vivo/FW studies/NNS :/: Nitrates/NNS :/: The/DT blood/NN pressure/NN lowering/JJ effects/NNS of/IN sublingual/JJ nitrates/NNS (/-LRB- 0.4/CD mg/NN )/-RRB- taken/VBN 1/CD and/CC 4/CD hours/NNS after/IN vardenafil/NN and/CC increases/NNS in/IN heart/NN rate/NN when/WRB taken/VBN at/IN 1/CD ,/, 4/CD and/CC 8/CD hours/NNS were/VBD potentiated/VBN by/IN a/DT 20/CD mg/NN dose/NN of/IN Vardenafil/NN in/IN healthy/JJ middle-aged/JJ subjects/NNS ./.


DrugDDI.d253
DrugDDI.d253.s23
These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.

These/DT effects/NNS were/VBD not/RB observed/VBN when/WRB Vardenafil/NN 20/CD mg/NN was/VBD taken/VBN 24/CD hours/NNS before/IN the/DT NTG/NN ./.


DrugDDI.d253
DrugDDI.d253.s24
Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.

Potentiation/NN of/IN the/DT hypotensive/JJ effects/NNS of/IN nitrates/NNS for/IN patients/NNS with/IN ischemic/JJ heart/NN disease/NN has/VBZ not/RB been/VBN evaluated/VBN ,/, and/CC concomitant/JJ use/NN of/IN Vardenafil/NN and/CC nitrates/NNS is/VBZ contraindicated/VBN ./.


DrugDDI.d253
DrugDDI.d253.s25
Nifedipine : Vardenafil 20 mg , when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine , a drug that is metabolized via CYP3A4 .

Nifedipine/NN :/: Vardenafil/NN 20/CD mg/NN ,/, when/WRB co-administered/VBN with/IN slow-release/JJ nifedipine/NN 30/CD mg/NN or/CC 60/CD mg/NN once/RB daily/RB ,/, did/VBD not/RB affect/VB the/DT relative/JJ bioavailability/NN (/-LRB- AUC/NN )/-RRB- or/CC maximum/JJ concentration/NN (/-LRB- Cmax/NN )/-RRB- of/IN nifedipine/NN ,/, a/DT drug/NN that/WDT is/VBZ metabolized/VBN via/IN CYP3A4/NN ./.


DrugDDI.d253
DrugDDI.d253.s26
Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.

Nifedipine/NN did/VBD not/RB alter/VB the/DT plasma/NN levels/NNS of/IN Vardenafil/NN when/WRB taken/VBN in/IN combination/NN ./.


DrugDDI.d253
DrugDDI.d253.s27
In these patients whose hypertension was controlled with nifedipine , Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.

In/IN these/DT patients/NNS whose/WP$ hypertension/NN was/VBD controlled/VBN with/IN nifedipine/NN ,/, Vardenafil/NN 20/CD mg/NN produced/VBD mean/JJ additional/JJ supine/NN systolic/diastolic/JJ blood/NN pressure/NN reductions/NNS of/IN 6/5/CD mm/NN Hg/NN compared/VBN to/TO placebo/NN ./.


DrugDDI.d253
DrugDDI.d253.s28
Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin , significant hypotension developed in a substantial number of subjects.

Alpha-blockers/NNS :/: When/WRB Vardenafil/NN 10/CD or/CC 20/CD mg/NN was/VBD given/VBN to/TO healthy/JJ volunteers/NNS either/CC simultaneously/RB or/CC 6/CD hours/NNS after/IN a/DT 10/CD mg/NN dose/NN of/IN terazosin/NN ,/, significant/JJ hypotension/NN developed/VBD in/IN a/DT substantial/JJ number/NN of/IN subjects/NNS ./.


DrugDDI.d253
DrugDDI.d253.s29
With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

With/IN simultaneous/JJ dosing/NN of/IN Vardenafil/NN 10/CD mg/NN and/CC terazosin/NN 10/CD mg/NN ,/, 6/CD of/IN 8/CD subjects/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN of/IN less/JJR than/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s30
With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

With/IN simultaneous/JJ dosing/NN of/IN Vardenafil/NN 20/CD mg/NN and/CC terazosin/NN 10/CD mg/NN ,/, 2/CD of/IN 9/CD subjects/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN of/IN less/JJR than/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s31
When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.

When/WRB Vardenafil/NN dosing/NN was/VBD separated/VBN from/IN terazosin/NN 10/CD mg/NN by/IN 6/CD hours/NNS ,/, 7/CD of/IN 28/CD subjects/NNS who/WP received/VBD 20/CD mg/NN of/IN Vardenafil/NN experienced/VBN a/DT decrease/NN in/IN standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s32
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.

In/IN a/DT similar/JJ study/NN with/IN tamsulosin/NN in/IN healthy/JJ volunteers/NNS ,/, 1/CD of/IN 24/CD subjects/NNS dosed/VBN with/IN Vardenafil/NN 20/CD mg/NN and/CC tamsulosin/NN 0.4/CD mg/NN separated/VBN by/IN 6/CD hours/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s33
Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.

Two/CD of/IN 16/CD subjects/NNS dosed/VBN simultaneously/RB with/IN Vardenafil/NN 10/CD mg/NN and/CC tamsulosin/NN 0.4/CD mg/NN experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s34
The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.

The/DT administration/NN of/IN lower/JJR doses/NNS of/IN Vardenafil/NN with/IN alpha-blockers/NNS has/VBZ not/RB been/VBN completely/RB evaluated/VBN to/TO determine/VB if/IN they/PRP can/MD be/VB safely/RB administered/VBN together/RB ./.


DrugDDI.d253
DrugDDI.d253.s35
Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.

Based/VBN on/IN these/DT data/NNS ,/, Vardenafil/NN should/MD not/RB be/VB used/VBN in/IN patients/NNS on/IN alpha-blocker/NN therapy/NN ./.


DrugDDI.d253
DrugDDI.d253.s36
Ritonavir and indinavir : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20%.

Ritonavir/NN and/CC indinavir/NN :/: Upon/IN concomitant/JJ administration/NN of/IN 5/CD mg/NN of/IN Vardenafil/NN with/IN 600/CD mg/NN BID/NN ritonavir/NN ,/, the/DT Cmax/NN and/CC AUC/NN of/IN ritonavir/NN were/VBD reduced/VBN by/IN approximately/RB 20/CD %./NN


DrugDDI.d253
DrugDDI.d253.s37
Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir , the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.

Upon/IN administration/NN of/IN 10/CD mg/NN of/IN Vardenafil/NN with/IN 800/CD mg/NN TID/NN indinavir/NN ,/, the/DT Cmax/NN and/CC AUC/NN of/IN indinavir/NN were/VBD reduced/VBN by/IN 40/CD %/NN and/CC 30/CD %/NN ,/, respectively/RB ./.


DrugDDI.d253
DrugDDI.d253.s38
Alcohol : Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.

Alcohol/NN :/: Alcohol/NN (/-LRB- 0.5/CD g/kg/NN body/NN weight/NN :/: approximately/RB 40/CD mL/NN of/IN absolute/JJ alcohol/NN in/IN a/DT 70/CD kg/NN person/NN )/-RRB- and/CC vardenafil/NN plasma/NN levels/NNS were/VBD not/RB altered/VBN when/WRB dosed/VBN simultaneously/RB ./.


DrugDDI.d253
DrugDDI.d253.s39
Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).

Vardenafil/NN (/-LRB- 20/CD mg/NN )/-RRB- did/VBD not/RB potentiate/VB the/DT hypotensive/JJ effects/NNS of/IN alcohol/NN during/IN the/DT 4-hour/JJ observation/NN period/NN in/IN healthy/JJ volunteers/NNS when/WRB administered/VBN with/IN alcohol/NN (/-LRB- 0.5/CD g/kg/NN body/NN weight/NN )./CD


DrugDDI.d253
DrugDDI.d253.s40
Aspirin : Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).

Aspirin/NN :/: Vardenafil/NN (/-LRB- 10/CD mg/NN and/CC 20/CD mg/NN )/-RRB- did/VBD not/RB potentiate/VB the/DT increase/NN in/IN bleeding/JJ time/NN caused/VBN by/IN aspirin/NN (/-LRB- two/CD 81/CD mg/NN tablets/NNS )./CD


DrugDDI.d253
DrugDDI.d253.s41
Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide ( glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).

Other/JJ interactions/NNS :/: Vardenafil/NN had/VBD no/DT effect/NN on/IN the/DT pharmacodynamics/NNS of/IN glyburide/NN (/-LRB- glucose/NN and/CC insulin/NN concentrations/NNS )/-RRB- and/CC warfarin/NN (/-LRB- prothrombin/NN time/NN or/CC other/JJ pharmacodynamic/JJ parameters/NNS )./NN


DrugDDI.d528
DrugDDI.d528.s0
Zidovudine : There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.

Zidovudine/NN :/: There/EX is/VBZ no/DT significant/JJ pharmacokinetic/JJ interaction/NN between/IN ZDV/NN and/CC zalcitabine/NN which/WDT has/VBZ been/VBN confirmed/VBN clinically/RB ./.


DrugDDI.d528
DrugDDI.d528.s1
Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).

Zalcitabine/NN also/RB has/VBZ no/DT significant/JJ effect/NN on/IN the/DT intracellular/JJ phosphorylation/NN of/IN ZDV/NN ,/, as/IN shown/VBN in/FW vitro/FW in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS or/CC in/IN two/CD other/JJ cell/NN lines/NNS (/-LRB- U937/NN and/CC Molt-4/NN )./NN


DrugDDI.d528
DrugDDI.d528.s2
In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.

In/IN the/DT same/JJ study/NN it/PRP was/VBD shown/VBN that/IN didanosine/NN and/CC stavudine/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT intracellular/JJ phosphorylation/NN of/IN zalcitabine/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./.


DrugDDI.d528
DrugDDI.d528.s3
Lamivudine : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.

Lamivudine/NN :/: In/FW vitro/FW studies/NNS in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ,/, U937/NN and/CC Molt-4/NN cells/NNS revealed/VBD that/IN lamivudine/NN significantly/RB inhibited/VBD zalcitabine/NN phosphorylation/NN in/IN a/DT dose/NN dependent/JJ manner/NN ./.


DrugDDI.d528
DrugDDI.d528.s4
Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.

Effects/NNS were/VBD already/RB seen/VBN with/IN doses/NNS corresponding/VBG to/TO relevant/JJ plasma/NN levels/NNS in/IN humans/NNS ,/, and/CC the/DT intracellular/JJ phosphorylation/NN of/IN zalcitabine/NN to/TO its/PRP$ three/CD metabolites/NNS (/-LRB- including/VBG the/DT active/JJ zalcitabine/NN triphosphate/NN metabolite/NN )/-RRB- was/VBD significantly/RB inhibited/VBN ./.


DrugDDI.d528
DrugDDI.d528.s5
Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100); .

Zalcitabine/NN inhibited/VBD lamivudine/NN phosphorylation/NN at/IN high/JJ concentration/NN ratios/NNS (/-LRB- 10/CD and/CC 100/CD )/-RRB- ;/: ./.


DrugDDI.d528
DrugDDI.d528.s6
however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine .

however/RB ,/, it/PRP is/VBZ considered/VBN to/TO be/VB unlikely/JJ that/IN this/DT decrease/NN of/IN phosphorylated/VBN lamivudine/NN concentration/NN is/VBZ of/IN clinical/JJ significance/NN ,/, as/IN lamivudine/NN is/VBZ a/DT more/RBR efficient/JJ substrate/NN for/IN deoxycytidine/NN kinase/NN than/IN zalcitabine/NN ./.


DrugDDI.d528
DrugDDI.d528.s7
These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine .

These/DT in/FW vitro/FW studies/NNS suggest/VBP that/IN concomitant/JJ administration/NN of/IN zalcitabine/NN and/CC lamivudine/NN in/IN humans/NNS may/MD result/VB in/IN sub-therapeutic/JJ concentrations/NNS of/IN active/JJ phosphorylated/JJ zalcitabine/NN ,/, which/WDT may/MD lead/VB to/TO a/DT decreased/VBN antiretroviral/JJ effect/NN of/IN zalcitabine/NN ./.


DrugDDI.d528
DrugDDI.d528.s9
Concomitant use of zalcitabine and lamivudine is not recommended.

Concomitant/JJ use/NN of/IN zalcitabine/NN and/CC lamivudine/NN is/VBZ not/RB recommended/VBN ./.


DrugDDI.d528
DrugDDI.d528.s10
Saquinavir : The combination of HIVID , saquinavir , and ZDV has been studied (as triple combination) in adults.

Saquinavir/NN :/: The/DT combination/NN of/IN HIVID/NN ,/, saquinavir/NN ,/, and/CC ZDV/NN has/VBZ been/VBN studied/VBN (/-LRB- as/IN triple/JJ combination/NN )/-RRB- in/IN adults/NNS ./.


DrugDDI.d528
DrugDDI.d528.s11
Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together.

Pharmacokinetic/JJ data/NNS suggest/VBP that/IN absorption/NN ,/, metabolism/NN ,/, and/CC elimination/NN of/IN each/DT of/IN these/DT drugs/NNS are/VBP unchanged/JJ when/WRB they/PRP are/VBP used/VBN together/RB ./.


DrugDDI.d528
DrugDDI.d528.s12
Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.

Drugs/NNS Associated/VBN With/IN Peripheral/JJ Neuropathy/NN :/: The/DT concomitant/JJ use/NN of/IN HIVID/NN with/IN drugs/NNS that/WDT have/VBP the/DT potential/NN to/TO cause/VB peripheral/JJ neuropathy/NN should/MD be/VB avoided/VBN where/WRB possible/JJ ./.


DrugDDI.d528
DrugDDI.d528.s13
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .

Drugs/NNS that/WDT have/VBP been/VBN associated/VBN with/IN peripheral/JJ neuropathy/NN include/VBP antiretroviral/JJ nucleoside/NN analogues/NNS ,/, chloramphenicol/NN ,/, cisplatin/NN ,/, dapsone/NN ,/, disulfiram/NN ,/, ethionamide/NN ,/, glutethimide/NN ,/, gold/NN ,/, hydralazine/NN ,/, iodoquinol/NN ,/, isoniazid/NN ,/, metronidazole/NN ,/, nitrofurantoin/NN ,/, phenytoin/NN ,/, ribavirin/NN ,/, and/CC vincristine/NN ./.


DrugDDI.d528
DrugDDI.d528.s14
Concomitant use of HIVID with didanosine is not recommended.

Concomitant/JJ use/NN of/IN HIVID/NN with/IN didanosine/NN is/VBZ not/RB recommended/VBN ./.


DrugDDI.d528
DrugDDI.d528.s15
Intravenous Pentamidin e: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.

Intravenous/JJ Pentamidin/NN e/NN :/: Treatment/NN with/IN HIVID/NN should/MD be/VB interrupted/VBN when/WRB the/DT use/NN of/IN a/DT drug/NN that/WDT has/VBZ the/DT potential/NN to/TO cause/VB pancreatitis/NN is/VBZ required/VBN ./.


DrugDDI.d528
DrugDDI.d528.s16
Death due to fulminant pancreatitis possibly related to intravenous pentamidin e and HIVID has been reported.

Death/NN due/IN to/TO fulminant/JJ pancreatitis/NN possibly/RB related/JJ to/TO intravenous/JJ pentamidin/NN e/NN and/CC HIVID/NN has/VBZ been/VBN reported/VBN ./.


DrugDDI.d528
DrugDDI.d528.s17
If intravenous pentamidin e is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.

If/IN intravenous/JJ pentamidin/NN e/NN is/VBZ required/VBN to/TO treat/VB Pneumocystis/NN carinii/NN pneumonia/NNS ,/, treatment/NN with/IN HIVID/NN should/MD be/VB interrupted/VBN ./.


DrugDDI.d528
DrugDDI.d528.s18
Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).

Amphotericin/NN ,/, Foscarnet/NN ,/, and/CC Aminoglycosides/NN :/: Drugs/NNS such/JJ as/IN amphotericin/NN ,/, foscarnet/NN ,/, and/CC aminoglycosides/NNS may/MD increase/VB the/DT risk/NN of/IN developing/VBG peripheral/JJ neuropathy/NN or/CC other/JJ HIVID/NN -associated/JJ adverse/JJ events/NNS by/IN interfering/VBG with/IN the/DT renal/JJ clearance/NN of/IN zalcitabine/NN (/-LRB- thereby/RB raising/VBG systemic/JJ exposure/NN )./NN


DrugDDI.d528
DrugDDI.d528.s19
Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.

Patients/NNS who/WP require/VBP the/DT use/NN of/IN one/CD of/IN these/DT drugs/NNS with/IN HIVID/NN should/MD have/VBP frequent/JJ clinical/JJ and/CC laboratory/JJ monitoring/NN with/IN dosage/JJ adjustment/NN for/IN any/DT significant/JJ change/NN in/IN renal/JJ function/NN ./.


DrugDDI.d528
DrugDDI.d528.s20
Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine .

Probenecid/NN or/CC Cimetidine/NN :/: Concomitant/JJ administration/NN of/IN probenecid/NN or/CC cimetidine/NN decreases/VBZ the/DT elimination/NN of/IN zalcitabine/NN ,/, most/RBS likely/RB by/IN inhibition/NN of/IN renal/JJ tubular/JJ secretion/NN of/IN zalcitabine/NN ./.


DrugDDI.d528
DrugDDI.d528.s21
Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.

Patients/NNS receiving/VBG these/DT drugs/NNS in/IN combination/NN with/IN zalcitabine/NN should/MD be/VB monitored/VBN for/IN signs/NNS of/IN toxicity/NN and/CC the/DT dose/NN of/IN zalcitabine/NN reduced/VBD if/IN warranted/VBN ./.


DrugDDI.d528
DrugDDI.d528.s22
Magnesium /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium /aluminum-containing antacid products.

Magnesium/NN /Aluminum-containing/JJ Antacid/JJ Products/NNS :/: Absorption/NN of/IN zalcitabine/NN is/VBZ moderately/RB reduced/VBN (/-LRB- approximately/RB 25/CD %/NN )/-RRB- when/WRB coadministered/VBN with/IN magnesium/NN /aluminum-containing/NN antacid/JJ products/NNS ./.


DrugDDI.d528
DrugDDI.d528.s23
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum-containing antacids .

The/DT clinical/JJ significance/NN of/IN this/DT reduction/NN is/VBZ not/RB known/VBN ,/, hence/RB zalcitabine/NN is/VBZ not/RB recommended/VBN to/TO be/VB ingested/VBN simultaneously/RB with/IN magnesium/NN //: aluminum-containing/JJ antacids/NNS ./.


DrugDDI.d528
DrugDDI.d528.s24
Metoclopramide : Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.

Metoclopramide/NN :/: Bioavailability/NN is/VBZ mildly/RB reduced/VBN (/-LRB- approximately/RB 10/CD %/NN )/-RRB- when/WRB zalcitabine/NN and/CC metoclopramide/NN are/VBP coadministered/VBN ./.


DrugDDI.d528
DrugDDI.d528.s25
Doxorubicin : Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.

Doxorubicin/NN :/: Doxorubicin/NN caused/VBD a/DT decrease/NN in/IN zalcitabine/NN phosphorylation/NN (/-LRB- 50/CD %/NN inhibition/NN of/IN total/JJ phosphate/NN formation/NN )/-RRB- in/IN U937/Molt/NN 4/CD cells/NNS ./.


DrugDDI.d528
DrugDDI.d528.s26
Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.

Although/IN there/EX may/MD be/VB decreased/VBN zalcitabine/NN activity/NN because/IN of/IN lessened/JJ active/JJ metabolite/NN formation/NN ,/, the/DT clinical/JJ relevance/NN of/IN these/DT in/FW vitro/FW results/NNS are/VBP not/RB known/VBN ./.


